1
00:00:05,440 --> 00:00:07,880
WE WOULD LIKE TO AGAIN WELCOME

2
00:00:07,880 --> 00:00:10,520
THE MEMBERS OF BOTH THE BOARD OF

3
00:00:10,520 --> 00:00:11,520
SCIENTIFIC ADVISERS AND THE

4
00:00:11,520 --> 00:00:14,200
NATIONAL CANCER ADVISORY BOARD

5
00:00:14,200 --> 00:00:16,520
AND EX-OFFICIO MEMBERS AND

6
00:00:16,520 --> 00:00:17,880
PRESIDENT CANCER PANEL MEMBERS

7
00:00:17,880 --> 00:00:18,800
STAFF AND GUESTS.

8
00:00:18,800 --> 00:00:20,840
TODAY WE HAVE NEW CONCEPTS SO

9
00:00:20,840 --> 00:00:24,400
THERE ARE NO REISSUES EXCEPT FOR

10
00:00:24,400 --> 00:00:25,600
THE PRAIRIE ISSUES AND IN THAT

11
00:00:25,600 --> 00:00:26,680
INSTANCE, THERE WILL BE NO

12
00:00:26,680 --> 00:00:30,600
CONFLICTS SINCE THE VOTE WILL BE

13
00:00:30,600 --> 00:00:31,720
ON BLOCK.

14
00:00:31,720 --> 00:00:34,560
TO OUR EIGHT NEW CONCEPTS THEY

15
00:00:34,560 --> 00:00:36,960
HAVE BEEN ASSIGNED TO REVIEWERS

16
00:00:36,960 --> 00:00:39,120
TO EACH AND DEFER A NEW CONCEPT

17
00:00:39,120 --> 00:00:44,280
AND CONCUR OR NON CONCUR WITH

18
00:00:44,280 --> 00:00:47,920
THE PRAIRIE ISSUES.

19
00:00:47,920 --> 00:00:48,720
MEMBERS MAY PARTICIPATE IN THE

20
00:00:48,720 --> 00:00:51,640
EACH CONCEPT AND ONLY BSA

21
00:00:51,640 --> 00:00:53,920
MEMBERS WILL VOTE.

22
00:00:53,920 --> 00:00:57,040
PLEASE LET'S TROY TO KEEP AN EYE

23
00:00:57,040 --> 00:00:58,440
ON THE CLOCK AND BE MINDFUL OF

24
00:00:58,440 --> 00:01:00,000
THE NUMBER OF CONCEPTS THAT WE

25
00:01:00,000 --> 00:01:02,000
HAVE TO DISCUSS.

26
00:01:02,000 --> 00:01:03,440
IMPORTANT OF COURSE TO RAISE

27
00:01:03,440 --> 00:01:04,440
PRESSING QUESTIONS AND WE ALWAYS

28
00:01:04,440 --> 00:01:08,640
HAVE THE OPPORTUNITY TO DIRECT

29
00:01:08,640 --> 00:01:09,760
QUESTIONS TO PROGRAM OFFICERS

30
00:01:09,760 --> 00:01:10,680
FOLLOWING OUR DISCUSSION AS LONG

31
00:01:10,680 --> 00:01:11,720
AS WE'VE HAD SUFFICIENT

32
00:01:11,720 --> 00:01:13,800
DISCUSSION TO BE ABLE TO HOLD A

33
00:01:13,800 --> 00:01:18,720
VOTE.

34
00:01:18,720 --> 00:01:19,360
AND DURING THE VOTING I WILL ASK

35
00:01:19,360 --> 00:01:22,280
HOW MANY MEMBERS DIS APPROVE

36
00:01:22,280 --> 00:01:22,440
AND.

37
00:01:22,440 --> 00:01:26,800
>> PAUL OUT AND COUNT AND
RECORD

38
00:01:26,800 --> 00:01:27,280
THE VOTE.

39
00:01:27,280 --> 00:01:28,200
AS WE'VE DONE IN PRIOR

40
00:01:28,200 --> 00:01:35,200
ENTEROVIENTEROVIRTUALMEETINGS IR

41
00:01:35,200 --> 00:01:38,560
DISAPPROVAL AND CAUSE FOR VERB

42
00:01:38,560 --> 00:01:41,160
USING THE ON-LINE PLATFORM AND

43
00:01:41,160 --> 00:01:45,120
HAND RAISING FUNCTION AND ASK

44
00:01:45,120 --> 00:01:46,120
FOR ABSTENTIONS.

45
00:01:46,120 --> 00:01:50,520
THE FIRST CONCEPT IS

46
00:01:50,520 --> 00:02:00,920
CO-OPERATIVE AGREEMENT.

47
00:02:01,760 --> 00:02:02,240
THE MATAS ADVERTISE RESEARCH

48
00:02:02,240 --> 00:02:02,880
NETWORK AND AND THIS IS A UO1

49
00:02:02,880 --> 00:02:03,680
MECHANISMS AND Dr. JOANNA

50
00:02:03,680 --> 00:02:08,720
WATSON IS PRIOR TO TODAY ARE

51
00:02:08,720 --> 00:02:09,960
DOCTORS CON JOIN US FOR THE

52
00:02:09,960 --> 00:02:12,280
DISCUSSION TODAY BUT WAS PART OF

53
00:02:12,280 --> 00:02:15,120
THE GROUP DISCUSSION IN THE

54
00:02:15,120 --> 00:02:16,520
PREVIOUS INCOMPETENTER ACTION

55
00:02:16,520 --> 00:02:22,280
WITH Dr. WATSON.

56
00:02:22,280 --> 00:02:22,920
Dr. WATSON, GO AHEAD WITH YOUR

57
00:02:22,920 --> 00:02:23,240
PRESENTATION.

58
00:02:23,240 --> 00:02:23,760
>> THANK YOU, VERY MUCH.

59
00:02:23,760 --> 00:02:24,400
GOOD AFTERNOON, I WOULD LIKE TO

60
00:02:24,400 --> 00:02:26,920
START BY THANKING THE BSA

61
00:02:26,920 --> 00:02:28,040
SUBCOMMITTEE FOR THEIR TIME AND

62
00:02:28,040 --> 00:02:31,200
HELPFUL COMMENTS AND THE ENTIRE

63
00:02:31,200 --> 00:02:33,040
BSA COMMITTEE TO PRESENT A

64
00:02:33,040 --> 00:02:34,800
CONCEPT FOR THE MATAS TA

65
00:02:34,800 --> 00:02:36,360
ADVERTISE RESEARCH CONCEPTING

66
00:02:36,360 --> 00:02:38,640
USING THE UO1 MECHANISM AND IT'S

67
00:02:38,640 --> 00:02:42,040
BEING PUT FOURTH BY THE MET MET

68
00:02:42,040 --> 00:02:47,920
PRAG ATTIC TEAM OF CHRISTINE,

69
00:02:47,920 --> 00:02:58,600
BRUNILDE GRILL AND MYSELF.

70
00:02:58,600 --> 00:02:59,200
METNET WAS ESTABLISHED AS A WAY

71
00:02:59,200 --> 00:02:59,760
TO INCENTIVIZE COLLABORATIVE

72
00:02:59,760 --> 00:03:04,960
BASIC RESEARCH AND IT EXPANDS

73
00:03:04,960 --> 00:03:07,880
OUR MECHANIC ADVERTISE TICK AND

74
00:03:07,880 --> 00:03:18,560
BIOLOGICAL CASES TO CONSIDER THE

75
00:03:21,720 --> 00:03:22,400
MECHANISM THE STRUCTURE IS SHOWN

76
00:03:22,400 --> 00:03:24,480
HERE ON THE LEFT, WITH THE

77
00:03:24,480 --> 00:03:28,280
MINIMUM REQUIRED ELEMENTS IN

78
00:03:28,280 --> 00:03:28,480
GREEN.

79
00:03:28,480 --> 00:03:30,200
TO PROMOTE THE USE OF SYSTEMS

80
00:03:30,200 --> 00:03:32,640
LEVEL APPROACHES, EACH CENTER

81
00:03:32,640 --> 00:03:34,600
WAS REQUIRED TO ADDRESS TWO

82
00:03:34,600 --> 00:03:37,680
RESEARCH THEMES THAT SPAN THE

83
00:03:37,680 --> 00:03:39,520
MATAS TA IS CONTINUUM AND

84
00:03:39,520 --> 00:03:41,840
INTERACTION AND CROSS TALK AND

85
00:03:41,840 --> 00:03:43,160
DORMANCY AND RESPONSES TO

86
00:03:43,160 --> 00:03:44,360
THERAPY AND EACH CENTER

87
00:03:44,360 --> 00:03:46,120
PARTICIPATE IN A MONTHLY

88
00:03:46,120 --> 00:03:47,280
STEERING COMMITTEE MEETING AND

89
00:03:47,280 --> 00:03:48,560
RESOURCE AND DATA SHARING

90
00:03:48,560 --> 00:03:51,920
WORKING GROUP AND A PATIENT

91
00:03:51,920 --> 00:03:53,880
ADVOCACY WORKING GROUP.

92
00:03:53,880 --> 00:03:58,160
WE RECEIVED A ROBUST RESPONSE OF

93
00:03:58,160 --> 00:03:58,920
39U54 APPLICATIONS IN RESPONSE

94
00:03:58,920 --> 00:04:01,240
TO THE RFA AND WE'VE BEEN ABLE

95
00:04:01,240 --> 00:04:05,040
TO FUND FOUR CENTERS.

96
00:04:05,040 --> 00:04:07,120
THIS IS A BUSY SLIDE AND I'LL

97
00:04:07,120 --> 00:04:08,720
WALK EVERYBODY THROUGH IT.

98
00:04:08,720 --> 00:04:11,160
THE NAMES OF THE CENTER CONTACT

99
00:04:11,160 --> 00:04:13,560
PIs ARE IN THE CENTER OF THE

100
00:04:13,560 --> 00:04:14,040
CIRCLES.

101
00:04:14,040 --> 00:04:16,680
THESE FOUR SELECTED CENTERS ARE

102
00:04:16,680 --> 00:04:18,680
INTEGRATED ON MULTIPLE LEVELS.

103
00:04:18,680 --> 00:04:20,040
FIRST, THE INTEGRATED THROUGH

104
00:04:20,040 --> 00:04:24,360
SHARED ORGAN OR TISSUE BIOLOGY

105
00:04:24,360 --> 00:04:26,320
WITH THE SOLID CENTER COLORS.

106
00:04:26,320 --> 00:04:27,760
SECOND, THEY'RE INTEGRATED

107
00:04:27,760 --> 00:04:29,440
THROUGH BIOLOGICAL PROCESSES OR

108
00:04:29,440 --> 00:04:31,960
SYSTEMS WHICH IS DENOTED BY THE

109
00:04:31,960 --> 00:04:33,360
OUT OF COLORED RANKS AND THIRD

110
00:04:33,360 --> 00:04:34,960
THE INTEGRATED THROUGH THE

111
00:04:34,960 --> 00:04:36,160
REQUIRED RESEARCH THEMES WHICH

112
00:04:36,160 --> 00:04:40,640
IS DENOTED BY THE SINGLE BOLD

113
00:04:40,640 --> 00:04:40,920
LETTERS.

114
00:04:40,920 --> 00:04:42,560
WE BELIEVE SUCH INTEGRATION

115
00:04:42,560 --> 00:04:43,680
ACROSS MULTIPLE MASS ET CETERA

116
00:04:43,680 --> 00:04:45,600
IS KEY TO DEVELOPING A

117
00:04:45,600 --> 00:04:48,400
SUCCESSFUL NETWORK AS IT

118
00:04:48,400 --> 00:04:48,880
PROVIDES AMPLE MOODS AND

119
00:04:48,880 --> 00:04:51,120
OPPORTUNITIES FOR INTERACTION

120
00:04:51,120 --> 00:04:52,240
AND COLLABORATION TOWARDS THE

121
00:04:52,240 --> 00:04:54,200
GOAL OF GENERATING A MORE

122
00:04:54,200 --> 00:04:57,920
COMPREHENSIVE PICTURE OF

123
00:04:57,920 --> 00:04:58,320
METASTASIS.

124
00:04:58,320 --> 00:04:59,720
ALL FOUR CENTERS EXPLORE

125
00:04:59,720 --> 00:05:01,320
INTERACTIONS AND CROSS WALK

126
00:05:01,320 --> 00:05:04,280
WITHIN THE TUMOR MICRO

127
00:05:04,280 --> 00:05:04,560
ENVIRONMENT.

128
00:05:04,560 --> 00:05:07,040
THREE EXPLORE HOW METASTATIC

129
00:05:07,040 --> 00:05:08,160
CELLS RESPOND TO DIFFERENT

130
00:05:08,160 --> 00:05:10,120
STANDARD OF CARE THERAPIES AND

131
00:05:10,120 --> 00:05:12,280
TWO EXPLORE EARLY DISSEMINATION

132
00:05:12,280 --> 00:05:15,000
OF BREAST OR COLORECTAL CANCER

133
00:05:15,000 --> 00:05:16,240
CELLS YET ONLY ONE TOUCHES ON

134
00:05:16,240 --> 00:05:18,960
THE TOPIC OF DORMANCY.

135
00:05:18,960 --> 00:05:20,640
SO WITH THIS IS BACKGROUND WE

136
00:05:20,640 --> 00:05:22,680
REALIZE THAT THERE ARE IMPORTANT

137
00:05:22,680 --> 00:05:24,680
SCIENTIFIC OPPORTUNITIES IN

138
00:05:24,680 --> 00:05:26,600
METASTASIS THAT COULD STRENGTHEN

139
00:05:26,600 --> 00:05:30,480
THE METNET OVER ALL.

140
00:05:30,480 --> 00:05:31,520
THESE OPPORTUNITIES INCLUDE

141
00:05:31,520 --> 00:05:34,160
STUDIES OF METASTASIS FROM OTHER

142
00:05:34,160 --> 00:05:36,040
PRIMARY SITES SUCH AS THE

143
00:05:36,040 --> 00:05:37,800
PROSTATE OR THE PANCREAS OR

144
00:05:37,800 --> 00:05:40,360
SITES THAT HAVE UNIQUE MICRO

145
00:05:40,360 --> 00:05:41,720
ENVIRONMENTS, PHYSIOLOGY AND

146
00:05:41,720 --> 00:05:44,200
HIGHER INCREASING METASTATIC

147
00:05:44,200 --> 00:05:44,520
RATES.

148
00:05:44,520 --> 00:05:48,240
AND THIS OPPORTUNITIES TO STUDY

149
00:05:48,240 --> 00:05:50,040
METASTASIS TO OTHER SECONDARY

150
00:05:50,040 --> 00:05:51,960
SITES SUCH AS THE BONE OR LUNG.

151
00:05:51,960 --> 00:05:54,120
THESE ARE COMMON SIGHTS BUT

152
00:05:54,120 --> 00:05:55,320
THEY'RE NOT REPRESENTED WITHIN

153
00:05:55,320 --> 00:05:56,720
THE METNET.

154
00:05:56,720 --> 00:06:01,480
DURING OUR DISCUSSION, BSA

155
00:06:01,480 --> 00:06:02,480
SUBCOMMITTEE MEMBER MEMBERS THE

156
00:06:02,480 --> 00:06:04,960
NEED TO UNDERSTAND THE BONE

157
00:06:04,960 --> 00:06:08,520
MATAS SIS AND REALLY ENCOURAGE

158
00:06:08,520 --> 00:06:10,200
THE FOCUS OF CANCER THAT'S

159
00:06:10,200 --> 00:06:11,840
CONTINUE TO BE ASSOCIATED WITH

160
00:06:11,840 --> 00:06:14,160
HIGH OR INCREASING RATES OF

161
00:06:14,160 --> 00:06:16,520
METASTASIS AND MORTALITY.

162
00:06:16,520 --> 00:06:18,560
OBVIOUSLY THERE ARE SOME

163
00:06:18,560 --> 00:06:19,200
ADDITIONAL OPPORTUNITIES THAT

164
00:06:19,200 --> 00:06:21,040
COULD INCLUDE A DEEPER

165
00:06:21,040 --> 00:06:22,440
INVESTIGATION INTO SOME OF THE

166
00:06:22,440 --> 00:06:23,840
OTHER PROCESSES AND SUCH AS HOW

167
00:06:23,840 --> 00:06:27,000
THE NEURO SIGNALING NETWORKS AND

168
00:06:27,000 --> 00:06:29,520
INNOVATION CONTRIBUTE TO

169
00:06:29,520 --> 00:06:31,080
METASTASIS AND WE RECOGNIZE IS

170
00:06:31,080 --> 00:06:32,560
AN IMPORTANT EMERGING AREA IN

171
00:06:32,560 --> 00:06:36,960
CANCER BIOLOGY.

172
00:06:36,960 --> 00:06:44,360
NEXT SLIDE, WE BELIEVE THAT

173
00:06:44,360 --> 00:06:45,600
EMPHASIZING THIS THEME WOULD BE

174
00:06:45,600 --> 00:06:47,240
APPROPRIATE IN THIS CONCEPT.

175
00:06:47,240 --> 00:06:49,200
AND THE BSA SUBCOMMITTEE ASKED

176
00:06:49,200 --> 00:06:51,680
ABOUT THE SIGNIFICANCE OF

177
00:06:51,680 --> 00:06:54,200
FOCUSING ON DORMANCY IT'S A

178
00:06:54,200 --> 00:06:55,680
CRITICAL CONTRIBUTE OR TO

179
00:06:55,680 --> 00:06:59,440
RESISTANCE TO THERAPIES AND

180
00:06:59,440 --> 00:06:59,920
DISEASE RECURRENCE.

181
00:06:59,920 --> 00:07:02,160
MORE OVER, THE STUDY OF DORM

182
00:07:02,160 --> 00:07:04,800
ANNIE WHICH INVOLVES CELL AND

183
00:07:04,800 --> 00:07:09,480
EXTRINSIC AND TRINSIC PROCESSES

184
00:07:09,480 --> 00:07:10,880
LENDS ITSELF WELL TO FULLY

185
00:07:10,880 --> 00:07:12,520
DEFINE THE MECHANISMS INVOLVED.

186
00:07:12,520 --> 00:07:14,160
THUS, WE REALLY THINK THE METNET

187
00:07:14,160 --> 00:07:17,320
WOULD BE STRENGTHED BY PROVIDING

188
00:07:17,320 --> 00:07:18,720
OPPORTUNITIES OR A CONCERTED

189
00:07:18,720 --> 00:07:19,920
EFFORT IN THIS AREA.

190
00:07:19,920 --> 00:07:22,520
FOR EXAMPLE, WE KNOW THAT

191
00:07:22,520 --> 00:07:26,160
DIFFERENT BREAST CANCER SUB

192
00:07:26,160 --> 00:07:28,760
TYPES METASTASIZE TO DIFFERENT

193
00:07:28,760 --> 00:07:29,840
SYSTEMS AND WHAT IS THE

194
00:07:29,840 --> 00:07:30,720
MECHANISM THAT'S DRIVE THESE

195
00:07:30,720 --> 00:07:32,160
DETERMINE ANNIE AND IT'S

196
00:07:32,160 --> 00:07:33,880
IMPORTANT TO STUDY MECHANISMS

197
00:07:33,880 --> 00:07:35,120
ASSOCIATED WITH ESTABLISHING

198
00:07:35,120 --> 00:07:38,120
MAINTAINING OR EMERGING FROM A

199
00:07:38,120 --> 00:07:46,160
DETERMINDORMANT STATE AND NEXT .

200
00:07:46,160 --> 00:07:48,600
WE WOULD LIKE TO PROPOSE TO

201
00:07:48,600 --> 00:07:49,960
STRATEGICALLY BUILD OUT AND

202
00:07:49,960 --> 00:07:51,080
STRENGTHEN THE METNET.

203
00:07:51,080 --> 00:07:52,840
BUILDING ON THE MOMENTUM AND THE

204
00:07:52,840 --> 00:07:55,280
INTEREST IN USING SYSTEMS LEVEL

205
00:07:55,280 --> 00:07:56,440
APPROACHES TO ADDRESS CRITICAL

206
00:07:56,440 --> 00:07:58,200
QUESTIONS IN MATAS TA ADVERTISE

207
00:07:58,200 --> 00:07:59,120
AS EVIDENCE BY THE CONTINUED

208
00:07:59,120 --> 00:08:01,400
INTEREST IN THE RFA, EVEN THOUGH

209
00:08:01,400 --> 00:08:02,160
IT'S EXPIRED.

210
00:08:02,160 --> 00:08:03,640
I WOULD ALSO LIKE TO POINT OUT

211
00:08:03,640 --> 00:08:05,920
THAT DURING THE REVIEW OF THE

212
00:08:05,920 --> 00:08:08,200
U54 APPLICATIONS, EVEN AMONG THE

213
00:08:08,200 --> 00:08:09,440
CENTER APPLICATIONS THAT WERE

214
00:08:09,440 --> 00:08:12,560
NOT SELECTED FOR FUNDING

215
00:08:12,560 --> 00:08:13,480
CONSIDERATION, MANY OF THE

216
00:08:13,480 --> 00:08:16,200
INDIVIDUAL PROJECTS WERE

217
00:08:16,200 --> 00:08:16,920
ENTHUSIASTICALLY RECEIVED AND

218
00:08:16,920 --> 00:08:19,880
SOME OF THESE FOCUSED ON BONE

219
00:08:19,880 --> 00:08:25,200
METASTASIS OR DORMANCY.

220
00:08:25,200 --> 00:08:26,720
U01 MECHANISM MAY ENCOURAGE

221
00:08:26,720 --> 00:08:28,280
SUBMISSION OF THESE PROJECTION,

222
00:08:28,280 --> 00:08:30,040
PARTICULARLY THOSE THAT WOULD

223
00:08:30,040 --> 00:08:31,600
ADDRESS THE OPPORTUNITY BARRIERS

224
00:08:31,600 --> 00:08:34,240
WE IDENTIFIED IN THE CONCEPTS.

225
00:08:34,240 --> 00:08:35,880
TO GIVE YOU AN IDEA OF THE

226
00:08:35,880 --> 00:08:39,000
PORTFOLIO AND THE AREAS OF

227
00:08:39,000 --> 00:08:40,480
METASTASIS, DORMANCY AND SYSTEMS

228
00:08:40,480 --> 00:08:44,600
APPROACHES WE USED TWO METHODS.

229
00:08:44,600 --> 00:08:46,880
A HERCULEAN EFFORT AND MANUALLY

230
00:08:46,880 --> 00:08:49,840
CURATED THE ENTIRE PORTFOLIO OF

231
00:08:49,840 --> 00:08:53,040
MORE THAN 300 AWARDS AND WE ALSO

232
00:08:53,040 --> 00:08:55,520
DOUG A SEARCH OF ABSTRACT AND

233
00:08:55,520 --> 00:08:59,560
SEC SPECIFIC AIMS USING KEY WORS

234
00:08:59,560 --> 00:09:03,240
AND COMPOUND PHRASING.

235
00:09:03,240 --> 00:09:05,120
THE AWARDS MAKE UP 3% OF THE

236
00:09:05,120 --> 00:09:07,520
BRANCH PORTFOLIO AND 6% OF THE

237
00:09:07,520 --> 00:09:09,480
NCI COMPETING PORTFOLIO.

238
00:09:09,480 --> 00:09:11,520
AND THE BSA SUBCOMMITTEE

239
00:09:11,520 --> 00:09:12,840
QUESTIONED WHY WE THOUGHT THIS

240
00:09:12,840 --> 00:09:14,000
NUMBER WAS SO LOW.

241
00:09:14,000 --> 00:09:15,440
AND THE UNDERSTANDING LOW

242
00:09:15,440 --> 00:09:16,840
REPRESENTATION IN THE PORTFOLIO

243
00:09:16,840 --> 00:09:19,880
IS NEVER A SIMPLE TASK AND NONE

244
00:09:19,880 --> 00:09:23,920
THE LESS, WE ACKNOWLEDGE THAT

245
00:09:23,920 --> 00:09:24,640
THERE'S WILL BE RECENT PROGRESS

246
00:09:24,640 --> 00:09:26,000
IN OVERCOMING TECHNICAL

247
00:09:26,000 --> 00:09:29,080
CHALLENGE THAT'S HAVE PREVIOUSLY

248
00:09:29,080 --> 00:09:31,000
LIMITED STUDIES IN DETERMINE

249
00:09:31,000 --> 00:09:31,280
ANTSY.

250
00:09:31,280 --> 00:09:34,280
IN MY DISCUSSION, SHE SAID HER

251
00:09:34,280 --> 00:09:35,680
COLLEAGUES HAVE A DIFFICULT TIME

252
00:09:35,680 --> 00:09:36,720
GETTING WILL APPLICATIONS

253
00:09:36,720 --> 00:09:41,440
THROUGH PEER REVIEW AND SO THAT

254
00:09:41,440 --> 00:09:42,560
CAN BE ONE REASON.

255
00:09:42,560 --> 00:09:44,120
MY BRANCH NUMBERS ARE ACCURATE

256
00:09:44,120 --> 00:09:48,480
AND THE NCI PORTFOLIO NUMBERS

257
00:09:48,480 --> 00:09:51,600
AND UNDERESTIMATE THE TOTAL

258
00:09:51,600 --> 00:09:52,680
DORMANCY BECAUSE THE WAY THE

259
00:09:52,680 --> 00:09:55,560
SEARCH WAS DONE REQUIRING BOTH

260
00:09:55,560 --> 00:09:56,920
METASTASIS AND DETERMINE ANTSY

261
00:09:56,920 --> 00:09:59,320
TERMS AND SOME FOCUS ON

262
00:09:59,320 --> 00:10:00,520
REACTIVATION RATHER THAN

263
00:10:00,520 --> 00:10:01,520
DORMANCY AND OTHERS EXPLORE IN

264
00:10:01,520 --> 00:10:04,280
THE CONTEXT OF THE PRIMARY TUMOR

265
00:10:04,280 --> 00:10:06,280
OR RESPONSE TO THERAPY AND

266
00:10:06,280 --> 00:10:08,760
WITHOUT NECESSARILY CONSIDERING

267
00:10:08,760 --> 00:10:09,560
METASTASIS.

268
00:10:09,560 --> 00:10:10,880
REGARDLESS, I THINK EVEN

269
00:10:10,880 --> 00:10:14,520
CONSIDERING SUCH GRANTS THE SIZE

270
00:10:14,520 --> 00:10:16,240
OF THE PORTFOLIO IS NOT

271
00:10:16,240 --> 00:10:18,040
DRAMATICALLY AND I BELIEVE THAT

272
00:10:18,040 --> 00:10:20,240
THIS REFLECTS THE OVER ALL SMALL

273
00:10:20,240 --> 00:10:23,040
SIZE OF THE DORMANCY COMMUNITY.

274
00:10:23,040 --> 00:10:25,320
THE OTHER ASPECT IS THE SYSTEMS

275
00:10:25,320 --> 00:10:28,840
APPROACHES AND WITHIN THE TM

276
00:10:28,840 --> 00:10:29,800
PORTFOLIO, THIS IS STUDIES THAT

277
00:10:29,800 --> 00:10:31,960
LOOK AT SYSTEMIC EFFECTS OF

278
00:10:31,960 --> 00:10:36,160
CANCER AND FOUR TO FIVE% FIVE PT

279
00:10:36,160 --> 00:10:36,960
OF THE AWARDS.

280
00:10:36,960 --> 00:10:40,000
THE TERMS OF SYSTEMS BIOLOGY

281
00:10:40,000 --> 00:10:42,440
IDENTIFIED SIX AWARDS AND THOSE

282
00:10:42,440 --> 00:10:43,840
MOST WERE ASSOCIATED WITH THE

283
00:10:43,840 --> 00:10:48,000
CANCER SYSTEMS BIOLOGY

284
00:10:48,000 --> 00:10:48,440
CONSORTIUM.

285
00:10:48,440 --> 00:10:50,080
SO WE'RE PROPOSING THE

286
00:10:50,080 --> 00:10:52,040
APPLICATIONS AT THE FOLLOWING

287
00:10:52,040 --> 00:10:52,640
REQUIREMENTS.

288
00:10:52,640 --> 00:10:54,440
THEY MUST APPLY SYSTEMS LEVEL

289
00:10:54,440 --> 00:10:56,560
APPROACHES TO ADDRESS ONE OF THE

290
00:10:56,560 --> 00:11:00,280
ORIGINAL METNET FOA THEMES

291
00:11:00,280 --> 00:11:01,400
ENSURING INTEGRATION TO THE

292
00:11:01,400 --> 00:11:03,760
CURRENT METNET CENTERS AND THE

293
00:11:03,760 --> 00:11:05,280
APPLICANTS MUST DESIGNATE A

294
00:11:05,280 --> 00:11:06,720
RESOURCE AND DATA SHARING

295
00:11:06,720 --> 00:11:08,360
MANAGER AND AN ADMINISTRATIVE

296
00:11:08,360 --> 00:11:11,760
MANAGER TO FACILITATE SHARING OF

297
00:11:11,760 --> 00:11:13,280
RESOURCES AND DATA AND GENERAL

298
00:11:13,280 --> 00:11:16,160
COMMUNITY INDICATIONS

299
00:11:16,160 --> 00:11:16,520
RESPECTIVELY.

300
00:11:16,520 --> 00:11:17,960
THE RESOURCE AND DATA SHARING

301
00:11:17,960 --> 00:11:19,720
MANAGER WILL BE CRITICAL AS THE

302
00:11:19,720 --> 00:11:21,960
NEW POLICY ON DATA SHARING GOES

303
00:11:21,960 --> 00:11:23,600
INTO EFFECT NEXT YEAR AND WE

304
00:11:23,600 --> 00:11:24,760
WOULD ALSO ASK THE APPLICANTS

305
00:11:24,760 --> 00:11:28,160
HAVE A SMALL SET ASIDE FOR PILOT

306
00:11:28,160 --> 00:11:29,800
PROJECTS AND AT LEAST 25,000 IN

307
00:11:29,800 --> 00:11:33,480
OUT YEARS TO FACILITATE THE

308
00:11:33,480 --> 00:11:34,560
INTRANET WORK COLLABORATIONS.

309
00:11:34,560 --> 00:11:36,640
AT THE RECOMMENDATION OF THE BSA

310
00:11:36,640 --> 00:11:37,800
SUBCOMMITTEE WE WILL PLACE

311
00:11:37,800 --> 00:11:39,480
EMPHASIS ON UNDERSTANDING

312
00:11:39,480 --> 00:11:41,880
MECHANISMS OF METASTASIS ACROSS

313
00:11:41,880 --> 00:11:47,840
DIVERSE PATIENT POPULATIONS.

314
00:11:47,840 --> 00:11:49,360
SO THERE ARE BENEFITS TO USING

315
00:11:49,360 --> 00:11:50,520
THE CO-OPERATIVE AGREEMENT.

316
00:11:50,520 --> 00:11:52,600
IT WOULD HELP ALIGN THE RESEARCH

317
00:11:52,600 --> 00:11:53,600
PROJECTS AND INVESTIGATORS WITH

318
00:11:53,600 --> 00:11:55,480
THE RESPONSIBILITIES AND CONDUCT

319
00:11:55,480 --> 00:11:56,840
GUIDELINES THAT WE'VE ALREADY

320
00:11:56,840 --> 00:11:59,040
OUTLINED AND SET FOR THE U54

321
00:11:59,040 --> 00:12:00,720
CENTERS SO WE WOULD BE CREATING

322
00:12:00,720 --> 00:12:02,480
A LEVEL PLAYING FIELD.

323
00:12:02,480 --> 00:12:04,240
AND A CO-OPERATIVE AGREEMENT

324
00:12:04,240 --> 00:12:06,080
WILL PERMIT ENFORCING AS MUCH AS

325
00:12:06,080 --> 00:12:09,040
WE CAN, AND THE PARTICIPATION

326
00:12:09,040 --> 00:12:09,640
REQUIREMENTS IN THE STEERING

327
00:12:09,640 --> 00:12:10,680
COMMITTEE AND THE RESOURCE AND

328
00:12:10,680 --> 00:12:12,600
DATA SHARING WORKING GROUPS AND

329
00:12:12,600 --> 00:12:14,560
THE CO-OPERATIVE AGREEMENTS

330
00:12:14,560 --> 00:12:17,040
WHICH REQUIRE SUBSTANTIVE

331
00:12:17,040 --> 00:12:19,360
PROGRAM INVOLVEMENT HELPING IN

332
00:12:19,360 --> 00:12:21,360
FACILITATING SOME INTRANET WORK

333
00:12:21,360 --> 00:12:22,560
COLLABORATION AND COMMUNICATION

334
00:12:22,560 --> 00:12:26,600
AND FACILITATING EXCESS TO OTHER

335
00:12:26,600 --> 00:12:30,400
RESOURCE AND PROGRAMS AND HELP

336
00:12:30,400 --> 00:12:34,880
WITH COMMUNICATION FOR THE INTRA

337
00:12:34,880 --> 00:12:35,520
DISCIPLINARY TEAMS.

338
00:12:35,520 --> 00:12:37,800
WE PROPOSED THAT THIS CONCEPT

339
00:12:37,800 --> 00:12:40,160
STOBBE ISSUED AS A PAK FOR

340
00:12:40,160 --> 00:12:41,880
APPLICATIONS AND WE DON'T

341
00:12:41,880 --> 00:12:44,600
REQUEST ANY SET ASIDE THESE

342
00:12:44,600 --> 00:12:48,320
APPLICATIONS WILL BE INTER DIS

343
00:12:48,320 --> 00:12:49,680
MINNAAR' REQUIRE A REVIEW LOCUS

344
00:12:49,680 --> 00:12:50,840
WE WOULD LIKE TWO RECEIPT DAYS

345
00:12:50,840 --> 00:12:53,760
FOR THREE YEARS AND WE WOULD

346
00:12:53,760 --> 00:12:54,840
ANTICIPATE TWO TO THREE

347
00:12:54,840 --> 00:12:56,160
APPLICATIONS SELECTED FOR

348
00:12:56,160 --> 00:12:57,840
FUNDING CONSIDERATION EACH ROUND

349
00:12:57,840 --> 00:13:00,560
AND THIS WOULD BE BASED ON

350
00:13:00,560 --> 00:13:01,720
PRIORITIES AND THAT ARE GOING TO

351
00:13:01,720 --> 00:13:05,800
FIT WITHIN THE MET NET AND

352
00:13:05,800 --> 00:13:06,960
AVAILABLE FUNDING AND IMPACT

353
00:13:06,960 --> 00:13:11,720
SCORE AND THE SUBCOMMITTEE

354
00:13:11,720 --> 00:13:12,680
ACQUIRED BUDGETS WHICH WOULD BE

355
00:13:12,680 --> 00:13:15,480
FROM THE RANGE OF A LARGE RO1

356
00:13:15,480 --> 00:13:19,320
BUT KEPT AT A REQUEST OF

357
00:13:19,320 --> 00:13:20,720
$500,000 PER YEAR IN DIRECT

358
00:13:20,720 --> 00:13:22,920
COSTS, NEXT SLIDE.

359
00:13:22,920 --> 00:13:25,560
THIS IS MY FINE A SLIDE JUST TO

360
00:13:25,560 --> 00:13:26,960
OUTLINE THE GOAL OF THE CONCEPT

361
00:13:26,960 --> 00:13:30,400
WHICH IS TO ADD UR1 RESEARCH

362
00:13:30,400 --> 00:13:38,600
PROJECTS AND SYSTEMS LEVEL THE

363
00:13:38,600 --> 00:13:39,680
RESEARCH NETWORK SO THANK YOU

364
00:13:39,680 --> 00:13:41,240
FOR YOUR ATTENTION AND I'M VERY

365
00:13:41,240 --> 00:13:51,720
HAPPY TO TAKE ANY QUESTIONS.

366
00:14:01,960 --> 00:14:04,680
>> SO, THANK YOU Dr.
WATSON

367
00:14:04,680 --> 00:14:06,600
AND YOUR TEAM FOR GREAT

368
00:14:06,600 --> 00:14:09,040
PRESENTATION AND ALSO FOR BEING

369
00:14:09,040 --> 00:14:10,680
SO RESPONSIVE TO THAT COMMENTS

370
00:14:10,680 --> 00:14:15,280
AND QUERY.

371
00:14:15,280 --> 00:14:17,160
AS WAS NOTED, THE SUBCOMMITTEE

372
00:14:17,160 --> 00:14:19,080
MEMBERS MET WITH Dr. WATSON

373
00:14:19,080 --> 00:14:20,800
AND HER COLLEAGUES IN TWO

374
00:14:20,800 --> 00:14:26,240
PARALLEL MEETINGS TO DISCUSS THE

375
00:14:26,240 --> 00:14:27,720
METASTASIS PROPOSAL THAT WAS

376
00:14:27,720 --> 00:14:32,320
NICELY PRESENTED AND AS WE HEARD

377
00:14:32,320 --> 00:14:34,080
THIS PROPOSAL SPECIFICS PANS OF

378
00:14:34,080 --> 00:14:37,880
A EXITING METNET FRAMEWORK WITH

379
00:14:37,880 --> 00:14:40,600
THE GOAL OF REALLY CREATING A

380
00:14:40,600 --> 00:14:42,200
MORE COMPREHENSIVE PICTURE OF

381
00:14:42,200 --> 00:14:47,960
DISEASE USING A BIOLOGY APPROACH

382
00:14:47,960 --> 00:14:50,040
AND I WOULD SAY THE SUBCOMMITTEE

383
00:14:50,040 --> 00:14:51,560
WAS UNANIMOUS AND IT'S VERY

384
00:14:51,560 --> 00:14:56,000
STRONG SUPPORT FOR IT PROPOSAL,

385
00:14:56,000 --> 00:14:58,320
WE WILL ACKNOWLEDGE THAT THE

386
00:14:58,320 --> 00:15:00,600
METNET PROGRAM IS NEW AND IT'S

387
00:15:00,600 --> 00:15:03,600
NOT POSSIBLE TO HAVE A SORT OF

388
00:15:03,600 --> 00:15:05,240
COMPREHENSIVE EVALUATION OF THE

389
00:15:05,240 --> 00:15:07,080
PROGRAM TO DATE AND THIS MIGHT

390
00:15:07,080 --> 00:15:09,320
BE SOMETHING THAT OTHERS IN THIS

391
00:15:09,320 --> 00:15:11,200
GROUP MIGHT QUESTION BUT

392
00:15:11,200 --> 00:15:12,200
NEVERTHELESS, THE SUBCOMMITTEE

393
00:15:12,200 --> 00:15:15,120
IDENTIFIED A NUMBER OF REASONS

394
00:15:15,120 --> 00:15:16,600
FOR STRONG SUPPORT FOR THE

395
00:15:16,600 --> 00:15:19,040
PROPOSAL AND OF COURSE, STARTING

396
00:15:19,040 --> 00:15:22,080
WITH THE FACT THERE'S A STRONG

397
00:15:22,080 --> 00:15:24,280
SCIENTIFIC RATIONALE TO EXPAND

398
00:15:24,280 --> 00:15:26,480
WORK IN THIS AREA GIVEN THE

399
00:15:26,480 --> 00:15:28,520
METASTATIC DISEASE IN POOR

400
00:15:28,520 --> 00:15:30,440
TENDING, POOR PATIENT OUTCOMES

401
00:15:30,440 --> 00:15:32,880
AND I THINK WE ALSO REALLY

402
00:15:32,880 --> 00:15:37,960
APPRECIATED THAT THERE'S A

403
00:15:37,960 --> 00:15:39,960
STRONG INTEREST IN THIS AREA.

404
00:15:39,960 --> 00:15:42,280
WE WERE INSTRUCT BY THE FACT THE

405
00:15:42,280 --> 00:15:45,000
INITIAL METNET ISSUED IN MAY OF

406
00:15:45,000 --> 00:15:48,920
2020 RESULTED IN 39U54

407
00:15:48,920 --> 00:15:50,040
APPLICATIONS OVER TWO RECEIPT

408
00:15:50,040 --> 00:15:51,440
DATES WITH FOUR OF THOSE

409
00:15:51,440 --> 00:15:52,560
ACTUALLY BEING FUND SOD THERE

410
00:15:52,560 --> 00:15:56,200
ARE A LOT OF REALLY STRONG

411
00:15:56,200 --> 00:15:58,600
PROJECTS AND PENT UP DEMAND FOR

412
00:15:58,600 --> 00:16:02,080
RESEARCH FUNDING IN THIS AREA.

413
00:16:02,080 --> 00:16:04,520
WE ALSO APPRECIATED, AS WAS

414
00:16:04,520 --> 00:16:06,040
HIGHLIGHTED BY Dr. WATSON,

415
00:16:06,040 --> 00:16:10,000
THAT MANY OF THE AREAS IN THE

416
00:16:10,000 --> 00:16:12,360
INITIAL CALL FOR APPLICATIONS

417
00:16:12,360 --> 00:16:16,400
DID GET REPRESENTED IN THE CORE

418
00:16:16,400 --> 00:16:19,080
U54s THAT HAVE BEEN FUNDED BUT

419
00:16:19,080 --> 00:16:20,280
DORMANCY WAS UNDER REPRESENTED

420
00:16:20,280 --> 00:16:22,320
AND REMAINS IN THE PORTFOLIO

421
00:16:22,320 --> 00:16:24,400
ANALYSIS AN AREA THAT IS UNDER

422
00:16:24,400 --> 00:16:25,240
REPRESENTED AND I THINK Dr.

423
00:16:25,240 --> 00:16:31,360
WATSON DID A REALLY NICE JOB OF

424
00:16:31,360 --> 00:16:32,440
ARTICULATING WHY IT'S A

425
00:16:32,440 --> 00:16:33,720
IMPORTANT AREA FOR FURTHER

426
00:16:33,720 --> 00:16:36,080
RESEARCH AND ALSO ARTICULATING

427
00:16:36,080 --> 00:16:42,600
SOME CONFIDENCE THEY ARE ARE

428
00:16:42,600 --> 00:16:44,880
PROJECTS AND WE HEAD IT FROM THE

429
00:16:44,880 --> 00:16:45,920
BSA SUBCOMMITTEE.

430
00:16:45,920 --> 00:16:47,360
WE HAD A ROBUST DISCUSSION AND

431
00:16:47,360 --> 00:16:49,960
WE REALIZED A FEW QUESTIONS AND

432
00:16:49,960 --> 00:16:52,400
MADE SOME MINOR SUGGESTIONS FOR

433
00:16:52,400 --> 00:16:53,600
IMPROVEMENT ALL OF WHICH HAVE

434
00:16:53,600 --> 00:16:59,520
BEEN FULLY ADDRESSED AS WAS

435
00:16:59,520 --> 00:17:03,440
OUTLINED IN THE REPORT.

436
00:17:03,440 --> 00:17:05,720
WE ALSO REQUESTED A COUPLE OF

437
00:17:05,720 --> 00:17:07,240
CHANGES THAT WERE ADOPTED IN THE

438
00:17:07,240 --> 00:17:10,520
CURRENT PROPOSAL INCLUDING A

439
00:17:10,520 --> 00:17:12,880
REQUEST TO EXPAND THE COAST OF

440
00:17:12,880 --> 00:17:14,440
EMPHASIS FOR CANCER THAT'S HAVE

441
00:17:14,440 --> 00:17:16,040
RISING MORTALITY RATES AND IT'S

442
00:17:16,040 --> 00:17:18,480
BEEN INCORPORATED TO ENCOURAGE

443
00:17:18,480 --> 00:17:19,560
APPLICATIONS AND AREAS THAT HAVE

444
00:17:19,560 --> 00:17:21,600
BEEN DIFFICULT TO TREAT SUCH AS

445
00:17:21,600 --> 00:17:23,800
METASTASIS TO BONE AND IT'S BEEN

446
00:17:23,800 --> 00:17:25,320
INCORPORATED TO ENCOURAGE THE

447
00:17:25,320 --> 00:17:27,200
STUDY OF DIVERSE POPULATIONS AND

448
00:17:27,200 --> 00:17:29,160
ENCOURAGE APPLICATIONS FROM JUNE

449
00:17:29,160 --> 00:17:31,040
INVESTIGATORS ALL OF WHICH HAVE

450
00:17:31,040 --> 00:17:33,360
BEEN NOW HIGHLIGHTED IN THE

451
00:17:33,360 --> 00:17:35,880
UPDATED PROPOSAL.

452
00:17:35,880 --> 00:17:37,520
SO, WITH THAT I'LL JUST SAY

453
00:17:37,520 --> 00:17:39,400
VERY, VERY STRONG SUPPORT FROM

454
00:17:39,400 --> 00:17:44,800
THE SUBCOMMITTEE AND SEE IF

455
00:17:44,800 --> 00:17:46,400
Dr. WANTS TO MAKE ANY

456
00:17:46,400 --> 00:17:47,000
ADDITIONAL COMMENTS.

457
00:17:47,000 --> 00:17:48,520
>> THANK YOU, SO, I HAVE
VERY

458
00:17:48,520 --> 00:17:49,120
LITTLE TO ADD.

459
00:17:49,120 --> 00:17:50,560
I THINK THE ONE THING I'D LIKE

460
00:17:50,560 --> 00:17:54,360
TO EMPHASIS IS JUST THAT DURING

461
00:17:54,360 --> 00:17:56,440
THE INITIAL COMPETITION, THERE

462
00:17:56,440 --> 00:17:59,000
WERE SO MANY APPLICATIONS

463
00:17:59,000 --> 00:17:59,520
RECEIVED.

464
00:17:59,520 --> 00:18:01,880
I THINK THAT RALLY JUSTIFY THE

465
00:18:01,880 --> 00:18:04,680
NECESSITY TO EXPAND, LIKE

466
00:18:04,680 --> 00:18:06,360
ALWAYS, WE DON'T FUND ENOUGH AND

467
00:18:06,360 --> 00:18:08,040
THIS ONE WAS CLEARLY AN AREA

468
00:18:08,040 --> 00:18:14,200
GROWING A LOT OF CENTER AND IT

469
00:18:14,200 --> 00:18:15,280
WOULD BE GREAT TO GO BACK INTO

470
00:18:15,280 --> 00:18:16,680
THE POOL AND ADD TO WHAT IS

471
00:18:16,680 --> 00:18:17,560
GOING ON.

472
00:18:17,560 --> 00:18:18,760
VERY LITTLE TO ADD OTHER THAN I

473
00:18:18,760 --> 00:18:23,520
THINK GIVING IT MY FULL SUPPORT

474
00:18:23,520 --> 00:18:26,960
FOR THIS.

475
00:18:26,960 --> 00:18:35,200
>> ANY QUESTIONS OR
COMMENTS?

476
00:18:35,200 --> 00:18:37,280
>> I WANT TO CONGRATULATE
YOU ON

477
00:18:37,280 --> 00:18:41,320
A QUICKLY IMPORTANT AREA OF

478
00:18:41,320 --> 00:18:43,080
RESEARCH AND THE FACT YOU ARE

479
00:18:43,080 --> 00:18:44,840
MAKING THE AWARD WORTH IT TO

480
00:18:44,840 --> 00:18:46,920
APPLY FOR BECAUSE I'VE SEEN SOME

481
00:18:46,920 --> 00:18:48,640
OF THESE INITIATIVES WHERE YOU

482
00:18:48,640 --> 00:18:50,960
KNOW THEY WERE MAYBE LIKE 75K

483
00:18:50,960 --> 00:18:53,240
FOR THREE YEARS AND WHICH WAS

484
00:18:53,240 --> 00:18:54,920
NOT A LOT OF INCENTIVE FOR

485
00:18:54,920 --> 00:18:56,360
PEOPLE WHO ARE WORKING HARD IN

486
00:18:56,360 --> 00:18:57,960
THIS AREA SO CONGRATULATIONS ON

487
00:18:57,960 --> 00:18:58,760
ALL OF THAT.

488
00:18:58,760 --> 00:19:02,160
>> THANK YOU, VERY MUCH.

489
00:19:02,160 --> 00:19:11,840
>> YOUR HAND IS UP.

490
00:19:11,840 --> 00:19:22,080
STILL MUTED.

491
00:19:30,920 --> 00:19:32,760
>> I HAVE A QUESTION AND A

492
00:19:32,760 --> 00:19:32,960
COMMENT.

493
00:19:32,960 --> 00:19:36,360
I WAS JUST CURIOUS AS TO WHAT IS

494
00:19:36,360 --> 00:19:38,160
THE CORE WAS INTENDED TO DO AND

495
00:19:38,160 --> 00:19:41,520
A LOT OF THESE GET TAGGED ON FOR

496
00:19:41,520 --> 00:19:44,440
YOUR U01 MECHANISMS AND I'M

497
00:19:44,440 --> 00:19:45,760
CURIOUS ABOUT THAT AND ALSO THEY

498
00:19:45,760 --> 00:19:51,520
TALKED ABOUT THE DIVERSE AND AND

499
00:19:51,520 --> 00:19:52,600
IT WILL BE INTERESTING TO HAVE A

500
00:19:52,600 --> 00:19:53,880
CONVERSATION OR SO BUT TO

501
00:19:53,880 --> 00:19:55,960
UNDERSTAND WHAT IT ACTUALLY

502
00:19:55,960 --> 00:19:56,560
MEANS.

503
00:19:56,560 --> 00:19:57,880
AGAIN, THESE THINGS GET TAGGED

504
00:19:57,880 --> 00:20:00,600
ON AND IT IS A VISION ON OUT

505
00:20:00,600 --> 00:20:02,440
COME THAT IS DESIGNED TO BE

506
00:20:02,440 --> 00:20:04,360
ACCOMPLISHED AS PART OF THESE

507
00:20:04,360 --> 00:20:06,120
APPLICATIONS SO I'M JUST CURIOUS

508
00:20:06,120 --> 00:20:08,720
ABOUT THOSE.

509
00:20:08,720 --> 00:20:10,960
>> I'M SORRY, I MISSED THE
FIRST

510
00:20:10,960 --> 00:20:13,080
PART OF YOUR QUESTION IN TERMS

511
00:20:13,080 --> 00:20:14,680
OF THE ADMINISTRATIVE CORE OR

512
00:20:14,680 --> 00:20:17,440
THE RESOURCE?

513
00:20:17,440 --> 00:20:20,400
>> I'M NOT SURE IF MY
WORDS ARE

514
00:20:20,400 --> 00:20:22,600
COMING THROUGH DIRECTLY.

515
00:20:22,600 --> 00:20:24,600
WHAT DIVERSE COMPONENTS OF THE

516
00:20:24,600 --> 00:20:28,800
APPLICATION IS SUPPOSED TO BE

517
00:20:28,800 --> 00:20:29,120
ACCOMPLISHING.

518
00:20:29,120 --> 00:20:32,840
>> SO, FOR THE U01 THERE
WOULD

519
00:20:32,840 --> 00:20:35,720
BE A DESIGNATED RESOURCE AND

520
00:20:35,720 --> 00:20:37,760
DATA SHARING MANAGER AND IT'S

521
00:20:37,760 --> 00:20:39,560
BECAUSE CURRENTLY, WE DO NOT

522
00:20:39,560 --> 00:20:41,760
HAVE A COORDINATING CENTER THAT

523
00:20:41,760 --> 00:20:43,000
COORDINATES ALL OF THESE THINGS

524
00:20:43,000 --> 00:20:45,800
AND SO BY HAVING A VERY

525
00:20:45,800 --> 00:20:48,040
SPECIFIED PERSON WHO IS

526
00:20:48,040 --> 00:20:51,160
RESPONSIBLE, THAT ALLOWS THAT

527
00:20:51,160 --> 00:20:53,840
DISCUSSION THE SYNCHRONIZATION

528
00:20:53,840 --> 00:20:55,640
OF THE TYPES OF DATA, HOW IT'S

529
00:20:55,640 --> 00:20:57,240
GOING TO BE SHARED ACROSS THE

530
00:20:57,240 --> 00:20:57,800
NETWORK.

531
00:20:57,800 --> 00:21:01,000
SO THAT PROVIDES THAT.

532
00:21:01,000 --> 00:21:05,320
IN TERMS OF DIVERSE POPULATIONS,

533
00:21:05,320 --> 00:21:07,840
IT IS VERY MUCH A FUNCTION OF IF

534
00:21:07,840 --> 00:21:10,080
SOMEONE WAS GOING TO PROPOSE

535
00:21:10,080 --> 00:21:13,400
THEY WANTED TO LOOK AT

536
00:21:13,400 --> 00:21:15,160
METASTATIC PROSTATE CANCER THAT

537
00:21:15,160 --> 00:21:16,480
THE SAMPLES THEY'RE USING ARE

538
00:21:16,480 --> 00:21:19,240
GOING TO BE REPRESENTATIVE OF

539
00:21:19,240 --> 00:21:27,200
WHAT IS SEEN IN A CLINICAL

540
00:21:27,200 --> 00:21:28,720
PRACTICE.

541
00:21:28,720 --> 00:21:30,040
>> I DON'T SEE ANY OTHER
HANDS

542
00:21:30,040 --> 00:21:33,680
SO WE CAN MOVE TO VOTING.

543
00:21:33,680 --> 00:21:35,200
THE DISCUSSION DOES NOT SEEM TO

544
00:21:35,200 --> 00:21:37,080
BE HEADING IN THE DIRECTION

545
00:21:37,080 --> 00:21:38,480
WHERE DEFERRAL IS ON THE TABLE

546
00:21:38,480 --> 00:21:39,920
SO WE'RE GOING TO LOOK FOR

547
00:21:39,920 --> 00:21:43,160
APPROVAL OR DISAPPROVAL VOTES.

548
00:21:43,160 --> 00:21:44,920
WOULD YOU LIKE TO MAKE A MOTION.

549
00:21:44,920 --> 00:21:48,320
>> I MOVE TO APPROVE THIS

550
00:21:48,320 --> 00:21:48,600
PROPOSAL.

551
00:21:48,600 --> 00:21:50,160
>> CAN I HAVE A SECOND.

552
00:21:50,160 --> 00:21:51,160
>> SECOND.

553
00:21:51,160 --> 00:21:52,840
>> THANK YOU.

554
00:21:52,840 --> 00:21:58,440
ANY FURTHER DISCUSSION?

555
00:21:58,440 --> 00:22:01,240
>> JUST A SIDE BAR COMMENT
SINCE

556
00:22:01,240 --> 00:22:02,080
I SECONDED.

557
00:22:02,080 --> 00:22:07,880
THIS IS A AN EXTREME AN EXTREMED

558
00:22:07,880 --> 00:22:09,920
CRITICAL AND UNDERFUNDED IN THE

559
00:22:09,920 --> 00:22:15,720
NCI'S PORTFOLIO.

560
00:22:15,720 --> 00:22:19,560
>> NOTED.

561
00:22:19,560 --> 00:22:20,960
>> OK.

562
00:22:20,960 --> 00:22:22,760
WE'LL TAKE A FINAL VOTE NOW.

563
00:22:22,760 --> 00:22:25,600
LOOKING FOR DISAPPROVAL VOTES.

564
00:22:25,600 --> 00:22:27,600
THE MOTION IS FOR APPROVAL.

565
00:22:27,600 --> 00:22:28,800
EITHER VOICE YOUR DISAPPROVAL

566
00:22:28,800 --> 00:22:36,840
VOTE OR RAISE YOUR HAND.

567
00:22:36,840 --> 00:22:38,480
LOOKING ACROSS THREE SCREENS

568
00:22:38,480 --> 00:22:38,680
HERE.

569
00:22:38,680 --> 00:22:43,520
I DON'T SEE ANY.

570
00:22:43,520 --> 00:22:45,280
>> IT'S UNANIMOUS
APPROVAL.

571
00:22:45,280 --> 00:22:46,920
>> NO ABSTENTIONS?

572
00:22:46,920 --> 00:22:48,280
JUST MAKING SURE.

573
00:22:48,280 --> 00:22:51,000
I DON'T HAVE ANY PRE SUBMITTED.

574
00:22:51,000 --> 00:22:51,800
GREAT.

575
00:22:51,800 --> 00:22:53,440
OK.

576
00:22:53,440 --> 00:22:54,680
FANTASTIC.

577
00:22:54,680 --> 00:22:55,600
MOVING ALONG.

578
00:22:55,600 --> 00:22:59,600
THE NEXT IS NEW CONCEPT AND NEW

579
00:22:59,600 --> 00:23:01,600
RFA AND BASIC/TRANSLATIONAL

580
00:23:01,600 --> 00:23:03,400
RESEARCH ON HEALTH DISPARITIES

581
00:23:03,400 --> 00:23:06,440
ON HIV/AIDS AND CANCER.

582
00:23:06,440 --> 00:23:09,040
Dr. BETSY READ-CONNOLE IS

583
00:23:09,040 --> 00:23:10,760
PRESENTING AND THE SUBCOMMITTEES

584
00:23:10,760 --> 00:23:17,520
ARE Dr. QU --

585
00:23:17,520 --> 00:23:19,640
>> THANK YOU FOR LISTENING
TO

586
00:23:19,640 --> 00:23:21,640
OUR IDEAS FOR A NEW CONCEPT ON

587
00:23:21,640 --> 00:23:23,400
BASIC TRANSLATIONAL RESEARCH ON

588
00:23:23,400 --> 00:23:25,560
HEALTH DISPARITIES IN HIV/AIDS

589
00:23:25,560 --> 00:23:27,400
AND CANCER.

590
00:23:27,400 --> 00:23:33,400
WITH A CLINICAL TRIAL OPTION.

591
00:23:33,400 --> 00:23:36,160
I'M BETSY READ-CONNOLE AND I'M

592
00:23:36,160 --> 00:23:39,280
JOINED BY MY COLLEAGUES Dr.

593
00:23:39,280 --> 00:23:40,960
TIFFANY WALLACE FROM THE CENTER

594
00:23:40,960 --> 00:23:43,080
TO REDUCE CANCER HEALTH

595
00:23:43,080 --> 00:23:45,680
DISPARITIES AND MY COLLEAGUES

596
00:23:45,680 --> 00:23:54,640
FROM THE OFFICE OF HIV AND AIDS

597
00:23:54,640 --> 00:23:54,920
MALIGNANCY.

598
00:23:54,920 --> 00:24:03,760
NEXT SLIDE, PLEASE.

599
00:24:03,760 --> 00:24:06,000
FIRST, I WOULD LIKE TO THANK MY

600
00:24:06,000 --> 00:24:07,960
THREE BSA REVIEWS FOR THEIR

601
00:24:07,960 --> 00:24:09,080
HELPFUL AND THOUGHTFUL

602
00:24:09,080 --> 00:24:11,520
SUGGESTION AND I'VE TRIED TO

603
00:24:11,520 --> 00:24:12,320
EITHER INCORPORATE THEIR

604
00:24:12,320 --> 00:24:13,640
SUGGESTIONS INTO THE SLIDES OR

605
00:24:13,640 --> 00:24:14,960
THEY WILL BE VERBALLY EXPRESSED

606
00:24:14,960 --> 00:24:18,920
DURING THE ORAL PRESENTATION.

607
00:24:18,920 --> 00:24:21,560
IN THE WAY OF THE PURPOSE FOR

608
00:24:21,560 --> 00:24:24,520
THE RFA IS A FOCUS ON THE

609
00:24:24,520 --> 00:24:26,120
BIOLOGICAL INTERACTIONS OF

610
00:24:26,120 --> 00:24:27,800
CANCER HEALTH DISPARITIES IN

611
00:24:27,800 --> 00:24:30,480
LARGE POPULATIONS.

612
00:24:30,480 --> 00:24:33,680
WITH AN UNDERLINE HIV AIDS

613
00:24:33,680 --> 00:24:34,720
INFECTION.

614
00:24:34,720 --> 00:24:36,640
THROUGH BASIC MECHANISTIC

615
00:24:36,640 --> 00:24:37,560
TRANSLATIONAL STUD EYES TO

616
00:24:37,560 --> 00:24:38,840
INVESTIGATE HOW LIVE INTERACTS

617
00:24:38,840 --> 00:24:41,400
WITH THE DISPARITIES TO PROMOTE

618
00:24:41,400 --> 00:24:45,240
THE NON AIDS AND AIDS DEFINING

619
00:24:45,240 --> 00:24:46,200
CANCER INITIATION PROGRESSION

620
00:24:46,200 --> 00:24:52,200
AND THE RESULTING PATHOGENIC

621
00:24:52,200 --> 00:24:53,640
DISEASE SEE QUELL A.

622
00:24:53,640 --> 00:25:04,160
AS A WAY OF THE BACKGROUND, SUCH

623
00:25:07,560 --> 00:25:10,760
AS BLACK, AMERICAN, LATINX

624
00:25:10,760 --> 00:25:11,600
COMMUNITIES, WOMEN OF COLOR,

625
00:25:11,600 --> 00:25:13,520
PEOPLE WHO INJECT DRUGS, MEN WHO

626
00:25:13,520 --> 00:25:16,120
HAVE SEX WITH MEN AND

627
00:25:16,120 --> 00:25:17,320
TRANSGENDER PERSONS.

628
00:25:17,320 --> 00:25:19,240
AND PERSONS WITH CANCER AND NIH

629
00:25:19,240 --> 00:25:23,640
ARE AMPLIFIED IN CERTAIN RACIAL

630
00:25:23,640 --> 00:25:26,880
AND ETHNIC POPULATIONS, LOW

631
00:25:26,880 --> 00:25:28,080
SOCIOECONOMIC GROUPS, PEOPLE

632
00:25:28,080 --> 00:25:30,720
LIVING IN GEOGRAPHICALLY

633
00:25:30,720 --> 00:25:32,160
ISOLATED AREAS AND PEOPLE WITH

634
00:25:32,160 --> 00:25:34,480
LIMITED ACCESS TO PROVEN

635
00:25:34,480 --> 00:25:35,920
SCREENING AND TEST AND HIGHER

636
00:25:35,920 --> 00:25:39,400
RATES OF ADVANCED CANCER

637
00:25:39,400 --> 00:25:39,760
DIAGNOSIS.

638
00:25:39,760 --> 00:25:42,680
THESE ARE PARTIALLY DRIVEN BY

639
00:25:42,680 --> 00:25:46,760
HEALTHCARE PROVIDERS, SHORTAGES,

640
00:25:46,760 --> 00:25:54,160
LOW HEALTH LIT ARE  ER LITERACY.

641
00:25:54,160 --> 00:25:56,240
THE MOST PREVALENT IN THE U.S.

642
00:25:56,240 --> 00:25:57,280
POPULATION AMONG PERSONS LIVING

643
00:25:57,280 --> 00:26:01,480
WITH HIV ARE NON HODGKINS LIMB

644
00:26:01,480 --> 00:26:03,840
NOAM A, ANNAL AND LUNG CANCER

645
00:26:03,840 --> 00:26:06,120
AND THE IDEA FOR THIS RFA ON

646
00:26:06,120 --> 00:26:09,080
HEALTH DISPARITIES HIV AND

647
00:26:09,080 --> 00:26:12,120
CANCER, WAS ENDORSED BY THE

648
00:26:12,120 --> 00:26:15,960
HIV/AIDS MALIGNANCY BSA AD HOC

649
00:26:15,960 --> 00:26:19,200
SUBCOMMITTEE AND I WOULD ALSO

650
00:26:19,200 --> 00:26:22,360
MENTION THAT IN DECEMBER OF

651
00:26:22,360 --> 00:26:25,040
2019, THE CANCER TO -- THE

652
00:26:25,040 --> 00:26:26,920
CENTER TO REDUCE CANCER HEALTH

653
00:26:26,920 --> 00:26:28,640
DISPARITIES HELD A NICE WORKSHOP

654
00:26:28,640 --> 00:26:31,600
ON HEALTH DISPARITIES AND CANCER

655
00:26:31,600 --> 00:26:33,040
AND I WAS QUITE STRUCK BY THE

656
00:26:33,040 --> 00:26:35,840
FACT THERE WAS NO INCLUDED HIV

657
00:26:35,840 --> 00:26:39,240
AND CANCER RESEARCH IN THEIR

658
00:26:39,240 --> 00:26:43,200
PRESENTATIONS AND SO I

659
00:26:43,200 --> 00:26:47,000
APPROACHED Dr. SPRINGFIELD AND

660
00:26:47,000 --> 00:26:47,960
HER PROGRAM PAPAL AND SAID YOU

661
00:26:47,960 --> 00:26:49,760
KNOW I THINK WE SHOULD DO

662
00:26:49,760 --> 00:26:51,600
SOMETHING ABOUT THIS TO MAYBE

663
00:26:51,600 --> 00:26:53,720
JUMP START THE FIELD A LITTLE

664
00:26:53,720 --> 00:26:56,200
BIT BECAUSE WE KNOW THIS IS A

665
00:26:56,200 --> 00:26:56,800
DRASTIC NEED.

666
00:26:56,800 --> 00:27:01,040
AND IN THE WAY OF -- NEXT SLIDE

667
00:27:01,040 --> 00:27:01,720
PLEASE.

668
00:27:01,720 --> 00:27:04,040
LOOKING AT POTENTIAL BIOLOGICAL

669
00:27:04,040 --> 00:27:06,000
DIFFERENCES IN DISEASES WITHOUT

670
00:27:06,000 --> 00:27:11,360
AN UNDERLYING HIV INFECTION, IN

671
00:27:11,360 --> 00:27:15,480
A REPORT ANALYZING SIGH TOLL GEE

672
00:27:15,480 --> 00:27:17,640
CASES, FILES FOR AFRICAN

673
00:27:17,640 --> 00:27:27,600
AMERICAN AND CAUCASIAN WOMEN, TY

674
00:27:27,600 --> 00:27:29,040
WERE FOUND IN AFRICAN AMERICAN

675
00:27:29,040 --> 00:27:32,960
WOMEN COMPARED TO CAUCASIAN

676
00:27:32,960 --> 00:27:33,360
WOMEN.

677
00:27:33,360 --> 00:27:34,680
AND ANOTHER LARGE STUDY LOOKED

678
00:27:34,680 --> 00:27:37,800
AT THE IMMUNE PROFILES OF

679
00:27:37,800 --> 00:27:39,480
EUROPEANS AND AFRICANS IN

680
00:27:39,480 --> 00:27:42,800
RESPONSE TO BACTERIAL AND VIRAL

681
00:27:42,800 --> 00:27:44,640
INFLUENZA INFECTIONS.

682
00:27:44,640 --> 00:27:46,080
AND STRONG DIFFERENCES WERE

683
00:27:46,080 --> 00:27:49,480
FOUND THAT PREDOMINANTLY

684
00:27:49,480 --> 00:27:53,160
INFECTED THE ANTI VIRAL AND

685
00:27:53,160 --> 00:27:55,000
INFLAMMATION GENES AND DIFFER IN

686
00:27:55,000 --> 00:27:56,120
RESPONSIVENESS BETWEEN AFRICANS

687
00:27:56,120 --> 00:27:58,400
AND EUROPEANS.

688
00:27:58,400 --> 00:28:04,040
AND IN THE NEXT SLIDE, I SHOW A

689
00:28:04,040 --> 00:28:07,320
STUDY RELATED TO THE FORM OF

690
00:28:07,320 --> 00:28:12,360
CANCER AMONG THE HIV POSITIVE

691
00:28:12,360 --> 00:28:17,760
POPULATION WHICH IS KAPOSI

692
00:28:17,760 --> 00:28:19,800
SARCOMA AND THIS IS THE HAZARD

693
00:28:19,800 --> 00:28:23,520
RATIO FOR AFRICAN AMERICANS IS

694
00:28:23,520 --> 00:28:24,680
STATISTICALLY SIGNIFICANTLY

695
00:28:24,680 --> 00:28:29,880
INCREASING ABOVE THAT OF WHITE

696
00:28:29,880 --> 00:28:31,800
OR CAUCASIAN AMERICANS AND ALL

697
00:28:31,800 --> 00:28:32,000
OTHERS.

698
00:28:32,000 --> 00:28:33,880
WHEN YOU LOOK AT THE RIGHT-HAND

699
00:28:33,880 --> 00:28:42,240
PANEL YOU SEE THE SURVIVAL RATE

700
00:28:42,240 --> 00:28:44,600
IS MUCH PEER ARE FOR THOSE

701
00:28:44,600 --> 00:28:47,120
LIVING IN THE SOUTH COMPARED TO

702
00:28:47,120 --> 00:28:48,640
THE DASH LINE SLIGHTLY ABOVE

703
00:28:48,640 --> 00:28:48,880
THAT.

704
00:28:48,880 --> 00:28:51,520
SEEING THESE BIOLOGICAL

705
00:28:51,520 --> 00:28:52,840
DIFFERENCES, WHAT ARE WAYS THAT

706
00:28:52,840 --> 00:28:55,360
WE CAN ACTUALLY ADDRESS THIS?

707
00:28:55,360 --> 00:29:00,440
SO, WE TURNED TO A PORTFOLIO

708
00:29:00,440 --> 00:29:07,200
ANALYSIS SHOWN ON THE NEXT

709
00:29:07,200 --> 00:29:09,240
SLIDE.

710
00:29:09,240 --> 00:29:11,960
BETWEEN FY2018 AND 2022 LOOKING

711
00:29:11,960 --> 00:29:14,800
FOR HEALTH DISPARITIES, HIV, AND

712
00:29:14,800 --> 00:29:17,320
CANCER, WE FOUND A TOTAL OF SIX

713
00:29:17,320 --> 00:29:19,800
GRANTS IN THE NCI PORTFOLIO.

714
00:29:19,800 --> 00:29:23,440
AND I MAY ALSO POINT OUT THAT

715
00:29:23,440 --> 00:29:25,040
THESE WERE -- FOUR OF THESE

716
00:29:25,040 --> 00:29:29,440
GRANTS WERE IN RESPONSE TO

717
00:29:29,440 --> 00:29:32,240
RFAs AND THAT NCI HAD PUT

718
00:29:32,240 --> 00:29:36,240
FORWARD AND TWO ADDITIONAL ONES

719
00:29:36,240 --> 00:29:36,960
PUT FORWARD.

720
00:29:36,960 --> 00:29:40,000
IF WE LOOK AT THE OTHER

721
00:29:40,000 --> 00:29:43,400
INSTITUTES WITHIN THE NIH, THERE

722
00:29:43,400 --> 00:29:47,960
ARE PROJECTS FUNDED BY NIAID AND

723
00:29:47,960 --> 00:29:53,440
WEST INRELATED TONING THE HIV EC

724
00:29:53,440 --> 00:29:54,920
AND THEY HAVE HEALTH DISPARITIES

725
00:29:54,920 --> 00:29:57,280
IN NIH RESEARCH BUT NOTHING

726
00:29:57,280 --> 00:30:02,160
RELATED TO CANCER.

727
00:30:02,160 --> 00:30:07,040
AS A RESULT OF THIS PORTFOLIO

728
00:30:07,040 --> 00:30:09,400
ANALYSIS, AND PUTTING OUR HEADS

729
00:30:09,400 --> 00:30:10,720
TOGETHER, WE CAME WITH

730
00:30:10,720 --> 00:30:12,080
SUGGESTIONS OF THE FOLLOWING

731
00:30:12,080 --> 00:30:19,520
RESEARCH TOPIC AREAS.

732
00:30:19,520 --> 00:30:22,840
THESE ARE NOT INCLUSIVE BUT OUR

733
00:30:22,840 --> 00:30:24,360
SUGGESTIONS AND THE SUDDEN HE'S

734
00:30:24,360 --> 00:30:34,200
OF HOW WE INTERACT AND GENETIC

735
00:30:34,200 --> 00:30:37,960
DEPOSIT' GENETIC CANCER

736
00:30:37,960 --> 00:30:38,480
SUSCEPTIBLE DIFFERENCE AND

737
00:30:38,480 --> 00:30:41,880
RESPONSES TO CANCER AND THE

738
00:30:41,880 --> 00:30:44,040
MICRO ENVIRONMENT OR TUMOR AND

739
00:30:44,040 --> 00:30:47,000
MICRO AND ANALYSIS AND AS WELL

740
00:30:47,000 --> 00:30:49,800
AS STUDIES THAT INVESTIGATE THE

741
00:30:49,800 --> 00:30:55,440
ROLE OF CO INFECTIONS AND KAPOSI

742
00:30:55,440 --> 00:30:57,320
SARCOMA AND HEPATITIS B AND

743
00:30:57,320 --> 00:31:00,600
HEPATITIS C VIRUSES AND CON

744
00:31:00,600 --> 00:31:02,800
CANCER AND OUTCOMES IN

745
00:31:02,800 --> 00:31:04,960
MARGINALIZED POPULATIONS AND

746
00:31:04,960 --> 00:31:07,000
THAT HAVE THE HEALTH DISPARITIES

747
00:31:07,000 --> 00:31:08,520
AND ARE SEVERELY AND DIS POURS

748
00:31:08,520 --> 00:31:11,520
ATLY EFFECTED BY HIV.

749
00:31:11,520 --> 00:31:16,880
I WOULD ALSO MAKE A NOTE WITHIN

750
00:31:16,880 --> 00:31:18,840
MY DISCUSSIONS WITH THE BSA

751
00:31:18,840 --> 00:31:22,600
REVIEWERS THEY THOUGHT THIS WAS

752
00:31:22,600 --> 00:31:26,240
QUITE -- THIS WAS A INDICT BROAD

753
00:31:26,240 --> 00:31:28,160
AND I EXPLAINED TO THEM THAT

754
00:31:28,160 --> 00:31:34,600
UNFORTUNATELY THE HIV AND CANCER

755
00:31:34,600 --> 00:31:35,880
NUMBER OF INVESTIGATORS IS NOT

756
00:31:35,880 --> 00:31:37,920
THAT LARGE AND IF WE WIDDLE

757
00:31:37,920 --> 00:31:42,440
THINGS DOWN AND WE ARE NOT GOING

758
00:31:42,440 --> 00:31:43,480
TO RECEIVE SUFFICIENT

759
00:31:43,480 --> 00:31:46,200
APPLICATIONS IN RESPONSE TO OUR

760
00:31:46,200 --> 00:31:46,360
RFA.

761
00:31:46,360 --> 00:31:51,160
I WOULD ALSO MAKE A NOTE THAT

762
00:31:51,160 --> 00:31:52,200
SOCIAL DETERMINANTS OF HEALTH

763
00:31:52,200 --> 00:31:54,080
ARE NOT PART OF THIS SPECIFIC

764
00:31:54,080 --> 00:31:56,600
INITIATIVE AND THEY WILL BE

765
00:31:56,600 --> 00:31:58,440
VIEWED AS OUT OF SCOPE AND THAT

766
00:31:58,440 --> 00:32:01,440
ACCEPTED FOR REVIEW AND THAT

767
00:32:01,440 --> 00:32:05,480
SOCIAL DETERMINANTS OF HEALTH

768
00:32:05,480 --> 00:32:06,880
WILL YOU COVERED IN A CONCEPT

769
00:32:06,880 --> 00:32:14,360
THAT IS BEING DEVELOPED BY CRCHD

770
00:32:14,360 --> 00:32:15,960
AND -- SO OUR JUSTIFICATION FOR

771
00:32:15,960 --> 00:32:19,080
THE USE OF AN RFA WAS A

772
00:32:19,080 --> 00:32:21,320
NECESSARY MECHANISM TO

773
00:32:21,320 --> 00:32:23,600
INCENTIVIZE INVESTIGATORS TO

774
00:32:23,600 --> 00:32:26,680
JUMP START THE FIELD OF HEALTH

775
00:32:26,680 --> 00:32:27,960
DISPARITIES WITH AN HIV

776
00:32:27,960 --> 00:32:30,600
INFECTION AND I WILL MENTION DEN

777
00:32:30,600 --> 00:32:32,520
THAT IT WAS ENDORSED AS AN IDEA

778
00:32:32,520 --> 00:32:40,160
BY THE BSA AD HOC SUB COMMITTED

779
00:32:40,160 --> 00:32:44,000
TO THE OFFICE OF HIV RESEARCH

780
00:32:44,000 --> 00:32:46,800
AND FOR FY23 AND IT WAS APPROVED

781
00:32:46,800 --> 00:32:50,920
BY THE OAR AND MARCH OF 24 OF

782
00:32:50,920 --> 00:32:51,600
THIS YEAR.

783
00:32:51,600 --> 00:33:00,120
THE APPLICATIONS WILL BE THEY

784
00:33:00,120 --> 00:33:10,640
WILL REQUIRE EXPERTISE AND LIKE

785
00:33:21,560 --> 00:33:24,560
COMMUNITY ENGAGEMENT GOING ON

786
00:33:24,560 --> 00:33:26,160
THROUGHOUT NIH.

787
00:33:26,160 --> 00:33:28,800
NEXT SLIDE, PLEASE.

788
00:33:28,800 --> 00:33:31,440
SO, OUR EVALUATION PIECE FOR

789
00:33:31,440 --> 00:33:35,680
THIS RFA, SO, FIRST OF ALL, THE

790
00:33:35,680 --> 00:33:40,320
SCIENTIFIC STAFF LISTED ON THE

791
00:33:40,320 --> 00:33:42,840
FIRST SLIDE AND WE WILL CONVENE

792
00:33:42,840 --> 00:33:45,680
AND TRACK THE APPLICATION 0

793
00:33:45,680 --> 00:33:47,080
RECEIPT FUNDING PLAN APPROVAL

794
00:33:47,080 --> 00:33:49,920
AND CLOSE OUT AND WE'LL DESCRIBE

795
00:33:49,920 --> 00:33:51,320
THE PROGRESS AND ACCOMPLISHMENTS

796
00:33:51,320 --> 00:33:55,240
AND ADVANCEMENT ANNOUNCEMENTS

797
00:33:55,240 --> 00:33:58,360
AND TRACK THE NUMBER OF IMPACT

798
00:33:58,360 --> 00:34:00,040
FACTORS OF PUBLICATIONS.

799
00:34:00,040 --> 00:34:03,520
AS WELL, I THINK WE'LL ALSO

800
00:34:03,520 --> 00:34:06,360
FOLLOW THE PROGRESS OF

801
00:34:06,360 --> 00:34:08,840
DEVELOPMENTS LIKE ANTIBODIES

802
00:34:08,840 --> 00:34:12,840
INTRODUCED, ORGANOIDS, MOLECULAR

803
00:34:12,840 --> 00:34:13,840
CON TRUCKS AND THEY WILL BE

804
00:34:13,840 --> 00:34:16,720
AVAILABLE TO THE RESEARCH

805
00:34:16,720 --> 00:34:18,000
COMMUNITY FOR FUTURE STUDIES ON

806
00:34:18,000 --> 00:34:20,080
HEALTH DISPARITIES, CANCER AND

807
00:34:20,080 --> 00:34:20,320
HIV.

808
00:34:20,320 --> 00:34:23,920
AND I WOULD ALSO MENTION THAT WE

809
00:34:23,920 --> 00:34:26,640
AS PROGRAM STAFF CAN CERTAINLY

810
00:34:26,640 --> 00:34:31,160
BE STRONG ADVOCATES TO HELP THE

811
00:34:31,160 --> 00:34:33,360
RESEARCH COMMUNITY ON MAKING

812
00:34:33,360 --> 00:34:35,560
THEM AWARE OF THESE NEW TOOLS

813
00:34:35,560 --> 00:34:42,520
THAT ARE HOPEFULLY WILL BE

814
00:34:42,520 --> 00:34:43,000
AVAILABLE.

815
00:34:43,000 --> 00:34:47,720
WE WILL ALSO SERVE ADDITIONAL

816
00:34:47,720 --> 00:34:48,120
JUDGES.

817
00:34:48,120 --> 00:34:49,640
AND FINALLY ON THE

818
00:34:49,640 --> 00:34:51,680
ADMINISTRATIVE SIDE, WE ARE

819
00:34:51,680 --> 00:34:54,800
PROPOSING RO1s FOR FIVE YEARS

820
00:34:54,800 --> 00:34:57,560
AND R21s FOR TWO YEARS AND WE

821
00:34:57,560 --> 00:34:58,920
HAVE ANTICIPATED RECEIPT DATES

822
00:34:58,920 --> 00:35:02,400
AND WE ARE REQUESTING TWO AND

823
00:35:02,400 --> 00:35:04,320
DECEMBER 2022 AND DECEMBER OF

824
00:35:04,320 --> 00:35:06,400
2023 AND WE ANTICIPATE FUNDING

825
00:35:06,400 --> 00:35:09,400
SEVEN TO EIGHT RO1s AND FIVE

826
00:35:09,400 --> 00:35:12,800
TO SIX R21 APPLICATIONS FOR TWO

827
00:35:12,800 --> 00:35:15,360
YEARS AND OR FIVE YEARS OR TWO

828
00:35:15,360 --> 00:35:18,520
YEARS AND WE HAVE TO FUND IN

829
00:35:18,520 --> 00:35:22,400
JULY OF 2023 AND JULY OF 2024

830
00:35:22,400 --> 00:35:27,320
AND THE SET ASIDE IS COMING FROM

831
00:35:27,320 --> 00:35:28,560
DOLLARS FOR APPLICATIONS THAT

832
00:35:28,560 --> 00:35:31,440
MEET THE LAR PRIORITY GUIDELINES

833
00:35:31,440 --> 00:35:33,760
AND THE FIRST YEAR BUDGET TOTAL

834
00:35:33,760 --> 00:35:36,400
IS FIVE MILLION DOLLARS AND THE

835
00:35:36,400 --> 00:35:40,240
TOTAL PROJECT PERIOD FOR THE TWO

836
00:35:40,240 --> 00:35:44,200
RECEIPT DATES IS A TOTAL OF

837
00:35:44,200 --> 00:35:46,320
$50 MILLION TOTAL COST.

838
00:35:46,320 --> 00:35:48,320
THAT IS MY LAST SLIDE AND I'M

839
00:35:48,320 --> 00:35:49,800
HAPPY TO TAKE ANY QUESTIONS

840
00:35:49,800 --> 00:35:50,280
ANYONE MAY HAVE.

841
00:35:50,280 --> 00:35:54,400
THANK YOU FOR YOUR ATTENTION.

842
00:35:54,400 --> 00:35:56,640
>> GREAT.

843
00:35:56,640 --> 00:35:59,040
THANK YOU.

844
00:35:59,040 --> 00:36:01,280
MY WANT TO OPEN UP THE

845
00:36:01,280 --> 00:36:01,600
DISCUSSION.

846
00:36:01,600 --> 00:36:02,080
>> SOUNDS GREAT.

847
00:36:02,080 --> 00:36:05,400
I WANT TO START BY THANKING YOU

848
00:36:05,400 --> 00:36:06,800
FOR SUCH AN EXCELLENT

849
00:36:06,800 --> 00:36:08,680
PRESENTATION AND I WANT TO THANK

850
00:36:08,680 --> 00:36:13,160
MY COLLEAGUES WHO SERVED ON THE

851
00:36:13,160 --> 00:36:15,840
SUBCOMMITTEE FOR THEIR EXCELLENT

852
00:36:15,840 --> 00:36:16,280
COMMENTS.

853
00:36:16,280 --> 00:36:20,240
SO OUR SUBCOMMITTEE MET ONE TIME

854
00:36:20,240 --> 00:36:27,200
AND MY COLLEAGUES ALSO SUBMITTED

855
00:36:27,200 --> 00:36:29,320
WRITTEN FRONTS ON THIS RFA.

856
00:36:29,320 --> 00:36:32,600
THERE WAS UNANIMOUS SUPPORT FOR

857
00:36:32,600 --> 00:36:33,280
THIS PROGRAM.

858
00:36:33,280 --> 00:36:35,400
IT'S NOTABLE THIS CAME OUT OF A

859
00:36:35,400 --> 00:36:37,360
BSA SUBCOMMITTEE AND THERE'S A

860
00:36:37,360 --> 00:36:40,120
SPECIFIC EMPHASIS ON HEALTH

861
00:36:40,120 --> 00:36:43,120
DISPARITIES AMONG PATIENTS WHO

862
00:36:43,120 --> 00:36:47,960
ARE HIV POSITIVE AND LOOKING AT

863
00:36:47,960 --> 00:36:49,600
CANCER OUTCOMES IN THAT GROUP

864
00:36:49,600 --> 00:36:53,680
AND THE FOCUS OF THIS RFA AS

865
00:36:53,680 --> 00:36:56,520
MENTIONED BY Dr. READ-CONNOLE

866
00:36:56,520 --> 00:36:58,880
IS ON THE RESEARCH AND THE RFA

867
00:36:58,880 --> 00:37:01,480
WILL SUPPORT R01 AND R21

868
00:37:01,480 --> 00:37:02,840
APPLICANTS AND THE SPECIFIC

869
00:37:02,840 --> 00:37:06,040
FOCUS HAS BEEN WELL CLARIFIED

870
00:37:06,040 --> 00:37:10,480
AND YOU KNOW, FOCUSING ON THE

871
00:37:10,480 --> 00:37:18,160
CAUSES, GENETIC ASPECT AND

872
00:37:18,160 --> 00:37:20,200
MICROBIOME AND THE MEASURES OF

873
00:37:20,200 --> 00:37:21,760
SUCCESS ENCLOUD TRADITIONAL

874
00:37:21,760 --> 00:37:24,320
MEASURES OF IMPACT AND

875
00:37:24,320 --> 00:37:25,200
PUBLICATIONS AS WELL AS THE

876
00:37:25,200 --> 00:37:26,440
SCHOOLS DEVELOPED FROM THE

877
00:37:26,440 --> 00:37:32,440
TRANCATTRANCATIONAL RESEARCH.

878
00:37:32,440 --> 00:37:35,800
THE COMMENTS HAVE BEEN WELL

879
00:37:35,800 --> 00:37:37,160
ADDRESS BY THE TEAM AND THOSE

880
00:37:37,160 --> 00:37:39,800
COMMENTS RELATED TO SPECIFY WHY

881
00:37:39,800 --> 00:37:42,600
THE SOCIAL DETERMINANTS OF

882
00:37:42,600 --> 00:37:43,880
HEALTH WOULD NOT BE COVERED IN

883
00:37:43,880 --> 00:37:45,400
THIS APPLICATION AND I THINK

884
00:37:45,400 --> 00:37:48,240
THAT WAS WELL DESCRIBED IN HER

885
00:37:48,240 --> 00:37:50,240
PRESENTATION AND SPECIFYING MORE

886
00:37:50,240 --> 00:37:53,600
CLEARLY THIS SUCCESS METRICS AND

887
00:37:53,600 --> 00:37:55,600
SPECIFYING THE DISPARITY SO I

888
00:37:55,600 --> 00:37:57,920
THINK THE POPULATION HAVE BEEN

889
00:37:57,920 --> 00:37:59,320
WELL DESCRIBED INCLUDING THOSE

890
00:37:59,320 --> 00:38:00,680
POPULATIONS THAT HAVE A HIGHER

891
00:38:00,680 --> 00:38:03,120
INSTANCE OF HIV INFECTION AND

892
00:38:03,120 --> 00:38:04,200
INCLUDING BLACKS, HISPANICS,

893
00:38:04,200 --> 00:38:12,760
DRUG USERS AND AND THERE WAS A

894
00:38:12,760 --> 00:38:14,200
SUGGESTION TO EXPAND THE METRICS

895
00:38:14,200 --> 00:38:16,800
FOR SUCCESS AS WELL AND THOSE

896
00:38:16,800 --> 00:38:20,560
HAVE BEEN WELL DESCRIBED IN THE

897
00:38:20,560 --> 00:38:21,080
PRESENTATION.

898
00:38:21,080 --> 00:38:23,120
SO JUST A RECAP, THIS AGAIN HAS

899
00:38:23,120 --> 00:38:25,160
BEEN WELL ENDORSED AS IT CAME

900
00:38:25,160 --> 00:38:28,240
FROM THE BSA SUBCOMMITTEE AND AS

901
00:38:28,240 --> 00:38:31,320
Dr. READ-CONNOLE MENTIONED

902
00:38:31,320 --> 00:38:33,240
IT'S BEEN APPROVED BY THE OFFICE

903
00:38:33,240 --> 00:38:35,600
OF RESEARCH AND FUNDING IS

904
00:38:35,600 --> 00:38:36,800
AVAILABLE FOR THIS PARTICULAR

905
00:38:36,800 --> 00:38:37,600
RFA.

906
00:38:37,600 --> 00:38:37,880
>> GREAT.

907
00:38:37,880 --> 00:38:40,440
THANK YOU.

908
00:38:40,440 --> 00:38:40,720
MICHELLE.

909
00:38:40,720 --> 00:38:45,960
>> I WANT TO ADD, I THINK
OUR

910
00:38:45,960 --> 00:38:49,000
SENTIMENT IS VERY WELL BUT I WAS

911
00:38:49,000 --> 00:38:51,080
STRUCK IN ADDITION TO THE NEED

912
00:38:51,080 --> 00:38:53,720
TO STUDY HEALTH DISPARITIES

913
00:38:53,720 --> 00:38:55,400
ASPECT OF AIDS ASSOCIATED IN

914
00:38:55,400 --> 00:38:58,240
CANCER AND IT REALLY RESINATED

915
00:38:58,240 --> 00:39:00,360
WITH ME THAT RESPECT FROM THE

916
00:39:00,360 --> 00:39:01,600
CANCER HAS CHANGED OVER THE LAST

917
00:39:01,600 --> 00:39:04,160
FEW DECADES WITH AGING OF THE

918
00:39:04,160 --> 00:39:05,480
POPULATION AND CONTEMPORARY

919
00:39:05,480 --> 00:39:06,800
THERAPY AND I KNOW LITTLE ABOUT

920
00:39:06,800 --> 00:39:12,720
THE IDEOLOGY OF THE NEW CANCER

921
00:39:12,720 --> 00:39:18,400
AND AS WELL AS THE GOAL OF HIV

922
00:39:18,400 --> 00:39:19,880
AND VIRUSES ASSOCIATE INSIDE

923
00:39:19,880 --> 00:39:28,320
THIS PROCESS SO THIS IS VERY

924
00:39:28,320 --> 00:39:28,520
TIMELY.

925
00:39:28,520 --> 00:39:31,520
>> I DON'T HAVE ANYTHING
TO ADD.

926
00:39:31,520 --> 00:39:32,440
>> GREAT.

927
00:39:32,440 --> 00:39:36,440
>> OTHER MEMBERS, DO YOU
HAVE

928
00:39:36,440 --> 00:39:42,200
ANY COMMENTS OR QUESTIONS?

929
00:39:42,200 --> 00:39:43,040
>> A COUPLE.

930
00:39:43,040 --> 00:39:45,560
ONE IS A QUESTION.

931
00:39:45,560 --> 00:39:49,960
WHAT ABOUT THE INCLUSION OF

932
00:39:49,960 --> 00:39:52,080
COHORTS FROM SUB ZAHAR ANT

933
00:39:52,080 --> 00:39:53,840
AFRICA OR OTHER PLACES, IT

934
00:39:53,840 --> 00:39:55,040
WASN'T CLEAR WHETHER THOSE WOULD

935
00:39:55,040 --> 00:40:05,280
BE ALLOWABLE.

936
00:40:27,480 --> 00:40:32,200
>> YES, VERY MUCH WE WILL

937
00:40:32,200 --> 00:40:34,840
ENCLOUD THOSE AND WE ALSO KNOW

938
00:40:34,840 --> 00:40:37,640
MANY OF THE INVESTIGATORS THAT

939
00:40:37,640 --> 00:40:39,800
ARE IN THE FIELD OF HIV AND

940
00:40:39,800 --> 00:40:42,960
CANCER DO HAVE ACCESS TO THOSE

941
00:40:42,960 --> 00:40:49,680
DATASETS AND COLLABORATE IN SUB

942
00:40:49,680 --> 00:40:51,320
ZAHARANT AFRICA SO THEY WOULD BE

943
00:40:51,320 --> 00:40:52,120
ABLE TO APPLY.

944
00:40:52,120 --> 00:40:56,120
>> MY COMMENTS IS, SOCIAL

945
00:40:56,120 --> 00:40:57,280
DETERMINANTS OR HEALTH YOU CAN

946
00:40:57,280 --> 00:40:58,880
BAN THE WORD BUT IF YOU HAVE TO

947
00:40:58,880 --> 00:41:02,080
DO IT MICROBIOME AND

948
00:41:02,080 --> 00:41:04,520
INFLAMMATION AND NEURAL INPUT

949
00:41:04,520 --> 00:41:06,320
IT'S DIFFICULT TO DIS ENTANGLED

950
00:41:06,320 --> 00:41:07,960
FROM DISPARITIES SO I GUESS YOU

951
00:41:07,960 --> 00:41:08,920
HAVE TO BE CAREFUL IN THE WAY

952
00:41:08,920 --> 00:41:17,000
YOU WRITE IT.

953
00:41:17,000 --> 00:41:18,800
THEY ARE THE DISPARITIES.

954
00:41:18,800 --> 00:41:22,200
>> YES, CERTAINLY, WE
UNDERSTAND

955
00:41:22,200 --> 00:41:24,800
THAT, THANK YOU.

956
00:41:24,800 --> 00:41:29,000
>> IT'S A TOUGH BOUNDARY
TO TRY

957
00:41:29,000 --> 00:41:32,560
AND DRAW BUT CLEARLY OUR HOPE IS

958
00:41:32,560 --> 00:41:33,480
THAT THERE'S FLEXIBILITY THAT

959
00:41:33,480 --> 00:41:38,480
ALLOW PEOPLE LOOKING FOR FACTORS

960
00:41:38,480 --> 00:41:39,600
TO BE ADDRESSED.

961
00:41:39,600 --> 00:41:41,560
WITHOUT DOING SO,  I THINK YOU

962
00:41:41,560 --> 00:41:42,880
RUN THE RISK OF DOING SOMETHING

963
00:41:42,880 --> 00:41:46,520
THAT DOESN'T QUITE ADDRESS THE

964
00:41:46,520 --> 00:41:46,960
CONCERNS.

965
00:41:46,960 --> 00:41:49,000
ONE OTHER PIECE I THINK WAS

966
00:41:49,000 --> 00:41:52,000
MENTIONED TOO IS THAT THE

967
00:41:52,000 --> 00:41:53,200
COMPARISONS AND IT CAME TO ME

968
00:41:53,200 --> 00:41:54,920
BECAUSE I TALKED ABOUT COHORTS.

969
00:41:54,920 --> 00:41:56,480
MY UNDERSTANDING AND CORRECT ME

970
00:41:56,480 --> 00:41:59,000
IF I'M WRONG, IS THE INTENT IS

971
00:41:59,000 --> 00:42:02,720
TO COMPARE PEOPLE WITH HIV TO

972
00:42:02,720 --> 00:42:04,520
PEOPLE WHO DON'T HAVE HIV.

973
00:42:04,520 --> 00:42:07,880
AND IN THAT WE TROY TO

974
00:42:07,880 --> 00:42:09,080
DISENTANGLE OR UNDERSTAND BETTER

975
00:42:09,080 --> 00:42:10,640
WHAT THIS DRIVING BOTH TO

976
00:42:10,640 --> 00:42:14,200
DISPARITY WITHIN THAT POPULATION

977
00:42:14,200 --> 00:42:17,160
AND HIV BUT ALSO HETEROGENEITY

978
00:42:17,160 --> 00:42:17,880
OF PEOPLE WITH HIV.

979
00:42:17,880 --> 00:42:23,520
>> YES, THAT'S CORRECT.

980
00:42:23,520 --> 00:42:26,800
>> I DON'T SEE ANY OTHER
HANDS.

981
00:42:26,800 --> 00:42:31,440
SO, I THINK WE CAN MOVE TO

982
00:42:31,440 --> 00:42:31,680
VOTING.

983
00:42:31,680 --> 00:42:37,240
>> I MOVE TO A OF T PROVE.

984
00:42:37,240 --> 00:42:37,640
>> SECOND.

985
00:42:37,640 --> 00:42:39,480
>> SECOND.

986
00:42:39,480 --> 00:42:43,080
>> AND ANY FURTHER
DISCUSSION?

987
00:42:43,080 --> 00:42:49,680
>> AGAIN, THE DISCUSSION
IS NOT

988
00:42:49,680 --> 00:42:50,960
HEADING IN THE DIRECTION OF A

989
00:42:50,960 --> 00:42:54,560
DEFERRAL SO LOOKING SPECIFICALLY

990
00:42:54,560 --> 00:43:00,680
FOR IAPPROVAL AND DISAPPROVAL

991
00:43:00,680 --> 00:43:02,600
ASSUMING IF YOU ARE DIGITALLY

992
00:43:02,600 --> 00:43:03,680
CONNECTED YOU ARE PROVING AND

993
00:43:03,680 --> 00:43:05,840
THAT'S THE MOTION ON THE TABLE.

994
00:43:05,840 --> 00:43:07,880
ANYONE DISAPPROVAL, RAISE YOUR

995
00:43:07,880 --> 00:43:12,880
HANDS OR A VOICE OF A

996
00:43:12,880 --> 00:43:14,880
DISAPPROVAL VOTE PLEASE.

997
00:43:14,880 --> 00:43:16,720
I DO NOT SEE ANY.

998
00:43:16,720 --> 00:43:22,520
ANY ABSTENTIONS?

999
00:43:22,520 --> 00:43:24,440
NO.

1000
00:43:24,440 --> 00:43:24,760
OK, PAULETTE.

1001
00:43:24,760 --> 00:43:26,640
>> IT'S UNANIMOUS
APPROVAL.

1002
00:43:26,640 --> 00:43:28,160
>> WE ARE GOOD.

1003
00:43:28,160 --> 00:43:30,120
>> ALL RIGHT.

1004
00:43:30,120 --> 00:43:33,240
MOVING ALONG THE NEXT IS A PAR

1005
00:43:33,240 --> 00:43:34,440
CONCEPT MECHANISTIC LINKS

1006
00:43:34,440 --> 00:43:36,600
BETWEEN DIET, LIPID METABOLISM

1007
00:43:36,600 --> 00:43:38,760
AND TUMOR GROWTH AND PROGRESSION

1008
00:43:38,760 --> 00:43:42,440
AND Dr. CHRISTINE WILLIS IS

1009
00:43:42,440 --> 00:43:43,040
PRESENTING.

1010
00:43:43,040 --> 00:43:45,640
MEMBERS ARE DOCTORS WHO IS

1011
00:43:45,640 --> 00:43:47,600
UNABLE TO JOINS TODAY BUT DID

1012
00:43:47,600 --> 00:43:51,080
PARTICIPATE IN PRIOR DISCUSSIONS

1013
00:43:51,080 --> 00:43:55,040
AND WRATHMALL.

1014
00:43:55,040 --> 00:43:58,880
>> THANK YOU, Dr. FLARE
TEE.

1015
00:43:58,880 --> 00:44:01,080
I'M HAPPY TO PRESENT THIS ON

1016
00:44:01,080 --> 00:44:02,200
FUNDAMENTAL STUDIES OF

1017
00:44:02,200 --> 00:44:03,800
INFLUENCES ON LIPID MECHANISMS

1018
00:44:03,800 --> 00:44:05,840
OF TUMOR GROWTH AND PROGRESSION.

1019
00:44:05,840 --> 00:44:08,640
WHICH IS PART OF NCI SUPPORT FOR

1020
00:44:08,640 --> 00:44:11,200
ARE THE LARGER NIH 10-YEAR

1021
00:44:11,200 --> 00:44:14,760
STRATEGIC PLAN FOR NUTRITION

1022
00:44:14,760 --> 00:44:15,040
RESEARCH.

1023
00:44:15,040 --> 00:44:16,480
MY WAY OF BECOME GROUND I'D LIKE

1024
00:44:16,480 --> 00:44:19,520
TO TOUCH ON CANCER METABOLISM IN

1025
00:44:19,520 --> 00:44:22,480
GENERAL.

1026
00:44:22,480 --> 00:44:25,640
CANCER METABOLISM THREE

1027
00:44:25,640 --> 00:44:25,920
COMPONENTS.

1028
00:44:25,920 --> 00:44:28,480
THE BIOLOGY OF THE TUMOR, THE

1029
00:44:28,480 --> 00:44:30,240
TUMOR MICRO ENVIRONMENT AND

1030
00:44:30,240 --> 00:44:32,600
THESE THREE SYSTEMS ARE

1031
00:44:32,600 --> 00:44:33,960
INTERCONNECTED AND CAN'T REALLY

1032
00:44:33,960 --> 00:44:34,960
BE UNDERSTOOD WITHOUT REFERENCE

1033
00:44:34,960 --> 00:44:35,960
TO EACH OTHER.

1034
00:44:35,960 --> 00:44:38,600
BUT TODAY, I'M GOING TO FOCUS

1035
00:44:38,600 --> 00:44:41,080
SPECIFICALLY ON NUTRIENT

1036
00:44:41,080 --> 00:44:41,600
AVAILABILITY.

1037
00:44:41,600 --> 00:44:43,640
AND THE NUTRIENTS IN A TIMER

1038
00:44:43,640 --> 00:44:45,360
REQUIRES TO SUPPORT ITS

1039
00:44:45,360 --> 00:44:47,000
PROGRESSION CAN BE SOURCED FROM

1040
00:44:47,000 --> 00:44:48,800
A VARIETY OF PLACES AND THEY CAN

1041
00:44:48,800 --> 00:44:50,120
BE DRAWN DIRECTLY FROM THE

1042
00:44:50,120 --> 00:44:53,720
PLASMA OR FROM TUMOR FLUID AND

1043
00:44:53,720 --> 00:44:59,720
THEY CAN BE TAKEN FROM STROMAL

1044
00:44:59,720 --> 00:45:01,720
CELLS OR THEY CAN BE EXTRACTED

1045
00:45:01,720 --> 00:45:03,840
FROM THE EXTRA CELLULAR MATRIX,

1046
00:45:03,840 --> 00:45:05,280
AND THERE'S ANOTHER SOURCE THAT

1047
00:45:05,280 --> 00:45:07,040
WE TEND NOT TO THINK ABOUT AS

1048
00:45:07,040 --> 00:45:12,760
OFTEN AND THAT IS THE DIET.

1049
00:45:12,760 --> 00:45:16,320
RECENT WORK SUGGESTS THAT DIET

1050
00:45:16,320 --> 00:45:18,480
RESPONSE ITS LIPID METABOLISM

1051
00:45:18,480 --> 00:45:21,800
CONTROLS TUMOR GROWTH AND

1052
00:45:21,800 --> 00:45:22,240
PROGRESSION.

1053
00:45:22,240 --> 00:45:24,240
AND THIS EMERGING AREA PRESENTS

1054
00:45:24,240 --> 00:45:26,960
WITH US A UNIQUE OPPORTUNITY TO

1055
00:45:26,960 --> 00:45:28,320
SUPPORT THE ADVANCEMENT OF

1056
00:45:28,320 --> 00:45:31,000
FUNDAMENTAL CANCER BIOLOGY.

1057
00:45:31,000 --> 00:45:32,080
AND PARTICULARLY THERE'S BEEN A

1058
00:45:32,080 --> 00:45:33,720
NUMBER OF RECENT DISCOVERIES IN

1059
00:45:33,720 --> 00:45:40,480
THIS AREA THAT ARE TIMELY AND

1060
00:45:40,480 --> 00:45:40,880
SIGNIFICANT.

1061
00:45:40,880 --> 00:45:45,240
IT'S BEEN SHOWN THAT CALORIC

1062
00:45:45,240 --> 00:45:51,200
RESTRICTION IS TUMOR GROWTH BY

1063
00:45:51,200 --> 00:45:53,920
FATTY ACIDS AND IT SHOWED THAT

1064
00:45:53,920 --> 00:45:57,040
HIGH-FAT DIET COMPROMISES

1065
00:45:57,040 --> 00:45:58,800
ANTITUMOR BY INTERFERING WITH

1066
00:45:58,800 --> 00:46:02,000
THE TUMOR MIKE ROLL ENVIRONMENT

1067
00:46:02,000 --> 00:46:05,320
AND RESTRICTING DIETARY GLY

1068
00:46:05,320 --> 00:46:06,920
SCENERY DUCES TUMOR GROWTH BY

1069
00:46:06,920 --> 00:46:09,920
RECUSING TOXICS LIPID SPECIES

1070
00:46:09,920 --> 00:46:14,400
AND AS FINAL EXAMPLE DIETARY

1071
00:46:14,400 --> 00:46:16,640
ACID PROMOTES METASTASIS AND

1072
00:46:16,640 --> 00:46:18,960
THROUGH TUMOR ASSOCIATED SWAN

1073
00:46:18,960 --> 00:46:19,200
CELLS.

1074
00:46:19,200 --> 00:46:20,520
THIS IS ALSO AN IMPORTANT

1075
00:46:20,520 --> 00:46:22,000
OPPORTUNITY RIGHT NOW BECAUSE

1076
00:46:22,000 --> 00:46:23,880
THE FIELD OF FUNDAMENTAL CANCER

1077
00:46:23,880 --> 00:46:25,920
BIOLOGY IS JUST BEGINNING TO

1078
00:46:25,920 --> 00:46:28,000
HAVE MODELS THAT INCORPORATE THE

1079
00:46:28,000 --> 00:46:29,840
TUMOR MICRO ENVIRONMENT SO WE

1080
00:46:29,840 --> 00:46:31,880
HAVE THE ABILITY TO STUDY THIS

1081
00:46:31,880 --> 00:46:34,080
AND IN A MEANINGFUL WAY.

1082
00:46:34,080 --> 00:46:39,320
THERE'S BEEN A NUMBER OF RECENT

1083
00:46:39,320 --> 00:46:41,680
METH LOGICAL IN WAYS IN

1084
00:46:41,680 --> 00:46:43,480
COMPUTATIONAL MODELS WHICH ARE

1085
00:46:43,480 --> 00:46:45,120
IMPORTANT FOR UNDERSTANDING THIS

1086
00:46:45,120 --> 00:46:47,040
AREA AND THE KIND OF SYSTEMS BY

1087
00:46:47,040 --> 00:46:47,800
OLE GOUGH APPROACHES THAT ARE

1088
00:46:47,800 --> 00:46:54,520
ALSO IMPORTANT FOR UNDERSTANDING

1089
00:46:54,520 --> 00:46:54,840
THAT AREA.

1090
00:46:54,840 --> 00:46:57,200
IT'S A COMPLEX PROBLEM.

1091
00:46:57,200 --> 00:46:58,800
THE TUMOR MICRO ENVIRONMENT IS

1092
00:46:58,800 --> 00:47:01,760
COMPLEX WITH DIFFERENT KINDS OF

1093
00:47:01,760 --> 00:47:04,440
CELLS AND LIPID BIO CHEMISTRY

1094
00:47:04,440 --> 00:47:05,680
COMPLEX WHEN YOU CONSIDER THE

1095
00:47:05,680 --> 00:47:07,280
HEAD GROUPS THAT LIPIDS CAN HAVE

1096
00:47:07,280 --> 00:47:08,680
AND THE LENGTH OF THE CHAIN AND

1097
00:47:08,680 --> 00:47:10,160
THE POSITION OF THE NUMBER OF

1098
00:47:10,160 --> 00:47:12,320
DOUBLE BONDS, THERE ARE MORE

1099
00:47:12,320 --> 00:47:13,120
THAN 100,000 DIFFERENT SPECIES

1100
00:47:13,120 --> 00:47:15,680
OF LIPIDS PRESENT.

1101
00:47:15,680 --> 00:47:16,880
THERE ARE STILL CHALLENGES

1102
00:47:16,880 --> 00:47:18,600
AROUND THE ISSUE OF KWANTATION

1103
00:47:18,600 --> 00:47:20,880
OF DIETARY VARIABLES AND HOW WE

1104
00:47:20,880 --> 00:47:26,800
DEFINE A HIGH FAT DIET.

1105
00:47:26,800 --> 00:47:28,800
OR CALORIC RESTRICTION AND THERE

1106
00:47:28,800 --> 00:47:30,000
ARE INSUFFICIENT BRIDGES BETWEEN

1107
00:47:30,000 --> 00:47:31,960
RESEARCH ON NUTRITION AND

1108
00:47:31,960 --> 00:47:33,240
FUNDAMENTAL CANCER BIOLOGY AND

1109
00:47:33,240 --> 00:47:34,800
WE HOPE THIS PROPOSED CONCEPT

1110
00:47:34,800 --> 00:47:38,400
WILL HELP ADDRESS THESE

1111
00:47:38,400 --> 00:47:48,600
CHALLENGES.

1112
00:47:51,040 --> 00:47:55,680
THEY HAVE FOCUSED ON OTHER

1113
00:47:55,680 --> 00:47:57,280
DIFFERENT AREAS AND BEHAVIORAL

1114
00:47:57,280 --> 00:48:01,840
SIGNS AND MICROBIOME AND THEY

1115
00:48:01,840 --> 00:48:04,320
ARE FOCUSED ON EPIDEMIOLOGY AND

1116
00:48:04,320 --> 00:48:08,400
RISK AND PREVENTION AND

1117
00:48:08,400 --> 00:48:09,240
MICROBIOME.

1118
00:48:09,240 --> 00:48:10,880
IN RECENT YEARS BETWEEN FISCAL

1119
00:48:10,880 --> 00:48:13,280
2017 AND 2021, NCI MADE 15

1120
00:48:13,280 --> 00:48:17,480
AWARDS SO THAT'S 15 AWARDS IN

1121
00:48:17,480 --> 00:48:20,320
FIVE YEARS ON APPLICATION THAT'S

1122
00:48:20,320 --> 00:48:21,520
INCORPORATED DIET OF WHAT ARE

1123
00:48:21,520 --> 00:48:28,680
MORE ASPECTS OF IT'S A SMALL

1124
00:48:28,680 --> 00:48:31,080
PORTFOLIO AND THIS CONCEPT WOULD

1125
00:48:31,080 --> 00:48:34,800
CONSIST OF TWO PASRs USING THE

1126
00:48:34,800 --> 00:48:39,720
RO1 AND R21 MECHANISMS AND RO1

1127
00:48:39,720 --> 00:48:41,040
MADE UNDER THIS PROGRAM WOULD BE

1128
00:48:41,040 --> 00:48:44,840
RENEWED FOR THE PARENTS AND THE

1129
00:48:44,840 --> 00:48:46,320
AWARDS WE WOULD LIKE TO MAKE

1130
00:48:46,320 --> 00:48:47,880
WOULD BE AIMED AT ACHIEVING

1131
00:48:47,880 --> 00:48:55,280
THREE PURPOSES AND THROUGH WHICH

1132
00:48:55,280 --> 00:48:59,160
MODULATES TUMOR GROWTH AND

1133
00:48:59,160 --> 00:49:02,320
PROGRESSION THROUGH THE WITH THE

1134
00:49:02,320 --> 00:49:04,480
FIELDS, AND TO STIMULATE

1135
00:49:04,480 --> 00:49:06,040
RESEARCH AND TOOL DEVELOPMENT

1136
00:49:06,040 --> 00:49:09,080
AND IN THIS AREA AND THE CONCEPT

1137
00:49:09,080 --> 00:49:09,920
ALLIANCE WITH GOAL FOUR WHICH IS

1138
00:49:09,920 --> 00:49:11,880
TO IMPROVE THE USE OF FOOD AS

1139
00:49:11,880 --> 00:49:14,040
MEDICINE AND OTHER RECENT NIH

1140
00:49:14,040 --> 00:49:15,520
STRATEGIC PLAN FOR NUTRITION AND

1141
00:49:15,520 --> 00:49:17,080
RESEARCH AND MY COLLEAGUES, MY

1142
00:49:17,080 --> 00:49:20,800
MEDICAL COLLEAGUES HAVE MORE

1143
00:49:20,800 --> 00:49:24,160
ELEMENTARY DESCRIBED THE NEED

1144
00:49:24,160 --> 00:49:25,680
FOR ADDITIONAL TO HELP THEM MAKE

1145
00:49:25,680 --> 00:49:28,760
DIETARY RECOMMENDATIONS TO

1146
00:49:28,760 --> 00:49:30,720
PATIENTS.

1147
00:49:30,720 --> 00:49:32,640
THE PROPOSED CONCEPT FILLS A GAP

1148
00:49:32,640 --> 00:49:36,040
THAT IS IDENTIFIED HERE AT NCI

1149
00:49:36,040 --> 00:49:37,560
AND IT'S IDENTIFIED BY SUBJECT

1150
00:49:37,560 --> 00:49:41,120
MATTER EXPERTS DURING THE

1151
00:49:41,120 --> 00:49:43,200
JULY 2021 WORKSHOP ON DIET AS A

1152
00:49:43,200 --> 00:49:45,560
MODIFIER OF TUMOR METABOLISM.

1153
00:49:45,560 --> 00:49:47,640
THE IDEA IS TO STAB A COMMUNITY

1154
00:49:47,640 --> 00:49:48,880
OF PRACTICE THROUGH SEVERAL

1155
00:49:48,880 --> 00:49:53,080
DIFFERENT INITIATIVES AND

1156
00:49:53,080 --> 00:49:54,040
BRINGING TOGETHER BIOLOGISTS

1157
00:49:54,040 --> 00:49:57,800
THROUGH THE AWARD AND IT WILL

1158
00:49:57,800 --> 00:49:59,880
STRONGLY ENCOURAGE APPLICANTS TO

1159
00:49:59,880 --> 00:50:02,360
EITHER USE AN MPI OR CO PI

1160
00:50:02,360 --> 00:50:03,920
MECHANISM TO ENSURE THERE'S

1161
00:50:03,920 --> 00:50:07,400
ADEQUATE EXPERTISE FROM

1162
00:50:07,400 --> 00:50:09,120
NUTRITIONISTS ON THE GRAND AND

1163
00:50:09,120 --> 00:50:11,040
APPLICATIONS THAT DO NOT HAVE

1164
00:50:11,040 --> 00:50:13,640
NUTRITION EXPERTS WHO WOULD BE

1165
00:50:13,640 --> 00:50:14,400
CONSIDERED NONRESPONSE I HAVE.

1166
00:50:14,400 --> 00:50:17,400
I WANT TA HOSPITAL A MEETING FOR

1167
00:50:17,400 --> 00:50:18,680
REWARDERS AND ESTABLISH OUR

1168
00:50:18,680 --> 00:50:19,640
WORKING GROUP AND OUR HOPE IS

1169
00:50:19,640 --> 00:50:22,320
THAT BETTER UNDERSTANDING OF THE

1170
00:50:22,320 --> 00:50:23,280
DIE AARTI INFLUENCES LIKE CANCER

1171
00:50:23,280 --> 00:50:24,720
WILL ADVANCE THE LONG-TERM GOAL

1172
00:50:24,720 --> 00:50:26,360
OF IMPROVING THE RECOMMENDATIONS

1173
00:50:26,360 --> 00:50:30,680
FOR PATIENTS AND DEVELOPMENT OF

1174
00:50:30,680 --> 00:50:32,000
METABOLIC THERAPIES AND JUST A

1175
00:50:32,000 --> 00:50:33,560
FEW EXAMPLES AND I WANT TO POINT

1176
00:50:33,560 --> 00:50:35,520
OUT THIS IS NOT AN INCLUSIVE

1177
00:50:35,520 --> 00:50:38,400
LIST JUST EXAMPLES AND WHAT ARE

1178
00:50:38,400 --> 00:50:40,320
THE MOLECULAR MECHANISMS THAT

1179
00:50:40,320 --> 00:50:42,320
MODERATE THE EFFECTS OF

1180
00:50:42,320 --> 00:50:44,800
DIFFERENT SPECIES ON DIETARY

1181
00:50:44,800 --> 00:50:47,080
LIPIDS SUCH AS ACID ON TUMOR

1182
00:50:47,080 --> 00:50:48,800
PROFESSION AND HOW TO DIET

1183
00:50:48,800 --> 00:50:50,000
DRIVEN VARIATIONS IN THE LEVEL

1184
00:50:50,000 --> 00:50:54,480
OR COMPOSITION OF FATTY ACIDS IN

1185
00:50:54,480 --> 00:51:00,520
FLUID IMPACT TUMOR AND STROMAL

1186
00:51:00,520 --> 00:51:02,120
CELLS AND MIGHT OWE CON DEGREAL

1187
00:51:02,120 --> 00:51:04,480
FUNCTION AND THE REACTIVE OXYGEN

1188
00:51:04,480 --> 00:51:06,280
SPECIES AND HOW THE DRIVER

1189
00:51:06,280 --> 00:51:10,520
MUTATIONS SUCH AS P53, KRAS AND

1190
00:51:10,520 --> 00:51:12,440
MYC IN TUMOR CELLS IN RESPONSE

1191
00:51:12,440 --> 00:51:13,160
TO DIET.

1192
00:51:13,160 --> 00:51:16,320
HOW ARE ALTERATIONS IN DIET

1193
00:51:16,320 --> 00:51:18,440
RESPONSIVE LIPID METABOLISM IN

1194
00:51:18,440 --> 00:51:21,080
TUMOR BUFFERED OR ENHANCED BY

1195
00:51:21,080 --> 00:51:22,440
THE TUMOR MICRO ENVIRONMENT AND

1196
00:51:22,440 --> 00:51:24,440
WHAT ARE THE MOLECULAR

1197
00:51:24,440 --> 00:51:25,760
MECHANISMS THROUGH DIET

1198
00:51:25,760 --> 00:51:27,840
RESPONSIVE CIRCULATING FACTORS

1199
00:51:27,840 --> 00:51:30,240
IN SUCH AND STEROID HOR MONTHS

1200
00:51:30,240 --> 00:51:31,280
INFLUENCE CANCER CELL METABOLISM

1201
00:51:31,280 --> 00:51:33,280
IN TUMOR PROCESS AND THE TUMOR

1202
00:51:33,280 --> 00:51:34,760
MICK REENVIRONMENT IN THE

1203
00:51:34,760 --> 00:51:36,560
ABSENCE OF WEIGHT GAIN AND

1204
00:51:36,560 --> 00:51:37,760
APPLICATION THAT'S EXAMINE HOW

1205
00:51:37,760 --> 00:51:39,160
ANY OF THE ABOVE TOPICS OR ANY

1206
00:51:39,160 --> 00:51:42,720
OTHER TOPICS THAT THEY SUBMIT

1207
00:51:42,720 --> 00:51:44,480
THAT WOULD BE RESPONSIVE

1208
00:51:44,480 --> 00:51:45,800
CONTRIBUTE TO HEALTH DISPARITIES

1209
00:51:45,800 --> 00:51:48,400
ARE WELCOMED AND ENCOURAGED.

1210
00:51:48,400 --> 00:51:49,560
PORTFOLIO ANALYSIS IS VERY

1211
00:51:49,560 --> 00:51:51,840
IMPORTANT TO US SO EVALUATION OF

1212
00:51:51,840 --> 00:51:52,600
AWARDS MADE UNDER THIS PROGRAM

1213
00:51:52,600 --> 00:51:54,200
WILL BE BASED ON MEASURABLE

1214
00:51:54,200 --> 00:51:55,760
PERFORMANCE CRITERIA AND

1215
00:51:55,760 --> 00:51:57,680
INCLUDING BUT NOT LIMITED TO THE

1216
00:51:57,680 --> 00:51:59,080
CHANGE IN THE NUMBER OF

1217
00:51:59,080 --> 00:52:02,440
COLLABORATIONS AND BETWEEN

1218
00:52:02,440 --> 00:52:04,560
NUTRITION SCIENTISTS AND

1219
00:52:04,560 --> 00:52:06,480
DETERMINED BY NETWORK ANALYSIS

1220
00:52:06,480 --> 00:52:08,200
AND THE TIMELY DISSEMINATION OF

1221
00:52:08,200 --> 00:52:10,080
RESEARCH FUNDING THROUGH PRE

1222
00:52:10,080 --> 00:52:11,840
PRINTS AND JOURNAL ARTICLES AND

1223
00:52:11,840 --> 00:52:13,400
THE DEVELOPMENT OF RESOURCES AS

1224
00:52:13,400 --> 00:52:14,920
WELL AS A SHARING OF THOSE

1225
00:52:14,920 --> 00:52:16,320
RESOURCES WITH THE WIDER

1226
00:52:16,320 --> 00:52:17,280
SCIENTIFIC COMMUNITY AND THE

1227
00:52:17,280 --> 00:52:19,160
ACTIVE PARTICIPATION OF AWARDEES

1228
00:52:19,160 --> 00:52:20,840
IN THE WORK BE GROUP AND OTHER

1229
00:52:20,840 --> 00:52:22,320
RELATED ACTIVITIES AND ADHERENCE

1230
00:52:22,320 --> 00:52:24,080
TO NCI POLICIES AND BEST

1231
00:52:24,080 --> 00:52:26,640
PRACTICES INCLUDING DATA

1232
00:52:26,640 --> 00:52:27,440
SHARING.

1233
00:52:27,440 --> 00:52:30,920
SO, TO SUMMARIZE, THEY CAN

1234
00:52:30,920 --> 00:52:31,600
DIRECTLY INFLUENCE TUMOR GROWTH

1235
00:52:31,600 --> 00:52:33,240
AND PROGR BOTH

1236
00:52:33,240 --> 00:52:34,880
CELL AUTONOMOUS MECHANISMS AND

1237
00:52:34,880 --> 00:52:37,240
THE PROPOSED CONCEPT FILLS A GAP

1238
00:52:37,240 --> 00:52:39,440
IN THE NCI PORTFOLIO AND WILL

1239
00:52:39,440 --> 00:52:41,040
LEVERAGE RECENT DISCOVERIES AND

1240
00:52:41,040 --> 00:52:43,120
METH LOGICAL INNOVATIONS TO

1241
00:52:43,120 --> 00:52:44,680
ADVANCE GOAL 4 OF THE 10-YEAR

1242
00:52:44,680 --> 00:52:46,520
NIH STRATEGIC PLAN FOR

1243
00:52:46,520 --> 00:52:47,840
NUTRITIONAL RESEARCH AND

1244
00:52:47,840 --> 00:52:49,520
APPLICANTS WILL BE EXPECTED TO

1245
00:52:49,520 --> 00:52:51,760
INCLUDE NUTRITIONISTS THROUGH AN

1246
00:52:51,760 --> 00:52:53,960
MPI OR CO-PI STRUCTURE

1247
00:52:53,960 --> 00:52:55,160
ESTABLISHING BRIDGES THROUGH A

1248
00:52:55,160 --> 00:52:56,720
HISTORICALLY SILOED COMMUNITIES

1249
00:52:56,720 --> 00:53:00,160
OF NUTRITION SIGNS AND MOLECULAR

1250
00:53:00,160 --> 00:53:00,800
METABOLISM AND BETTER

1251
00:53:00,800 --> 00:53:02,040
UNDERSTANDING OF DIETARY

1252
00:53:02,040 --> 00:53:04,720
INFLUENCES ON FUNDAMENTAL CANCER

1253
00:53:04,720 --> 00:53:06,960
METABOLISM THAT WILL ENHANCE

1254
00:53:06,960 --> 00:53:08,360
NUTRITIONAL RECOMMENDATIONS FOR

1255
00:53:08,360 --> 00:53:08,840
PATIENTS AS WELL AS THE

1256
00:53:08,840 --> 00:53:10,640
POTENTIAL DEVELOPMENT OF

1257
00:53:10,640 --> 00:53:11,920
METABOLIC THERAPIES.

1258
00:53:11,920 --> 00:53:12,960
I WANT TO THANK THE MEMBERS OF

1259
00:53:12,960 --> 00:53:14,520
THE SUBCOMMITTEE FOR THE VERY

1260
00:53:14,520 --> 00:53:15,760
HELPFUL SUGGESTIONS AND FOR

1261
00:53:15,760 --> 00:53:17,480
MEETING WITH US TO DISCUSS THIS

1262
00:53:17,480 --> 00:53:17,880
CONCEPT.

1263
00:53:17,880 --> 00:53:24,680
AND WITH THAT I YIELD TO THE

1264
00:53:24,680 --> 00:53:24,920
BOARD.

1265
00:53:24,920 --> 00:53:25,760
>> GREAT.

1266
00:53:25,760 --> 00:53:28,160
THANK YOU, CHRISTINE.

1267
00:53:28,160 --> 00:53:32,080
WOULD YOU LIKE TO START THE

1268
00:53:32,080 --> 00:53:32,360
DISCUSSION?

1269
00:53:32,360 --> 00:53:32,880
>>

1270
00:53:32,880 --> 00:53:36,280
>> SURE, SO, I WANT TO
JUST

1271
00:53:36,280 --> 00:53:37,440
THANK YOU Dr. WILLIS FOR HER

1272
00:53:37,440 --> 00:53:38,800
EXCELLENT PRESENTATIONS OF THIS

1273
00:53:38,800 --> 00:53:41,640
CONCEPT AND ALSO THANK THE

1274
00:53:41,640 --> 00:53:45,360
DOCTOR FOR BEING PART OF THE

1275
00:53:45,360 --> 00:53:46,280
SUBCOMMITTEE AND WE HAD AN

1276
00:53:46,280 --> 00:53:47,480
INITIAL MEETING OF THE

1277
00:53:47,480 --> 00:53:49,280
SUBCOMMITTEE AND MET WITH Dr.

1278
00:53:49,280 --> 00:53:51,960
WILLIS AND HER COLLEAGUES IN A

1279
00:53:51,960 --> 00:53:53,840
SECOND MEETING BUT THE REVIEWERS

1280
00:53:53,840 --> 00:53:55,480
ALL OF US FELT THIS WAS REALLY

1281
00:53:55,480 --> 00:53:58,800
AN IMPORTANT AND TIMELY TOPIC

1282
00:53:58,800 --> 00:54:00,160
AND THAT WILL DRAW A LOT OF

1283
00:54:00,160 --> 00:54:01,560
INTEREST FROM SCIENTISTS IN THE

1284
00:54:01,560 --> 00:54:03,440
FIELD AND IT'S ALSO INCREDIBLY

1285
00:54:03,440 --> 00:54:05,000
IMPORTANT TO PATIENTS WHO ARE

1286
00:54:05,000 --> 00:54:06,240
REALLY INTERESTED IN ANSWERS

1287
00:54:06,240 --> 00:54:07,960
HAVING THESE QUESTIONS AND SADLY

1288
00:54:07,960 --> 00:54:10,680
MANY OF THEM ARE NOT GETTING

1289
00:54:10,680 --> 00:54:12,400
THEIR DATA ON THIS FROM EVIDENCE

1290
00:54:12,400 --> 00:54:14,720
BASED SOURCES SO THIS WILL HELP

1291
00:54:14,720 --> 00:54:18,040
BUILD THAT EVIDENCE AND THE

1292
00:54:18,040 --> 00:54:21,480
PORTFOLIO REVIEW DOES INDICATE A

1293
00:54:21,480 --> 00:54:22,720
NEED FOR THE FUNDING

1294
00:54:22,720 --> 00:54:25,520
ANNOUNCEMENT SPECIFICALLY IN

1295
00:54:25,520 --> 00:54:28,160
THIS AREA AND YOU KNOW THIS AREA

1296
00:54:28,160 --> 00:54:30,320
IS A RESEARCH GAP WAS IDENTIFIED

1297
00:54:30,320 --> 00:54:35,720
AND THE JULY 2021 WORKSHOP AND

1298
00:54:35,720 --> 00:54:37,120
OTHER POSITIVES OF BEING PART OF

1299
00:54:37,120 --> 00:54:39,120
THE RPG POOL AND ABOUT THIS IDEA

1300
00:54:39,120 --> 00:54:41,120
OF HAVING AN ANNUAL MEETING FOR

1301
00:54:41,120 --> 00:54:44,200
GRANTEE TO MEET AND INCLUDING A

1302
00:54:44,200 --> 00:54:46,960
NUTRITIONIST ON THE TEAM TO SORT

1303
00:54:46,960 --> 00:54:48,440
OF BRIDGE THOSE LACK OF

1304
00:54:48,440 --> 00:54:50,440
COMMUNICATION BETWEEN THE TWO

1305
00:54:50,440 --> 00:54:51,640
FIELDS AND SOME CONCERNS THAT

1306
00:54:51,640 --> 00:54:53,080
WERE RAISED IN THE INITIAL

1307
00:54:53,080 --> 00:54:58,000
REVIEW WE WANTED TO SEE HOW IT

1308
00:54:58,000 --> 00:55:00,360
FITS IN WITH THE NUTRITION

1309
00:55:00,360 --> 00:55:03,400
STRATEGIC PLAN AND ELABORATION

1310
00:55:03,400 --> 00:55:04,840
ON THAT AND THE FOCUS OF THE

1311
00:55:04,840 --> 00:55:11,120
OTHER CONCERN WAS THE FOCUS OF

1312
00:55:11,120 --> 00:55:12,520
THE WHEN WE KNOW THERE ARE MANY

1313
00:55:12,520 --> 00:55:14,400
OTHER AREAS THAT ARE RELATED TO

1314
00:55:14,400 --> 00:55:17,360
NUTRITION THAT WOULD BE RELEVANT

1315
00:55:17,360 --> 00:55:18,920
TO AND THINKING ABOUT OBESITY

1316
00:55:18,920 --> 00:55:22,440
AND INFLAMMATION AND THEY

1317
00:55:22,440 --> 00:55:23,440
DESCRIBED THIS SORT OF TOUCHING

1318
00:55:23,440 --> 00:55:30,880
ON PART OF THE ELEPHANT AND AND

1319
00:55:30,880 --> 00:55:38,360
THE CANCER PREVENTION DIVISION

1320
00:55:38,360 --> 00:55:48,920
AND AND I'LL TURN IT OVER TO THE

1321
00:55:49,200 --> 00:55:53,200
DOCTOR TO SEE IF SHE WANTS TO

1322
00:55:53,200 --> 00:55:56,840
ADD ANYTHING.

1323
00:55:56,840 --> 00:55:58,080
>> OUR CONVERSATIONS ARE
WELL

1324
00:55:58,080 --> 00:56:01,120
AND I THINK I'LL JUST PUT A FEW

1325
00:56:01,120 --> 00:56:03,280
MORE POINTS OF FATAH SIS.

1326
00:56:03,280 --> 00:56:05,720
BREAKING DOWN OF SILOS BETWEEN

1327
00:56:05,720 --> 00:56:07,560
NUTRITIONIST AND MOLECULAR

1328
00:56:07,560 --> 00:56:08,680
METABOLISM PEOPLE WE FELT WAS

1329
00:56:08,680 --> 00:56:10,440
THE BIGGEST BENEFIT OF THIS AND

1330
00:56:10,440 --> 00:56:20,880
IT'S A REAL PROBLEM AND WE

1331
00:56:26,240 --> 00:56:27,640
WANTED TO MAKE SURE WAS CAPTURED

1332
00:56:27,640 --> 00:56:31,840
IN THE NUTRITION PART WAS

1333
00:56:31,840 --> 00:56:36,920
OBESITY AND I'LL PUT ANOTHER

1334
00:56:36,920 --> 00:56:38,720
PLUG IN MORROW BEES TEE AND WE

1335
00:56:38,720 --> 00:56:45,760
CAST A WIDE NET BUT IN GENERAL,

1336
00:56:45,760 --> 00:56:47,560
WE SAW THIS AS IMPORTANT AND

1337
00:56:47,560 --> 00:56:48,400
UNDERFUNDED AND RECOGNIZED BY

1338
00:56:48,400 --> 00:56:54,080
THE NCI.

1339
00:56:54,080 --> 00:57:04,680
ANY QUESTIONS OR COMMENTS?

1340
00:57:04,680 --> 00:57:06,920
>> WHEN YOU TALK ABOUT
CANCER

1341
00:57:06,920 --> 00:57:08,640
PATIENTS, AND SO DOES THIS

1342
00:57:08,640 --> 00:57:11,480
INCLUDE SURVIVE OR POPULATIONS

1343
00:57:11,480 --> 00:57:13,240
BECAUSE, DIET AND ISSUES

1344
00:57:13,240 --> 00:57:17,720
RELATING TO DIETARY IMPACT IN

1345
00:57:17,720 --> 00:57:19,440
THE SURVIVORS AND THIS IS A

1346
00:57:19,440 --> 00:57:21,640
MAJOR ISSUE SO YOU CAN CLARIFY

1347
00:57:21,640 --> 00:57:23,960
IF THIS IS RESPONSIVE IN IF

1348
00:57:23,960 --> 00:57:25,080
SOMEONE SUBMITS A APPLICATION IN

1349
00:57:25,080 --> 00:57:30,120
RESPONSE TO CANCER SURVIVORS?

1350
00:57:30,120 --> 00:57:33,400
>> SO I THINK IF THEY'RE
LOOKING

1351
00:57:33,400 --> 00:57:37,120
AT TUMOR GROWTH OR EXIT FROM DOR

1352
00:57:37,120 --> 00:57:38,800
MAN SEE AND HOW THAT WOULD BE

1353
00:57:38,800 --> 00:57:39,600
CONSIDERED RESPONSIVE.

1354
00:57:39,600 --> 00:57:42,040
I WOULD CONSIDER THAT

1355
00:57:42,040 --> 00:57:42,600
RESPONSIVE, SURE.

1356
00:57:42,600 --> 00:57:44,600
AND I WOULD ALSO LIKE TO ADD, WE

1357
00:57:44,600 --> 00:57:45,680
WOULD CONSIDER APPLICATIONS THAT

1358
00:57:45,680 --> 00:57:49,120
DEALT WITH OBESITY AND

1359
00:57:49,120 --> 00:57:50,720
MICROBIOME AND LIPID METABOLISM

1360
00:57:50,720 --> 00:57:52,000
TO BE RESPONSIVE SO WE AGREE

1361
00:57:52,000 --> 00:57:56,040
THAT THOSE ARE IMPORTANT TOPICS

1362
00:57:56,040 --> 00:58:00,240
AS WELL.

1363
00:58:00,240 --> 00:58:02,520
>> THIS IS, I THINK THIS
IS

1364
00:58:02,520 --> 00:58:07,400
TERRIFIC AREA AND THAT NEEDS

1365
00:58:07,400 --> 00:58:08,040
INVESTMENTS.

1366
00:58:08,040 --> 00:58:09,680
DRUGS MODIFY THROUGH THE

1367
00:58:09,680 --> 00:58:13,640
METABOLISM AS WELL SO DO YOU

1368
00:58:13,640 --> 00:58:17,640
INVASION THAT FUNCTION OF TREAT

1369
00:58:17,640 --> 00:58:18,760
STRATEGIES AND THE STUDY OF THAT

1370
00:58:18,760 --> 00:58:22,720
WOULD BE PART OF THE RESPONSIVE

1371
00:58:22,720 --> 00:58:23,080
APPLICATIONS?

1372
00:58:23,080 --> 00:58:25,800
>> YOU BROKE UP A LITTLE
BIT.

1373
00:58:25,800 --> 00:58:26,080
I'M SORRY.

1374
00:58:26,080 --> 00:58:29,120
I THINK YOU ASKED THE QUESTION

1375
00:58:29,120 --> 00:58:30,800
WHICH WAS, WE ALL AGREE THAT

1376
00:58:30,800 --> 00:58:32,600
THERE ARE DRUGS THAT WOULD

1377
00:58:32,600 --> 00:58:34,200
EFFECT METABOLISM AS WELL AND

1378
00:58:34,200 --> 00:58:36,120
WITH THOSE BE INCLUDED AND YES,

1379
00:58:36,120 --> 00:58:37,400
I THINK THAT THOSE WOULD BE

1380
00:58:37,400 --> 00:58:40,520
CONSIDERED RESPONSIVE.

1381
00:58:40,520 --> 00:58:41,360
>> LET ME TRY AGAIN.

1382
00:58:41,360 --> 00:58:43,480
I'M GOING TO TURN MY VIDEO OFF

1383
00:58:43,480 --> 00:58:44,360
IT MIGHT HELP.

1384
00:58:44,360 --> 00:58:46,880
WOULD THE DIET BE A FUNCTION OF

1385
00:58:46,880 --> 00:58:51,000
THE DRUGS THAT PEOPLE ARE

1386
00:58:51,000 --> 00:58:53,600
TAKING?

1387
00:58:53,600 --> 00:58:54,960
>> THAT'S A VERY
INTERESTING

1388
00:58:54,960 --> 00:58:56,480
QUESTION WOULD THE DIET BE A

1389
00:58:56,480 --> 00:58:59,440
FUNCTION OF THE DRUGS AND I

1390
00:58:59,440 --> 00:59:00,480
THINK THAT'S WORTH

1391
00:59:00,480 --> 00:59:01,640
INVESTIGATING, YEAH, SO I THINK

1392
00:59:01,640 --> 00:59:05,320
IT'S AN INTERESTING QUESTION,

1393
00:59:05,320 --> 00:59:05,480
YES.

1394
00:59:05,480 --> 00:59:08,800
>> ARE YOU, ARE YOU
PLANNING TO

1395
00:59:08,800 --> 00:59:12,840
INVOLVE PATIENT ADVOCATES?

1396
00:59:12,840 --> 00:59:14,440
>> I THINK THAT THAT WOULD
BE A

1397
00:59:14,440 --> 00:59:16,160
GREAT THING IF PATIENT ADVOCATES

1398
00:59:16,160 --> 00:59:20,080
WOULD LIKE TO BE INVOLVED IN

1399
00:59:20,080 --> 00:59:23,160
THIS AS WELL.

1400
00:59:23,160 --> 00:59:25,040
>> SOME REQUIRE PATIENT

1401
00:59:25,040 --> 00:59:25,280
ADVOCATES.

1402
00:59:25,280 --> 00:59:26,920
>> HERE BECAUSE WE'RE
DEALING

1403
00:59:26,920 --> 00:59:31,320
WITH FUNDAMENTAL RESEARCH, AND

1404
00:59:31,320 --> 00:59:33,080
THAT IS WHETHER IS FOCUSED IS ON

1405
00:59:33,080 --> 00:59:34,680
THE FUNDAMENTAL BIOLOGY OF THIS

1406
00:59:34,680 --> 00:59:36,920
BECAUSE IT'S SO EARLY ON AND SO

1407
00:59:36,920 --> 00:59:39,160
I WOULD DEFER TO THE PIs

1408
00:59:39,160 --> 00:59:40,240
PROBABLY ON THAT AND I CAN

1409
00:59:40,240 --> 00:59:44,000
IMAGINE THAT FOR SOME PROJECTS

1410
00:59:44,000 --> 00:59:46,240
IT DEPENDS ON THE PROJECTS IT

1411
00:59:46,240 --> 00:59:52,400
SOMETHING WE WOULD BE OPEN TO.

1412
00:59:52,400 --> 00:59:54,160
>> THIS IS A GREAT
INITIATIVE

1413
00:59:54,160 --> 00:59:57,440
AND I'M A LITTLE BIT FUSED BY

1414
00:59:57,440 --> 00:59:59,120
THE FACT THAT THIS DOES

1415
00:59:59,120 --> 01:00:02,920
EMPHASIZE FUNDAMENTAL SCIENCE

1416
01:00:02,920 --> 01:00:05,000
BUT YOU ARE REALLY PRIORITIZING

1417
01:00:05,000 --> 01:00:09,000
MPI APPLICATIONS FROM

1418
01:00:09,000 --> 01:00:15,960
NUTRITIONISTS WHICH, IS THAT

1419
01:00:15,960 --> 01:00:17,400
IMPLYING CLINICAL NUTRITIONISTS

1420
01:00:17,400 --> 01:00:18,800
OR JUST SCIENTISTS.

1421
01:00:18,800 --> 01:00:20,000
A LOT OF THOSE FOLKS ARE

1422
01:00:20,000 --> 01:00:22,120
OBVIOUSLY REALLY IMPORTANT I

1423
01:00:22,120 --> 01:00:24,960
THINK IN THE THOUGHT PROCESS BUT

1424
01:00:24,960 --> 01:00:26,320
MAYBE LESS INVOLVED NATURALXA

1425
01:00:26,320 --> 01:00:28,320
FUNDAMENTAL SCIEN AND THAT WAS R

1426
01:00:28,320 --> 01:00:30,440
OUTCOME OF OUR WORKSHOP IN 2021

1427
01:00:30,440 --> 01:00:32,760
IN THE SUMMER OF 2021 IS ALL OF

1428
01:00:32,760 --> 01:00:34,960
OUR PANELISTS SPOKE AT LENGTH

1429
01:00:34,960 --> 01:00:39,320
ABOUT THE NEED TO INVOLVE MORE

1430
01:00:39,320 --> 01:00:42,200
LINKS BETWEEN DIFFERENT PARTS OF

1431
01:00:42,200 --> 01:00:44,720
THE CARE FROM NUTRITIONISTS AND

1432
01:00:44,720 --> 01:00:46,280
FUNDAMENTAL BIOLOGIST AND SO THE

1433
01:00:46,280 --> 01:00:48,200
IDEA HERE IS THAT THIS IS A

1434
01:00:48,200 --> 01:00:49,960
FUNDAMENTAL BIOLOGY

1435
01:00:49,960 --> 01:00:51,880
INVESTIGATION BUT BECAUSE DIET

1436
01:00:51,880 --> 01:00:53,840
IMPACTS THE FUNDAMENTAL POLL HE

1437
01:00:53,840 --> 01:00:57,040
CAN YOU LAR METABOLISM AT THE

1438
01:00:57,040 --> 01:00:58,600
CELLULAR LEVEL THAT WE WANT TO

1439
01:00:58,600 --> 01:01:01,360
INCLUDE THE NUTRITIONISTS AND

1440
01:01:01,360 --> 01:01:02,480
JOIN THOSE TWO FIELDS TOGETHER

1441
01:01:02,480 --> 01:01:05,480
AND SORT OF BRIDGE THAT

1442
01:01:05,480 --> 01:01:07,040
HISTORICALLY EXISTING DIVISION

1443
01:01:07,040 --> 01:01:08,840
SO IT'S CERTAINLY A FUNDAMENTAL

1444
01:01:08,840 --> 01:01:10,120
BIOLOGY INITIATIVE AND WE THINK

1445
01:01:10,120 --> 01:01:11,280
IT'S IMPORTANT BECAUSE WE NEED

1446
01:01:11,280 --> 01:01:12,520
TO UNDERSTAND, AS ONE OF THE

1447
01:01:12,520 --> 01:01:14,280
BOARD MEMBERS JUST SAID, VERY

1448
01:01:14,280 --> 01:01:15,080
ELOQUENTLY, WE NEED TO

1449
01:01:15,080 --> 01:01:18,560
UNDERSTAND THE FUNDAMENTAL

1450
01:01:18,560 --> 01:01:19,920
MOLECULAR METABOLISM IN ORDER TO

1451
01:01:19,920 --> 01:01:21,720
MAKE GOOD RECOMMENDATION TO

1452
01:01:21,720 --> 01:01:22,000
PATIENTS.

1453
01:01:22,000 --> 01:01:23,440
THE IDEA IS TO HAVE A

1454
01:01:23,440 --> 01:01:25,960
FUNDAMENTAL MOLECULAR METABOLISM

1455
01:01:25,960 --> 01:01:27,800
INITIATIVE THAT INCORPORATES ADD

1456
01:01:27,800 --> 01:01:29,160
VOICE FROM NUTRITION SCIENTIST

1457
01:01:29,160 --> 01:01:31,520
AND NUTRITIONIST AND DIETITIANS.

1458
01:01:31,520 --> 01:01:35,760
>> SO NUTRITIONIST IS
BEING

1459
01:01:35,760 --> 01:01:36,120
DEFIND BROADLY.

1460
01:01:36,120 --> 01:01:36,480
>> RIGHT.

1461
01:01:36,480 --> 01:01:39,480
>> SO NUTRITIONAL
EPIDEMIOLOGIST

1462
01:01:39,480 --> 01:01:41,040
OR NUTRITIONAL SCIENTIST WOULD

1463
01:01:41,040 --> 01:01:41,520
BE --

1464
01:01:41,520 --> 01:01:43,120
>> IF THAT'S THE MOST

1465
01:01:43,120 --> 01:01:44,160
APPROPRIATE THING FOR THAT

1466
01:01:44,160 --> 01:01:45,600
PROJECT, YES.

1467
01:01:45,600 --> 01:01:49,240
>> THANK YOU.

1468
01:01:49,240 --> 01:01:51,120
>> I WAS ASKING TO
REQUEST, I

1469
01:01:51,120 --> 01:01:53,400
THINK BEING A LITTLE BIT MORE

1470
01:01:53,400 --> 01:01:55,320
PRECISE ABOUT WHAT A

1471
01:01:55,320 --> 01:02:00,120
NUTRITIONIST IS GOING TO BE

1472
01:02:00,120 --> 01:02:00,400
IMPORTANT.

1473
01:02:00,400 --> 01:02:04,720
>> OK.

1474
01:02:04,720 --> 01:02:10,880
>> I THINK BEFORE --

1475
01:02:10,880 --> 01:02:13,000
>> HOWARD, GO AHEAD.

1476
01:02:13,000 --> 01:02:17,320
>> WE BRING UP THIS ISSUE
OF

1477
01:02:17,320 --> 01:02:18,800
DRUGS AND WHAT SKILLS SETS MIGHT

1478
01:02:18,800 --> 01:02:21,600
BE APPLICABLE TO THIS KIND OF

1479
01:02:21,600 --> 01:02:23,520
RESEARCH, I JUST WANTED TO PUT

1480
01:02:23,520 --> 01:02:28,600
IN TWO CENTS FOR ONE IS THAT

1481
01:02:28,600 --> 01:02:31,200
IMMUNO ONOLOGISTS AND THE SECOND

1482
01:02:31,200 --> 01:02:32,720
IS THE NUCLEAR MEDICINE PEOPLE.

1483
01:02:32,720 --> 01:02:35,480
I THINK YOU KNOW THERE'S BELIEF

1484
01:02:35,480 --> 01:02:39,440
AMONG SOME THAT THE HEALTH OF

1485
01:02:39,440 --> 01:02:40,440
THE LIMP NODE SYSTEM AND THE

1486
01:02:40,440 --> 01:02:47,520
IMPACT OF FIRST LINE TREATMENTS

1487
01:02:47,520 --> 01:02:57,760
LIKE PLATINUM.

1488
01:03:12,840 --> 01:03:15,080
IT MITIGATE THE TOXICITY TO

1489
01:03:15,080 --> 01:03:17,640
NORMAL ISSUE AND THE PATENT THAT

1490
01:03:17,640 --> 01:03:19,440
WAS DEVELOPED AROUND THAT AND

1491
01:03:19,440 --> 01:03:21,760
IT'S BEEN HELD UP AND NUCLEAR

1492
01:03:21,760 --> 01:03:28,320
MEDICINE AND IN INDUSTRY AND

1493
01:03:28,320 --> 01:03:29,960
SOME ARE THESE TESTED AS MICRO

1494
01:03:29,960 --> 01:03:33,080
PET WHERE YOU CAN DO PET SCANS

1495
01:03:33,080 --> 01:03:35,600
ON ANIMAL MODELS AND THE BELIEVE

1496
01:03:35,600 --> 01:03:37,400
THAT THAT CAN REFER YOU TO

1497
01:03:37,400 --> 01:03:38,400
PEOPLE AND I DON'T KNOW THAT

1498
01:03:38,400 --> 01:03:39,880
MANY ACADEMIC GROUPS THAT ARE

1499
01:03:39,880 --> 01:03:42,240
USING THOSE TECHNOLOGIES BUT YOU

1500
01:03:42,240 --> 01:03:44,920
KNOW, IT'S SOMETHING THAT HAS

1501
01:03:44,920 --> 01:03:46,680
GUIDED TREATMENTS AND MAYBE

1502
01:03:46,680 --> 01:03:48,080
INTEREST IN CERTAIN TUMOR TYPES.

1503
01:03:48,080 --> 01:03:54,400
IF YOU SAW CON SIS TAN SEE AMONG

1504
01:03:54,400 --> 01:03:58,680
LIMB NOAM A AND SOLID TUMORS YOU

1505
01:03:58,680 --> 01:04:00,320
MAY MAKE DIRECTING TREATMENT

1506
01:04:00,320 --> 01:04:01,880
TOWARDS LYMPHOMA AND THEY FELT

1507
01:04:01,880 --> 01:04:03,160
THEY'RE MORE SUSCEPTIBLE TO

1508
01:04:03,160 --> 01:04:05,400
THESE KINDS OF MANIPULATIONS AS

1509
01:04:05,400 --> 01:04:08,200
A THERAPEUTIC APPROACH.

1510
01:04:08,200 --> 01:04:11,080
>> THANK YOU, THAT IS AN

1511
01:04:11,080 --> 01:04:14,640
EXCELLENT POINT.

1512
01:04:14,640 --> 01:04:16,760
>> I. HAPPY TO TAKE IT OFF
LINE

1513
01:04:16,760 --> 01:04:18,600
BUT I WAS GOING TO ASK ABOUT

1514
01:04:18,600 --> 01:04:19,600
COMMUNITY OF PRACTICE BECAUSE

1515
01:04:19,600 --> 01:04:22,120
THAT WOULD JUST EXCITED TO SEE

1516
01:04:22,120 --> 01:04:23,480
THAT BUT NO NEED TO SPEND TIME

1517
01:04:23,480 --> 01:04:26,640
ON IT HERE.

1518
01:04:26,640 --> 01:04:27,840
>> THANK YOU.

1519
01:04:27,840 --> 01:04:29,720
I THINK WE'LL MOVE TO VOTING.

1520
01:04:29,720 --> 01:04:33,640
THE DISCUSSION IS NOT HEADING IN

1521
01:04:33,640 --> 01:04:37,520
A DIRECTION OF DEFERRAL SO WE

1522
01:04:37,520 --> 01:04:39,400
GET A MOTION FOR APPROVAL VERSUS

1523
01:04:39,400 --> 01:04:39,720
DISAPPROVAL.

1524
01:04:39,720 --> 01:04:42,000
>> I MOVE FOR APPROVAL OF
THE

1525
01:04:42,000 --> 01:04:43,040
PAR.

1526
01:04:43,040 --> 01:04:43,680
>> GREAT, CAN I GET A
SECOND.

1527
01:04:43,680 --> 01:04:44,520
>> I SECOND.

1528
01:04:44,520 --> 01:04:45,960
>> GREAT.

1529
01:04:45,960 --> 01:04:51,760
NEED FOR FURTHER DISCUSSION?

1530
01:04:51,760 --> 01:04:53,040
>> AND I THINK YOUR HAND
IS

1531
01:04:53,040 --> 01:04:54,880
STILL UP FROM THE PRIOR

1532
01:04:54,880 --> 01:04:56,280
QUESTION.

1533
01:04:56,280 --> 01:04:59,560
HOWARD THE SAME.

1534
01:04:59,560 --> 01:05:01,640
OTHERWISE, NO EVIDENCE.

1535
01:05:01,640 --> 01:05:03,680
GREAT.

1536
01:05:03,680 --> 01:05:04,280
OK.

1537
01:05:04,280 --> 01:05:05,120
SO, ANY FURTHER DISCUSSION WE'LL

1538
01:05:05,120 --> 01:05:08,320
TAKE A FINAL VOTE AND SUBMISSION

1539
01:05:08,320 --> 01:05:09,720
FOR APPROVAL SO I WILL SEE

1540
01:05:09,720 --> 01:05:11,520
APPROVAL UNLESS YOU VOSS A

1541
01:05:11,520 --> 01:05:16,760
DISAPPROVAL VOTE OR RAISE YOUR

1542
01:05:16,760 --> 01:05:23,960
HAND.

1543
01:05:23,960 --> 01:05:27,400
>> ANY AB TENSION.

1544
01:05:27,400 --> 01:05:28,720
>> WE'RE GOOD.

1545
01:05:28,720 --> 01:05:30,000
>> WE'RE GOOD.

1546
01:05:30,000 --> 01:05:30,760
>> THANK YOU.

1547
01:05:30,760 --> 01:05:33,280
>> NEXT IS AN RFA CONCEPT

1548
01:05:33,280 --> 01:05:43,760
ADVANCING ADOLESCENT TOBACCO

1549
01:05:50,680 --> 01:05:50,880
SEES ACE.

1550
01:05:50,880 --> 01:05:52,280
>> THANK YOU FOR THIS

1551
01:05:52,280 --> 01:05:54,000
OPPORTUNITY TO PRESENT OUR

1552
01:05:54,000 --> 01:05:59,120
CONCEPT ADVANCING ADOLESCENT

1553
01:05:59,120 --> 01:06:02,440
TOBACCO CESSATION INTERVENTION

1554
01:06:02,440 --> 01:06:02,840
RESEARCH.

1555
01:06:02,840 --> 01:06:06,920
I'LL BEGIN BY PROVIDING A BRIEF

1556
01:06:06,920 --> 01:06:07,200
BACKGROUND.

1557
01:06:07,200 --> 01:06:09,160
MOST TOBACCO USE BEGINS IN

1558
01:06:09,160 --> 01:06:10,720
ADOLESCENTS, WITH USES

1559
01:06:10,720 --> 01:06:14,520
ESCALATING IN THE MID TO LATE

1560
01:06:14,520 --> 01:06:15,680
ADOLESCENT PERIOD AROUND HIGH

1561
01:06:15,680 --> 01:06:16,920
SCHOOL AND THE FEW YEARS BEYOND

1562
01:06:16,920 --> 01:06:18,760
AND HELPING YOU TO QUIT TOBACCO

1563
01:06:18,760 --> 01:06:20,600
USE EARLY IS CRITICAL TO CANCER

1564
01:06:20,600 --> 01:06:23,480
PREVENTION AND CONTROL AS COULD

1565
01:06:23,480 --> 01:06:24,920
ANNA VOID A SUBSTANTIAL AMOUNT

1566
01:06:24,920 --> 01:06:26,520
OF THE TOBACCO CAUSE MORBIDITY

1567
01:06:26,520 --> 01:06:29,120
AND MORTALITY BUT IT'S

1568
01:06:29,120 --> 01:06:30,360
INCREASINGLY COMPLICATED IN

1569
01:06:30,360 --> 01:06:31,800
RECENT YEARS AND WE'RE NOT JUST

1570
01:06:31,800 --> 01:06:36,080
PRIMARILY FOCUS ON CIGARETTES

1571
01:06:36,080 --> 01:06:37,600
ANYMORE, THERE'S TOBACCO PRODUCT

1572
01:06:37,600 --> 01:06:39,840
USE ON THE MARKET AND IN USE BY

1573
01:06:39,840 --> 01:06:44,320
ADOLESCENTS INCLUDING THE

1574
01:06:44,320 --> 01:06:46,480
NICOTINE Ns AND YOU MAY KNOW

1575
01:06:46,480 --> 01:06:49,160
AS E CIGARETTES AS WELL AS CIGAR

1576
01:06:49,160 --> 01:06:51,280
PRODUCTS LIKE LITTLE CIGARS AND

1577
01:06:51,280 --> 01:06:53,000
THESE OFTEN COME IN FLAVORS AND

1578
01:06:53,000 --> 01:06:54,480
MARKETING THAT APPEALS TO YOUTH

1579
01:06:54,480 --> 01:06:56,720
AND THIS PRODUCT DIVERSITY HAS

1580
01:06:56,720 --> 01:07:01,120
MORE COMPLEX USE PATTERNS AND

1581
01:07:01,120 --> 01:07:02,440
SUCH AS DUEL OR THE USE OF TWO

1582
01:07:02,440 --> 01:07:04,040
OR MORE PRODUCTS IN THE SAME

1583
01:07:04,040 --> 01:07:06,440
TIME PERIOD AND IN RECENT YEARS,

1584
01:07:06,440 --> 01:07:07,840
AS THE AVAILABILITY OF CANNABIS

1585
01:07:07,840 --> 01:07:09,760
HAS INCREASED, CO USE OF

1586
01:07:09,760 --> 01:07:16,880
CANNABIS AND TOBACCO IS MORE

1587
01:07:16,880 --> 01:07:27,040
PREVALENT.

1588
01:08:43,800 --> 01:08:45,560
>> ADOLESCENCE IS UNIQUE
TIME

1589
01:08:45,560 --> 01:08:47,120
PERIOD AND IT'S THE PERIOD AT

1590
01:08:47,120 --> 01:08:48,400
WHICH INDIVIDUALS ARE MOST AT

1591
01:08:48,400 --> 01:08:50,760
RISK OF INITIATION AND

1592
01:08:50,760 --> 01:08:52,600
ESCALATION OF TOBACCO USE AND

1593
01:08:52,600 --> 01:08:54,120
ADOLESCENT TOBACCO USE DEVELOPS

1594
01:08:54,120 --> 01:08:56,920
ALONG VARIOUS TRAJECTORIES WITH

1595
01:08:56,920 --> 01:08:58,280
SUBSTANTIAL HETEROGENEITY IN

1596
01:08:58,280 --> 01:09:00,680
THESE PATTERNS AND SOME QUICKLY

1597
01:09:00,680 --> 01:09:02,000
ESCALATE TO DAY LIE USE AND

1598
01:09:02,000 --> 01:09:03,400
OTHERS PERSIST AT LOW LEVELS

1599
01:09:03,400 --> 01:09:06,320
OVER TIME.

1600
01:09:06,320 --> 01:09:07,640
INTERVENING DURING THE

1601
01:09:07,640 --> 01:09:10,880
ADOLESCENT YEARS PROVIDES UNIQUE

1602
01:09:10,880 --> 01:09:11,960
LAYERS OF OPPORTUNITY TO DISRUPT

1603
01:09:11,960 --> 01:09:13,400
THIS USE EARLY OR TREAT

1604
01:09:13,400 --> 01:09:14,720
ESTABLISHED DEPENDENTS EARLY

1605
01:09:14,720 --> 01:09:18,000
BEFORE IT SOLIDIFIES LONG-TERM

1606
01:09:18,000 --> 01:09:25,320
USE AND IT'S HEALTH CONSEQUENCE.

1607
01:09:25,320 --> 01:09:26,200
HAVE ADOLESCENTS IS A UNIQUE

1608
01:09:26,200 --> 01:09:28,760
PERIOD OF NEURO COGNITIVE AND

1609
01:09:28,760 --> 01:09:31,360
PSYCHOSOCIAL DEVELOPMENT WITH A

1610
01:09:31,360 --> 01:09:33,560
INTENSE FOCUS ON ESTABLISHING

1611
01:09:33,560 --> 01:09:34,840
PEER RELATIONSHIPS AND ONES'

1612
01:09:34,840 --> 01:09:36,840
IDENTITY AND IT'S THE TYPE WHERE

1613
01:09:36,840 --> 01:09:39,280
THE PREFRONTAL CORTEX IS STILL

1614
01:09:39,280 --> 01:09:40,440
ACTIVELY DEVELOPING WHICH IS THE

1615
01:09:40,440 --> 01:09:41,640
AREA OF THE BRAIN GOVERNING

1616
01:09:41,640 --> 01:09:46,200
LEARNING MEMORY AND IMPULSE

1617
01:09:46,200 --> 01:09:49,200
CONTROL AND SO THEY ARE NOT

1618
01:09:49,200 --> 01:09:52,000
FULLY FORMED AND SO IT'S

1619
01:09:52,000 --> 01:09:53,240
IMPORTANT TREATMENT IMPLICATIONS

1620
01:09:53,240 --> 01:09:55,000
AND IMPORTANT IMPLICATIONS FOR

1621
01:09:55,000 --> 01:09:59,880
THE APPROACHES THAT WE TAKE WITH

1622
01:09:59,880 --> 01:10:10,240
YOUTH FOR SEESATION.

1623
01:10:11,040 --> 01:10:12,720
AND WE HAVE THE REPORT TRYING TO

1624
01:10:12,720 --> 01:10:15,640
QUIT AND HOWEVER, WE CURRENTLY

1625
01:10:15,640 --> 01:10:19,400
HAVE FEW VALIDATED TOBACCO

1626
01:10:19,400 --> 01:10:22,960
ASSOCIATION INTERVENTION TO

1627
01:10:22,960 --> 01:10:33,560
OFFER THEM AND AND REVIEWED IN 7

1628
01:10:34,600 --> 01:10:37,440
BY THE COCHRAN GROUP AND 2020 BY

1629
01:10:37,440 --> 01:10:39,640
THE TASK FORCE REVIEWING PRIMARY

1630
01:10:39,640 --> 01:10:42,240
CARE FEASIBLE CESSATION

1631
01:10:42,240 --> 01:10:43,440
INTERVENTIONS AND THEY

1632
01:10:43,440 --> 01:10:44,800
RECOVID-19 BEHAVIORAL

1633
01:10:44,800 --> 01:10:47,960
INTERCEPTIONS TESTED IN

1634
01:10:47,960 --> 01:10:49,080
ADOLESCENCE THAT STUDIED THE

1635
01:10:49,080 --> 01:10:50,600
EFFECTS OF MEDICATIONS THAT ARE

1636
01:10:50,600 --> 01:10:54,640
FDA APPROVED FOR ADULT TOBACCO

1637
01:10:54,640 --> 01:10:56,000
CESSATION AND THE MAJOR

1638
01:10:56,000 --> 01:10:57,240
TAKEAWAYS FROM THESE REVIEWS

1639
01:10:57,240 --> 01:10:58,840
THERE WAS LITTLE SUPPORT FOR THE

1640
01:10:58,840 --> 01:11:00,680
CURRENT TESTED BEHAVIORAL

1641
01:11:00,680 --> 01:11:01,720
INTERVENTIONS WITH THE EXCEPTION

1642
01:11:01,720 --> 01:11:03,040
OF THE COCHRAN FINDING AND

1643
01:11:03,040 --> 01:11:04,960
EFFECT FOR GROUP COUNSELING

1644
01:11:04,960 --> 01:11:06,680
INTERVENTIONS LEGALITIES AND

1645
01:11:06,680 --> 01:11:08,320
THERE WAS NO SUPPORT FROM

1646
01:11:08,320 --> 01:11:10,240
MEDICATIONS USING IN ADOLESCENT

1647
01:11:10,240 --> 01:11:11,600
POPULATIONS TO DATE AND THE

1648
01:11:11,600 --> 01:11:14,760
STUDIES FOCUSED ON CIGARETTE

1649
01:11:14,760 --> 01:11:15,800
SMOKING CESSATION SO THERE'S

1650
01:11:15,800 --> 01:11:17,320
EVIDENCE FOR NON CIGARETTE

1651
01:11:17,320 --> 01:11:19,880
TOBACCO PRODUCTS AND STUDIES AND

1652
01:11:19,880 --> 01:11:20,880
POPULATIONS THAT EXPERIENCE

1653
01:11:20,880 --> 01:11:27,040
GREATER PREVENT AND BOTH

1654
01:11:27,040 --> 01:11:28,120
ACKNOWLEDGE THEY MAY PROMISE

1655
01:11:28,120 --> 01:11:29,680
TREATMENT DELIVERY AS WE ALL

1656
01:11:29,680 --> 01:11:33,000
KNOW ADOLESCENTS ARE MADE AND

1657
01:11:33,000 --> 01:11:36,680
USERS OF APPS AND TEXT MESSAGES

1658
01:11:36,680 --> 01:11:39,080
BUT INTERESTS A GAP IN TREATMENT

1659
01:11:39,080 --> 01:11:40,240
DELIVERING THESE PLATFORMS.

1660
01:11:40,240 --> 01:11:45,000
AND NEXT SLIDE, PLEASE.

1661
01:11:45,000 --> 01:11:46,840
AND OVER THE PAST FEW YEARS,

1662
01:11:46,840 --> 01:11:49,320
THERE'S BEEN A REMARKABLE

1663
01:11:49,320 --> 01:11:50,880
ALIGNMENT AMONG NCI AND AMONG

1664
01:11:50,880 --> 01:11:53,000
OUR FEDERAL PARTNERS AS WELL AS

1665
01:11:53,000 --> 01:11:55,720
THE SCIENTIFIC COMMUNITY AND THE

1666
01:11:55,720 --> 01:11:57,400
CLINICAL PARTNERS ON RESEARCH

1667
01:11:57,400 --> 01:11:59,600
NEEDS AND THE URGENCY OF

1668
01:11:59,600 --> 01:12:06,680
TREATING ADOLESCENT TOBACCO USE.

1669
01:12:06,680 --> 01:12:09,880
WHEN WE CONDUCTED -- NEXT SLIDE,

1670
01:12:09,880 --> 01:12:10,200
PLEASE.

1671
01:12:10,200 --> 01:12:12,480
WHEN WE CONDUCTED AN NIH WIDE

1672
01:12:12,480 --> 01:12:14,000
PORTFOLIO SEARCH WE FOUND VERY

1673
01:12:14,000 --> 01:12:15,520
FEW CURRENTLY ACTIVE GRANTS

1674
01:12:15,520 --> 01:12:17,720
CONDUCTING THIS TYPE OF RESEARCH

1675
01:12:17,720 --> 01:12:23,400
AND NON AT NCI.

1676
01:12:23,400 --> 01:12:25,680
TO MEET THIS CRITICAL NEED WE'VE

1677
01:12:25,680 --> 01:12:27,520
PROPOSED THIS RFA WITH THE GOAL

1678
01:12:27,520 --> 01:12:29,080
TO STIMULATE RESEARCH ON THE

1679
01:12:29,080 --> 01:12:31,000
DEVELOPMENT AND EVALUATION OF

1680
01:12:31,000 --> 01:12:32,280
TOBACCO CESSATION INTERVENTIONS

1681
01:12:32,280 --> 01:12:34,680
FOR ADOLESCENTS WITH THIS

1682
01:12:34,680 --> 01:12:35,920
ADOLESCENT PERIOD AND WE ARE

1683
01:12:35,920 --> 01:12:37,320
INTERESTED IN WELL DESIGNED

1684
01:12:37,320 --> 01:12:39,080
INTERVENTIONS THAT FOCUS ON THE

1685
01:12:39,080 --> 01:12:41,440
UNIQUE NEEDS OF ADOLESCENT

1686
01:12:41,440 --> 01:12:43,640
TOBACCO USE TEARS WILL TREAT

1687
01:12:43,640 --> 01:12:46,440
THIS TOBACCO DEPENDENCE EARLY OR

1688
01:12:46,440 --> 01:12:50,320
DISRUPT TOBACCO USE AND

1689
01:12:50,320 --> 01:12:51,320
APPLICATION TO ADDRESS THE RANGE

1690
01:12:51,320 --> 01:12:55,640
OF TOBACCO PRODUCTS AND THESE

1691
01:12:55,640 --> 01:13:05,080
MORE COMPLEX AS WELL AS VERY

1692
01:13:05,080 --> 01:13:06,200
IMPORTANTLY RESEARCH THAT BUILT

1693
01:13:06,200 --> 01:13:10,240
IN DESIGNS FOR AND PLANS FOR

1694
01:13:10,240 --> 01:13:11,000
DISSEMINATION AND IMPLEMENTATION

1695
01:13:11,000 --> 01:13:16,280
FROM THE BEGINNING STAGES OF THE

1696
01:13:16,280 --> 01:13:23,360
GRANT AND NEXT SLIDE, PLEASE.

1697
01:13:23,360 --> 01:13:25,400
SO SOME OF OUR EXAMPLE RESEARCH

1698
01:13:25,400 --> 01:13:26,400
QUESTIONS AND IN THE INTEREST OF

1699
01:13:26,400 --> 01:13:28,440
TIME I WON'T READ THEM ALL BUT

1700
01:13:28,440 --> 01:13:30,480
THEY RANGE FROM INCLUDING A

1701
01:13:30,480 --> 01:13:32,760
FOCUS ON THESE EFFECTIVE DIGITAL

1702
01:13:32,760 --> 01:13:33,760
THERAPEUTIC INTERVENTIONS AND

1703
01:13:33,760 --> 01:13:35,920
UNDERSTANDING HOW TO EFFECTIVELY

1704
01:13:35,920 --> 01:13:38,040
INTERVIEW WITH YOUTH ACROSS

1705
01:13:38,040 --> 01:13:39,960
THESE DIFFUSE PATTERNS AND

1706
01:13:39,960 --> 01:13:42,680
TRAJECTORIES OVER TIME AND AS

1707
01:13:42,680 --> 01:13:44,680
WELL AS HOW TO BETTER ENGAGE AND

1708
01:13:44,680 --> 01:13:46,000
EFFECTIVELY ENGAGE YOUTH IN

1709
01:13:46,000 --> 01:13:47,640
SUBGROUPS EXPERIENCED TOBACCO

1710
01:13:47,640 --> 01:13:49,120
RELATED HEALTH DISPARITIES AND

1711
01:13:49,120 --> 01:13:51,880
NEXT SLIDE, PLEASE.

1712
01:13:51,880 --> 01:13:54,120
SO WE PROPOSED FUNDING 10 AWARDS

1713
01:13:54,120 --> 01:13:57,560
USING BOTH THE RO1 AND R34

1714
01:13:57,560 --> 01:13:59,480
PLANNING MECHANISMS.

1715
01:13:59,480 --> 01:14:05,080
WE ARE ASKING FOR TWO RECEIPT

1716
01:14:05,080 --> 01:14:09,600
DATES WITH THE PLAN FOR TWO

1717
01:14:09,600 --> 01:14:20,040
AWARDS AND AND WE WILL ALLOW

1718
01:14:27,320 --> 01:14:37,800
LARGER BUDGETS FOR THE 104 SO WE

1719
01:14:43,920 --> 01:14:46,360
FOCUS ON ADOLESCENTS IN THIS

1720
01:14:46,360 --> 01:14:47,880
PERIOD TO ADDRESS WHAT WE SEE AS

1721
01:14:47,880 --> 01:14:49,280
THE AREA OF GREATEST NEED WITH

1722
01:14:49,280 --> 01:14:50,920
THE RESPECT TO THE EXISTING

1723
01:14:50,920 --> 01:14:52,440
EVIDENCE ON TOBACCO USE PATTERNS

1724
01:14:52,440 --> 01:14:54,880
AND ESCALATION AND THE GREATEST

1725
01:14:54,880 --> 01:14:58,800
EVIDENCE IN GAPS IN TREATMENTS

1726
01:14:58,800 --> 01:15:00,280
AVAILABLE FOR THIS AGE GROUP AND

1727
01:15:00,280 --> 01:15:04,720
WE SOLICIT RO1s TO TEST

1728
01:15:04,720 --> 01:15:05,520
INTERVENTION S WITH STRONG

1729
01:15:05,520 --> 01:15:07,160
PRELIMINARY DATA BUT WE ALSO

1730
01:15:07,160 --> 01:15:10,040
WOULD LIKE TO USE THE RO234

1731
01:15:10,040 --> 01:15:12,400
MECHANISM TO ALLOW FOR SOME

1732
01:15:12,400 --> 01:15:14,120
OTHER CLINICAL TRIAL PLANNING

1733
01:15:14,120 --> 01:15:24,640
GRANT ACTIVITIES AND THIS IS AND

1734
01:15:27,800 --> 01:15:29,520
ALLOW FOR ADEQUATE RESEARCH TEAM

1735
01:15:29,520 --> 01:15:30,080
S

1736
01:15:30,080 --> 01:15:31,760
FEASIBILITY AND STUDIES TO

1737
01:15:31,760 --> 01:15:33,080
IDENTIFY THE EFFECTIVE

1738
01:15:33,080 --> 01:15:34,720
RECRUITMENT RETENTION AND

1739
01:15:34,720 --> 01:15:35,800
ENGAGEMENT STRATEGIES FOR WHICH

1740
01:15:35,800 --> 01:15:38,520
THIS IS MORE CHALLENGING IN

1741
01:15:38,520 --> 01:15:39,880
PREVIOUS ADOLESCENT RESEARCH AND

1742
01:15:39,880 --> 01:15:42,960
THE RFA WILL ALLOW A SPECIALIZED

1743
01:15:42,960 --> 01:15:44,600
REGREW UP WHO ARE KNOWLEDGEABLE

1744
01:15:44,600 --> 01:15:46,040
ABOUT THIS DEVELOPMENT PERIOD AS

1745
01:15:46,040 --> 01:15:49,640
WELL AS TOBACCO CESSATION AND

1746
01:15:49,640 --> 01:15:51,320
FACILITATES THE CONVENE OF

1747
01:15:51,320 --> 01:15:52,440
GRANTEES TO DEVELOP SHARED

1748
01:15:52,440 --> 01:15:54,400
MEASURES AND METHODS ESPECIALLY

1749
01:15:54,400 --> 01:15:56,120
OUTCOME MEASURES WHICH WILL

1750
01:15:56,120 --> 01:15:57,840
ENHANCE ABILITY ACROSS STUDIES

1751
01:15:57,840 --> 01:15:59,640
AS WELL AS THE ABILITY FOR

1752
01:15:59,640 --> 01:16:02,600
THE GRANDE TO SHARE CHALLENGE

1753
01:16:02,600 --> 01:16:13,120
THIS IS REAL-TIME AND THE USE OF

1754
01:16:16,560 --> 01:16:17,080
TOBACCO PRODUCTS.

1755
01:16:17,080 --> 01:16:18,920
WE'RE GRATEFUL FOR THE

1756
01:16:18,920 --> 01:16:21,200
OPPORTUNITY TO HAVE MET WITH OUR

1757
01:16:21,200 --> 01:16:24,840
BSA SUBCOMMITTEE REVIEWERS.

1758
01:16:24,840 --> 01:16:26,800
AND OBTAIN THEIR INSIGHTFUL

1759
01:16:26,800 --> 01:16:28,080
FEEDBACK AND WE INCORPORATED

1760
01:16:28,080 --> 01:16:30,640
SOME OF THIS INTO THE TALK AND

1761
01:16:30,640 --> 01:16:34,320
FOR TIMES SAKE I'LL EYE LIGHT A

1762
01:16:34,320 --> 01:16:45,040
FEW ADDITIONAL POINT AND ALSO,

1763
01:16:45,040 --> 01:16:46,520
ACKNOWLEDGING THAT FROM THE

1764
01:16:46,520 --> 01:16:48,120
TREATMENTS TO DATE HAVE NOT BEEN

1765
01:16:48,120 --> 01:16:49,360
EFFECTIVE IN ADOLESCENT

1766
01:16:49,360 --> 01:16:50,960
POPULATION AND THEY'RE NOT THE

1767
01:16:50,960 --> 01:16:53,040
FOCUS OF THIS RFA AND WE SHOULD

1768
01:16:53,040 --> 01:16:55,920
ALLOW APPLICATIONS WHERE

1769
01:16:55,920 --> 01:17:00,480
TREATMENTS ARE ADJUNCT TO THE

1770
01:17:00,480 --> 01:17:07,560
BEHAVIOR TREATMENT PROTEASOMES

1771
01:17:07,560 --> 01:17:11,200
FROM IS THANK YOU FOR YOUR TIME

1772
01:17:11,200 --> 01:17:12,160
AND LOOK FORWARD TO THAT

1773
01:17:12,160 --> 01:17:18,680
DISCUSSION AND ANSWERING YOUR

1774
01:17:18,680 --> 01:17:18,920
QUESTIONS.

1775
01:17:18,920 --> 01:17:20,440
>> THANK YOU, VERY MUCH.

1776
01:17:20,440 --> 01:17:26,960
LET'S START WITH THE DISCUSSION.

1777
01:17:26,960 --> 01:17:37,040
>>

1778
01:17:40,800 --> 01:17:43,560
>> THANK YOU FOR SUCH AN

1779
01:17:43,560 --> 01:17:44,600
OUTSTANDING PRESENTATION AND

1780
01:17:44,600 --> 01:17:46,680
VERY INFORMATIVE AND ALSO THANK

1781
01:17:46,680 --> 01:17:52,960
YOU TO Dr. BASIN FOR THEIR

1782
01:17:52,960 --> 01:17:58,360
COMMENTS ON THIS RFA.

1783
01:17:58,360 --> 01:18:00,160
SO, I THINK IT WAS CLEARLY

1784
01:18:00,160 --> 01:18:01,960
INDICATED THE NEED FOR THIS RFA

1785
01:18:01,960 --> 01:18:05,480
AND WE CERTAINLY HAVE A DERTH OF

1786
01:18:05,480 --> 01:18:07,000
INFORMATION ON EFFECTIVE SMOKING

1787
01:18:07,000 --> 01:18:17,520
OR T TOBACCO SEESATION FOR TOOLS

1788
01:18:17,520 --> 01:18:18,880
AND HELPING ORGANIZATIONS AND

1789
01:18:18,880 --> 01:18:22,960
SCIENTISTS WITHIN THE TOBACCO

1790
01:18:22,960 --> 01:18:33,520
CONTROL FIELD THERE'S A DERTH IN

1791
01:18:39,800 --> 01:18:40,960
OF RESEARCH IN THIS AREA FUNDED

1792
01:18:40,960 --> 01:18:44,600
BY THE NCI.

1793
01:18:44,600 --> 01:18:46,720
THE SUBCOMMITTEE WAS SUPPORTIVE

1794
01:18:46,720 --> 01:18:51,880
OF THE PRIORITY AREAS THAT WERE

1795
01:18:51,880 --> 01:18:53,640
IDENTIFIED TO IN THIS RFA AND

1796
01:18:53,640 --> 01:18:56,040
THAT INCLUDED FOCUSING ON

1797
01:18:56,040 --> 01:18:58,720
DEVELOPING INTERVENTIONS THAT

1798
01:18:58,720 --> 01:19:01,560
TARGET DIFFERENT PHASES OF THE

1799
01:19:01,560 --> 01:19:04,760
TRAJECTORIES FOR TOBACCO USE AND

1800
01:19:04,760 --> 01:19:05,440
A LOT OF THE OPPORTUNITY EFFORTS

1801
01:19:05,440 --> 01:19:06,840
IN TERMS OF INTERVENTIONS HAVE

1802
01:19:06,840 --> 01:19:09,040
BEEN FOCUSED MOSTLY ON

1803
01:19:09,040 --> 01:19:12,160
ADOLESCENTS WHO ARE ADDICTED TO

1804
01:19:12,160 --> 01:19:14,480
TOBACCO AND TO FOCUS ON THE

1805
01:19:14,480 --> 01:19:16,400
ESCALATION PREVENTING THE

1806
01:19:16,400 --> 01:19:19,040
ESCALATION IN TOBACCO USE IS A

1807
01:19:19,040 --> 01:19:23,760
REAL NOVEL AND POTENTIALLY

1808
01:19:23,760 --> 01:19:25,080
EFFECTIVE TARGET.

1809
01:19:25,080 --> 01:19:28,200
AND IN ADDITION, AS YOU SAW,

1810
01:19:28,200 --> 01:19:31,080
THERE IS A REAL CHANGING OF THE

1811
01:19:31,080 --> 01:19:32,360
LANDSCAPE OF TOBACCO PRODUCTS

1812
01:19:32,360 --> 01:19:35,080
CURRENTLY OUT IN THE MARKET AND

1813
01:19:35,080 --> 01:19:38,720
WE HAVE NOT ONLY THE ELECTRONIC

1814
01:19:38,720 --> 01:19:41,240
SYSTEMS AND WE NOW ARE GOING TO

1815
01:19:41,240 --> 01:19:43,320
HAVE POACHES THAT COME IN

1816
01:19:43,320 --> 01:19:48,600
DIFFERENT FLAVORS AND A LOT OF

1817
01:19:48,600 --> 01:19:49,840
LITTLE CIGARS APPEALS TO YOUTH

1818
01:19:49,840 --> 01:19:54,640
SO IT'S A VERY COMPLEX

1819
01:19:54,640 --> 01:19:55,880
ENVIRONMENT AND THE ADOLESCENTS

1820
01:19:55,880 --> 01:19:57,680
ARE ACTUALLY RESPONDING TO THE

1821
01:19:57,680 --> 01:20:02,520
MARKETPLACE BY TAKING UP SOME

1822
01:20:02,520 --> 01:20:04,320
THESE NEWER PRODUCTS AND WE NEED

1823
01:20:04,320 --> 01:20:05,600
TO GET AHEAD OF THE GAME AND

1824
01:20:05,600 --> 01:20:07,200
COME OUT WITH INTERVENTIONS IN

1825
01:20:07,200 --> 01:20:09,640
TERMS OF REDUCING THE USE OF

1826
01:20:09,640 --> 01:20:12,240
THESE VARIOUS PRODUCTS AND WE

1827
01:20:12,240 --> 01:20:13,800
ALSO THOUGHT THAT THE PRIORITY

1828
01:20:13,800 --> 01:20:16,760
OF UTILIZING TECHNOLOGY IS VERY

1829
01:20:16,760 --> 01:20:21,480
IMPORTANT AND ESPECIALLY IN

1830
01:20:21,480 --> 01:20:22,680
ENHANCING INTERVENTIONS AND THAT

1831
01:20:22,680 --> 01:20:26,440
ARE MORE ADOLESCENT OR YOUTH

1832
01:20:26,440 --> 01:20:28,720
FRIENDLY AND WHAT IS REALLY GOOD

1833
01:20:28,720 --> 01:20:30,960
AND CERTAINLY USING TECHNOLOGY

1834
01:20:30,960 --> 01:20:33,560
WILL EXPAND REACH.

1835
01:20:33,560 --> 01:20:39,440
WE DID THINK THAT THE RFA NOW

1836
01:20:39,440 --> 01:20:40,880
RESPONDS TO SOME OF THE ISSUES

1837
01:20:40,880 --> 01:20:44,280
THAT WERE RAISED BY THE GROUP,

1838
01:20:44,280 --> 01:20:46,360
PARTICULARLY AS IT RELATES TO

1839
01:20:46,360 --> 01:20:48,920
MAKING SURE THAT THERE IS A

1840
01:20:48,920 --> 01:20:53,000
FOCUS ON SERVING DIVERSE

1841
01:20:53,000 --> 01:20:56,800
POPULATIONS, AND ALSO MAKING

1842
01:20:56,800 --> 01:21:00,240
SURE THAT THIS RFA INCORPORATES

1843
01:21:00,240 --> 01:21:03,440
IMPLEMENTAI AM NOT SCIENCE WITHE

1844
01:21:03,440 --> 01:21:08,880
RESEARCH PROPOSALS AND BRINGING,

1845
01:21:08,880 --> 01:21:10,960
I GUESS LET'S SEE, JUST TAKING A

1846
01:21:10,960 --> 01:21:13,600
LOOK HERE, AND ACTUALLY BRINGING

1847
01:21:13,600 --> 01:21:15,120
GREATER FOCUS TO SOME OF THE

1848
01:21:15,120 --> 01:21:17,440
COGNITIVE BEHAVIORAL TOOLS WOULD

1849
01:21:17,440 --> 01:21:20,640
BE COMPLIMENTARY TO THESE TOOLS.

1850
01:21:20,640 --> 01:21:22,160
AND I THINK THAT'S REALLY SOME

1851
01:21:22,160 --> 01:21:27,000
OF THE PRIMARY ISSUES THAT WE

1852
01:21:27,000 --> 01:21:30,800
WERE CONCERNED WITH.

1853
01:21:30,800 --> 01:21:32,240
DO YOU HAVE ANY OTHER COMMENTS

1854
01:21:32,240 --> 01:21:38,880
THAT YOU WOULD LIKE TO ADD?

1855
01:21:38,880 --> 01:21:40,240
>> NOT MUCH ON MY PART.

1856
01:21:40,240 --> 01:21:41,640
I HAD QUESTIONS ABOUT HOW THE

1857
01:21:41,640 --> 01:21:43,920
METH LOGIC RESEARCH WAS GOING TO

1858
01:21:43,920 --> 01:21:54,160
BE INCORPORATED.

1859
01:22:06,800 --> 01:22:08,240
THIS IS A NEEDED FUNDING

1860
01:22:08,240 --> 01:22:09,600
ANNOUNCEMENT AND WILL GENERATE

1861
01:22:09,600 --> 01:22:13,640
USEFUL AND IMPACTFUL RESEARCH.

1862
01:22:13,640 --> 01:22:16,560
>> THE ONLY THING THAT I
WILL

1863
01:22:16,560 --> 01:22:18,840
ADD, THIS IS THOUGHTFUL IN TERMS

1864
01:22:18,840 --> 01:22:20,800
OF THE STRUCTURE OF THE RFA TO

1865
01:22:20,800 --> 01:22:22,040
BRING IN THE PLANNING BRANT

1866
01:22:22,040 --> 01:22:27,440
BECAUPLAN GRANTS BECAUSETHERE'SG

1867
01:22:27,440 --> 01:22:29,000
PLANNING FOR FEASIBILITY FOR

1868
01:22:29,000 --> 01:22:30,800
AWFUL THESE ISSUES AND BEFORE

1869
01:22:30,800 --> 01:22:33,360
ACTUALLY IMPLEMENTING AN OPEN

1870
01:22:33,360 --> 01:22:35,400
TRIAL WITHIN THESE SO I LIKE THE

1871
01:22:35,400 --> 01:22:37,640
MECHANISM VERY MUCH IN TERMS OF

1872
01:22:37,640 --> 01:22:40,240
THE COMBINATION OF RO1 COMES

1873
01:22:40,240 --> 01:22:44,320
R34s IN TERMS OF PLANNING

1874
01:22:44,320 --> 01:22:46,080
GRANTS SO HER GROUP HAVE BEEN

1875
01:22:46,080 --> 01:22:49,920
VERY RESPONSIVE TO OUR QUESTIONS

1876
01:22:49,920 --> 01:22:50,480
AND COMMENTS.

1877
01:22:50,480 --> 01:22:52,520
>> THANK YOU, WE HAVE SIX
HANDS

1878
01:22:52,520 --> 01:22:54,600
RAISED.

1879
01:22:54,600 --> 01:22:56,280
FANTASTIC ENTHUSISM BUT LET'S

1880
01:22:56,280 --> 01:22:57,800
KEEP THE QUESTIONS TERSE AND

1881
01:22:57,800 --> 01:22:59,360
ANSWERS THE SAME.

1882
01:22:59,360 --> 01:23:00,400
MIKE YOU ARE FIRST I THINK.

1883
01:23:00,400 --> 01:23:07,000
>> YES SO,  QUICK
QUESTION, YOU

1884
01:23:07,000 --> 01:23:10,560
SAID NIAID WILL COME ON BOARD,

1885
01:23:10,560 --> 01:23:11,440
WHAT DOES THAT MEAN.

1886
01:23:11,440 --> 01:23:13,640
>> THANK YOU FOR THE
QUESTION.

1887
01:23:13,640 --> 01:23:16,600
WE ARE IN DISCUSSIONS WITH OUR

1888
01:23:16,600 --> 01:23:18,280
NIAID COLLEAGUES AND KEVIN

1889
01:23:18,280 --> 01:23:22,400
WALTON PUT IN CHIEF AT NIAID ON

1890
01:23:22,400 --> 01:23:24,120
THE LINE TODAY AND HERE WITH YOU

1891
01:23:24,120 --> 01:23:28,160
THANK YOU VERY MUCH FOR BEING

1892
01:23:28,160 --> 01:23:28,560
HERE.

1893
01:23:28,560 --> 01:23:32,880
AND THEY INTEND TO JOIN OUR RFA

1894
01:23:32,880 --> 01:23:34,680
AND CONTRIBUTE BUT KEVIN IF YOU

1895
01:23:34,680 --> 01:23:37,560
WOULD LIKE TO ANSWER MORE IN

1896
01:23:37,560 --> 01:23:41,440
DEPTH, FEEL  FRO TO UNMUTE AND .

1897
01:23:41,440 --> 01:23:49,920
>> THANK YOU, VERY MUCH,
SO,

1898
01:23:49,920 --> 01:23:54,120
NIADA AND YOUTH CESSATION IS SO

1899
01:23:54,120 --> 01:23:55,360
ENTRANCE GENERAL WE'RE SO

1900
01:23:55,360 --> 01:23:58,640
FOCUSED ON THE INCREASED USE OF

1901
01:23:58,640 --> 01:24:06,240
Ns SO WE INTEND TO SIGN ON AND

1902
01:24:06,240 --> 01:24:08,520
FUND WORTHY APPLICATIONS AND WE

1903
01:24:08,520 --> 01:24:10,800
USE THE R34 MECHANISM ROUTINELY

1904
01:24:10,800 --> 01:24:13,280
AND OUR DIVISION SO WE'RE VERY

1905
01:24:13,280 --> 01:24:15,080
COMFORTABLE WITH THAT AS WELL

1906
01:24:15,080 --> 01:24:21,800
WITH THE R01, OF COURSE.

1907
01:24:21,800 --> 01:24:23,840
>> THANK YOU.

1908
01:24:23,840 --> 01:24:25,280
THANK YOU FOR THAT WONDERFUL

1909
01:24:25,280 --> 01:24:27,680
TALK AND THIS IS VERY WORTH

1910
01:24:27,680 --> 01:24:28,440
WHILE PROJECT.

1911
01:24:28,440 --> 01:24:32,760
I JUST HAD A QUESTION ABOUT THE

1912
01:24:32,760 --> 01:24:34,760
WORDINGS AT BEGINNING THE ETHNIC

1913
01:24:34,760 --> 01:24:36,960
AND RACIAL DIFFERENCES IN

1914
01:24:36,960 --> 01:24:38,760
TOBACCO USE DEPENDING ON THE

1915
01:24:38,760 --> 01:24:39,040
PRODUCT.

1916
01:24:39,040 --> 01:24:41,760
BUT THEN IN THE LAST SLIDE, THE

1917
01:24:41,760 --> 01:24:44,440
WORDINGS WAS SUCH THAT IT WAS

1918
01:24:44,440 --> 01:24:46,400
HIGH-RISK POPULATIONS AND I JUST

1919
01:24:46,400 --> 01:24:49,200
WANT TO MAKE SURE THAT IT'S --

1920
01:24:49,200 --> 01:24:51,960
IN MY OPINION IT NEEDS TO BE

1921
01:24:51,960 --> 01:24:52,720
SPECIFICALLY CALLED OUT AS

1922
01:24:52,720 --> 01:24:56,880
RACIAL AND ETHNIC DIFFERENCES

1923
01:24:56,880 --> 01:24:58,520
THAT SHOULD BE HIGHLIGHTED IN

1924
01:24:58,520 --> 01:25:01,320
THE RESEARCH AND I DON'T KNOW IF

1925
01:25:01,320 --> 01:25:02,920
YOU WANT TO REQUIRE OR STRONGLY

1926
01:25:02,920 --> 01:25:04,760
RECOMMEND IT BUT I THINK YOU

1927
01:25:04,760 --> 01:25:09,400
LIMIT THE DATA YOU GET OUT IF YU

1928
01:25:09,400 --> 01:25:12,120
DON'T CALL OUT RACIAL DIVERSITY

1929
01:25:12,120 --> 01:25:12,920
IN THE RFA.

1930
01:25:12,920 --> 01:25:14,480
>> THANK YOU SO MUCH FOR
THAT

1931
01:25:14,480 --> 01:25:14,760
COMMENT.

1932
01:25:14,760 --> 01:25:19,000
YES, WE DO PLAN TO CALL THAT OUT

1933
01:25:19,000 --> 01:25:21,440
AND AS WELL AS THE NEED TO

1934
01:25:21,440 --> 01:25:25,040
CONSIDER RESEARCH QUESTIONS AND

1935
01:25:25,040 --> 01:25:26,760
THE PROVE ABILITY OF THE

1936
01:25:26,760 --> 01:25:28,200
INTERVENTIONS FOR NOT JUST

1937
01:25:28,200 --> 01:25:30,480
RACIAL AND ETHNIC GROUPS THAT

1938
01:25:30,480 --> 01:25:31,760
HAVE DISPROPORTIONATE USE OF

1939
01:25:31,760 --> 01:25:33,960
PARTICULAR PRODUCTS OR IN

1940
01:25:33,960 --> 01:25:35,720
GENERAL WERE EFFECTED BY TOBACCO

1941
01:25:35,720 --> 01:25:38,760
USE AND POPULATION PANELISTS AND

1942
01:25:38,760 --> 01:25:39,640
MENTAL HEALTH CONDITIONS ALSO

1943
01:25:39,640 --> 01:25:43,360
HAVE A HIGHER USE AND LGBTQ

1944
01:25:43,360 --> 01:25:48,000
YOUTH ARE ALSO USING TOBACCO

1945
01:25:48,000 --> 01:25:48,880
PRODUCTS AND WE'LL BE MORE

1946
01:25:48,880 --> 01:25:50,000
SPECIFIC ABOUT THIS WHEN WE HAVE

1947
01:25:50,000 --> 01:25:51,800
THEM IN THE RFA, ABSOLUTELY,

1948
01:25:51,800 --> 01:25:52,040
THANK YOU.

1949
01:25:52,040 --> 01:25:55,000
>> GREAT.

1950
01:25:55,000 --> 01:26:00,000
>> I JUST WANTED TO BEING
OWE ED

1951
01:26:00,000 --> 01:26:01,520
I'M SUPPORTIVE OF THIS CONCEPT.

1952
01:26:01,520 --> 01:26:04,000
A COUPLE OF QUESTIONS, ONE IS,

1953
01:26:04,000 --> 01:26:05,640
YOU KNOW, I WONDERED IF THERE

1954
01:26:05,640 --> 01:26:08,240
WAS CONSIDERATION GIVEN TO BIO

1955
01:26:08,240 --> 01:26:10,320
MARKERS TO VALIDATE

1956
01:26:10,320 --> 01:26:11,000
SELF-REPORTED INFORMATION AND I

1957
01:26:11,000 --> 01:26:12,960
KNOW THE HISTORICALLY THESE

1958
01:26:12,960 --> 01:26:15,560
STUDIES HAVE INCLUDED

1959
01:26:15,560 --> 01:26:15,880
BIOMARKERS.

1960
01:26:15,880 --> 01:26:17,200
I KNOW THAT BECAUSE OF PRODUCTS

1961
01:26:17,200 --> 01:26:18,960
HAVE CHANGED I DON'T KNOW IF THE

1962
01:26:18,960 --> 01:26:20,840
BIOMARKERS ARE STILL AS VALID AS

1963
01:26:20,840 --> 01:26:27,280
THEY WERE DECADES AGO.

1964
01:26:27,280 --> 01:26:28,760
THE OFTEN TIMES INTERVENTIONS

1965
01:26:28,760 --> 01:26:30,480
HAVE A SHORT TERM EFFECT AND I

1966
01:26:30,480 --> 01:26:32,280
WONDERED IF YOU ARE ENCOURAGING

1967
01:26:32,280 --> 01:26:33,800
OUTCOMES REALLY TO THE

1968
01:26:33,800 --> 01:26:35,480
MAINTENANCE OR THE LONG-TERM

1969
01:26:35,480 --> 01:26:41,040
EFFECT OF THE INTERVENTION?

1970
01:26:41,040 --> 01:26:42,320
>> THANK YOU FOR THOSE

1971
01:26:42,320 --> 01:26:42,600
QUESTIONS.

1972
01:26:42,600 --> 01:26:47,360
I DO THINK WE WILL ENCOURAGE THE

1973
01:26:47,360 --> 01:26:49,760
BIOCHEMICAL CLIPS FOR INSTANCE

1974
01:26:49,760 --> 01:26:51,400
AND YOU ARE RIGHT IT'S A LITTLE

1975
01:26:51,400 --> 01:26:52,920
MORE COMPLICATED WITH THE

1976
01:26:52,920 --> 01:26:58,200
DIVERSITY OF TOBACCO PRODUCTS

1977
01:26:58,200 --> 01:27:01,760
BUT THE BY-PRODUCT OF NICOTINE

1978
01:27:01,760 --> 01:27:02,640
IS MEASURED IN THOSE PRODUCTS

1979
01:27:02,640 --> 01:27:05,080
AND FROM USE OF THESE PRODUCTS

1980
01:27:05,080 --> 01:27:08,880
AND IT WOULD BE USEFUL BUT YES,

1981
01:27:08,880 --> 01:27:10,800
WE WILL ENCOURAGE THAT IN THE

1982
01:27:10,800 --> 01:27:14,360
FRA OR FEASIBLE AS WELL AS

1983
01:27:14,360 --> 01:27:20,920
CONSIDER INCLUDING LANGUAGE TO

1984
01:27:20,920 --> 01:27:24,160
PLAN FOR THE UNDERSTANDING OF

1985
01:27:24,160 --> 01:27:26,200
THE CONTINUED USE OF TREATMENTS

1986
01:27:26,200 --> 01:27:27,800
OR THE MAINTENANCE OF THE

1987
01:27:27,800 --> 01:27:29,880
EFFECTS OF LONG-TERM FOLLOW-UP

1988
01:27:29,880 --> 01:27:30,720
AND ET CETERA.

1989
01:27:30,720 --> 01:27:32,520
WE SO DEFINITELY WILL

1990
01:27:32,520 --> 01:27:33,200
INCORPORATE THAT.

1991
01:27:33,200 --> 01:27:37,600
THANK YOU FOR HIGHLIGHTING THAT.

1992
01:27:37,600 --> 01:27:40,600
>> ALSO, GREAT
PRESENTATION.

1993
01:27:40,600 --> 01:27:45,840
AND I'M REALLY GLAD THAT THIS

1994
01:27:45,840 --> 01:27:47,960
AREA IS BEING PERSUADE.

1995
01:27:47,960 --> 01:27:53,440
DIN YGIVENYOUR PRESENTATION IF A

1996
01:27:53,440 --> 01:27:54,720
WAY YOU COULD ENCOURAGE PEOPLE

1997
01:27:54,720 --> 01:27:57,760
TO THINK ABOUT PARTNERSHIP OR

1998
01:27:57,760 --> 01:28:00,000
COMMUNITY ORGANIZATIONS OR

1999
01:28:00,000 --> 01:28:02,720
GROUPS THAT HAVE REACHED INTO

2000
01:28:02,720 --> 01:28:04,680
THE GROUPS THAT YOU WOULD ALSO

2001
01:28:04,680 --> 01:28:06,040
LIKE TO REACH?

2002
01:28:06,040 --> 01:28:08,320
I'M THINKING OF YMCA AFTER

2003
01:28:08,320 --> 01:28:10,000
SCHOOL PROGRAMS OR SCHOOLS OR

2004
01:28:10,000 --> 01:28:12,480
OTHER PLACES BUT TO START TO

2005
01:28:12,480 --> 01:28:13,840
ENCOURAGE INVESTIGATORS TO THINK

2006
01:28:13,840 --> 01:28:15,920
ABOUT THAT A LITTLE BIT MORE

2007
01:28:15,920 --> 01:28:19,800
UPSTREAM AND SIMILARLY THINKING

2008
01:28:19,800 --> 01:28:23,200
ABOUT SORT OF THE END USER, THE

2009
01:28:23,200 --> 01:28:25,680
TEAM PERSPECTIVE AND HOW YOU

2010
01:28:25,680 --> 01:28:27,600
MIGHT INCORPORATE SIMILAR TO HOW

2011
01:28:27,600 --> 01:28:29,680
WE TALK ABOUT PATIENT ADVOCATES

2012
01:28:29,680 --> 01:28:31,560
THAT ADVISE AND GUIDANCE FROM

2013
01:28:31,560 --> 01:28:33,400
THE BEGINNING AS PART OF WHAT

2014
01:28:33,400 --> 01:28:38,600
YOU PUT OUT IN THE RFA.

2015
01:28:38,600 --> 01:28:40,800
>> AND AN ENTHUSIASTIC YES
ON

2016
01:28:40,800 --> 01:28:42,000
ALL OF THOSE POINTS.

2017
01:28:42,000 --> 01:28:43,840
THIS WAS ACTUALLY PART OF OUR

2018
01:28:43,840 --> 01:28:45,520
DISCUSSION WITH OUR SUBCOMMITTEE

2019
01:28:45,520 --> 01:28:46,880
MEMBERS WHICH I REALLY

2020
01:28:46,880 --> 01:28:50,880
APPRECIATED AND WE ALL WERE

2021
01:28:50,880 --> 01:28:53,600
DISCUSSING THE NEED TO INCLUDE

2022
01:28:53,600 --> 01:28:54,480
IMPLEMENTATION SCIENTISTS ON THE

2023
01:28:54,480 --> 01:28:56,320
TEAMS OF COURSE FROM THE

2024
01:28:56,320 --> 01:29:01,200
BEGINNING OF THE DESIGN OF THE

2025
01:29:01,200 --> 01:29:02,160
INTERVENTION TO THE HE CAN

2026
01:29:02,160 --> 01:29:04,400
TIVENESS STAGE BUT IT'S CRITICAL

2027
01:29:04,400 --> 01:29:06,480
TO ENCOURAGE IN THE RFA

2028
01:29:06,480 --> 01:29:08,200
INVOLVEMENT IN YOUTH AND IN

2029
01:29:08,200 --> 01:29:10,600
DESIGN AND DEVELOPMENT AS WELL

2030
01:29:10,600 --> 01:29:13,200
AS THOSE COMMUNITY-BASED CONTEXT

2031
01:29:13,200 --> 01:29:16,360
IN WHICH THEY LIVE COMMUNITY

2032
01:29:16,360 --> 01:29:18,200
BASED PARTNERS AND TO ENHANCE

2033
01:29:18,200 --> 01:29:21,560
THE UPTICK AND ACTUAL REACH AND

2034
01:29:21,560 --> 01:29:23,960
USE OF THE INTERVENTIONED IF

2035
01:29:23,960 --> 01:29:25,360
THEY'RE FOUND EFFECTIVE.

2036
01:29:25,360 --> 01:29:29,200
WE ALSO THINK WE CAN ENCOURAGE

2037
01:29:29,200 --> 01:29:32,520
CBPR METHODS SO WE HAVE RESEARCH

2038
01:29:32,520 --> 01:29:35,440
METHODS THAT WOULD BE AS WELL AS

2039
01:29:35,440 --> 01:29:36,560
INCLUDING IMPLEMENTATION SCIENCE

2040
01:29:36,560 --> 01:29:38,720
AND METRICS SO THAT THEY CAN

2041
01:29:38,720 --> 01:29:40,360
BEING MEASURED AGO ALONG THE

2042
01:29:40,360 --> 01:29:40,520
WAY.

2043
01:29:40,520 --> 01:29:42,000
SO THOSE ARE SOME THINGS THAT WE

2044
01:29:42,000 --> 01:29:43,120
PLAN TO INCREASE.

2045
01:29:43,120 --> 01:29:45,000
THANK YOU.

2046
01:29:45,000 --> 01:29:45,240
>> GREAT.

2047
01:29:45,240 --> 01:29:48,240
IF YOU CAN PICK UP THE COMMENTS

2048
01:29:48,240 --> 01:29:52,520
IN THE CHAT REGARDING

2049
01:29:52,520 --> 01:29:56,960
MEDICATIONS USED TO TRYING TO

2050
01:29:56,960 --> 01:30:06,480
SUPPORT ASSOCIATION AND ALSO THE

2051
01:30:06,480 --> 01:30:06,960
FOCUS.

2052
01:30:06,960 --> 01:30:09,720
WE CAN MOVE TO VOTING.

2053
01:30:09,720 --> 01:30:11,280
NO COMMENTS THAT SUPPORTED

2054
01:30:11,280 --> 01:30:14,760
DEFERRAL SO I'M LOOKING FOR A

2055
01:30:14,760 --> 01:30:15,000
MOTION.

2056
01:30:15,000 --> 01:30:16,360
>> I MOVE TO APPROVE.

2057
01:30:16,360 --> 01:30:18,520
>> GREAT.

2058
01:30:18,520 --> 01:30:19,000
>> SECOND.

2059
01:30:19,000 --> 01:30:20,240
>> SECOND.

2060
01:30:20,240 --> 01:30:20,520
>> GREAT.

2061
01:30:20,520 --> 01:30:20,960
THANK YOU.

2062
01:30:20,960 --> 01:30:29,800
ANY FURTHER DISCUSSION?

2063
01:30:29,800 --> 01:30:30,960
SEEING NO HANDS.

2064
01:30:30,960 --> 01:30:32,800
WE'LL GO TO FINAL VOTING.

2065
01:30:32,800 --> 01:30:35,000
THE MOTION IS FOR APPROVAL.

2066
01:30:35,000 --> 01:30:37,440
WE WILL ASSUME APPROVAL VOTES

2067
01:30:37,440 --> 01:30:39,080
UNLESS YOU VOTE DISAPPROVAL,

2068
01:30:39,080 --> 01:30:46,760
RAISE YOUR HAND.

2069
01:30:46,760 --> 01:30:54,000
ANY A ABSTENTIONS?

2070
01:30:54,000 --> 01:30:56,640
>> IT'S UNANIMOUS.

2071
01:30:56,640 --> 01:30:56,920
>> GREAT.

2072
01:30:56,920 --> 01:31:04,880
NEXT CONCEPT IS IN RFA.

2073
01:31:04,880 --> 01:31:07,040
CANNABIS AND CAN ABBA NODE USE

2074
01:31:07,040 --> 01:31:08,680
IN ADULT CANCER PATIENTS DURING

2075
01:31:08,680 --> 01:31:10,720
TREATMENT ACCESSING BENEFITS AND

2076
01:31:10,720 --> 01:31:14,360
HARMS AND Dr. FREEDMAN IS THE

2077
01:31:14,360 --> 01:31:16,600
CHAIR Dr. CORONADO FOR

2078
01:31:16,600 --> 01:31:18,960
CHAIRING TWO SUBCOMMITTEES FOR

2079
01:31:18,960 --> 01:31:22,400
THIS MEETING.

2080
01:31:22,400 --> 01:31:24,200
GO AHEAD WITH YOUR PRESENTATION.

2081
01:31:24,200 --> 01:31:25,480
>> THANK YOU, VERY MUCH.

2082
01:31:25,480 --> 01:31:27,400
I'M PLEASED TO BE PRESENTING

2083
01:31:27,400 --> 01:31:29,080
THIS RFA CONCEPT TO YOU ON BOW

2084
01:31:29,080 --> 01:31:31,440
HALF OF MY COLLEAGUES FROM OUR

2085
01:31:31,440 --> 01:31:37,120
CANNABIS AND CANCER RESEARCH

2086
01:31:37,120 --> 01:31:37,520
GROUP.

2087
01:31:37,520 --> 01:31:39,480
THIS CONCEPT WAS DEVELOPED AS A

2088
01:31:39,480 --> 01:31:40,600
COLLABORATIVE EFFORT WITH

2089
01:31:40,600 --> 01:31:42,160
SUBSTANTIALLY INVOLVEMENT FROM

2090
01:31:42,160 --> 01:31:42,960
OUR INTEREST GROUP MEMBERS AND

2091
01:31:42,960 --> 01:31:45,200
IS A RESULT OF THE INPUT

2092
01:31:45,200 --> 01:31:48,160
SURVIVOR ADVOCATES AND KEY

2093
01:31:48,160 --> 01:31:50,360
STAKEHOLDERS.

2094
01:31:50,360 --> 01:31:50,680
NEXT SLIDE.

2095
01:31:50,680 --> 01:31:52,200
THE RAPIDLY INCREASING

2096
01:31:52,200 --> 01:31:53,560
AVAILABILITY IN USE OF CANNABIS

2097
01:31:53,560 --> 01:31:56,320
BY CANCER PATIENTS, OF LACK OF

2098
01:31:56,320 --> 01:31:57,880
EVIDENCE BASED AVAILABLE IN THE

2099
01:31:57,880 --> 01:31:59,800
HARMS OF BENEFITS DURING CANCER

2100
01:31:59,800 --> 01:32:01,640
TREATMENT, AND THE CHALLENGE TO

2101
01:32:01,640 --> 01:32:03,840
CLINICAL TRIALS DUE TO FEDERAL

2102
01:32:03,840 --> 01:32:05,240
REGULATORY ISSUES, CALLS FOR A

2103
01:32:05,240 --> 01:32:06,920
RAPID INFUSION OF MULTIPLE

2104
01:32:06,920 --> 01:32:09,160
STUDIES ADDRESSING CANNABIS USE.

2105
01:32:09,160 --> 01:32:11,040
THE PURPOSE OF THIS RFA CONCEPT

2106
01:32:11,040 --> 01:32:13,000
IS TO SUPPORT OBSERVATIONAL

2107
01:32:13,000 --> 01:32:14,840
RESEARCH STUDIES TO ASSESS THE

2108
01:32:14,840 --> 01:32:18,960
BENEFITS OF HOMES OF CANNABIS

2109
01:32:18,960 --> 01:32:22,280
AND CAN CANNABINOID USE.

2110
01:32:22,280 --> 01:32:23,600
IT CAN HAVE IMPORTANT EVIDENCE

2111
01:32:23,600 --> 01:32:27,560
OF THE BENEFITS AND HARMS OF

2112
01:32:27,560 --> 01:32:29,880
CANNABIS AND CAN AB INOID AND TO

2113
01:32:29,880 --> 01:32:32,960
CONDUCT FUTURE CLINICAL TRIALS.

2114
01:32:32,960 --> 01:32:33,920
NEXT SLIDE.

2115
01:32:33,920 --> 01:32:35,840
SO WE WERE TALKING ABOUT

2116
01:32:35,840 --> 01:32:38,520
CANNABIS OR CANNABINOIDS AND WE

2117
01:32:38,520 --> 01:32:40,680
REFER TO THE PLANT WE REFER TO

2118
01:32:40,680 --> 01:32:45,120
ANY CANNABIS PLANTS,

2119
01:32:45,120 --> 01:32:46,760
CANNABINOIDS, THC AND AS WELL AS

2120
01:32:46,760 --> 01:32:48,120
PRESCRIPTION CANNABINOIDS OR ANY

2121
01:32:48,120 --> 01:32:49,520
OTHER TRUCKS MADE WITH OR

2122
01:32:49,520 --> 01:32:50,920
DERIVED FROM CANNABIS.

2123
01:32:50,920 --> 01:32:52,320
AND FOR THIS PRESENTATION, I'M

2124
01:32:52,320 --> 01:32:54,400
GOING TO USE THE TERM CANNABIS

2125
01:32:54,400 --> 01:32:59,160
TO REFER TO CAN A BUSINESS AND

2126
01:32:59,160 --> 01:33:00,560
CANNABINOIDS.

2127
01:33:00,560 --> 01:33:02,400
SO, TO HELP US LEARN MORE ABOUT

2128
01:33:02,400 --> 01:33:04,360
THE STATE OF CANNABIS AND CANCER

2129
01:33:04,360 --> 01:33:06,400
RESEARCH, OUR INTEREST GROUP PUT

2130
01:33:06,400 --> 01:33:09,360
TOGETHER A CONFERENCE ON THE

2131
01:33:09,360 --> 01:33:11,280
TOPIC AND EXACTLY WHAT IT

2132
01:33:11,280 --> 01:33:13,240
RELATED DECEMBER 2021, WE WERE

2133
01:33:13,240 --> 01:33:18,040
ABLE TO PUT OUT A JNCI MONOGRAPH

2134
01:33:18,040 --> 01:33:22,800
DEVOTED TO THIS SYMPOSIUM.

2135
01:33:22,800 --> 01:33:24,200
I'LL START BY PROVIDING

2136
01:33:24,200 --> 01:33:26,120
BACKGROUND OF WHAT WE LEARNED.

2137
01:33:26,120 --> 01:33:27,520
THE LEGAL LANDSCAPE OF MEDICAL

2138
01:33:27,520 --> 01:33:32,080
AND NON MEDICAL CANNABIS USE HAS

2139
01:33:32,080 --> 01:33:34,480
CHANGED OVER THE AND STATE

2140
01:33:34,480 --> 01:33:36,000
POLICIES AND THERE ARE 37 STATES

2141
01:33:36,000 --> 01:33:37,240
IN THE DISTRICT OF COLOMBIA THAT

2142
01:33:37,240 --> 01:33:39,560
HAVE LEGALIZED CANNABIS FROM

2143
01:33:39,560 --> 01:33:42,200
MEDICAL CONDITIONS AND OF THESE,

2144
01:33:42,200 --> 01:33:45,760
19 STATES IN DC HAVE LEGALIZED

2145
01:33:45,760 --> 01:33:48,160
ADULT USE OF CANNABIS.

2146
01:33:48,160 --> 01:33:48,760
NEXT SLIDE.

2147
01:33:48,760 --> 01:33:50,920
AT THE SAME TIME, THE AVAILABLE

2148
01:33:50,920 --> 01:33:51,720
DELIVERY METHODS OF THESE

2149
01:33:51,720 --> 01:33:53,440
CANNABIS PRODUCTS HAVE ALSO

2150
01:33:53,440 --> 01:33:55,000
UNDERGONE SUBSTANTIAL CHANGES

2151
01:33:55,000 --> 01:33:58,120
AND THAT INCLUDE OIL, INHALED IN

2152
01:33:58,120 --> 01:33:58,880
TOPICAL FORMS.

2153
01:33:58,880 --> 01:34:01,200
NEXT SLIDE, PLEASE.

2154
01:34:01,200 --> 01:34:03,560
AND CANCER PATIENTS USE CANNABIS

2155
01:34:03,560 --> 01:34:04,840
DURING TREATMENT TO MANAGE

2156
01:34:04,840 --> 01:34:06,400
SYMPTOMS SUCH AS ANXIETY, LOSS

2157
01:34:06,400 --> 01:34:09,360
OF APPETITE, NAUSEA, PAIN AND

2158
01:34:09,360 --> 01:34:11,200
SLEEP DISTURBANCE AND THERE'S

2159
01:34:11,200 --> 01:34:13,200
SOME EVIDENCE FURTHER BENEFICIAL

2160
01:34:13,200 --> 01:34:15,240
EFFECTS AND THIS 2017 STUDY

2161
01:34:15,240 --> 01:34:16,800
SHOWED THAT LARGE PERCENTAGES OF

2162
01:34:16,800 --> 01:34:18,440
CANCER PATIENTS REPORTED USING

2163
01:34:18,440 --> 01:34:20,440
CANNABIS FOR PHYSICAL AND NEURO

2164
01:34:20,440 --> 01:34:22,000
PSYCHIATRIC SYMPTOMS AND

2165
01:34:22,000 --> 01:34:24,040
RECREATIONAL PURPOSES, AND O TO

2166
01:34:24,040 --> 01:34:26,160
TREAT THEIR CANCER AND THIS

2167
01:34:26,160 --> 01:34:27,520
STUDY FOUND THAT ONE IN FOUR

2168
01:34:27,520 --> 01:34:28,960
CANCER PATIENTS ARE USING

2169
01:34:28,960 --> 01:34:34,080
CANNABIS DURING THEIR TREATMENT.

2170
01:34:34,080 --> 01:34:36,600
WE THINK THIS MIGHT BE A LITTLE

2171
01:34:36,600 --> 01:34:41,160
HIGHER NOW.

2172
01:34:41,160 --> 01:34:43,320
OBSERVATIONAL STUDIES ALTHOUGH

2173
01:34:43,320 --> 01:34:46,600
SMALL, CONSISTENTLY SHOWED AN

2174
01:34:46,600 --> 01:34:48,120
ASSOCIATION BETWEEN CANNABIS USE

2175
01:34:48,120 --> 01:34:49,640
AND POOR OUTCOMES WITH PATIENTS

2176
01:34:49,640 --> 01:34:51,280
IN ADVANCE CANCER TREATED WITH

2177
01:34:51,280 --> 01:34:52,520
I'M UNION OWE THERAPY.

2178
01:34:52,520 --> 01:34:54,560
GIVEN THE INCREASE USE OF

2179
01:34:54,560 --> 01:34:55,640
IMMUNOTHERAPY AND CANNABIS IN

2180
01:34:55,640 --> 01:34:58,040
CANCER PATIENTS, HAVE A BETTER

2181
01:34:58,040 --> 01:34:58,960
UNDERSTANDING OF THE POSSIBLE

2182
01:34:58,960 --> 01:34:59,920
INCOMPETENTER ACTIONS BETWEEN

2183
01:34:59,920 --> 01:35:04,600
THE TWO THERAPIES IS NEEDED.

2184
01:35:04,600 --> 01:35:07,200
MOST U.S. MEDICAL ONCOLOGIST

2185
01:35:07,200 --> 01:35:08,520
ENGAGE IN DISCUSSIONS ABOUT

2186
01:35:08,520 --> 01:35:11,320
CANNABIS USE WITH PATIENTS, FEW

2187
01:35:11,320 --> 01:35:12,640
FEEL SUFFICIENTLY INFORMED TO

2188
01:35:12,640 --> 01:35:15,680
MAKE RECOMMENDATIONS.

2189
01:35:15,680 --> 01:35:16,400
PATIENTS OFTEN ARRANGE A

2190
01:35:16,400 --> 01:35:18,560
QUESTIONS ABOUT CANNABIS.

2191
01:35:18,560 --> 01:35:19,200
DO STUDIES SHOW THAT CANNABIS

2192
01:35:19,200 --> 01:35:21,680
CAN IMPROVE MY SYSTEMS AND HELP

2193
01:35:21,680 --> 01:35:24,080
TO TREAT MY CANCER.

2194
01:35:24,080 --> 01:35:25,600
WHAT ARE THE RISKS OF USING

2195
01:35:25,600 --> 01:35:27,040
CANNABIS IN IS IT SAFE WITH

2196
01:35:27,040 --> 01:35:28,720
OPIOIDS, WHAT ARE THE LAWS AND

2197
01:35:28,720 --> 01:35:29,800
REGULATIONS OF MY STATE AND WHAT

2198
01:35:29,800 --> 01:35:31,040
TYPES OF PRODUCTS ARE AVAILABLE

2199
01:35:31,040 --> 01:35:36,400
TO ME?

2200
01:35:36,400 --> 01:35:37,640
EVIDENCE GAPS WERE IDENTIFIED

2201
01:35:37,640 --> 01:35:40,200
FROM OUR SYMPOSIUM AND KEY AMONG

2202
01:35:40,200 --> 01:35:41,720
THEM ENCLOUD A NEED TO

2203
01:35:41,720 --> 01:35:42,960
UNDERSTAND HOW AND WHY CANCER

2204
01:35:42,960 --> 01:35:45,000
PATIENTS ARE CURRENTLY USING

2205
01:35:45,000 --> 01:35:46,240
CANNABIS AND WHETHER THE

2206
01:35:46,240 --> 01:35:47,560
BENEFITS AND HARMS OF CANNABIS

2207
01:35:47,560 --> 01:35:49,360
USE AMONG CANCER PATIENTS AND

2208
01:35:49,360 --> 01:35:51,400
ASSOCIATED WITH CANCER AND ITS

2209
01:35:51,400 --> 01:35:53,240
TREATMENT AND CO-MORBIDITY AND

2210
01:35:53,240 --> 01:35:57,040
OTHER MEDICATIONS THEY MAY BE

2211
01:35:57,040 --> 01:35:57,480
USING.

2212
01:35:57,480 --> 01:35:58,720
SO, ONCE AGAIN THE PURPOSE OF

2213
01:35:58,720 --> 01:36:00,640
THIS RFA IS TO SUPPORT OBJECT

2214
01:36:00,640 --> 01:36:02,080
VISIONAL RESEARCH STUDIES TO

2215
01:36:02,080 --> 01:36:03,960
ASSESS THE BENEFITS AND HOMES OF

2216
01:36:03,960 --> 01:36:05,880
CANNABIS USE AMONG CANCER

2217
01:36:05,880 --> 01:36:07,880
PATIENTS IN ADAPTIVE TREATMENT.

2218
01:36:07,880 --> 01:36:10,280
WE ARE REALLY LOOKING FOR

2219
01:36:10,280 --> 01:36:11,920
WELL-DESIGNED PERSPECTIVE COHORT

2220
01:36:11,920 --> 01:36:14,320
STUDIES OF CANCER PATIENTS WITH

2221
01:36:14,320 --> 01:36:15,480
TUMORS CURRENTLY RECEIVING

2222
01:36:15,480 --> 01:36:16,960
TREATMENT AND COMPARING THOSE

2223
01:36:16,960 --> 01:36:18,960
USING CANNABIS TO THOSE NOT

2224
01:36:18,960 --> 01:36:22,080
USING CANNABIS.

2225
01:36:22,080 --> 01:36:22,800
NEXT SLIDE.

2226
01:36:22,800 --> 01:36:24,000
THE NUMBER OF KEY RESEARCH

2227
01:36:24,000 --> 01:36:25,400
QUESTIONS THAT NEED TO BE

2228
01:36:25,400 --> 01:36:25,800
ADDRESSED.

2229
01:36:25,800 --> 01:36:27,400
THESE INCLUDE WHAT ADVERSE

2230
01:36:27,400 --> 01:36:29,080
EFFECTS OF CANNABIS USE ARE

2231
01:36:29,080 --> 01:36:33,720
OBSERVED IN KANG  CANCER PATIEND

2232
01:36:33,720 --> 01:36:35,240
DOSE OF FREQUENCY AND DIFFERENT

2233
01:36:35,240 --> 01:36:37,520
SO HE ISES WITH IMPROVING CANCER

2234
01:36:37,520 --> 01:36:39,160
PATIENT SYMPTOMS AND HOW IS

2235
01:36:39,160 --> 01:36:40,480
CANNABIS USE ASSOCIATED WITH

2236
01:36:40,480 --> 01:36:43,160
CANCER PATIENT USE OF

2237
01:36:43,160 --> 01:36:44,480
MEDICATIONS AND TO MIMIC

2238
01:36:44,480 --> 01:36:48,520
SYMPTOMS FOR CANCER OR CANCER

2239
01:36:48,520 --> 01:36:51,000
RELATED TREATMENTS.

2240
01:36:51,000 --> 01:36:52,360
THE EFFECTS OF CANNABIS USE ARE

2241
01:36:52,360 --> 01:36:54,480
OBSERVED IN CANCER PATIENTS WITH

2242
01:36:54,480 --> 01:36:56,400
REGARDS TO CANCER THERAPIES AND

2243
01:36:56,400 --> 01:36:57,680
MEDICATIONS USE INFORM SYMPTOM

2244
01:36:57,680 --> 01:36:59,000
MANAGEMENT IN A LOT OF THE

2245
01:36:59,000 --> 01:37:00,320
BIOLOGICAL EFFECTS OF CANNABIS

2246
01:37:00,320 --> 01:37:05,320
USE DURING CANCER TREATMENT.

2247
01:37:05,320 --> 01:37:07,240
SO STUDIES SUBMIT TODAY THIS

2248
01:37:07,240 --> 01:37:08,920
INCLUDE WELL DESIGNED

2249
01:37:08,920 --> 01:37:10,440
PERSPECTIVE COHORT STUDIES OF

2250
01:37:10,440 --> 01:37:12,520
CANCER PATIENT COMPARED TO THOSE

2251
01:37:12,520 --> 01:37:14,240
USING CANNABIS TO THOSE NOT

2252
01:37:14,240 --> 01:37:15,640
USING.

2253
01:37:15,640 --> 01:37:16,320
OBTAIN DETAILED INFORMATION NOT

2254
01:37:16,320 --> 01:37:20,480
JUST ON PATTERNS OF CANNABIS AND

2255
01:37:20,480 --> 01:37:24,320
PATIENT DEMOGRAPHICS, CLINICAL

2256
01:37:24,320 --> 01:37:25,840
DISEASE CHARACTERISTICS AND THEY

2257
01:37:25,840 --> 01:37:28,160
OTHER USE PATIENT SYMPTOM

2258
01:37:28,160 --> 01:37:29,720
SURVEYS THAT MEASURE SYMPTOM

2259
01:37:29,720 --> 01:37:31,040
PREVALENCE AND SEVERITY OVER

2260
01:37:31,040 --> 01:37:34,640
SEVERAL TIME PERIODS AND IN

2261
01:37:34,640 --> 01:37:36,680
ADDITION, PROPOSALS COULD

2262
01:37:36,680 --> 01:37:37,800
COLLECT BIOLOGICAL SPECIMENS

2263
01:37:37,800 --> 01:37:40,160
SUCH AS BLOOD AND THERE'S A

2264
01:37:40,160 --> 01:37:42,000
RANGE OF POTENTIAL OUTCOMES THAT

2265
01:37:42,000 --> 01:37:44,200
APPLICANTS CAN LOOK AT INCLUDING

2266
01:37:44,200 --> 01:37:46,840
QUALITY OF LIFE, SYMPTOMS,

2267
01:37:46,840 --> 01:37:50,200
MEDICATION REDUCTIONS, SURVIVAL

2268
01:37:50,200 --> 01:37:51,560
OUTCOMES, AND BIOMARKERS OF THE

2269
01:37:51,560 --> 01:37:53,920
EFFECT SUCH AS LIVER, KIDNEY AND

2270
01:37:53,920 --> 01:37:58,680
INFLAMMATORY MARKERS.

2271
01:37:58,680 --> 01:38:00,480
THERE'S A NED TO PROVIDE FUNDING

2272
01:38:00,480 --> 01:38:02,080
TO SUPPORT PROJECTS AT THIS TIME

2273
01:38:02,080 --> 01:38:03,520
FOR SEVERAL REASONS.

2274
01:38:03,520 --> 01:38:05,600
WE HAVE AN AWARD ANY GRANTS ON

2275
01:38:05,600 --> 01:38:07,840
THE BENEFIT OR HARMS OF CANNABIS

2276
01:38:07,840 --> 01:38:09,720
USE IN CANCER PATIENTS FOR AT

2277
01:38:09,720 --> 01:38:11,280
LEAST SIX YEARS.

2278
01:38:11,280 --> 01:38:12,920
AND THERE'S A REAL URGENT NEED

2279
01:38:12,920 --> 01:38:14,400
TO COLLECT THIS INFORMATION TO

2280
01:38:14,400 --> 01:38:17,560
INFORM CLINICAL TRIALS AND THE

2281
01:38:17,560 --> 01:38:19,600
RFI WOULD ENSURE FUNDING OF

2282
01:38:19,600 --> 01:38:20,840
DIVERSE POPULATIONS ACROSS

2283
01:38:20,840 --> 01:38:22,520
DIFFERENT U.S. STATES, CARE

2284
01:38:22,520 --> 01:38:27,320
SETTINGS, CANCER SITES, STAGES

2285
01:38:27,320 --> 01:38:28,720
AND OUTCOMES AND THE

2286
01:38:28,720 --> 01:38:30,680
CO-OPERATIVE AGREEMENT ALLOW

2287
01:38:30,680 --> 01:38:31,840
SUBSTANTIAL INVOLVEMENT TO

2288
01:38:31,840 --> 01:38:34,200
ENHANCE RESEARCH COLLABORATIONS

2289
01:38:34,200 --> 01:38:35,920
ACROSS STUDIES THROW SHOWING

2290
01:38:35,920 --> 01:38:37,600
SURVEYS, DATA AND RESOURCES AND

2291
01:38:37,600 --> 01:38:39,440
THIS INITIATIVE WOULD ALLOW FOR

2292
01:38:39,440 --> 01:38:40,520
SPECIALIZED SCIENTIFIC REVIEW

2293
01:38:40,520 --> 01:38:43,240
WITH EXPERTISE IN THE CLINICAL

2294
01:38:43,240 --> 01:38:44,280
EPIDEMIOLOGY OF CANNABIS AND

2295
01:38:44,280 --> 01:38:49,120
CANCER RESEARCH.

2296
01:38:49,120 --> 01:38:52,520
SO WE'RE ASKING FOR FOUR-AWARD

2297
01:38:52,520 --> 01:38:56,080
GRANTS OF FIVE YEARS AND ONE U24

2298
01:38:56,080 --> 01:39:00,560
OVER A PERIOD OF FIVE YEARS.

2299
01:39:00,560 --> 01:39:02,720
AND THIS FUNDING IS STARTED IN

2300
01:39:02,720 --> 01:39:04,480
FISCAL YEAR '23 AND GOES FOR

2301
01:39:04,480 --> 01:39:06,640
FIVE YEARS THROUGH FISCAL YEAR

2302
01:39:06,640 --> 01:39:09,800
'27 FOR A TOTAL COST OF

2303
01:39:09,800 --> 01:39:12,560
$20.5 MILLION.

2304
01:39:12,560 --> 01:39:13,440
NEXT SLIDE.

2305
01:39:13,440 --> 01:39:15,040
WITH A VERY GOOD MEETING WITH

2306
01:39:15,040 --> 01:39:17,240
OUR BSA SUBCOMMITTEE AND I WANT

2307
01:39:17,240 --> 01:39:19,840
TO THANK THEM FOR THEIR I

2308
01:39:19,840 --> 01:39:20,640
INSIGHTFUL COMMENTS.

2309
01:39:20,640 --> 01:39:22,080
IF YOU HAVE A FEW QUESTIONS ON

2310
01:39:22,080 --> 01:39:23,720
PATIENT REPORTED OUTCOMES AND

2311
01:39:23,720 --> 01:39:26,160
WE'LL EMPHASIZE THE RFA A

2312
01:39:26,160 --> 01:39:28,080
PATIENT CENTERED APPROACH WITH

2313
01:39:28,080 --> 01:39:29,600
FOLLOW-UP AND PROs COLLECTED

2314
01:39:29,600 --> 01:39:31,200
OVER A PERIOD OF TIME AND A

2315
01:39:31,200 --> 01:39:33,200
QUESTION ABOUT WHAT WE MEANT BY

2316
01:39:33,200 --> 01:39:33,920
BIOLOGICAL MEASURES OF EFFECT

2317
01:39:33,920 --> 01:39:36,200
AND WE REALLY REFERRED TO

2318
01:39:36,200 --> 01:39:38,320
BIOLOGICAL MECHANISMS OF ACTION

2319
01:39:38,320 --> 01:39:39,760
POTENTIALLY EFFECTING CANCER

2320
01:39:39,760 --> 01:39:41,920
THERAPY SUCH AS LIVER, KIDNEY,

2321
01:39:41,920 --> 01:39:44,360
FUNCTION, AND INFLAMMATORY

2322
01:39:44,360 --> 01:39:46,840
MARKERS WE ARE NOT EMPHASIZING

2323
01:39:46,840 --> 01:39:50,040
THE MEASURE OF CBD OR THC FOR A

2324
01:39:50,040 --> 01:39:51,800
NUMBER OF REASONS ALTHOUGH THAT

2325
01:39:51,800 --> 01:39:52,960
IS CERTAINLY POSSIBLE.

2326
01:39:52,960 --> 01:39:54,240
AND THERE'S A QUESTION ABOUT WHY

2327
01:39:54,240 --> 01:39:55,640
AREN'T WE FUNDING CLINICAL

2328
01:39:55,640 --> 01:39:57,400
TRIALS RIGHT NOW?

2329
01:39:57,400 --> 01:39:59,280
AND THERE ARE A NUMBER OF

2330
01:39:59,280 --> 01:40:01,640
SIGNIFICANT BARRIERS TO THE

2331
01:40:01,640 --> 01:40:03,200
INITIATION OF CANNABIS CLINICAL

2332
01:40:03,200 --> 01:40:05,840
TRIALS IN CANCER AND WE FEEL

2333
01:40:05,840 --> 01:40:07,520
THAT OBSERVATIONAL STUD SEIZE

2334
01:40:07,520 --> 01:40:09,880
REALLY A FIRST STEP RIGHT NOW TO

2335
01:40:09,880 --> 01:40:11,560
INFORM WHAT THE RELEVANT END

2336
01:40:11,560 --> 01:40:13,600
POINTS ARE, WHAT THE APPROPRIATE

2337
01:40:13,600 --> 01:40:14,800
PATIENT POPULATIONS ARE, WHAT

2338
01:40:14,800 --> 01:40:17,200
ARE THE POSSIBLE HARMS INCLUDING

2339
01:40:17,200 --> 01:40:19,840
CANNABIS AND USE DISORDER AND

2340
01:40:19,840 --> 01:40:21,200
REALLY TO UNDERSTAND THE

2341
01:40:21,200 --> 01:40:22,440
POTENTIAL CANNABIS PRODUCTS,

2342
01:40:22,440 --> 01:40:23,880
DOSES, DELIVERY METHODS, THAT

2343
01:40:23,880 --> 01:40:25,840
SHOULD BE TESTED IN FUTURE

2344
01:40:25,840 --> 01:40:26,240
TRIALS.

2345
01:40:26,240 --> 01:40:27,640
THIS IS A QUESTION ABOUT DO WE

2346
01:40:27,640 --> 01:40:29,920
INCLUDE SURGICAL PATIENTS IN

2347
01:40:29,920 --> 01:40:31,280
TREATMENT AND WE DO AS WELL AS

2348
01:40:31,280 --> 01:40:36,720
THOSE UNDERGOING RADIATION AND

2349
01:40:36,720 --> 01:40:38,080
SYSTEM THERAPY AND IT'S FOLLOWED

2350
01:40:38,080 --> 01:40:39,560
UP BEYOND THE INITIAL ACTIVE

2351
01:40:39,560 --> 01:40:40,720
TREATMENT TIME PERIOD.

2352
01:40:40,720 --> 01:40:42,320
WORE ALSO ENCOURAGING POPULATION

2353
01:40:42,320 --> 01:40:45,040
BASED RECRUITMENT AND WE KNOW

2354
01:40:45,040 --> 01:40:48,800
THAT MANY STATE REGISTRIES ARE

2355
01:40:48,800 --> 01:40:51,000
ALLOWED FOR RAPID CASE

2356
01:40:51,000 --> 01:40:52,400
ASCERTAINMENT AND WHAT WE REALLY

2357
01:40:52,400 --> 01:40:55,960
ARE INTERESTING HERE IS IN THE

2358
01:40:55,960 --> 01:40:56,760
DENOMINATOR AND UNDERSTANDING

2359
01:40:56,760 --> 01:41:02,680
WHERE THE PATIENTS ARE RECRUITED

2360
01:41:02,680 --> 01:41:03,040
FROM.

2361
01:41:03,040 --> 01:41:05,040
SO, JUST TO SUMMARIZE, THIS

2362
01:41:05,040 --> 01:41:06,240
INITIATIVE WOULD ASSESS HOW AND

2363
01:41:06,240 --> 01:41:09,320
WHY CANCER PATIENTS ARE USING

2364
01:41:09,320 --> 01:41:11,960
CANNABIS, IDENTIFY THE REAL

2365
01:41:11,960 --> 01:41:13,400
BENEFITS AND HARMS OF CANNABIS

2366
01:41:13,400 --> 01:41:15,120
USE, AND CONTRIBUTING EVIDENCE

2367
01:41:15,120 --> 01:41:16,760
TO CLINICIANS AND PATIENTS RIGHT

2368
01:41:16,760 --> 01:41:18,240
NOW AND PROVIDE THE CRITICAL

2369
01:41:18,240 --> 01:41:19,680
INFORMATION THAT WE NEED TO

2370
01:41:19,680 --> 01:41:23,400
DESIGN AND CONDUCT FUTURE

2371
01:41:23,400 --> 01:41:25,080
CLINICAL TRIALS.

2372
01:41:25,080 --> 01:41:27,280
I JUST WANTED TO REMIND

2373
01:41:27,280 --> 01:41:30,120
EVERYBODY THAT WE DID PUBLISH A

2374
01:41:30,120 --> 01:41:33,200
NO SEE FROM OUR INTEREST GROUP

2375
01:41:33,200 --> 01:41:35,600
ON BASIC BENEFITS OF CANNABIS

2376
01:41:35,600 --> 01:41:37,760
ACTION AND FOCUS ON CANCER

2377
01:41:37,760 --> 01:41:39,080
BIOLOGY, INTERCEPTIONS,

2378
01:41:39,080 --> 01:41:44,320
TREATMENT, RESISTANCE AND CANCER

2379
01:41:44,320 --> 01:41:44,920
SYMPTOMS.

2380
01:41:44,920 --> 01:41:50,200
AND THIS NOSI COMPLIMENTS IS

2381
01:41:50,200 --> 01:41:50,360
RFA.

2382
01:41:50,360 --> 01:41:51,440
THANK YOU FOR YOUR TIME AND I

2383
01:41:51,440 --> 01:41:55,760
WANT TO THANK THE SUBCOMMITTEES

2384
01:41:55,760 --> 01:42:05,440
AS WELL.

2385
01:42:05,440 --> 01:42:07,960
>> I JUST WANT TO THANK
Dr.

2386
01:42:07,960 --> 01:42:12,280
FREEDMAN FOR SUCH A THOROUGH AND

2387
01:42:12,280 --> 01:42:13,240
OUTSTANDING PRESENTATION.

2388
01:42:13,240 --> 01:42:14,800
I WANT TO THANK MY COLLEAGUES

2389
01:42:14,800 --> 01:42:20,280
THAT SERVED ON THE SUBCOMMITTEE.

2390
01:42:20,280 --> 01:42:24,320
WE MET A SYNCHRONOUSLY SO I MET

2391
01:42:24,320 --> 01:42:27,640
SEPARATELY ABOUT Dr. FREEDMAN

2392
01:42:27,640 --> 01:42:30,160
AND THE TEAM AT NCI BUT I

2393
01:42:30,160 --> 01:42:30,800
REVIEWED ALL THE COMMENTS FROM

2394
01:42:30,800 --> 01:42:32,000
THE SUBCOMMITTEE MEMBERS.

2395
01:42:32,000 --> 01:42:34,000
IN GENERAL, THERE WAS TREMENDOUS

2396
01:42:34,000 --> 01:42:37,480
SUPPORT FOR THIS RFA AND WE KNOW

2397
01:42:37,480 --> 01:42:39,800
AND I THINK Dr. FREEDMAN MADE

2398
01:42:39,800 --> 01:42:41,840
A STRONG CASE FOR THE NEED FOR

2399
01:42:41,840 --> 01:42:44,280
GREATER UNDERSTANDING OF HOW

2400
01:42:44,280 --> 01:42:47,080
PATIENTS ARE USING CANNABIS,

2401
01:42:47,080 --> 01:42:48,440
WHAT CLINICIANS AND PATIENTS

2402
01:42:48,440 --> 01:42:50,720
NEED TO UNDERSTAND ABOUT THEIR

2403
01:42:50,720 --> 01:42:54,440
USE AND HOW WE CAME IN CLINICAL

2404
01:42:54,440 --> 01:42:55,640
TRIALS AND THEY'RE ALL REALLY

2405
01:42:55,640 --> 01:43:05,480
IMPORTANT TOPICS AND I THINK AS

2406
01:43:05,480 --> 01:43:06,960
BOB POINTED OUT THEY SHOWED

2407
01:43:06,960 --> 01:43:08,360
THERE'S RELATIVELY HIGH USE OF

2408
01:43:08,360 --> 01:43:09,760
CANNABIS AMONG PATIENTS

2409
01:43:09,760 --> 01:43:12,200
UNDERGOING ACTIVE CANCER

2410
01:43:12,200 --> 01:43:13,440
TREATMENT NEARLY A QUARTER OF

2411
01:43:13,440 --> 01:43:15,080
THE PATIENTS REPORTED USING

2412
01:43:15,080 --> 01:43:18,240
CANNABIS AND WE KNOW ALMOST

2413
01:43:18,240 --> 01:43:19,360
NOTHING ABOUT THE HARMS AND

2414
01:43:19,360 --> 01:43:27,320
BENEFITS OF THEIR USE AND THEY

2415
01:43:27,320 --> 01:43:29,760
THINK IT IMPORTANT BE LIMITED TO

2416
01:43:29,760 --> 01:43:31,360
OBSERVATIONAL STUDIES AND

2417
01:43:31,360 --> 01:43:33,560
ESPECIALLY GIVEN HOW LITTLE IS

2418
01:43:33,560 --> 01:43:38,040
KNOWN ABOUT CANNABIS USE AND THE

2419
01:43:38,040 --> 01:43:40,680
FACT THAT REGULATIONS AND THE

2420
01:43:40,680 --> 01:43:41,440
CAR GORIZATION OF CANNABIS AT

2421
01:43:41,440 --> 01:43:43,440
THIS POINT DON'T ALLOW FOR THE

2422
01:43:43,440 --> 01:43:45,440
RANDOMIZATION OF PARTICIPANTS TO

2423
01:43:45,440 --> 01:43:48,600
CANNABIS OR NON CANNABIS ARM.

2424
01:43:48,600 --> 01:43:54,400
I THINK THAT Dr. FREED MAN DID

2425
01:43:54,400 --> 01:43:56,800
HIGHLIGHTS THE COMMITTEE AND SO

2426
01:43:56,800 --> 01:43:58,880
I'LL SAY I THINK THAT THERE WAS

2427
01:43:58,880 --> 01:44:02,840
TREMENDOUS SUPPORT ACROSS THE

2428
01:44:02,840 --> 01:44:03,960
COMMITTEE IN SET AGO SIDE FUNDS

2429
01:44:03,960 --> 01:44:07,080
FOR THIS RFA.

2430
01:44:07,080 --> 01:44:08,680
I'LL DEFER TO MY COLLEAGUES ON

2431
01:44:08,680 --> 01:44:15,000
MY SUBCOMMITTEE.

2432
01:44:15,000 --> 01:44:18,120
>> I'LL GO.

2433
01:44:18,120 --> 01:44:22,800
>> FIRST AND FOREMOST
THANK YOU

2434
01:44:22,800 --> 01:44:25,880
FOR INVOLVING ME AND I COULDN'T

2435
01:44:25,880 --> 01:44:33,120
GROW MORE WITH Dr. QURAN ADD CO.

2436
01:44:33,120 --> 01:44:35,320
I WANT TO HIGHLIGHT TWO

2437
01:44:35,320 --> 01:44:36,880
COMMENTS, ONE WAS THANK YOU

2438
01:44:36,880 --> 01:44:38,680
Dr. FREEDMAN FOR PUTTING THAT

2439
01:44:38,680 --> 01:44:39,160
IN.

2440
01:44:39,160 --> 01:44:42,120
80% OF CANCER PATIENTS WITH

2441
01:44:42,120 --> 01:44:44,160
SOLID TUMORS REQUIRE SURGICAL

2442
01:44:44,160 --> 01:44:45,360
INTERVENTION AND AT SOME TIME OR

2443
01:44:45,360 --> 01:44:50,200
THE OTHER AND IT GOES FROM

2444
01:44:50,200 --> 01:44:52,160
DIAGNOSIS, TREATMENT,

2445
01:44:52,160 --> 01:44:53,200
RECONSTRUCTION OR SOMETHING LIKE

2446
01:44:53,200 --> 01:44:58,440
THAT SO INTEREST ADDITIONALLY WL

2447
01:44:58,440 --> 01:45:00,880
FOR ONCOLOGY PATIENTS WE THINK

2448
01:45:00,880 --> 01:45:02,160
LONG-TERM CHEMOTHERAPY OR

2449
01:45:02,160 --> 01:45:04,120
SOMETHING LIKE THAT BUT WE WANT

2450
01:45:04,120 --> 01:45:06,480
TO BE CONSCIOUS OF THIS GROUP OF

2451
01:45:06,480 --> 01:45:08,240
PATIENTS THAT ARE ACTIVELY

2452
01:45:08,240 --> 01:45:11,360
GETTING TREATED BY SURGERY OR

2453
01:45:11,360 --> 01:45:13,560
RADIATION THAT MIGHT BE

2454
01:45:13,560 --> 01:45:16,120
CONSIDERED FOR THIS AS WELL.

2455
01:45:16,120 --> 01:45:17,480
THE SECOND POINT THAT I WANTED

2456
01:45:17,480 --> 01:45:23,640
TO MAKE QUICKLY IS THAT THE

2457
01:45:23,640 --> 01:45:24,840
ADDICTION POTENTIAL OF THESE

2458
01:45:24,840 --> 01:45:30,600
DRUGS DESPITE THEIR BENEFITS AND

2459
01:45:30,600 --> 01:45:32,080
I O OVERSEE GLAD WATT TRAINING

2460
01:45:32,080 --> 01:45:34,840
PROGRAMS AND ONE OF THE FASTEST

2461
01:45:34,840 --> 01:45:39,720
RISING TRAINING PROGRAMS IS

2462
01:45:39,720 --> 01:45:40,720
ADDICTION MEDICINE AND IN THE

2463
01:45:40,720 --> 01:45:42,040
NUMBER OF PATIENTS WE'RE SEEING

2464
01:45:42,040 --> 01:45:44,360
AND ON MY CAMPUS WE JUST STARTED

2465
01:45:44,360 --> 01:45:46,160
A ADDICTION MEDICINE FELLOWSHIP

2466
01:45:46,160 --> 01:45:48,200
LESS THAN A YEAR OR TWO AGO AND

2467
01:45:48,200 --> 01:45:49,360
WE'RE ALREADY INCREASING THE

2468
01:45:49,360 --> 01:45:55,400
SIZE OF THAT AND OVER ALL WE HAD

2469
01:45:55,400 --> 01:45:57,040
GOOD SUPPORT FOR THIS AND WE

2470
01:45:57,040 --> 01:45:59,160
JUST WANT TO KEEP THOSE TWO

2471
01:45:59,160 --> 01:46:02,200
THINGS IN MIND AND THANK YOU FOR

2472
01:46:02,200 --> 01:46:05,680
IN CONCLUDING ME.

2473
01:46:05,680 --> 01:46:09,320
>>

2474
01:46:09,320 --> 01:46:11,160
>> IT'S LEFT THE STATION
AND IT

2475
01:46:11,160 --> 01:46:13,760
NEEDS TO CATCH UP DID HE TELL

2476
01:46:13,760 --> 01:46:14,720
PRACTICESLY BAD.

2477
01:46:14,720 --> 01:46:16,160
ONE COMMENT I WILL MAKE TO THIS

2478
01:46:16,160 --> 01:46:19,600
GROUP AND WE TALKED ABOUT THIS A

2479
01:46:19,600 --> 01:46:21,800
LOT IS MAYBE IT'S A QUESTION AND

2480
01:46:21,800 --> 01:46:25,640
I DO THINK THAT WE NEED TO BE

2481
01:46:25,640 --> 01:46:27,120
THINKING ABOUT CLINICAL TRIALS

2482
01:46:27,120 --> 01:46:31,840
AND IF WE GET INFORMATION FROM

2483
01:46:31,840 --> 01:46:33,720
ANY OF THE PROJECTS FUNDED BY

2484
01:46:33,720 --> 01:46:35,680
THIS WE NEED TO BE ABLE TO MOVE

2485
01:46:35,680 --> 01:46:39,680
ON CLINICAL TRIALS AND I'M

2486
01:46:39,680 --> 01:46:41,480
CURIOUS IF THERE'S LOGISTIC OUT

2487
01:46:41,480 --> 01:46:44,480
THERE AND FEDERAL REGULATION AND

2488
01:46:44,480 --> 01:46:46,400
I'M CURIOUS IS THERE ANYTHING WE

2489
01:46:46,400 --> 01:46:51,640
CAN DO AND THE BSA TO SORT OF

2490
01:46:51,640 --> 01:46:53,760
HELP BREAKDOWN THESE BARRIERS IN

2491
01:46:53,760 --> 01:46:55,640
PLACE WITH BEING ABLE TO DO

2492
01:46:55,640 --> 01:46:57,000
THESE TYPES OF CLINICAL TRIALS

2493
01:46:57,000 --> 01:47:04,400
IN TERMS OF THOSE REGULATIONS.

2494
01:47:04,400 --> 01:47:07,200
>> SO, I CAN TELL YOU THAT

2495
01:47:07,200 --> 01:47:08,800
THERE'S BEEN A LOT OF DISCUSSION

2496
01:47:08,800 --> 01:47:12,280
IN NCI AND ACROSS NI-AND WOVE

2497
01:47:12,280 --> 01:47:14,880
BEEN WORKING WITH OUR COLLEAGUES

2498
01:47:14,880 --> 01:47:19,200
AT NIDA ABOUT DEVELOPING WAYS TO

2499
01:47:19,200 --> 01:47:23,040
HELP INVESTIGATORS CONNECT THOSE

2500
01:47:23,040 --> 01:47:24,560
CLINICAL TRIALS AND THERE ARE

2501
01:47:24,560 --> 01:47:26,840
REGULATORY ISSUES AND ONE OF THE

2502
01:47:26,840 --> 01:47:33,800
BIGGEST ISSUE IS GETTING AN IMD

2503
01:47:33,800 --> 01:47:35,600
AND RECRUITING PATIENTS AND I

2504
01:47:35,600 --> 01:47:40,640
MEAN, Dr. COOPER FROM IMPOSE

2505
01:47:40,640 --> 01:47:42,080
YUM WHAT A BEAUTIFUL ARTICLE ON

2506
01:47:42,080 --> 01:47:44,400
THIS AND THERE'S A LOT OF ISSUES

2507
01:47:44,400 --> 01:47:49,640
AND I THINK THAT HAVING NCI AND

2508
01:47:49,640 --> 01:47:51,320
ENGAGE WITH ABOUT THIS IS GOING

2509
01:47:51,320 --> 01:47:55,880
TO BE IMPORTANT AND A LOT OF IT

2510
01:47:55,880 --> 01:47:57,360
IS FACILITATING THE RESEARCH AND

2511
01:47:57,360 --> 01:47:58,800
THERE'S A LOT OF REGULATORY

2512
01:47:58,800 --> 01:48:00,240
ISSUES THAT WE HAVE TO OVERCOME

2513
01:48:00,240 --> 01:48:04,800
AND WE SHOULD MAKE IT AS EASY AS

2514
01:48:04,800 --> 01:48:05,680
POSSIBLE FOR OUR INVESTIGATORS

2515
01:48:05,680 --> 01:48:07,760
TO GET THE CLASS ONE LICENSES

2516
01:48:07,760 --> 01:48:09,320
AND REGISTRATION AND TO KNOW HOW

2517
01:48:09,320 --> 01:48:13,760
TO DO IT AND SO THAT THEY GET

2518
01:48:13,760 --> 01:48:15,000
ACCESS TO THE TYPE OF PRODUCTS

2519
01:48:15,000 --> 01:48:17,160
AND THAT THEY NEED TO SO YEAH,

2520
01:48:17,160 --> 01:48:20,880
THERE'S A LOT TO BE DONE AND I

2521
01:48:20,880 --> 01:48:21,880
THINK THAT THIS IS THE FIRST

2522
01:48:21,880 --> 01:48:23,320
STEP BUT KNOW THERE ARE INTEREST

2523
01:48:23,320 --> 01:48:26,160
GROUPS THAT HAS A CLINICAL TYPES

2524
01:48:26,160 --> 01:48:28,080
AND WORKING GROUPS ON THIS AND

2525
01:48:28,080 --> 01:48:32,160
IT'S WORKING PASSION ATLY TO TRY

2526
01:48:32,160 --> 01:48:37,720
TO MOVE THAT FORWARD.

2527
01:48:37,720 --> 01:48:38,840
>> THANK YOU.

2528
01:48:38,840 --> 01:48:41,000
AND YOUR COLLEAGUES AND I WANTED

2529
01:48:41,000 --> 01:48:44,040
TO JUST ECHO WHAT Dr. BARKER

2530
01:48:44,040 --> 01:48:45,080
SHARED JUST INTERNALLY THE SPEED

2531
01:48:45,080 --> 01:48:47,240
OF THIS AND THE SURGERY URGENCY

2532
01:48:47,240 --> 01:48:51,040
OF THIS ISSUE WE TALKED ABOUT AT

2533
01:48:51,040 --> 01:48:54,240
OUR LAST JOINT MEETING.

2534
01:48:54,240 --> 01:48:56,480
I CAN TAKE THIS OFF LINE BUT IN

2535
01:48:56,480 --> 01:49:01,360
FISCAL YEAR 2020 A DOZEN NCI

2536
01:49:01,360 --> 01:49:05,400
COMPANIES GOT SUPPLEMENT THIS IS

2537
01:49:05,400 --> 01:49:14,240
THIS AREA AND WHERE THE PROJECTS

2538
01:49:14,240 --> 01:49:14,880
MIGHT BE, THANK YOU.

2539
01:49:14,880 --> 01:49:18,440
>> SO WE FUNDED THROUGH

2540
01:49:18,440 --> 01:49:21,400
SUPPLEMENTS 12 CANCER CENTERS

2541
01:49:21,400 --> 01:49:22,800
AND THEY'RE EACH GOING TO

2542
01:49:22,800 --> 01:49:24,040
COLLECT A THOUSAND CANCER

2543
01:49:24,040 --> 01:49:25,840
PATIENTS THAT ARE USE OF

2544
01:49:25,840 --> 01:49:27,360
CANNABIS AND PATTERNS OF USE AND

2545
01:49:27,360 --> 01:49:29,600
IT'S REALLY A CROSS SEXUAL STUDY

2546
01:49:29,600 --> 01:49:32,600
AND WE ARE USING WHAT WE LEARNED

2547
01:49:32,600 --> 01:49:35,360
ALREADY FROM PRELIMINARY DATA

2548
01:49:35,360 --> 01:49:37,160
AND HAVING INCOP RATED THAT INTO

2549
01:49:37,160 --> 01:49:39,360
THIS CONCEPT INCLUDING BEER

2550
01:49:39,360 --> 01:49:43,200
SEEING PREVALENCE RATES MUCH

2551
01:49:43,200 --> 01:49:45,480
HIGHER THAN ONE FOUR AND 24% AND

2552
01:49:45,480 --> 01:49:48,680
30% AND EVEN HIGHER THAN THAT

2553
01:49:48,680 --> 01:49:50,960
AND WE HAVEN'T ANALYSIS HASN'T

2554
01:49:50,960 --> 01:49:51,880
BEEN COMPLETED AND THERE'S

2555
01:49:51,880 --> 01:49:56,680
BUT THERE'S A LOT OF USE OUT

2556
01:49:56,680 --> 01:49:58,040
THERE AND THE TYPES OF PRODUCTS

2557
01:49:58,040 --> 01:49:59,160
THAT THEY'RE USING AND HOW

2558
01:49:59,160 --> 01:50:00,800
THEY'RE USING IT WILL BE

2559
01:50:00,800 --> 01:50:02,840
INFORMATIVE AND TO MOVE BEYOND

2560
01:50:02,840 --> 01:50:05,400
THE CROSS SECTIONAL DESIGN TO A

2561
01:50:05,400 --> 01:50:10,680
COHORT DESIGN COLLECTING HARMS

2562
01:50:10,680 --> 01:50:12,760
AND BENEFITS.

2563
01:50:12,760 --> 01:50:15,360
>> THANK YOU FOR THE
QUESTION.

2564
01:50:15,360 --> 01:50:20,920
I DON'T SEE ANY FURTHER HANDS.

2565
01:50:20,920 --> 01:50:24,440
>> I'M VERY SUPPORTIVE OF
THIS

2566
01:50:24,440 --> 01:50:26,480
BUT I WANTED TO RACE WHAT MIGHT

2567
01:50:26,480 --> 01:50:29,520
BE FROM A LAY PERSPECTIVE SEEING

2568
01:50:29,520 --> 01:50:31,240
THE OBVIOUS MIX MESSAGE IF YOU

2569
01:50:31,240 --> 01:50:33,120
LOOK THAT THE RFA AND THE

2570
01:50:33,120 --> 01:50:34,880
PREVIOUS ONE AND SO IN THE

2571
01:50:34,880 --> 01:50:36,600
PREVIOUS RFA WE'RE SAYING YOU

2572
01:50:36,600 --> 01:50:38,680
KNOW, ADOLESCENTS SMOKING CAUSES

2573
01:50:38,680 --> 01:50:40,520
CANCER AND SO DON'T DO IT AND

2574
01:50:40,520 --> 01:50:44,520
THIS RFA WE'RE SAYING, WHEN THEY

2575
01:50:44,520 --> 01:50:48,760
GET CANCERS LIGHT UP.

2576
01:50:48,760 --> 01:50:49,720
IT'S OK.

2577
01:50:49,720 --> 01:50:53,800
SO HOW CAN WE, WHAT IS THE RIGHT

2578
01:50:53,800 --> 01:50:55,200
MESSAGES THAT MAY IN FACT BE THE

2579
01:50:55,200 --> 01:50:58,800
CASE AND I UNDERSTAND ONE

2580
01:50:58,800 --> 01:51:00,800
THOUGHT WOULD BE CAN WE

2581
01:51:00,800 --> 01:51:03,480
EXPLICITLY, I KNOW IN THE LAST

2582
01:51:03,480 --> 01:51:05,480
RFA, IT WAS MENTIONED, IT WAS

2583
01:51:05,480 --> 01:51:10,120
MAINLY TOBACCO BUT IT WAS ARE

2584
01:51:10,120 --> 01:51:13,280
PART OF THIS SO MAYBE WE CAN

2585
01:51:13,280 --> 01:51:15,600
EXPLICITLY LINK IT TO THE PREF

2586
01:51:15,600 --> 01:51:26,080
RFA AS WELL AS THE TITLE AND

2587
01:52:20,920 --> 01:52:22,160
IT'S A FINE MESSAGE.

2588
01:52:22,160 --> 01:52:24,240
>> MAYBE IT'S JUST WORKING

2589
01:52:24,240 --> 01:52:25,720
TOGETHER TO MAKE SURE THE

2590
01:52:25,720 --> 01:52:27,160
MESSAGING WAS ON POINT.

2591
01:52:27,160 --> 01:52:30,480
>> ABSOLUTELY.

2592
01:52:30,480 --> 01:52:36,520
>> I THINK WE CAN MOVE TO

2593
01:52:36,520 --> 01:52:37,520
VOTING.

2594
01:52:37,520 --> 01:52:38,240
GLORIA, DO I MAKE A MOTION.

2595
01:52:38,240 --> 01:52:39,960
>> I WOULD MOVE TO
APPROVE.

2596
01:52:39,960 --> 01:52:45,080
>> SECOND.

2597
01:52:45,080 --> 01:52:46,480
>> SECOND.

2598
01:52:46,480 --> 01:52:55,880
>> ANY FURTHER DISCUSSION?

2599
01:52:55,880 --> 01:52:57,160
MOTION FOR APPROVAL.

2600
01:52:57,160 --> 01:52:59,960
LOCKING FOR ANY VOTES OF

2601
01:52:59,960 --> 01:53:00,360
DISAPPROVAL?

2602
01:53:00,360 --> 01:53:06,840
BY RAISE OF HANDS OR VOICE.

2603
01:53:06,840 --> 01:53:11,760
ANY A ABSTENTIONS?

2604
01:53:11,760 --> 01:53:13,640
I SEE NONE.

2605
01:53:13,640 --> 01:53:17,040
>> IT'S UNANIMOUS.

2606
01:53:17,040 --> 01:53:17,720
>> VERY GOOD.

2607
01:53:17,720 --> 01:53:19,680
MOVING ALONG, NEXT IS ANOTHER

2608
01:53:19,680 --> 01:53:21,520
RFA CONCEPT CANCER SCREENING

2609
01:53:21,520 --> 01:53:23,080
RESEARCH NETWORK TO EVALUATE

2610
01:53:23,080 --> 01:53:24,840
MULTI CANCER EARLY DETECTION

2611
01:53:24,840 --> 01:53:26,560
ASSAY FOR CLINICAL UTILITY IN

2612
01:53:26,560 --> 01:53:30,160
CANCER SCREENING.

2613
01:53:30,160 --> 01:53:36,800
Dr. CASTLE WILL BE PRESENTING.

2614
01:53:36,800 --> 01:53:40,600
SO CHAIRED SUPPORTED BY Dr.S

2615
01:53:40,600 --> 01:53:41,720
AND GO AHEAD.

2616
01:53:41,720 --> 01:53:42,600
>> THANK YOU.

2617
01:53:42,600 --> 01:53:43,720
HELLO AND THANK YOU FOR THE

2618
01:53:43,720 --> 01:53:45,240
OPPORTUNITY TO PRESENT THIS

2619
01:53:45,240 --> 01:53:46,360
CONCEPT TO YOU AND I'M

2620
01:53:46,360 --> 01:53:48,160
PRESENTING ON BOW HALF OF THE

2621
01:53:48,160 --> 01:53:52,000
DCP AND THE CLINICAL TRIAL TEAM

2622
01:53:52,000 --> 01:53:53,680
AND MANY OF WHOM ARE HERE

2623
01:53:53,680 --> 01:53:55,360
INCLUDING COLLEAGUES FROM THE

2624
01:53:55,360 --> 01:53:57,400
FDA AND I'M STANDING IN FOR LORI

2625
01:53:57,400 --> 01:54:02,720
WHO LEADS THIS PROJECT WHO IS

2626
01:54:02,720 --> 01:54:04,760
JOINING BY PHONE FROM LONDON.

2627
01:54:04,760 --> 01:54:07,520
THERE ARE TWO COMPONENTS TO THIS

2628
01:54:07,520 --> 01:54:08,720
PROPOSAL AND THE ESTABLISHMENT

2629
01:54:08,720 --> 01:54:11,960
OF A CANCER SCREENING RESEARCH

2630
01:54:11,960 --> 01:54:12,920
NETWORK INFRASTRUCTURE AND THE

2631
01:54:12,920 --> 01:54:14,960
FIRST STUDY WE WANT TO CONDUCT

2632
01:54:14,960 --> 01:54:17,800
IN THIS NETWORK OF FEASIBILITY

2633
01:54:17,800 --> 01:54:22,320
STUDY FOR THE MULTI CANCER EARL

2634
01:54:22,320 --> 01:54:24,360
DETECTION OR MCED AND THIS IS A

2635
01:54:24,360 --> 01:54:25,680
RIGHT TIME FOR BOTH, GIVEN THE

2636
01:54:25,680 --> 01:54:27,200
CALL FOR THE WHITE HOUSE FOR

2637
01:54:27,200 --> 01:54:28,960
IMPROVING CANCER PREVENTION AND

2638
01:54:28,960 --> 01:54:30,560
SCREENING AND THE CHALLENGES

2639
01:54:30,560 --> 01:54:32,160
ASSOCIATED WITH CANCER SCREENING

2640
01:54:32,160 --> 01:54:34,120
AND THE EMERGENCE OF

2641
01:54:34,120 --> 01:54:35,920
TECHNOLOGIES AND THANK YOU TO

2642
01:54:35,920 --> 01:54:42,160
TRAY, SIL VOW A VE SIL VOW A ANL

2643
01:54:42,160 --> 01:54:44,680
AND WE ARE GRATEFUL TO DCP AND

2644
01:54:44,680 --> 01:54:50,960
NETANTHENCI.

2645
01:54:50,960 --> 01:54:52,160
THIS IS OUR TSUNAMI SLIDE AND

2646
01:54:52,160 --> 01:54:59,800
THE NEED FOR THE IT WAS CAN

2647
01:54:59,800 --> 01:55:02,560
COMPANIES ENTERING THE MULTI

2648
01:55:02,560 --> 01:55:06,240
DETECTION SPACE AND THIS IS NOT

2649
01:55:06,240 --> 01:55:08,840
A COMPREHENSIVE LIST AND IT IS

2650
01:55:08,840 --> 01:55:10,120
AN EMERGING SPACE.

2651
01:55:10,120 --> 01:55:11,520
SOME OF THE COMPANIES, THE

2652
01:55:11,520 --> 01:55:12,720
CANCERS THEY TARGET AND

2653
01:55:12,720 --> 01:55:14,560
BIOMARKERS THEY USE ARE SHOWN IN

2654
01:55:14,560 --> 01:55:16,440
A SUPPLEMENTAL SLIDE ONE.

2655
01:55:16,440 --> 01:55:18,560
LET'S JUST SAY THAT THERE'S A

2656
01:55:18,560 --> 01:55:22,440
LOT OF PRESSURE THAT IS BEING

2657
01:55:22,440 --> 01:55:23,520
EXERTED TO INTRODUCE THESE

2658
01:55:23,520 --> 01:55:24,400
TECHNOLOGIES BEFORE DO YOU

2659
01:55:24,400 --> 01:55:30,760
DILIGENCE HAS BEEN DONE.

2660
01:55:30,760 --> 01:55:32,160
THE DEVELOPMENT OF THE NETWORK

2661
01:55:32,160 --> 01:55:33,880
INFRASTRUCTURE TO CONDUCT CANCER

2662
01:55:33,880 --> 01:55:34,880
SCREENING CLINICAL TRIALS AND

2663
01:55:34,880 --> 01:55:36,160
OTHER IMPORTANT SCREENING

2664
01:55:36,160 --> 01:55:39,000
STUDIES IS ONE PURPOSE OF THE

2665
01:55:39,000 --> 01:55:43,160
INITIAL EFFORTS IS TO CONDUCT

2666
01:55:43,160 --> 01:55:44,480
THIS FEASIBILITY CALLED THE VAN

2667
01:55:44,480 --> 01:55:47,560
GUARD STUDY IN REPARATION FOR A

2668
01:55:47,560 --> 01:55:49,360
LARGE RANDOMIZED CONTROL TRIAL

2669
01:55:49,360 --> 01:55:52,200
OR RCT TO EVALUATE TECHNOLOGIES

2670
01:55:52,200 --> 01:55:54,080
OR ASSAYS FOR THE PURPOSE OF

2671
01:55:54,080 --> 01:56:04,400
CANCER SCREENING.

2672
01:56:16,720 --> 01:56:18,520
WITHOUT CLINICAL BENEFITS SUCH

2673
01:56:18,520 --> 01:56:21,520
AS MORTALITY REDUCTION AND

2674
01:56:21,520 --> 01:56:22,360
POTENTIAL HARMS AND MORBIDITY DO

2675
01:56:22,360 --> 01:56:28,800
YOU TO TREATMENT OF DISEASE AND

2676
01:56:28,800 --> 01:56:30,680
USING ASSAY FOR CANCER SCREENING

2677
01:56:30,680 --> 01:56:32,080
AND HOW BEST TO SCREEN FOR

2678
01:56:32,080 --> 01:56:34,040
MULTIPLE CANCERS WITH DIFFERENT

2679
01:56:34,040 --> 01:56:35,640
LATEN SEE AND HOW IT COORDINATE

2680
01:56:35,640 --> 01:56:38,560
CARE AFTER A POSITIVE TEST

2681
01:56:38,560 --> 01:56:39,680
RESULT AND WE WOULDN'T THINK

2682
01:56:39,680 --> 01:56:40,880
ABOUT RECOMMENDING A DRUG

2683
01:56:40,880 --> 01:56:42,680
WITHOUT CAREFUL EVALUATION OF

2684
01:56:42,680 --> 01:56:44,560
ITS EFFICACY AND SAFETY

2685
01:56:44,560 --> 01:56:45,560
ESPECIALLY IN THE GENERALLY

2686
01:56:45,560 --> 01:56:47,440
HEALTHY POPULATION SO WHY WOULD

2687
01:56:47,440 --> 01:56:51,680
WE DO IT FOR SCREENING AND THEY

2688
01:56:51,680 --> 01:56:53,400
ARE DONE OUTSIDE THE BODY BUT

2689
01:56:53,400 --> 01:56:55,560
THE DOWNSTREAM EVALUATION AND

2690
01:56:55,560 --> 01:56:57,640
SCREEN POSITIVES ARE IN VIVO AND

2691
01:56:57,640 --> 01:57:01,520
THERE ARE HARMS ASSOCIATED WITH

2692
01:57:01,520 --> 01:57:01,840
IT.

2693
01:57:01,840 --> 01:57:04,960
NEXT SLIDE, PLEASE.

2694
01:57:04,960 --> 01:57:07,080
AND TRIALS ARE NODED TO EVALUATE

2695
01:57:07,080 --> 01:57:09,200
STRATEGIES THAT AIM TO REFINE

2696
01:57:09,200 --> 01:57:10,640
RISK STRATIFICATION OF IMAGING

2697
01:57:10,640 --> 01:57:12,280
FINDINGS AND DETERMINE WHEN TO

2698
01:57:12,280 --> 01:57:16,440
DEFER BUY ON TEE, LUNG CANCER

2699
01:57:16,440 --> 01:57:18,680
AND PULMONARY, BREAST CANCER,

2700
01:57:18,680 --> 01:57:24,000
AND DOWNGRADING TO BI-ADDS 3 AND

2701
01:57:24,000 --> 01:57:26,280
ACTIVE AND LOW GRADE CANCER AND

2702
01:57:26,280 --> 01:57:28,440
TRIALS ARE NEEDED TO EVALUATE

2703
01:57:28,440 --> 01:57:29,360
RISK STRATIFICATION FOR

2704
01:57:29,360 --> 01:57:29,640
SCREENING.

2705
01:57:29,640 --> 01:57:32,040
AND THE USE OF RISK SCORES LIKE

2706
01:57:32,040 --> 01:57:33,520
PRS TO GUIDE WHO NODES

2707
01:57:33,520 --> 01:57:34,600
SCREENING, HOW FREQUENTLY AND

2708
01:57:34,600 --> 01:57:37,160
HOW TO MANAGE A POSITIVE SCREEN,

2709
01:57:37,160 --> 01:57:40,640
AND MODIFY THE STARTING AGE FOR

2710
01:57:40,640 --> 01:57:43,360
SCREENING MODALITY LIKE

2711
01:57:43,360 --> 01:57:44,480
COLORECTAL SCREENING AND

2712
01:57:44,480 --> 01:57:50,240
STANDARD AGE SCREENING FOR COL

2713
01:57:50,240 --> 01:57:52,400
OLE RECTAL.

2714
01:57:52,400 --> 01:57:56,160
THE APPROACH AND RATIONED ALL

2715
01:57:56,160 --> 01:58:00,840
FOR CSRN DCP HAD A CSRN IN

2716
01:58:00,840 --> 01:58:01,840
COLLABORATION WITH QUESTIONS

2717
01:58:01,840 --> 01:58:03,600
RELATED TO CANCER SCREENING

2718
01:58:03,600 --> 01:58:04,840
CONTINUING WITH CARE AND

2719
01:58:04,840 --> 01:58:06,920
EFFICACY EFFECTIVENESS BEST

2720
01:58:06,920 --> 01:58:08,400
PRACTICES AND ADOPTION AND

2721
01:58:08,400 --> 01:58:09,840
ADAPTION AND IMPLEMENTATION FOR

2722
01:58:09,840 --> 01:58:12,520
EACH STEP IN THIS CONTINUUM.

2723
01:58:12,520 --> 01:58:14,240
CANCER SCREENING TRIALS REQUIRE

2724
01:58:14,240 --> 01:58:17,560
HEALTHCARE PROVIDERS OTHER THAN

2725
01:58:17,560 --> 01:58:18,480
ONCOLOGIST AND WE'RE DEALING

2726
01:58:18,480 --> 01:58:20,520
WITH HEALTHY POPULATION WHO'S

2727
01:58:20,520 --> 01:58:22,040
DON'T HAVE CANCER AND SCREENING

2728
01:58:22,040 --> 01:58:24,000
IS MUCH MORE THAN A TEST ITSELF

2729
01:58:24,000 --> 01:58:25,080
AND CANCER SCREENING IS A

2730
01:58:25,080 --> 01:58:26,760
PROCESS INVOLVING MULTIPLE

2731
01:58:26,760 --> 01:58:27,760
STEPS?

2732
01:58:27,760 --> 01:58:34,520
NON CON ONCOLOGY.

2733
01:58:34,520 --> 01:58:38,200
THESE ARE PRIMARY CARRYING

2734
01:58:38,200 --> 01:58:45,600
GASTRO WHO ARE EXPERTS IN CANCER

2735
01:58:45,600 --> 01:58:46,200
SCREENING.

2736
01:58:46,200 --> 01:58:47,880
AND THE SITE INVESTIGATORS TO

2737
01:58:47,880 --> 01:58:49,320
CONTRIBUTE SCIENTIFICALLY TO THE

2738
01:58:49,320 --> 01:58:51,160
DESIGN OF THE TRIAL OR TRIALS

2739
01:58:51,160 --> 01:58:52,560
IDENTIFYING AND IMPLEMENTING

2740
01:58:52,560 --> 01:58:55,000
WORK FLOW AND DIAGNOSTIC WORK

2741
01:58:55,000 --> 01:58:58,040
FOR CANCER SCREENING FOR

2742
01:58:58,040 --> 01:59:00,120
POSITIVE MCED TESTS AS WE'LL

2743
01:59:00,120 --> 01:59:02,640
HIGHLIGHT LATER THE COMPLEXITIES

2744
01:59:02,640 --> 01:59:04,960
ARE QUITE STAGGERING AND

2745
01:59:04,960 --> 01:59:06,480
ASSESSING THE HARMS AND ADVERSE

2746
01:59:06,480 --> 01:59:07,840
EFFECT AND OTHER UNEXPECTED

2747
01:59:07,840 --> 01:59:09,520
ISSUES AND WE NODE A

2748
01:59:09,520 --> 01:59:11,280
CONTEMPORARY COMMUNICATION IN

2749
01:59:11,280 --> 01:59:13,400
RECRUITMENT STRATEGY IN TRIAL

2750
01:59:13,400 --> 01:59:15,400
AND LOCAL LEVEL COMMUNICATION

2751
01:59:15,400 --> 01:59:16,080
RECRUITMENT EFFORTS.

2752
01:59:16,080 --> 01:59:23,480
NEXT SLIDE, PLEASE.

2753
01:59:23,480 --> 01:59:24,280
ESTABLISHING THE INFRASTRUCTURE

2754
01:59:24,280 --> 01:59:26,080
OR THE OBJECTIVES TO ESTABLISH

2755
01:59:26,080 --> 01:59:28,000
AN INFRASTRUCTURE NEEDED TO

2756
01:59:28,000 --> 01:59:29,720
IMPLEMENT SCREENING RCTs AND

2757
01:59:29,720 --> 01:59:31,560
OTHER STUDIES OF SCREENING

2758
01:59:31,560 --> 01:59:33,280
MANAGEMENT FOR PREVENTION AND

2759
01:59:33,280 --> 01:59:33,880
INCOMPETENTER EXCEPTION AND

2760
01:59:33,880 --> 01:59:36,960
WE'RE GOING TO START WITH THE

2761
01:59:36,960 --> 01:59:39,480
VAN GUARD STUDY AND CONDUCT

2762
01:59:39,480 --> 01:59:40,560
CANCER SCREENING TRIALS FOR

2763
01:59:40,560 --> 01:59:42,160
EMERGING TECHNOLOGIES FOR CANCER

2764
01:59:42,160 --> 01:59:46,040
SCREENING AND CONDUCT CLINICAL

2765
01:59:46,040 --> 01:59:46,600
UTILITY TRAILS.

2766
01:59:46,600 --> 01:59:48,680
AS YOU KNOW, YOU APPROVED EDRN

2767
01:59:48,680 --> 01:59:50,440
FOR ANOTHER ROUND AND BIOMARKERS

2768
01:59:50,440 --> 01:59:52,240
ARE GOING TO CONTINUE TO EMERGE

2769
01:59:52,240 --> 01:59:54,680
FROM EDRN AND WE NEED A PLACE IN

2770
01:59:54,680 --> 01:59:57,520
A STRUCTURE TO EVALUATE THEM.

2771
01:59:57,520 --> 01:59:58,880
CONDUCT CANCER SCREENING STUDIES

2772
01:59:58,880 --> 02:00:00,560
TO EVALUATE OTHER ASPECTS OF

2773
02:00:00,560 --> 02:00:02,480
CANCER SCREENING AND INCLUDING

2774
02:00:02,480 --> 02:00:03,800
CLINICAL WORK FLOW AND

2775
02:00:03,800 --> 02:00:05,240
COORDINATION OF CARE AND

2776
02:00:05,240 --> 02:00:06,720
ADAPTION IN IMPLEMENTATION OF

2777
02:00:06,720 --> 02:00:09,040
SCREENING STRATEGIES FOR DIVERSE

2778
02:00:09,040 --> 02:00:10,840
PRACTICE SETTINGS AND RISK

2779
02:00:10,840 --> 02:00:11,680
INFORMED SCREENINGS AND

2780
02:00:11,680 --> 02:00:13,760
MANAGEMENT AND PRAGMATIC TRIALS

2781
02:00:13,760 --> 02:00:14,680
OF SCREENING.

2782
02:00:14,680 --> 02:00:18,920
NEXT SLIDE, PLEASE.

2783
02:00:18,920 --> 02:00:20,720
THIS OUTLINES THE ORGANIZATIONAL

2784
02:00:20,720 --> 02:00:22,520
STRUCTURE OF THE CSRN AND

2785
02:00:22,520 --> 02:00:24,320
THERE'S A FIGURE COMING UP THAT

2786
02:00:24,320 --> 02:00:26,240
WILL ALSO EMPHASIZE THIS AND WE

2787
02:00:26,240 --> 02:00:29,160
ARE UTILIZING THE NCI CLINICAL

2788
02:00:29,160 --> 02:00:30,640
TRIALS ENTERPRISE SYSTEM AND IT

2789
02:00:30,640 --> 02:00:33,000
WILL MAKE THIS A LOT EASIER AND

2790
02:00:33,000 --> 02:00:37,640
WE'LL HAVE A COORDINATING AND

2791
02:00:37,640 --> 02:00:38,840
COMMUNICATION CENTER THAT WILL

2792
02:00:38,840 --> 02:00:39,960
PROVIDE CANCER SCREENING

2793
02:00:39,960 --> 02:00:41,400
LEADERSHIP AND OPERATIONS AND

2794
02:00:41,400 --> 02:00:43,040
COORDINATION FOR DEVELOPMENT AND

2795
02:00:43,040 --> 02:00:44,320
CONDUCT OF TRIALS AND STUDIES

2796
02:00:44,320 --> 02:00:46,160
AND COMMUNICATIONS FOR

2797
02:00:46,160 --> 02:00:47,800
RECRUITMENT AND RETENTION

2798
02:00:47,800 --> 02:00:48,600
EXPERTISE AND PROTOCOL

2799
02:00:48,600 --> 02:00:50,960
DEVELOPMENT AND MONITORING

2800
02:00:50,960 --> 02:00:53,880
AUDITING AND TRAINING AND A ONE

2801
02:00:53,880 --> 02:00:56,360
GRANT FOR A DATA MANAGEMENT AND

2802
02:00:56,360 --> 02:00:57,960
STATISTICAL CENTER AND PROVIDING

2803
02:00:57,960 --> 02:00:59,600
STATISTIC EXPERTISE FOR STUDY

2804
02:00:59,600 --> 02:01:02,440
DESIGN AND ANALYSIS AND DATA

2805
02:01:02,440 --> 02:01:04,480
MANAGEMENT WITH THE BIO

2806
02:01:04,480 --> 02:01:06,240
REPOSITORY.

2807
02:01:06,240 --> 02:01:08,040
NEXT SLIDE, PLEASE.

2808
02:01:08,040 --> 02:01:10,800
THEN THERE WILL BE 10 TO 15UG1

2809
02:01:10,800 --> 02:01:14,000
GRANTS THAT WILL BE THE ACCRUAL

2810
02:01:14,000 --> 02:01:15,960
IN SCREENING SITES ARE ACCESS

2811
02:01:15,960 --> 02:01:17,840
SITES AND INITIALLY THERE WOULD

2812
02:01:17,840 --> 02:01:21,800
BE 10 TO 15UG1 FUNDED CSRN SITES

2813
02:01:21,800 --> 02:01:26,240
IF WE LAUNCH THE RCT FOR THE

2814
02:01:26,240 --> 02:01:27,680
MCED TRIALS, WE NODE MORE SITES

2815
02:01:27,680 --> 02:01:29,120
BUZZ OF THE NUMBER OF PEOPLE WE

2816
02:01:29,120 --> 02:01:31,240
NEED TO RECRUIT AND THE 10 TO 15

2817
02:01:31,240 --> 02:01:34,680
WILL BE THE BASE CSRN NETWORK

2818
02:01:34,680 --> 02:01:36,360
AND YES, WE'LL LOOK FOR

2819
02:01:36,360 --> 02:01:38,000
INVESTIGATORS WITH EXPERTISE AND

2820
02:01:38,000 --> 02:01:40,080
CANCER SCREENING AND HISTORY OF

2821
02:01:40,080 --> 02:01:41,840
RECRUITING PARTICIPANTS ON TO

2822
02:01:41,840 --> 02:01:43,040
SCREENING AND PREVENTION

2823
02:01:43,040 --> 02:01:46,400
CLINICAL TRIALS AND STUDIES AND

2824
02:01:46,400 --> 02:01:49,480
INSTITUTIONS WITH DEMONSTRATED

2825
02:01:49,480 --> 02:01:51,040
PARTICIPANTS ON DISEASE

2826
02:01:51,040 --> 02:01:53,200
SCREENING CLINICAL TRIALS AND

2827
02:01:53,200 --> 02:01:56,200
ESPECIALLY CANCER SCREENING OR

2828
02:01:56,200 --> 02:01:56,680
PREVENTION.

2829
02:01:56,680 --> 02:01:59,520
HEALTHCARE SETTINGS, ACADEMIC,

2830
02:01:59,520 --> 02:02:01,520
COMMUNITY, HEALTHCARE SYSTEMS

2831
02:02:01,520 --> 02:02:04,040
AND PRACTICE-BASED RESEARCH

2832
02:02:04,040 --> 02:02:05,440
NETWORKS AND MOST IMPORTANTLY

2833
02:02:05,440 --> 02:02:06,600
DEMONSTRATED HISTORY OF

2834
02:02:06,600 --> 02:02:08,600
RECRUITING UNDERSERVED

2835
02:02:08,600 --> 02:02:11,880
POPULATIONS AND HAVING A

2836
02:02:11,880 --> 02:02:13,600
RECRUITMENT STRATEGY TO ACHIEVE

2837
02:02:13,600 --> 02:02:13,880
THAT.

2838
02:02:13,880 --> 02:02:17,480
NEXT SLIDE, PLEASE.

2839
02:02:17,480 --> 02:02:18,880
AND THIS JUST SORT OF OUTLINES

2840
02:02:18,880 --> 02:02:20,600
WHAT I JUST SAID.

2841
02:02:20,600 --> 02:02:23,160
HERE YOU CAN SEE THE

2842
02:02:23,160 --> 02:02:25,120
COORDINATING COMMUNICATION

2843
02:02:25,120 --> 02:02:26,880
CENTER AND THE DATA MANAGEMENT

2844
02:02:26,880 --> 02:02:28,920
AND STATISTICAL CENTER

2845
02:02:28,920 --> 02:02:32,040
COORDINATED WITH THE 10 TO 15

2846
02:02:32,040 --> 02:02:33,720
ACCRUAL SITES AND A STEERING

2847
02:02:33,720 --> 02:02:35,200
COMMITTEE OVERSEEING ALL OF THAT

2848
02:02:35,200 --> 02:02:37,880
AND THERE WOULD BE A WEB PORTAL

2849
02:02:37,880 --> 02:02:39,320
FOR PARTICIPANT USE AND WE'LL

2850
02:02:39,320 --> 02:02:42,240
HAVE A PARTICIPANT ADVISORY

2851
02:02:42,240 --> 02:02:44,000
COMMITTEE UP FRONT AT THE VERY

2852
02:02:44,000 --> 02:02:44,480
BEGINNING.

2853
02:02:44,480 --> 02:02:48,640
NEXT SLIDE, PLEASE.

2854
02:02:48,640 --> 02:02:51,320
WE'VE DONE A PORTFOLIO ANALYSIS.

2855
02:02:51,320 --> 02:02:55,640
MANY OF YOU ARE AWARE OF THE RO1

2856
02:02:55,640 --> 02:02:56,320
CLINICAL TRIALS GRANT PROGRAM

2857
02:02:56,320 --> 02:02:59,760
AND CLINICAL TRIALS EVALUATING

2858
02:02:59,760 --> 02:03:01,040
OPERATIONAL CHARACTERISTICS FOR

2859
02:03:01,040 --> 02:03:03,320
CANCER EARLY DETECTION

2860
02:03:03,320 --> 02:03:13,840
TECHNOLOGIES AND COMMUNICATIONS

2861
02:03:14,360 --> 02:03:19,320
AND RO1 EVEN IN A LARGE RO1 AND

2862
02:03:19,320 --> 02:03:23,880
THE ENCORE WHICH IS OUR OUR KEY

2863
02:03:23,880 --> 02:03:28,720
PROGRAM AND DCP AND A SUCCESS

2864
02:03:28,720 --> 02:03:30,560
ONCOLOGY AND OUR CHALLENGE

2865
02:03:30,560 --> 02:03:35,240
THAT'S EXIST AND PATIENT AND

2866
02:03:35,240 --> 02:03:37,600
CERTAIN TYPES AND IT'S REALLY

2867
02:03:37,600 --> 02:03:39,440
MEANT TO COMPLIMENT AND OTHER

2868
02:03:39,440 --> 02:03:40,680
TECHNOLOGIES THAT THE PIPELINES

2869
02:03:40,680 --> 02:03:42,200
THAT WE SUPPORT AND DISCOVERY

2870
02:03:42,200 --> 02:03:44,680
AND WE HAVE SEEN AN EX PANNING

2871
02:03:44,680 --> 02:03:46,600
NEED TO CONDUCT SCREENING TRIALS

2872
02:03:46,600 --> 02:03:49,560
TO ESTABLISH EFFICACY AND

2873
02:03:49,560 --> 02:03:51,360
BENEFITS TO RATIO IN THE GENERAL

2874
02:03:51,360 --> 02:03:52,840
POPULATION AND IT'S BEST

2875
02:03:52,840 --> 02:03:54,880
RECRUITED BY NON ONOLOGIST.

2876
02:03:54,880 --> 02:04:03,440
NEXT SLIDE, PLEASE.

2877
02:04:03,440 --> 02:04:06,600
COOPERATIVES AND INTER AND THE

2878
02:04:06,600 --> 02:04:08,840
USE OF EXISTING CLINICAL TRIALS

2879
02:04:08,840 --> 02:04:11,600
INFRASTRUCTURE AND A CTSU AND

2880
02:04:11,600 --> 02:04:14,720
CIRB AND CTIS AND MONITORING AND

2881
02:04:14,720 --> 02:04:18,520
AUDITING AND PROTOCOL REVIEW

2882
02:04:18,520 --> 02:04:23,520
PROCESS AND TRACKING AND AND

2883
02:04:23,520 --> 02:04:24,680
STATISTICAL METHODS AND ON THE

2884
02:04:24,680 --> 02:04:31,760
DATA AND FROM THE VAN GUARD AND

2885
02:04:31,760 --> 02:04:33,320
RESOURCE ALLOCATION AND FUNDING

2886
02:04:33,320 --> 02:04:36,680
TO ENSURE ADEQUATE RESOURCES FOR

2887
02:04:36,680 --> 02:04:41,840
THE OTHER LARGE TRIALS WE SEE IN

2888
02:04:41,840 --> 02:04:48,200
THE FUTURE.

2889
02:04:48,200 --> 02:04:55,800
AND AND PLEASE AND AND EARLY

2890
02:04:55,800 --> 02:04:58,440
TENSION AND WHAT HAPPENED AND

2891
02:04:58,440 --> 02:05:00,760
WHEN IN THE BLOOD AND MANY

2892
02:05:00,760 --> 02:05:01,960
MACKERS IN DEVELOPMENT AND

2893
02:05:01,960 --> 02:05:09,120
PATTERNS OF DNA METHYLATION AND

2894
02:05:09,120 --> 02:05:15,040
ET CETERA AND EACH MSET AS SET

2895
02:05:15,040 --> 02:05:16,600
AND AND IT'S A POSITIVE TEST

2896
02:05:16,600 --> 02:05:18,480
RESULT IS A SIGNAL FOR CANCER

2897
02:05:18,480 --> 02:05:21,120
BUT DOES NOT DIAGNOSE CANCER AND

2898
02:05:21,120 --> 02:05:26,040
SOME TASK SUGGESTION AND AND

2899
02:05:26,040 --> 02:05:28,400
POSITIVE MCED RESULT AND SOME

2900
02:05:28,400 --> 02:05:33,360
ASSAY COMPANIES TO REFINE AND

2901
02:05:33,360 --> 02:05:39,440
RESULT AND NEXT SLIDE, PLEASE.

2902
02:05:39,440 --> 02:05:40,920
THERE MANY MANY UNKNOWN AND

2903
02:05:40,920 --> 02:05:43,960
EARLY DETECTION ASSAYS AND

2904
02:05:43,960 --> 02:05:44,880
UNKNOWN SCREENING THE POPULATION

2905
02:05:44,880 --> 02:05:47,360
OF ASYMPTOMATIC PEOPLE FOR

2906
02:05:47,360 --> 02:05:49,880
CANCER WITH ASSAYS WITH A

2907
02:05:49,880 --> 02:05:57,400
MORTALITY REDUCTION FROM AND

2908
02:05:57,400 --> 02:06:00,640
UNKNOWN AND WHAT KINDS OF

2909
02:06:00,640 --> 02:06:03,680
DIAGNOSTIC AND NEEDED TO CARE

2910
02:06:03,680 --> 02:06:06,560
AND POSITIVE MCED TEST YOU DO

2911
02:06:06,560 --> 02:06:07,560
FIND CANCER AND HOW MANY PEOPLE

2912
02:06:07,560 --> 02:06:11,960
WOULD BE SUBJECTED TO UNNESS AND

2913
02:06:11,960 --> 02:06:13,520
COMPLICATIONS FROM THOSE

2914
02:06:13,520 --> 02:06:15,920
PROCEDURES AND REAL PEOPLE STOP

2915
02:06:15,920 --> 02:06:20,240
STANDARD OF CARE SCREENING AND

2916
02:06:20,240 --> 02:06:22,240
POSITIVE TEST AND BLOOD TEST

2917
02:06:22,240 --> 02:06:26,720
MAKE A SCREENING MORE ACCESS

2918
02:06:26,720 --> 02:06:29,760
ABLE AND AND WHETHER THOSE TESTS

2919
02:06:29,760 --> 02:06:40,880
NED TO OVER ZOO -- IT WAS NCI SF

2920
02:06:40,880 --> 02:06:43,320
PROVIDEDDED RATIONAL AND TRIAL

2921
02:06:43,320 --> 02:06:48,560
IN THE FEEDBACK WAS AND EXPERTS

2922
02:06:48,560 --> 02:06:51,880
THAT NCI NEEDS TO ASSAY FOR

2923
02:06:51,880 --> 02:06:54,200
CLINICAL BENEFITS AND ON THE

2924
02:06:54,200 --> 02:06:56,360
NODE FOR RIGOROUS AND

2925
02:06:56,360 --> 02:06:59,680
UNDERSTANDING HARMS FROM MCED

2926
02:06:59,680 --> 02:07:02,640
ASSAY AND CONDUCT A STUDY TO

2927
02:07:02,640 --> 02:07:03,760
ASSESS FEASIBILITY RANDOMIZATION

2928
02:07:03,760 --> 02:07:06,640
AND THE CLINICAL WORK FLOW FOR

2929
02:07:06,640 --> 02:07:13,080
DIAGNOSTIC PATHWAY AND NEXT

2930
02:07:13,080 --> 02:07:13,600
SLIDE, PLEASE.

2931
02:07:13,600 --> 02:07:15,720
WE DID PUT OUT A REQUEST FOR

2932
02:07:15,720 --> 02:07:19,360
INFORMATION SO YOU PUT FROM

2933
02:07:19,360 --> 02:07:21,760
DEVELOPERS AND READINESS IS TO

2934
02:07:21,760 --> 02:07:23,360
PARTICIPATE IN SPONSORS EX

2935
02:07:23,360 --> 02:07:25,840
UTILITY AND TRIAL AND IT WAS

2936
02:07:25,840 --> 02:07:29,160
REALLY IN JANUARY 2021 AND 2022

2937
02:07:29,160 --> 02:07:33,800
AND MARCH 21 TO 222 AND WE'VE

2938
02:07:33,800 --> 02:07:37,040
HAD 18 RESPONSES AND AND OUR

2939
02:07:37,040 --> 02:07:38,840
ASSAY DEVELOPERS OF VARIOUS

2940
02:07:38,840 --> 02:07:40,280
TECHNOLOGIES AND ONE REQUEST TO

2941
02:07:40,280 --> 02:07:46,080
BE A PARTICIPANT AND TWO

2942
02:07:46,080 --> 02:07:49,560
EXAMPLES OF EMERGING AND WE ARE

2943
02:07:49,560 --> 02:07:52,200
IN THE PROCESS OF MEETING WITH

2944
02:07:52,200 --> 02:07:54,360
THESE COMPANIES ONE-ON-ONE AND

2945
02:07:54,360 --> 02:07:57,440
THERE'S BEEN OTHER COMPANIES

2946
02:07:57,440 --> 02:08:06,200
THAT NECESSARILY AND IN THIS

2947
02:08:06,200 --> 02:08:16,800
DISCUSSION AND ABOUT A TRIAL AN-

2948
02:09:33,600 --> 02:09:36,760
>> THIS IS WHAT THE VAN
GUARD

2949
02:09:36,760 --> 02:09:39,760
STUDY LOOKS LIKE AND THIS THROW

2950
02:09:39,760 --> 02:09:41,280
ARMS AND WE HAVE IT WRITTEN HERE

2951
02:09:41,280 --> 02:09:44,320
BECAUSE THEY HAVE DIFFERENT

2952
02:09:44,320 --> 02:09:46,520
MANAGEMENT ALGORITHMS AND SO IT

2953
02:09:46,520 --> 02:09:48,160
MADE SENSE TO HAVE A COUPLE OF

2954
02:09:48,160 --> 02:09:50,680
THEM HERE TO UNDERSTAND WHAT THE

2955
02:09:50,680 --> 02:09:52,440
LOGISTICS AND THIS IS GETS ON

2956
02:09:52,440 --> 02:09:56,040
RANGE OF POSITIVE AND HOW

2957
02:09:56,040 --> 02:10:01,240
VARIABLE THAT IS AND THE

2958
02:10:01,240 --> 02:10:04,040
OBJECTIVES AND RANDOMIZED AND

2959
02:10:04,040 --> 02:10:05,520
HEARINGS TO TESTING AND

2960
02:10:05,520 --> 02:10:06,880
DIAGNOSTIC FOLLOW-UP AND

2961
02:10:06,880 --> 02:10:09,440
EVALUATE FEASIBILITY OF PROTOCOL

2962
02:10:09,440 --> 02:10:11,960
DIAGNOSTIC WORKFORCE AND

2963
02:10:11,960 --> 02:10:16,560
DETERMINE AND BLOOD SPECIMENS

2964
02:10:16,560 --> 02:10:22,600
AND SO IDENTIFY FACILITATORS AND

2965
02:10:22,600 --> 02:10:28,520
AND PARTICIPANT AND GROUPS AND I

2966
02:10:28,520 --> 02:10:32,680
THINK AND ACTUALLY LED TO

2967
02:10:32,680 --> 02:10:34,840
IMPORTANT AND THE CONTROL

2968
02:10:34,840 --> 02:10:37,880
TRIALS.

2969
02:10:37,880 --> 02:10:45,680
NEXT SLIDE, NEEDED TO SUFFICIENT

2970
02:10:45,680 --> 02:10:49,160
NUMBERS OF SCREEN POSITIVES AND

2971
02:10:49,160 --> 02:10:49,960
ASSAYS TO DETECT SEVERAL OTHER

2972
02:10:49,960 --> 02:10:58,440
AND CANCER AND EXISTING ASSETS

2973
02:10:58,440 --> 02:11:05,080
AND 1% ARE RESULTING IN POSITIVE

2974
02:11:05,080 --> 02:11:06,480
AND DIAGNOSTIC RESOLUTION AND

2975
02:11:06,480 --> 02:11:08,040
ONE OF THE MAIN OBJECTIVES OF

2976
02:11:08,040 --> 02:11:10,320
THE VAN GUARD STUDY IS THE

2977
02:11:10,320 --> 02:11:11,840
APPROACH TO THE DIAGNOSTIC

2978
02:11:11,840 --> 02:11:13,920
PROCESS AND COLLECTION OF DATA

2979
02:11:13,920 --> 02:11:17,800
AND SO WE ESTIMATE 8,000 PERSONS

2980
02:11:17,800 --> 02:11:21,920
PER ARM AND 164 SCREEN POSITIVES

2981
02:11:21,920 --> 02:11:24,720
AND IT WAS AROUND DIAGNOSTIC

2982
02:11:24,720 --> 02:11:26,760
RESOLUTION AND SHOWN THE LEVEL.

2983
02:11:26,760 --> 02:11:33,240
NEXT SLIDE, PLEASE.

2984
02:11:33,240 --> 02:11:35,520
THE RANDOMIZED CONTROL TRIAL

2985
02:11:35,520 --> 02:11:39,560
DESIGN IS NOT IS DISSIMILAR FROM

2986
02:11:39,560 --> 02:11:41,280
VAN GUARD BUT IT'S A DIFFERENT

2987
02:11:41,280 --> 02:11:43,800
SUBSET OF CANCERS AND SO WE'LL

2988
02:11:43,800 --> 02:11:45,640
BE COMPARING THOSE BASICALLY

2989
02:11:45,640 --> 02:11:51,720
AGAINST THE STANDARD OF CARE AND

2990
02:11:51,720 --> 02:11:53,720
THAT IF WORE PLANNING ON TWO TO

2991
02:11:53,720 --> 02:11:55,400
START WITH BUT AS OTHER

2992
02:11:55,400 --> 02:11:58,000
TECHNOLOGIES EMERGE WE COULD ADD

2993
02:11:58,000 --> 02:11:59,520
ADDITIONAL ARMS IF YOU HIT NEXT

2994
02:11:59,520 --> 02:12:03,800
YOU WILL SEE THAT SHOW UP HERE.

2995
02:12:03,800 --> 02:12:04,120
NEXT.

2996
02:12:04,120 --> 02:12:07,720
THERE YOU GO.

2997
02:12:07,720 --> 02:12:10,040
AND THEN THE POINTS THIS IS SOME

2998
02:12:10,040 --> 02:12:13,080
OF THE DISCUSSION WITH OUR

2999
02:12:13,080 --> 02:12:14,680
REVIEWERS AND VAN GUARD HAS

3000
02:12:14,680 --> 02:12:19,240
FEASIBILITY AND FINALIZE DESIGN

3001
02:12:19,240 --> 02:12:21,720
LOGISTICS AND TO ASSESS BENEFITS

3002
02:12:21,720 --> 02:12:22,520
HARMS AND GENERALIZABILITY OF

3003
02:12:22,520 --> 02:12:24,320
THESE TEST AND I'M WORRIED THESE

3004
02:12:24,320 --> 02:12:28,400
TESTS WON'T WORK THE SAME IN

3005
02:12:28,400 --> 02:12:29,640
POPULATIONS THAT ARE UNDER

3006
02:12:29,640 --> 02:12:31,000
REPRESENTED IN SOME OF THE DATA

3007
02:12:31,000 --> 02:12:33,880
THAT GENERATED THESE BIOMARKERS.

3008
02:12:33,880 --> 02:12:36,920
AND WE ARE ASSAY AGNOSTIC AND

3009
02:12:36,920 --> 02:12:38,480
BOTH FROM THE BIOMARKER

3010
02:12:38,480 --> 02:12:40,280
PERSPECTIVE AND THE COMPANY

3011
02:12:40,280 --> 02:12:43,160
PERSPECTIVE AND MULTI-ARM

3012
02:12:43,160 --> 02:12:44,480
PLATFORM DESIGN ALLOW DROPPING

3013
02:12:44,480 --> 02:12:46,600
TESTED AND NOT PERFORM WELL AND

3014
02:12:46,600 --> 02:12:48,000
ADDING NEW ARMS FOR PROMISING

3015
02:12:48,000 --> 02:12:49,760
NEW TESTS AND DATA SHARING

3016
02:12:49,760 --> 02:12:52,520
ACCORDING TO THE FAIR PRINCIPLES

3017
02:12:52,520 --> 02:12:54,120
WILL BE REQUIRED AND WE'LL HAVE

3018
02:12:54,120 --> 02:12:57,520
. REPOSITORY WHICH WILL HAVE

3019
02:12:57,520 --> 02:12:58,760
VALIDATION OF NATURAL HISTORY

3020
02:12:58,760 --> 02:13:00,560
STUDIES AND COMPREHENSIVE

3021
02:13:00,560 --> 02:13:03,080
CHARACTERIZATION OF TUMOR

3022
02:13:03,080 --> 02:13:04,640
POTENTIALLY AT MOLECULAR STAGES

3023
02:13:04,640 --> 02:13:06,680
IN STATES WE'VE NEVER OBSERVED.

3024
02:13:06,680 --> 02:13:08,600
SO THIS WILL CATALYZE NEW

3025
02:13:08,600 --> 02:13:14,440
INTERCEPTION THERAPEUTIC

3026
02:13:14,440 --> 02:13:17,280
DEVELOPMENT IT'S SUPPLEMENTAL

3027
02:13:17,280 --> 02:13:18,880
BUT I CAN'T REMEMBER AND I

3028
02:13:18,880 --> 02:13:23,680
APOLOGIZE FOR THE TYPO, NEXT

3029
02:13:23,680 --> 02:13:33,960
SLIDE, PLEASE.

3030
02:13:59,200 --> 02:13:59,920
IT'S $73.5 MILLION OVER THE FOUR

3031
02:13:59,920 --> 02:14:01,320
YEARS TO GET STARTED.

3032
02:14:01,320 --> 02:14:04,600
NEXT SLIDE, PLEASE.

3033
02:14:04,600 --> 02:14:07,240
AND I'LL WRAP-UP WITH THE SLIDE

3034
02:14:07,240 --> 02:14:08,120
HERE.

3035
02:14:08,120 --> 02:14:11,240
WHICH IS THE MCED CLINICAL

3036
02:14:11,240 --> 02:14:15,120
TRIALS TEAM AND I JUST WANT TO

3037
02:14:15,120 --> 02:14:19,360
SAY THAT RECENTLY CMS

3038
02:14:19,360 --> 02:14:20,920
REPRESENTATIVES ARE JOINED AND

3039
02:14:20,920 --> 02:14:23,280
MANY OTHERS HAVE CONTRIBUTED AND

3040
02:14:23,280 --> 02:14:24,880
THEY'RE NOT LISTED HERE ASK TECH

3041
02:14:24,880 --> 02:14:26,080
TRANSFER IS NOW INVOLVED AND

3042
02:14:26,080 --> 02:14:27,080
THIS IS JUST ONE OF THE TEAMS

3043
02:14:27,080 --> 02:14:35,240
THAT IS WORKING ON THE TRANCE I

3044
02:14:35,240 --> 02:14:36,720
CAN'T SAY ENOUGH ABOUT THIS

3045
02:14:36,720 --> 02:14:38,360
DREAM TEAM AND IT'S AN HONOR AND

3046
02:14:38,360 --> 02:14:42,440
PRIVILEGE TO WORK WITH THIS ON

3047
02:14:42,440 --> 02:14:45,440
THIS PROJECT AND I APPRECIATE

3048
02:14:45,440 --> 02:14:49,440
THEIR HARD WORK AND GOOD HUMOR

3049
02:14:49,440 --> 02:14:51,560
AND I WANT TO THANK THEM AND

3050
02:14:51,560 --> 02:14:54,600
THANK YOU.

3051
02:14:54,600 --> 02:15:04,800
NEXT SLIDE.

3052
02:15:28,160 --> 02:15:29,200
AND AS NIL STATED THERE'S A

3053
02:15:29,200 --> 02:15:30,400
NUMBER OF THESE OVER THE LAST

3054
02:15:30,400 --> 02:15:33,040
COUPLE OF YEARS MARKETED AS DTC

3055
02:15:33,040 --> 02:15:34,120
TO CONSUMER PRODUCTS AND NOT A

3056
02:15:34,120 --> 02:15:35,800
LOT OF SUBSTANTIAL OVERSIGHT AND

3057
02:15:35,800 --> 02:15:38,120
SO THAT SECRETARY MOTIVATION AND

3058
02:15:38,120 --> 02:15:40,520
THE PANEL WHO IN ADDITION TO

3059
02:15:40,520 --> 02:15:43,520
MYSELF WERE SYLVIA AND MICHAEL

3060
02:15:43,520 --> 02:15:46,080
AND WE WERE UNANIMOUS IN THAT WE

3061
02:15:46,080 --> 02:15:48,040
THOUGHT THIS WOULD HAVE A HIGH

3062
02:15:48,040 --> 02:15:49,640
LIKELIHOOD OF ESTABLISHING THE

3063
02:15:49,640 --> 02:15:51,600
INFRASTRUCTURE AND ACHIEVING ITS

3064
02:15:51,600 --> 02:15:55,000
GOALS AND WE ALSO WANTED TO MAKE

3065
02:15:55,000 --> 02:15:59,080
IT CLEAR THAT THE PROGRAM THAT

3066
02:15:59,080 --> 02:16:00,400
PHILLIP HAS DESCRIBED HAS

3067
02:16:00,400 --> 02:16:01,720
MULTIPLE PARTS AND YOU COULD

3068
02:16:01,720 --> 02:16:03,440
CALL IT PARTS OR THREE PARTS

3069
02:16:03,440 --> 02:16:05,320
THAT THE FIRST PART IS THE

3070
02:16:05,320 --> 02:16:06,960
NETWORK OF CENTERS AND IT

3071
02:16:06,960 --> 02:16:08,280
ESTABLISHED THE INFRASTRUCTURE

3072
02:16:08,280 --> 02:16:18,840
FOR EVALUATING AND IF THEY WERE

3073
02:16:32,520 --> 02:16:41,880
SUCH AND WITH A MORE AMBITIOUS

3074
02:16:41,880 --> 02:16:42,360
SCOPE.

3075
02:16:42,360 --> 02:16:44,720
AS PHILLIP DESCRIBED, WE HAD A

3076
02:16:44,720 --> 02:16:45,880
VIGOROUS DISCUSSION IN THE

3077
02:16:45,880 --> 02:16:48,720
REVIEW PANEL AND SO I'LL

3078
02:16:48,720 --> 02:16:50,240
SUMMARIZE FOUR MAJOR POINTS MADE

3079
02:16:50,240 --> 02:16:52,360
THERE AND LET OTHERS ON THE

3080
02:16:52,360 --> 02:16:54,000
PANEL, SYLVIA AND MICHAEL CHIME

3081
02:16:54,000 --> 02:16:54,960
IN AS NEEDED.

3082
02:16:54,960 --> 02:16:56,600
BUT I WANT TODAY GO AHEAD AND

3083
02:16:56,600 --> 02:16:58,040
MAKE SURE THAT FELLOWSHIP I

3084
02:16:58,040 --> 02:17:01,200
WILL, I THINK LARGELY, YOU KNOW,

3085
02:17:01,200 --> 02:17:03,600
NOT COMPLETELY BUT LARGELY I

3086
02:17:03,600 --> 02:17:07,400
THINK HAZARDED THESE IN HIS

3087
02:17:07,400 --> 02:17:12,040
PRESENTATION SO ONE WAS WHILE

3088
02:17:12,040 --> 02:17:13,680
THERE WERE DETAILS WE WANTED TO

3089
02:17:13,680 --> 02:17:17,360
MAKE SURE THE OVER ARCHING, NOT

3090
02:17:17,360 --> 02:17:19,200
TO LOSE THE FOREST OR THE TREES

3091
02:17:19,200 --> 02:17:22,080
AND MAKE SURE THE OVER ALL

3092
02:17:22,080 --> 02:17:23,840
GENERAL GOAL OF AND LONG-TERM

3093
02:17:23,840 --> 02:17:25,680
POTENTIAL TO IMPROVE THESE

3094
02:17:25,680 --> 02:17:27,760
SCREENING PLATFORMS AND PATIENT

3095
02:17:27,760 --> 02:17:29,720
HEALTH WAS NOT LOST AMONG THE

3096
02:17:29,720 --> 02:17:33,000
TECHNICAL DETAILS AND I THINK IN

3097
02:17:33,000 --> 02:17:35,920
A SLIDE THAT HE CERTAINLY MADE

3098
02:17:35,920 --> 02:17:37,840
SOME CHANGES TO FOCUS ON THE BIG

3099
02:17:37,840 --> 02:17:41,160
PICTURE SO THAT WAS GREAT.

3100
02:17:41,160 --> 02:17:43,240
WE THOUGHT FURTHER DETAILS IN

3101
02:17:43,240 --> 02:17:44,880
THINKING, EVEN AS YOU SOLICIT

3102
02:17:44,880 --> 02:17:46,480
THESE DIFFERENT PROPOSALS

3103
02:17:46,480 --> 02:17:53,440
FURTHER DETAILS ON THE EXACT

3104
02:17:53,440 --> 02:18:00,160
KINDS OF WOULD BE GOOD IS OTHER

3105
02:18:00,160 --> 02:18:02,320
TYPES OF DATA BEING CONSIDERED

3106
02:18:02,320 --> 02:18:03,760
AND CERTAINLY CIRCULATING TUMOR

3107
02:18:03,760 --> 02:18:05,240
CELLS WERE MENTIONED AND WHAT

3108
02:18:05,240 --> 02:18:07,600
ABOUT OTHER FORMATS?

3109
02:18:07,600 --> 02:18:09,240
AND THE THIRD SET OF SUGGESTIONS

3110
02:18:09,240 --> 02:18:11,040
I'LL LET MICHAEL CHIME IN

3111
02:18:11,040 --> 02:18:12,240
BECAUSE HE CERTAINLY LED THOSE

3112
02:18:12,240 --> 02:18:13,640
POINTS DURING THE DISCUSSION.

3113
02:18:13,640 --> 02:18:16,720
THEY ALL RELATE TO DATA AND ALSO

3114
02:18:16,720 --> 02:18:19,760
ALGORITHMS SO IN WHICH PUBLIC

3115
02:18:19,760 --> 02:18:21,040
ROW POS TORIES WILL BE SHARED IN

3116
02:18:21,040 --> 02:18:22,560
A WAY THAT IS FIND ABLE AND

3117
02:18:22,560 --> 02:18:24,360
ACCESSIBLE AND INTER OPERABLE

3118
02:18:24,360 --> 02:18:27,920
AND REUSABLE, SHOULD WE SEEK NOT

3119
02:18:27,920 --> 02:18:30,680
ONLY TO EVALUATE THE SPECIFIC

3120
02:18:30,680 --> 02:18:33,720
MARKERS BUT ALSO THE

3121
02:18:33,720 --> 02:18:35,400
COMPUTATIONAL ALGORISMS THAT USE

3122
02:18:35,400 --> 02:18:36,760
THOSE MARKERS THAT IS TWO

3123
02:18:36,760 --> 02:18:37,440
DIFFERENT THINGS.

3124
02:18:37,440 --> 02:18:39,480
YOU COULD HAVE TWO ALGORITHMS

3125
02:18:39,480 --> 02:18:41,560
WITH THE SAME OR OVERLAPPING

3126
02:18:41,560 --> 02:18:44,040
SETS OF MARKSERS THAT MAY HAVE

3127
02:18:44,040 --> 02:18:46,240
DIFFERENT EFFICACY SO MICHAEL

3128
02:18:46,240 --> 02:18:49,400
CHIME IN AND THEN FINALLY, WE

3129
02:18:49,400 --> 02:18:51,400
THOUGHT THAT IT WAS OBVIOUS LOW

3130
02:18:51,400 --> 02:18:52,840
IMPORTANT TO COLLABORATE WITH

3131
02:18:52,840 --> 02:18:56,880
THE FDA ON THE SCREENING TESTS

3132
02:18:56,880 --> 02:19:02,240
AND THAT SAID, IT WAS PHILLIP

3133
02:19:02,240 --> 02:19:03,520
ASSURED US AND IT WAS GO AHEAD

3134
02:19:03,520 --> 02:19:05,960
TO SEE HE AND OTHERS REACHED OUT

3135
02:19:05,960 --> 02:19:08,480
TO FDA AND MEMBERS OF THE FDA

3136
02:19:08,480 --> 02:19:09,920
HAVE BEEN INVOLVED IN THIS

3137
02:19:09,920 --> 02:19:12,720
DESIGN OF THIS RFA CONCEPT.

3138
02:19:12,720 --> 02:19:17,920
SO WITH THAT I WILL LET MY CO

3139
02:19:17,920 --> 02:19:20,240
COMMITTEE MEMBERS CHIME IN.

3140
02:19:20,240 --> 02:19:22,600
>> I'M HAPPY TO.

3141
02:19:22,600 --> 02:19:26,400
>> SO THAT WAS REALLY
GREAT.

3142
02:19:26,400 --> 02:19:29,240
YOU REALLY CAPTURED OUR

3143
02:19:29,240 --> 02:19:29,640
DISCUSSION.

3144
02:19:29,640 --> 02:19:31,280
I JUST WANT TO HIGHLIGHT A FEW

3145
02:19:31,280 --> 02:19:33,160
THINGS THAT WERE MENTIONED AND I

3146
02:19:33,160 --> 02:19:34,440
THOUGHT PHIL'S PRESENTATION WAS

3147
02:19:34,440 --> 02:19:36,920
REALLY GREAT TOO.

3148
02:19:36,920 --> 02:19:40,920
FIRST, I APPLAUD THE NCI -- I

3149
02:19:40,920 --> 02:19:42,160
THINK THIS IS CRITICAL AND WE

3150
02:19:42,160 --> 02:19:45,120
HAVE TO DO THIS AND THESE FIRST

3151
02:19:45,120 --> 02:19:48,240
FEW STEPS ARE REALLY IMPORTANT

3152
02:19:48,240 --> 02:19:49,680
AND VERY WELL THOUGHT OUT AND I

3153
02:19:49,680 --> 02:19:57,000
GROW IT'S A DREAM TEAM AT THE N.

3154
02:19:57,000 --> 02:19:57,160
CI.

3155
02:19:57,160 --> 02:19:59,160
THE LANDSCAPE IS COMPLICATED AND

3156
02:19:59,160 --> 02:20:01,760
I'D LIKE TO HEAR MORE FROM THE

3157
02:20:01,760 --> 02:20:07,320
NCI ABOUT THIS PUBLIC-PRIVATE

3158
02:20:07,320 --> 02:20:11,520
PARTNERSHIP WORKING WITH

3159
02:20:11,520 --> 02:20:12,080
COMPANIES.

3160
02:20:12,080 --> 02:20:14,480
AND THERE ARE COMPANIES THAT ARE

3161
02:20:14,480 --> 02:20:18,720
WINNING BIG TRIALS AND THEY'RE

3162
02:20:18,720 --> 02:20:21,040
PUTTING HUNDREDS AND BILLIONS

3163
02:20:21,040 --> 02:20:28,240
AND IT'S MORE COMPLICATED IN THE

3164
02:20:28,240 --> 02:20:32,680
SCREENING AND SO I'M JUST

3165
02:20:32,680 --> 02:20:36,040
THINKING THAT WE NEED TO REALLY

3166
02:20:36,040 --> 02:20:39,440
THINK AHEAD ABOUT THE COMPLEXITY

3167
02:20:39,440 --> 02:20:45,880
WITH ALTERNATIVE TRIALS UNDERWAY

3168
02:20:45,880 --> 02:20:56,360
AND AND THESE, THE TYPES OF

3169
02:21:08,320 --> 02:21:09,680
SAMPLES AND THESE TRIALS

3170
02:21:09,680 --> 02:21:13,400
GENERATE AND GENERALLY NOT SURE

3171
02:21:13,400 --> 02:21:15,920
AND SO I WOULD LIKE TO

3172
02:21:15,920 --> 02:21:16,600
UNDERSTAND HOW THAT POLITICIANS.

3173
02:21:16,600 --> 02:21:18,160
ON THE OTHER HAND BOTH AS AN

3174
02:21:18,160 --> 02:21:19,800
ENTREPRENEUR AND AS A CANCER

3175
02:21:19,800 --> 02:21:21,520
BIOLOGIST AND PATHOLOGIST AND I

3176
02:21:21,520 --> 02:21:23,000
THINK THIS IS IMPORTANT WORK TO

3177
02:21:23,000 --> 02:21:25,560
GET REAL SCIENCE DONE AND THAT

3178
02:21:25,560 --> 02:21:30,600
IS BROADCAST FROM.

3179
02:21:30,600 --> 02:21:31,400
>> Provost McMahan: THE
FOR

3180
02:21:31,400 --> 02:21:33,040
PROFIT SECTOR TO CREATE RATIONAL

3181
02:21:33,040 --> 02:21:36,240
TEE SO I'M REALLY ENTHUSIASTIC

3182
02:21:36,240 --> 02:21:43,080
ABOUT THIS AND I'D LIKE TO SEE

3183
02:21:43,080 --> 02:21:44,720
HOW OF THOSE TWO IMPORTANT

3184
02:21:44,720 --> 02:21:47,320
ASSETS OF NCI ARE RECYCLE TO USE

3185
02:21:47,320 --> 02:21:50,000
AND OTHER PROGRAMS AND PHIL,

3186
02:21:50,000 --> 02:21:52,360
YOU'VE DONE A GREAT JOBGE ATG TD

3187
02:21:52,360 --> 02:21:54,640
WE WANT TO SEE THIS FUNDED AND

3188
02:21:54,640 --> 02:21:58,480
I'M ENTHUSIASTIC ABOUT IT AND I

3189
02:21:58,480 --> 02:22:01,720
WANT TO MAKE IT NEEDS TO

3190
02:22:01,720 --> 02:22:03,200
INTEGRATE BETTER WITH ITS OWN

3191
02:22:03,200 --> 02:22:04,360
SELF GOING FORWARD AND I AGREE

3192
02:22:04,360 --> 02:22:06,120
THE OUTREACH HERE IS SPECTACULAR

3193
02:22:06,120 --> 02:22:11,280
SO THANK YOU FOR THE SUMMARY AND

3194
02:22:11,280 --> 02:22:12,280
IT'S GREAT TO HAVE YOU HERE ON

3195
02:22:12,280 --> 02:22:16,760
THE BSA.

3196
02:22:16,760 --> 02:22:20,320
>> LET ME ADDRESS THESE

3197
02:22:20,320 --> 02:22:21,160
IMPORTANT TOPICS.

3198
02:22:21,160 --> 02:22:23,000
WE JUST RAN OUT OF SLIDES IN

3199
02:22:23,000 --> 02:22:24,680
TIME IN THE SUPPLEMENTAL SLIDES

3200
02:22:24,680 --> 02:22:30,640
WE GAVE A LIST OF 14 OF MAYBE 30

3201
02:22:30,640 --> 02:22:31,960
COMPANIES WITH DIFFERENT

3202
02:22:31,960 --> 02:22:35,800
TECHNOLOGIES AND THEREBY OWE

3203
02:22:35,800 --> 02:22:36,920
MARKERS AND WE CAN PUT THAT UP

3204
02:22:36,920 --> 02:22:39,240
IF YOU WANT AND ALSO, SOME DATA

3205
02:22:39,240 --> 02:22:42,520
ON THE MANAGEMENT ALGORITHMS AND

3206
02:22:42,520 --> 02:22:46,040
THE CHALLENGES OF DIAGNOSTIC

3207
02:22:46,040 --> 02:22:46,400
RESOLUTION.

3208
02:22:46,400 --> 02:22:49,720
COMING TO MICHAEL'S POINT, THE

3209
02:22:49,720 --> 02:22:51,120
COMPANIES USED SOME I FORGET

3210
02:22:51,120 --> 02:22:53,360
WHAT A RANGE WILL YOU LET'S SAY

3211
02:22:53,360 --> 02:22:57,760
FIVE TO 10 MILLS OF BLOOD.

3212
02:22:57,760 --> 02:23:04,760
IT'S OUR INTENTION TO BANK THE

3213
02:23:04,760 --> 02:23:15,240
BLOOD BECAUSE -- SO THERE'S

3214
02:23:24,280 --> 02:23:25,760
MULTIPLE TECHNOLOGIES THAT CAN

3215
02:23:25,760 --> 02:23:28,400
BE SUPPORTED BOTH BY THE TRIALS

3216
02:23:28,400 --> 02:23:30,520
ITSELF AND AS WELL AS THE

3217
02:23:30,520 --> 02:23:31,760
REPOSITORY SO I THINK THERE'S

3218
02:23:31,760 --> 02:23:34,360
GOING TO BE A LOT OF LEFTOVER

3219
02:23:34,360 --> 02:23:35,480
BLOOD.

3220
02:23:35,480 --> 02:23:38,240
YOU KNOW, YOU CAN COLLECT IF I

3221
02:23:38,240 --> 02:23:39,280
RECALL CORRECTLY SOMEONE CORRECT

3222
02:23:39,280 --> 02:23:46,080
ME IF SAY SOMETHING WRONG UP TO

3223
02:23:46,080 --> 02:23:50,320
60 MILLS.

3224
02:23:50,320 --> 02:23:52,600
AND I WOULD SAY IT'S OUR HOPE

3225
02:23:52,600 --> 02:23:55,040
AND OUR INTENTION TO

3226
02:23:55,040 --> 02:23:57,160
CHARACTERIZE ALL THE TUMORS THAT

3227
02:23:57,160 --> 02:24:04,000
ARE FOUND THIS THIS STUDY

3228
02:24:04,000 --> 02:24:14,560
BECAUSE AND ACCORDING TO GO THE

3229
02:24:16,000 --> 02:24:17,240
FAIR PRINCIPLES AND IN TERMS OF

3230
02:24:17,240 --> 02:24:18,080
THE COMPANIES, I DON'T KNOW THAT

3231
02:24:18,080 --> 02:24:19,320
THEY'RE GOING TO SHARE

3232
02:24:19,320 --> 02:24:29,680
INDIVIDUAL BIOMARKERS.

3233
02:24:30,680 --> 02:24:31,440
SO I DON'T KNOW THAT THEY'RE

3234
02:24:31,440 --> 02:24:36,480
GOING TO LET YOU INTO THE BLACK

3235
02:24:36,480 --> 02:24:39,920
BOX OF THEIR ALGORITHM AND

3236
02:24:39,920 --> 02:24:41,760
THEY'RE GOING TO DO THAT AND

3237
02:24:41,760 --> 02:24:45,160
PERHAPS I'M WRONG AND PERHAPS

3238
02:24:45,160 --> 02:24:47,240
OTHERS COULD WEIGH IN AND WHEN

3239
02:24:47,240 --> 02:24:49,000
YOU GET INTO INTELLECTUAL

3240
02:24:49,000 --> 02:24:50,480
PROPERTIES YOU CAN BE CHALLENGED

3241
02:24:50,480 --> 02:24:52,360
TO YOU HOLD THAT BAR HIGH LIKE

3242
02:24:52,360 --> 02:24:53,840
THAT AND THEY DON'T PARTICIPATE

3243
02:24:53,840 --> 02:24:55,240
AND WE'VE DONE A DISSERVICE

3244
02:24:55,240 --> 02:24:59,400
BECAUSE WE HAVE NOT EVALUATED

3245
02:24:59,400 --> 02:25:02,360
THE CLINICAL ASPECT AND WE KNOW

3246
02:25:02,360 --> 02:25:04,520
ABOUT THE POSITIVE RESULT AND

3247
02:25:04,520 --> 02:25:07,600
THE TOO BUT WE MAY NOT KNOW THE

3248
02:25:07,600 --> 02:25:11,680
SPECIFIC BIOMARKER THAT TURNED

3249
02:25:11,680 --> 02:25:21,800
ON AND.

3250
02:25:23,400 --> 02:25:25,640
>> LET'S KEEP THE PACE UP
AND

3251
02:25:25,640 --> 02:25:26,120
IAN YOU ARE NEXT.

3252
02:25:26,120 --> 02:25:28,640
>> JUST A FEW THINGS.

3253
02:25:28,640 --> 02:25:30,080
THANK YOU FOR YOUR COMMENTS AND

3254
02:25:30,080 --> 02:25:32,320
KUDOS TO PHIL AND LORI AND WHICH

3255
02:25:32,320 --> 02:25:34,360
WE HAVE DONE THIS FOR PSA40

3256
02:25:34,360 --> 02:25:35,680
YEARS AGO HAD WE DONE SO WE

3257
02:25:35,680 --> 02:25:38,760
WOULDN'T BE WHERE WE ARE TODAY

3258
02:25:38,760 --> 02:25:43,840
AND WE'VE LEARNED SOME.

3259
02:25:43,840 --> 02:25:47,600
SO, I IT MAKES YOUR BRAIN HURT

3260
02:25:47,600 --> 02:25:48,920
TO DESIGN THIS TRIAL AND

3261
02:25:48,920 --> 02:25:50,160
THINKING ABOUT THE STAND AR OF

3262
02:25:50,160 --> 02:25:51,680
CARE AND THE TASK FORCE STANDARD

3263
02:25:51,680 --> 02:25:54,320
OF CARE OR THE OTHER OPTIONS.

3264
02:25:54,320 --> 02:25:56,600
AND I THINK THAT I MADE COMMENTS

3265
02:25:56,600 --> 02:25:59,240
ABOUT CO-OPERATIVE GROUPS AND

3266
02:25:59,240 --> 02:26:00,760
PCBT AND SELECT WERE PREVENTION

3267
02:26:00,760 --> 02:26:04,960
TRIALS BUT THEY ACTUALLY WERE

3268
02:26:04,960 --> 02:26:06,600
DIAGNOSTICS, AS YOU KNOW.

3269
02:26:06,600 --> 02:26:08,120
SO, IT CAN BE DONE WITH

3270
02:26:08,120 --> 02:26:09,120
CO-OPERATIVE GROUPS AND I WOULD

3271
02:26:09,120 --> 02:26:10,440
ENCOURAGE YOU TO ENCLOUD THEM

3272
02:26:10,440 --> 02:26:11,520
BECAUSE WE'VE BEEN THERE AND

3273
02:26:11,520 --> 02:26:15,440
WHEN I SAY WE IT'S ALL THE

3274
02:26:15,440 --> 02:26:16,960
GROUPS AND THE WOVE DEALT WITH

3275
02:26:16,960 --> 02:26:18,840
THIS AND LEARNED HOW TO DO IT

3276
02:26:18,840 --> 02:26:21,040
AND HOW NOT TO DO AND I WOULD

3277
02:26:21,040 --> 02:26:24,360
JUST ENCOURAGE THE MOST

3278
02:26:24,360 --> 02:26:26,400
IMPORTANT AND I KNOW EVERYONE ON

3279
02:26:26,400 --> 02:26:28,360
THIS GALLERY AND IS THINKING

3280
02:26:28,360 --> 02:26:32,800
ABOUT IT IS A VERY FEARFUL

3281
02:26:32,800 --> 02:26:35,400
ATTENTION TO MORBIDITY.

3282
02:26:35,400 --> 02:26:37,640
COMPLICATIONS OF DIAGNOSIS,

3283
02:26:37,640 --> 02:26:40,080
COMPLICATIONS OF TREATMENTS AND

3284
02:26:40,080 --> 02:26:42,800
DIFFERENTIAL RATES OF THESE

3285
02:26:42,800 --> 02:26:46,080
BASED ON THE POPULATIONS

3286
02:26:46,080 --> 02:26:48,000
THEMSELVES AND THE NUMBER, IT'S

3287
02:26:48,000 --> 02:26:50,520
NOT RUNNING THIS IT'S THE BOY

3288
02:26:50,520 --> 02:26:52,320
ASS THAT CAN BE THAT CAN MAKE

3289
02:26:52,320 --> 02:26:54,000
THEIR WAYS INTO THIS AND

3290
02:26:54,000 --> 02:26:56,120
UNDERSERVED POPULATIONS

3291
02:26:56,120 --> 02:26:57,440
HISTORICALLY ARE LESS LIKELY TO

3292
02:26:57,440 --> 02:26:59,080
HAVE DIAGNOSTIC TESTS AND LESS

3293
02:26:59,080 --> 02:27:01,240
LIKELY TO BE TREATED AND THERE

3294
02:27:01,240 --> 02:27:04,800
ARE DIFFERENCES THAT MAY BE TEST

3295
02:27:04,800 --> 02:27:07,600
RELATED SO LONG-TERM FOLLOW-UP

3296
02:27:07,600 --> 02:27:11,080
OF THE SIDE EFFECTS,SPECIALLY RS

3297
02:27:11,080 --> 02:27:14,120
THAT CAN SHOW UP 30 YEARS LATER.

3298
02:27:14,120 --> 02:27:18,240
SO, I KUDOS TO YOU BUT IT REQUIS

3299
02:27:18,240 --> 02:27:19,840
A LOT OF THOUGHT AND A LOT OF

3300
02:27:19,840 --> 02:27:21,680
THE EXISTING INFRASTRUCTURE AND

3301
02:27:21,680 --> 02:27:24,480
WITHIN THE NCI AND THAT YOU SO

3302
02:27:24,480 --> 02:27:27,560
CAREFULLY BUILT UP AND IT CAN

3303
02:27:27,560 --> 02:27:30,240
HELP AND PASS.

3304
02:27:30,240 --> 02:27:30,560
THANK YOU.

3305
02:27:30,560 --> 02:27:34,880
>> THANK YOU.

3306
02:27:34,880 --> 02:27:36,280
>> THANK YOU, WE SPOKE A
LOT

3307
02:27:36,280 --> 02:27:37,720
ABOUT THE THOUGHTS I HAD.

3308
02:27:37,720 --> 02:27:39,400
THIS IS REALLY IMPORTANT.

3309
02:27:39,400 --> 02:27:42,360
THE APPROACH THAT CHRIS AND YOUR

3310
02:27:42,360 --> 02:27:43,280
TEAM HAS BUILT UP IT'S KUDOS TO

3311
02:27:43,280 --> 02:27:44,520
YOU AND I THINK THE IMPORTANCE

3312
02:27:44,520 --> 02:27:49,080
OF NCI DOING THIS WORK IS

3313
02:27:49,080 --> 02:27:53,520
UNREASONABLE AND AND THE

3314
02:27:53,520 --> 02:27:56,320
CLINICIAN AND IT'S IN THIS CASE

3315
02:27:56,320 --> 02:27:59,560
AND METHODOLOGY AND DELIVERY OF

3316
02:27:59,560 --> 02:28:10,000
CANCER SCREENING AND IN THIS

3317
02:28:10,360 --> 02:28:11,360
SPACE OF NOT KNOWING WHETHER

3318
02:28:11,360 --> 02:28:12,640
IT'S RIGHT OR WRONG AND I THINK

3319
02:28:12,640 --> 02:28:15,040
TO YOUR POINT, IAN, THIS REALLY

3320
02:28:15,040 --> 02:28:19,080
SHOULD ALSO PASS A U.S.

3321
02:28:19,080 --> 02:28:20,400
PREVENTATIVE TAX FORCE CRITERIA

3322
02:28:20,400 --> 02:28:22,880
AND IT'S A EFFECTIVENESS AND NOT

3323
02:28:22,880 --> 02:28:24,440
ABOUT THE EX SPEED YEN SEE OF

3324
02:28:24,440 --> 02:28:25,880
GETTING THIS IN TO MARKET SO WE

3325
02:28:25,880 --> 02:28:29,200
CAN MAKE MONEY AND I REALLY

3326
02:28:29,200 --> 02:28:35,600
ENCOURAGE NCI TO TAKE THIS ON AS

3327
02:28:35,600 --> 02:28:46,120
A AND INVOLVE THE POPULATIONS

3328
02:28:47,480 --> 02:28:49,680
THEY CAUSE MORTALITY AND

3329
02:28:49,680 --> 02:28:50,720
PANCREATIC CANCER AND LUNG

3330
02:28:50,720 --> 02:28:52,480
CANCER AND WE HAVE A TEST AND WE

3331
02:28:52,480 --> 02:28:54,360
CAN DO MUCH BETTER AND THE TEST

3332
02:28:54,360 --> 02:28:57,520
WE HAVE CURRENTLY ARE NOT IDEAL

3333
02:28:57,520 --> 02:28:59,760
AND I WISH WE HAD AN IDEAL TEST

3334
02:28:59,760 --> 02:29:01,520
BUT THERE ARE A LOT OF GAPS.

3335
02:29:01,520 --> 02:29:03,000
FALSE POSITIVES AND NEGATIVES SO

3336
02:29:03,000 --> 02:29:04,720
THEY'RE IMPROVEMENT IN THIS AND

3337
02:29:04,720 --> 02:29:06,360
SO I THINK THERE'S REALLY

3338
02:29:06,360 --> 02:29:08,240
IMPORTANT OPPORTUNITY TO GET IT

3339
02:29:08,240 --> 02:29:12,000
RIGHT AND AGAIN, REINFORCING AND

3340
02:29:12,000 --> 02:29:14,560
PHIL'S POINT WE ARE DOING THIS

3341
02:29:14,560 --> 02:29:21,480
ON ASYMPTOMATIC PEOPLE AND SO

3342
02:29:21,480 --> 02:29:30,880
MAKING SURE AND AND IT'S ABOVE

3343
02:29:30,880 --> 02:29:35,600
EX FFOR TEASE OF THAT GROUP.

3344
02:29:35,600 --> 02:29:37,840
THANK YOU.

3345
02:29:37,840 --> 02:29:43,920
>> FIRST, PHIL, YOUR
SCIENCE IS

3346
02:29:43,920 --> 02:29:45,400
SPECTACULAR AND THIS IS

3347
02:29:45,400 --> 02:29:46,520
ABSOLUTELY NEEDED AND I WORRY

3348
02:29:46,520 --> 02:29:48,320
ABOUT THE PSA THING AND IT MAY

3349
02:29:48,320 --> 02:29:50,680
BE THE HORSE IS ALREADY OUT OF

3350
02:29:50,680 --> 02:29:51,560
THE BARN BECAUSE.

3351
02:29:51,560 --> 02:29:54,800
>> DAN: COMPANIES ARE
ALREADY

3352
02:29:54,800 --> 02:29:59,720
MARKETING THIS AND I ASK YOU

3353
02:29:59,720 --> 02:30:01,280
BRING THE CO-OPERATIVE GROUPS IN

3354
02:30:01,280 --> 02:30:02,760
BECAUSE THOSE CO-OPERATIVE

3355
02:30:02,760 --> 02:30:05,120
GROUPS HAVE DONE SOME AMAZING

3356
02:30:05,120 --> 02:30:07,600
WORK IN SOME LARGE PREVENTION

3357
02:30:07,600 --> 02:30:09,960
TRIALS ALREADY AND THEY DO HAVE

3358
02:30:09,960 --> 02:30:11,640
SOME GENERAL HEALTH

3359
02:30:11,640 --> 02:30:13,240
PRACTITIONERS WHO ARE NOT CANCER

3360
02:30:13,240 --> 02:30:15,400
SPECIFIC DOCTORS WHO ARE RECRUIT

3361
02:30:15,400 --> 02:30:17,360
INTERESTING THAT AND IT MAY BE

3362
02:30:17,360 --> 02:30:19,840
FOR ECONOMIES OF SCALE.

3363
02:30:19,840 --> 02:30:22,440
THESE ARE UNDER THE CO-OPERATIVE

3364
02:30:22,440 --> 02:30:24,080
GROUPS ARE UNDER RESOURCED AND

3365
02:30:24,080 --> 02:30:25,400
HERE IS MONEY YOU ARE GOING TO

3366
02:30:25,400 --> 02:30:26,640
SPEND, MAYBE YOU CAN SPEND THAT

3367
02:30:26,640 --> 02:30:28,640
MONEY ON THE CO-OPERATIVE GROUPS

3368
02:30:28,640 --> 02:30:30,880
AND BEEF THEM UP A LITTLE BIT

3369
02:30:30,880 --> 02:30:31,640
AND HELP.

3370
02:30:31,640 --> 02:30:33,000
WE'VE HAD SOME INTERESTING

3371
02:30:33,000 --> 02:30:35,760
CONVERSATIONS IN THE CHAT HERE

3372
02:30:35,760 --> 02:30:38,880
ABOUT MINORITY ACCRUAL.

3373
02:30:38,880 --> 02:30:40,040
DIVERSITY IS ESPECIALLY

3374
02:30:40,040 --> 02:30:41,000
IMPORTANT HERE BECAUSE YOU CAN

3375
02:30:41,000 --> 02:30:44,440
DO A GREAT DEAL OF GOOD RISK

3376
02:30:44,440 --> 02:30:45,800
ASSESSMENT AND I DID SAY

3377
02:30:45,800 --> 02:30:47,160
SOMETHING A LITTLE CONTROVERSIAL

3378
02:30:47,160 --> 02:30:49,760
AND I'M A LITTLE WORRIED WORE

3379
02:30:49,760 --> 02:30:53,080
GOING TO GRAB IN FQHCs AND

3380
02:30:53,080 --> 02:30:56,800
CREATE DISPARITIES IN THESE

3381
02:30:56,800 --> 02:31:00,280
UNDER RESOURCED FQHCs FOR

3382
02:31:00,280 --> 02:31:02,160
THINGS OTHER THAN CANCER BY

3383
02:31:02,160 --> 02:31:03,320
CONSUMING TIME ON THE CT

3384
02:31:03,320 --> 02:31:05,000
SCANNERS AND OTHER THINGS SO IF

3385
02:31:05,000 --> 02:31:06,480
WE DO GO TO THESE CENTERS, WE

3386
02:31:06,480 --> 02:31:07,680
NEED TO MAKE SURE THEY'RE

3387
02:31:07,680 --> 02:31:09,160
ALREADY RESOURCED SUCH THAT THEY

3388
02:31:09,160 --> 02:31:19,680
COULD PROVIDE AND AMONGST IT'S

3389
02:31:24,120 --> 02:31:30,080
20 YEARS AND TO LET'S GIVE

3390
02:31:30,080 --> 02:31:34,040
DIVERSITY BUT LET'S NOT CREATE

3391
02:31:34,040 --> 02:31:35,640
DISPARITIES AT THE SAME TIME.

3392
02:31:35,640 --> 02:31:38,080
>> CONGRATULATIONS.

3393
02:31:38,080 --> 02:31:38,840
>> I AGREE WITH YOU.

3394
02:31:38,840 --> 02:31:40,120
IT WAS ONE OF THE VERY FIRST

3395
02:31:40,120 --> 02:31:43,480
THINGS WE DISCUSSED IS WHEN WE

3396
02:31:43,480 --> 02:31:44,680
STARTED TO THINK ABOUT THIS

3397
02:31:44,680 --> 02:31:48,320
TRIAL IS WE HAD TO MAKE SURE IN

3398
02:31:48,320 --> 02:31:50,520
OUR THINKING THAT THERE WOULD BE

3399
02:31:50,520 --> 02:31:52,560
POTENTIALLY UNDER INSURED OR

3400
02:31:52,560 --> 02:31:53,640
UNINSURED PEOPLE THAT WOULD BE

3401
02:31:53,640 --> 02:31:56,960
IN THIS TRIAL AND THAT WE HAD TO

3402
02:31:56,960 --> 02:32:00,400
GUARANTEE AND I EMPHASIZE

3403
02:32:00,400 --> 02:32:05,240
GUARANTEE THE FULL CARE AND SO

3404
02:32:05,240 --> 02:32:06,720
THAT WAS UNDERLINING PRINCIPLE

3405
02:32:06,720 --> 02:32:08,120
FROM THE VERY BEGINNING AND WE

3406
02:32:08,120 --> 02:32:18,880
WILL ADHERE TO THAT AS YOU KNOW

3407
02:32:18,880 --> 02:32:19,920
I WOULDN'T LEAVE IT BEHIND.

3408
02:32:19,920 --> 02:32:21,760
AS EXCITING AS THESE

3409
02:32:21,760 --> 02:32:23,120
TECHNOLOGIES ARE WE NEED THEM TO

3410
02:32:23,120 --> 02:32:24,200
WORK FOR EVERYBODY AND RECOGNIZE

3411
02:32:24,200 --> 02:32:28,640
SOME OF THE DOWNSTREAM ISSUES

3412
02:32:28,640 --> 02:32:35,640
THAT UNDER SERVE POPULATIONS ARE

3413
02:32:35,640 --> 02:32:38,920
PREDISPOSED TO.

3414
02:32:38,920 --> 02:32:42,040
>> I MIGHT HAVE MISSED IT
AND I

3415
02:32:42,040 --> 02:32:43,000
APOLOGIZED IF I DID.

3416
02:32:43,000 --> 02:32:45,960
DO YOU HAVE A SYSTEMATIC PROCESS

3417
02:32:45,960 --> 02:32:50,520
TO EVALUATE AND SELECT

3418
02:32:50,520 --> 02:32:51,800
BIOMARKERS FOR STUDY.

3419
02:32:51,800 --> 02:32:53,560
I DIDN'T HEAR ABOUT IT BUT I

3420
02:32:53,560 --> 02:32:55,320
WELL MAY HAVE MISSED IT IN THE

3421
02:32:55,320 --> 02:32:55,720
PRESENTATION?

3422
02:32:55,720 --> 02:33:00,400
>> WELL, WORE NOT
ASSESSING

3423
02:33:00,400 --> 02:33:01,760
BIOMARKERS, WE'RE ASSESSING TEST

3424
02:33:01,760 --> 02:33:05,200
AND THESE TESTS ARE PANELS.

3425
02:33:05,200 --> 02:33:09,440
WE'RE AGNOSTIC ABOUT THE PANEL

3426
02:33:09,440 --> 02:33:20,000
OR THE COMPANY OR THE TECHNOLOGY

3427
02:33:24,560 --> 02:33:26,720
THEY HAVE TOE GO THROUGH AND

3428
02:33:26,720 --> 02:33:28,920
EVALUATE AND WITH A REFERENCE

3429
02:33:28,920 --> 02:33:31,120
SET THAT IS ESTABLISHED BY BEING

3430
02:33:31,120 --> 02:33:34,320
ESTABLISHED RIGHT NOW BY THE

3431
02:33:34,320 --> 02:33:35,960
ALLIANCE AND THEN ONLY THEN CAN

3432
02:33:35,960 --> 02:33:37,800
THEY EVEN BE CONSIDERED FOR THE

3433
02:33:37,800 --> 02:33:39,040
FEASIBILITY STUDY AND THEN THEY

3434
02:33:39,040 --> 02:33:41,600
HAVE TO PASS THE FEASIBILITY

3435
02:33:41,600 --> 02:33:43,400
STUDY CAN WE ACTUALLY USE THAT

3436
02:33:43,400 --> 02:33:45,960
AS SAY IN A RANDOMIZED CONTROL

3437
02:33:45,960 --> 02:33:49,600
TRIALS BEFORE THEY EVER EVEN CAN

3438
02:33:49,600 --> 02:33:51,080
BE CONSIDERED AND THAT IS WHAT

3439
02:33:51,080 --> 02:33:53,000
WE HAVE SO FAR IF YOU HAVE OTHER

3440
02:33:53,000 --> 02:33:55,200
SUGGESTIONS ABOUT HOW WE HOLD

3441
02:33:55,200 --> 02:33:57,520
THEIR FEET TO THE FIRE, I'M

3442
02:33:57,520 --> 02:34:00,360
HAPPY TO HEAR IT.

3443
02:34:00,360 --> 02:34:04,320
>> THANK YOU.

3444
02:34:04,320 --> 02:34:05,960
>> GREAT AND THIS IS
AMAZING AND

3445
02:34:05,960 --> 02:34:07,760
I GUESS WITH THE SUBSTANTIAL

3446
02:34:07,760 --> 02:34:08,840
INVESTMENTS BEING PUT NO THIS

3447
02:34:08,840 --> 02:34:11,320
THOUGH I SAW THE MENTION OF .

3448
02:34:11,320 --> 02:34:13,920
REPOSITORY AND IS THAT GOING TO

3449
02:34:13,920 --> 02:34:18,440
BE CENTRALIZED OR A SET ASIDE

3450
02:34:18,440 --> 02:34:20,200
BUDGET AND JUST SEEING A RICH

3451
02:34:20,200 --> 02:34:21,920
OPPORTUNITY TO REALLY MAKE SURE

3452
02:34:21,920 --> 02:34:22,960
THAT YOU STAND SOMETHING UP THAT

3453
02:34:22,960 --> 02:34:25,600
IS ROBUST AND IT'S IMPORTANT TO

3454
02:34:25,600 --> 02:34:27,880
MAKE SURE THE RESOURCES ARE

3455
02:34:27,880 --> 02:34:29,320
THERE.

3456
02:34:29,320 --> 02:34:30,680
>> ANDY, THAT WAS AN
IMPORTANT

3457
02:34:30,680 --> 02:34:34,640
PART OF OF DESIGN AND WE'LL SEND

3458
02:34:34,640 --> 02:34:36,840
OUT THE RIDES OR THE SLIDES WILL

3459
02:34:36,840 --> 02:34:40,160
BE SHARED BUT THIS IS IF THESE

3460
02:34:40,160 --> 02:34:42,840
WORK THEY'LL FUEL MANY OTHER

3461
02:34:42,840 --> 02:34:44,920
DEVELOPMENT AND SO CREATING THIS

3462
02:34:44,920 --> 02:34:46,320
BIO REPOSITORY AND

3463
02:34:46,320 --> 02:34:49,040
CHARACTERIZING THE TUMORS, WE DO

3464
02:34:49,040 --> 02:34:51,920
FIND IS CRITICAL THIS AND I

3465
02:34:51,920 --> 02:34:53,520
REFERRED TO THIS IN THE PRIVATE

3466
02:34:53,520 --> 02:34:56,960
MEETING WITH THE REVIEWERS IS

3467
02:34:56,960 --> 02:34:59,080
OUR LUNAR LANDING AND I'M NOT

3468
02:34:59,080 --> 02:35:01,480
QUITE EVEN SURE WHERE IT WILL

3469
02:35:01,480 --> 02:35:02,960
GO, IF THOSE TECHNOLOGIES WORK

3470
02:35:02,960 --> 02:35:05,840
AT ALL.

3471
02:35:05,840 --> 02:35:08,400
WE'LL HAVE TO SEE AND EVALUATE

3472
02:35:08,400 --> 02:35:08,600
THEM.

3473
02:35:08,600 --> 02:35:10,240
>> THE COLLECTION OF
LIFESTYLE

3474
02:35:10,240 --> 02:35:13,160
DATA AND DIETARY COMPARISON AND

3475
02:35:13,160 --> 02:35:15,000
THAT AND IT IS ADDED AT THE LAST

3476
02:35:15,000 --> 02:35:18,360
MINUTE AND IT SHOULD BE

3477
02:35:18,360 --> 02:35:19,520
INCORPORATED AT THE LAST MINUTE.

3478
02:35:19,520 --> 02:35:23,240
>> I AGREE WITH YOU.

3479
02:35:23,240 --> 02:35:33,480
>> FIRST YOU  OF ALL THIS
IS WO.

3480
02:35:33,480 --> 02:35:34,960
THE WHOLE GROUP THAT WORKED ON

3481
02:35:34,960 --> 02:35:36,280
THIS AND I THINK THERE'S NO

3482
02:35:36,280 --> 02:35:38,800
QUESTION THAT WE NEED A CANCER

3483
02:35:38,800 --> 02:35:40,640
SCREENING THAT WORKS AND I KNOW

3484
02:35:40,640 --> 02:35:43,520
THERE'S BEEN SOME DISCUSSION

3485
02:35:43,520 --> 02:35:47,200
ABOUT RELATIONSHIPS WITH THE

3486
02:35:47,200 --> 02:35:57,680
CO-OPERATIVE GROUPS AND THEY

3487
02:36:33,720 --> 02:36:35,480
KNOW HOW TO DEVELOP THE NETWORKS

3488
02:36:35,480 --> 02:36:37,040
AND THEY HAVE DONE IT TIME AND

3489
02:36:37,040 --> 02:36:38,160
TIME AGAIN WITH ALL THE

3490
02:36:38,160 --> 02:36:39,040
CONVERSATIONS WE'VE BEEN HAVING

3491
02:36:39,040 --> 02:36:45,400
ABOUT THE IMPORTANCE OF

3492
02:36:45,400 --> 02:36:55,760
SCREENING THE BIGGEST

3493
02:36:58,600 --> 02:37:00,040
CONTRIBUTION WILL BE THE

3494
02:37:00,040 --> 02:37:01,120
INFRASTRUCTURE THAT WILL BE SET

3495
02:37:01,120 --> 02:37:03,560
UP THAT WILL INVOLVE THE PRIMARY

3496
02:37:03,560 --> 02:37:05,400
CARE PHYSICIANS ALL OF THESE

3497
02:37:05,400 --> 02:37:08,880
FOLKS THAT YOU GUYS ARE TALKING

3498
02:37:08,880 --> 02:37:10,360
ABOUT IN THE HEALTH CENTERS THAT

3499
02:37:10,360 --> 02:37:12,680
DO THIS TYPE OF SCREENING IN

3500
02:37:12,680 --> 02:37:14,480
ADDRESS THIS ON A DAY TO BAY

3501
02:37:14,480 --> 02:37:17,760
BASIS IN THEIR WORK AND EVEN

3502
02:37:17,760 --> 02:37:18,840
THOUGH WE'VE DONE SUCCESSFUL

3503
02:37:18,840 --> 02:37:22,120
PREVENTION AND SCREENING STUDIES

3504
02:37:22,120 --> 02:37:23,800
IN ENCORE, WE STILL STRUGGLE

3505
02:37:23,800 --> 02:37:25,680
EVEN AFTER MORE THAN A DECADE OF

3506
02:37:25,680 --> 02:37:27,760
TRYING AND TO REALLY ACTIVELY

3507
02:37:27,760 --> 02:37:30,080
ENGAGE THESE FOLKS AND IN THE

3508
02:37:30,080 --> 02:37:31,640
DESIGN AND THE CONDUCTS AND THE

3509
02:37:31,640 --> 02:37:34,200
LEADERSHIP OF THESE TRIALS AND

3510
02:37:34,200 --> 02:37:35,840
WHEN YOU THINK ABOUT THAT, THE

3511
02:37:35,840 --> 02:37:37,400
REASON YOU WANT THEM LEADING

3512
02:37:37,400 --> 02:37:38,840
THESE TRIALS IN THIS NETWORK TO

3513
02:37:38,840 --> 02:37:40,560
BE SET UP, IS BECAUSE THEY'RE

3514
02:37:40,560 --> 02:37:42,240
GOING TO KNOW THE RIGHT

3515
02:37:42,240 --> 02:37:43,240
QUESTIONS TO ASK AND THEY'RE

3516
02:37:43,240 --> 02:37:44,680
GOING TO HAVE ACCESS TO THE

3517
02:37:44,680 --> 02:37:45,800
PATIENTS AND THEY'RE GOING TO BE

3518
02:37:45,800 --> 02:37:47,560
THE ONES THAT ARE AS SOON AS WE

3519
02:37:47,560 --> 02:37:49,280
SEE THE RESULTS OF THESE TRIALS

3520
02:37:49,280 --> 02:37:54,360
THEY'RE GOING TO BE ABLE TIME TT

3521
02:37:54,360 --> 02:37:56,880
THE NEXT DAY SO KUDOS TO THIS

3522
02:37:56,880 --> 02:37:57,280
GROUP.

3523
02:37:57,280 --> 02:38:01,160
I CAN'T SAY ENOUGH ABOUT MAKING

3524
02:38:01,160 --> 02:38:03,240
SURE THIS MOVES FORWARD AND I

3525
02:38:03,240 --> 02:38:06,480
ALSO THINK THAT I WILL JUST ADD

3526
02:38:06,480 --> 02:38:09,280
THAT CONVERSATIONS WITH FOLKS IN

3527
02:38:09,280 --> 02:38:11,320
THE CO-OPERATIVE GROUPS FIT

3528
02:38:11,320 --> 02:38:12,600
NORTH KIND OF CONVERSATIONS THAT

3529
02:38:12,600 --> 02:38:15,640
WOULD ALLOW THESE NETWORKS TO

3530
02:38:15,640 --> 02:38:17,040
COMMUNICATE, I DO THINK IT WOULD

3531
02:38:17,040 --> 02:38:19,280
BE VERY BENEFICIAL BECAUSE I

3532
02:38:19,280 --> 02:38:20,680
THINK THEY'LL BE SOME TYPES OF

3533
02:38:20,680 --> 02:38:21,680
SCREENING STUDIES THAT WILL

3534
02:38:21,680 --> 02:38:23,800
STILL BE NEEDED IN THOSE

3535
02:38:23,800 --> 02:38:24,920
NETWORKS, FOR EXAMPLE, PATIENTS

3536
02:38:24,920 --> 02:38:27,800
WHO ARE ALREADY SCREENING HIGH

3537
02:38:27,800 --> 02:38:29,800
GENETIC RISK WHO ARE FOLLOWED BY

3538
02:38:29,800 --> 02:38:34,160
AN ONCOLOGIST SORRY PERHAPS

3539
02:38:34,160 --> 02:38:34,760
PEOPLE WHO ARE BEING SCREENED

3540
02:38:34,760 --> 02:38:35,760
FOR ONSET OF SECOND CANCERS

3541
02:38:35,760 --> 02:38:40,400
AFTER A CANCER TREATMENT.

3542
02:38:40,400 --> 02:38:42,440
THIS IS ADDRESSING A HUGE GAP

3543
02:38:42,440 --> 02:38:46,040
AND I JUST WANT TO REITERATE MY

3544
02:38:46,040 --> 02:38:48,440
SUPPORT AND THANK YOU FOR THIS

3545
02:38:48,440 --> 02:38:48,640
EFFORT.

3546
02:38:48,640 --> 02:38:50,040
>> THANK YOU, KAREN FOR
THE

3547
02:38:50,040 --> 02:38:51,320
GENEROUS WORDS AND WE ARE

3548
02:38:51,320 --> 02:38:52,560
TALKING TO THE CO-OPERATIVE

3549
02:38:52,560 --> 02:38:57,480
GROUPS ABOUT HIGH-RISK

3550
02:38:57,480 --> 02:39:00,920
POPULATIONS FOR MCED BECAUSE

3551
02:39:00,920 --> 02:39:02,760
THEY WOULD BE GOOD THROUGH THE

3552
02:39:02,760 --> 02:39:13,240
ENCORE AND OTHER MECHANISMS.

3553
02:39:17,800 --> 02:39:20,280
>> I'LL TAKE MY VIDEO OFF.

3554
02:39:20,280 --> 02:39:21,680
THIS IS SUCH AN INCREDIBLE

3555
02:39:21,680 --> 02:39:23,560
OPPORTUNITY BECAUSE THERE ARE

3556
02:39:23,560 --> 02:39:25,000
PEOPLE LIKE ME AND I'M SURE

3557
02:39:25,000 --> 02:39:26,720
MANY, MANY, MANY WHAT'S WOULD

3558
02:39:26,720 --> 02:39:30,400
LOVE TO GET ACCESS TO SEQUENCING

3559
02:39:30,400 --> 02:39:32,240
DATA AND SEQUENCING DATA FOR

3560
02:39:32,240 --> 02:39:36,440
THIS PURPOSE AND DEVELOPING THE

3561
02:39:36,440 --> 02:39:37,800
ASSAY SO THERE'S ALSO AN

3562
02:39:37,800 --> 02:39:40,480
OPPORTUNITY TO DO RESEARCH HERE

3563
02:39:40,480 --> 02:39:42,360
AND IN TERMS OF WHAT THAT

3564
02:39:42,360 --> 02:39:43,640
BIOMARKER PANEL SHOULD BE AND

3565
02:39:43,640 --> 02:39:45,840
I'M JUST WONDERING, IF AS YOU

3566
02:39:45,840 --> 02:39:52,640
TALK IT THROUGH, YOU DO -- THE

3567
02:39:52,640 --> 02:39:55,560
NCI DOES PAY FOR SEQUENCING DATA

3568
02:39:55,560 --> 02:39:59,880
IT'S CAPTURED IN THESE TRIALS IN

3569
02:39:59,880 --> 02:40:01,920
PARALLEL TO FOLKS CAN DEVELOP

3570
02:40:01,920 --> 02:40:03,480
ASSAYS BASED ON THE OUTCOMES SO

3571
02:40:03,480 --> 02:40:05,320
I'M JUST PUTTING IT OUT THERE

3572
02:40:05,320 --> 02:40:10,280
THERE COULD BE A PERIL

3573
02:40:10,280 --> 02:40:10,560
OPPORTUNITY.

3574
02:40:10,560 --> 02:40:13,160
>> GREAT POINT.

3575
02:40:13,160 --> 02:40:21,000
WE WILL FOLD THAT IN.

3576
02:40:21,000 --> 02:40:23,200
>> WE HAD ANNE WITH HER
HAND UP

3577
02:40:23,200 --> 02:40:27,120
AND HOWARD HAD HIS HAND.

3578
02:40:27,120 --> 02:40:28,800
>> HIS HAND WENT DOWN SO
I'M

3579
02:40:28,800 --> 02:40:30,000
HOPING THEY FELT THEIR QUESTION

3580
02:40:30,000 --> 02:40:32,480
WAS ADDRESSED.

3581
02:40:32,480 --> 02:40:33,880
>> I'M GOING TO BRING MINE
UP IN

3582
02:40:33,880 --> 02:40:36,040
OPEN SESSION LATER.

3583
02:40:36,040 --> 02:40:38,440
>> VERY GOOD.

3584
02:40:38,440 --> 02:40:42,680
>> WE BROKE Ar A RECORD IN
THE

3585
02:40:42,680 --> 02:40:44,080
COMMENTS IN THE CHAT AND ROBUST

3586
02:40:44,080 --> 02:40:46,360
COMMENTS ON THE FEDERALLY

3587
02:40:46,360 --> 02:40:47,640
QUALIFIED HEALTH CENTER SO IF

3588
02:40:47,640 --> 02:40:48,840
YOU COULD GRAB THOSE AND

3589
02:40:48,840 --> 02:40:49,760
INCORPORATE THOSE THAT WOULD BE

3590
02:40:49,760 --> 02:40:50,320
GREAT.

3591
02:40:50,320 --> 02:40:54,600
LET'S MOVE TO VOTING.

3592
02:40:54,600 --> 02:40:54,800
MOTION.

3593
02:40:54,800 --> 02:40:56,400
>> MOTION TO APPROVE.

3594
02:40:56,400 --> 02:40:58,840
>> SECOND.

3595
02:40:58,840 --> 02:40:59,240
>> SECOND.

3596
02:40:59,240 --> 02:41:03,640
>> ANY FURTHER DISCUSSION?

3597
02:41:03,640 --> 02:41:07,280
>> HEARING NONE.

3598
02:41:07,280 --> 02:41:08,680
MOTION IS FOR APPROVAL AND ANY

3599
02:41:08,680 --> 02:41:15,320
VOTES OF DISAPPROVAL?

3600
02:41:15,320 --> 02:41:17,720
ANY ABSTENTIONS?

3601
02:41:17,720 --> 02:41:19,680
>> IT'S UNANIMOUS
APPROVAL.

3602
02:41:19,680 --> 02:41:20,360
>> VERY GOOD.

3603
02:41:20,360 --> 02:41:24,040
LET'S KEEP MOVING.

3604
02:41:24,040 --> 02:41:26,280
NEXT IS RFA TRANSFORMATIVE

3605
02:41:26,280 --> 02:41:28,000
EDUCATIONAL ADVANCEMENT AND

3606
02:41:28,000 --> 02:41:31,440
MENTORING NETWORK AND TEAM AND

3607
02:41:31,440 --> 02:41:32,840
Dr. LEANNE BAILEY IS

3608
02:41:32,840 --> 02:41:34,480
PRESENTING AND THE SUB COMMIT

3609
02:41:34,480 --> 02:41:35,840
SEE CHAIRED BY SUSAN BAKER  AND

3610
02:41:35,840 --> 02:41:38,680
SUPPORTED BY MYSELF AND NELSON

3611
02:41:38,680 --> 02:41:40,680
CHOW AND DID PARTICIPATE IN OUR

3612
02:41:40,680 --> 02:41:42,240
GROUP DISCUSSION AND LOW AN, GO

3613
02:41:42,240 --> 02:41:45,400
AHEAD WITH YOUR PRESENTATION.

3614
02:41:45,400 --> 02:41:47,120
>> GOOD AFTERNOON, THANK
YOU FOR

3615
02:41:47,120 --> 02:41:54,200
THE OPPORTUNITY TO PRESENT THE

3616
02:41:54,200 --> 02:42:04,760
CONCEPT OF -- THIS IS FOR TEAM.

3617
02:42:08,600 --> 02:42:11,160
I'M DELIGHTED TO PRESENT THE

3618
02:42:11,160 --> 02:42:13,480
TRANSFORMATIVE EDUCATIONAL

3619
02:42:13,480 --> 02:42:14,560
ADVANCEMENT AND MENTORING

3620
02:42:14,560 --> 02:42:15,880
NETWORK TEAM FOR THE REST OF

3621
02:42:15,880 --> 02:42:17,280
THIS PRESENTATION.

3622
02:42:17,280 --> 02:42:18,600
AND I'LL BE PRESENTING THIS

3623
02:42:18,600 --> 02:42:20,480
CONCEPT ON BEHALF OF THE THE

3624
02:42:20,480 --> 02:42:23,080
WORKING GROUP NUMBER 2 OF THE

3625
02:42:23,080 --> 02:42:24,160
NCI EQUITY COUNCIL.

3626
02:42:24,160 --> 02:42:27,080
NEXT SLIDE, PLEASE.

3627
02:42:27,080 --> 02:42:29,600
SO, AS YOU ALL KNOW, NCI IS A

3628
02:42:29,600 --> 02:42:31,760
BIG PLACE AND THIS SLIDE REALLY

3629
02:42:31,760 --> 02:42:33,000
DETICKETS OUR BREADTH AND DEPTH

3630
02:42:33,000 --> 02:42:34,320
IN THE RESEARCH AND TRAINING

3631
02:42:34,320 --> 02:42:36,440
OPPORTUNITIES THAT THE INSTITUTE

3632
02:42:36,440 --> 02:42:36,800
SUPPORTS.

3633
02:42:36,800 --> 02:42:39,960
NEXT SLIDE, PLEASE.

3634
02:42:39,960 --> 02:42:41,720
RECENT EFFORTS BY BOTH NCI AND

3635
02:42:41,720 --> 02:42:43,360
THE NIH ARE PROVIDING THE

3636
02:42:43,360 --> 02:42:44,520
OPPORTUNITIES TO INCREASE

3637
02:42:44,520 --> 02:42:47,240
DIVERSITY OF FUNDED CANCER AND

3638
02:42:47,240 --> 02:42:47,880
INVESTIGATORS THROUGH PROGRAMS

3639
02:42:47,880 --> 02:42:49,320
SUCH AS THE N.

3640
02:42:49,320 --> 02:42:50,440
>> Catherine: CONTINUING

3641
02:42:50,440 --> 02:42:52,360
UMBRELLA OF RESEARCH EXPERIENCES

3642
02:42:52,360 --> 02:42:57,360
AND THE PARTNERSHIP TO ADVANCE

3643
02:42:57,360 --> 02:42:58,400
CANCER HEALTH EQUITY AND THERE'S

3644
02:42:58,400 --> 02:43:00,560
A GAP IN RACIAL AND ETHNIC

3645
02:43:00,560 --> 02:43:02,520
MINORITIES AND THE SCIENTIFIC

3646
02:43:02,520 --> 02:43:05,280
ENTERPRISE AND WORKFORCE.

3647
02:43:05,280 --> 02:43:05,960
TARGETED LEVERS OF REALLY NEEDED

3648
02:43:05,960 --> 02:43:15,760
SPECIFICALLY TARGETED OUTREACH

3649
02:43:15,760 --> 02:43:17,880
TO MINORITY SERVING INSTITUTIONS

3650
02:43:17,880 --> 02:43:20,160
TO IDENTIFY AND ASSIST WITH THE

3651
02:43:20,160 --> 02:43:23,520
DEVELOPMENT OF UNDER REPRESENTED

3652
02:43:23,520 --> 02:43:24,440
SCHOLARS MIGHT BE QUITE

3653
02:43:24,440 --> 02:43:25,720
BENEFICIAL AND ONE OF THE

3654
02:43:25,720 --> 02:43:27,120
MECHANISMS THAT NCI HAS USED

3655
02:43:27,120 --> 02:43:28,800
OVER THE LAST FIVE YEARS IS

3656
02:43:28,800 --> 02:43:32,960
TRAINING NAVIGATION AND IT'S

3657
02:43:32,960 --> 02:43:43,480
HELPED FOR VALUABLE WHO TO SPEAK

3658
02:43:53,680 --> 02:43:55,760
TO AND HOW TO RESPOND TO THE

3659
02:43:55,760 --> 02:43:57,840
PEER REVIEW PROCESS.

3660
02:43:57,840 --> 02:43:59,160
SO, SOMETIMES SCHOLARS ARE

3661
02:43:59,160 --> 02:44:03,080
SUCCESSFUL AND THE FIRST TRY AND

3662
02:44:03,080 --> 02:44:04,680
VERY -- IN A SMALL MINORITY

3663
02:44:04,680 --> 02:44:06,360
HOWEVER MANY TIMES THEY HAVE TO

3664
02:44:06,360 --> 02:44:09,000
REAPPLY AND RESPONDING TO NOT

3665
02:44:09,000 --> 02:44:11,040
ONLY PEER REVIEW BUT ENGAGING IN

3666
02:44:11,040 --> 02:44:21,520
TERMS AND HAVING TO TAKE AND WE

3667
02:44:21,520 --> 02:44:23,360
FOUND THAT HAVING A QUALIFIED

3668
02:44:23,360 --> 02:44:26,320
EXPERT TO ASSIST AND FOCUSED ON

3669
02:44:26,320 --> 02:44:28,200
THIS PROCESS WAS HIGHLY

3670
02:44:28,200 --> 02:44:29,680
ADVANTAGEOUS AND THE TEAM

3671
02:44:29,680 --> 02:44:31,480
PROGRAM IS INTERESTED IN AN PRE

3672
02:44:31,480 --> 02:44:33,360
DOCTORAL POSTDOC TO BAL AND

3673
02:44:33,360 --> 02:44:35,200
EARLY STAGE INVESTIGATIVE CAREER

3674
02:44:35,200 --> 02:44:39,880
FUNDS IN THE PIPELINE AND NEXT

3675
02:44:39,880 --> 02:44:42,240
SLIDE, PLEASE.

3676
02:44:42,240 --> 02:44:43,680
SO, THE IPSOS-REID

3677
02:44:43,680 --> 02:44:55,120
CONSTITPERSONAL AND TRANCEFISSIE

3678
02:45:01,240 --> 02:45:02,480
GEOGRAPHIC MANAGEMENT OF CANCER

3679
02:45:02,480 --> 02:45:06,720
HEALTH DISPARITIES PROGRAMS.

3680
02:45:06,720 --> 02:45:08,480
SO TRAINING NAVIGATION EFFORTS

3681
02:45:08,480 --> 02:45:11,160
IN FY2019 AND 2020 RESULT INSIDE

3682
02:45:11,160 --> 02:45:13,960
SUCCESSFUL APPLICATION TO CURE

3683
02:45:13,960 --> 02:45:17,640
AND 36% IN 2019 AND 45% IN 2020

3684
02:45:17,640 --> 02:45:20,400
AND IN COMPARISON TO THE NIH

3685
02:45:20,400 --> 02:45:23,200
SUCCESS RATE OF 30% FOR BOTH

3686
02:45:23,200 --> 02:45:23,760
YEARS.

3687
02:45:23,760 --> 02:45:25,400
SO, LOCALIZED NAVIGATION SUPPORT

3688
02:45:25,400 --> 02:45:31,080
AT THE INSTITUTIONAL LEVELS IS

3689
02:45:31,080 --> 02:45:34,640
REQUIRED THAT SCHOLARS RECEIVE

3690
02:45:34,640 --> 02:45:35,680
THAT CONTINUOUS PERSONAL

3691
02:45:35,680 --> 02:45:37,080
TRAINING AND COORDINATION

3692
02:45:37,080 --> 02:45:38,160
EDUCATION AND SUPPORT.

3693
02:45:38,160 --> 02:45:40,400
AND THIS IS ESSENTIALLY THE

3694
02:45:40,400 --> 02:45:41,560
VISION OF THE TEAM PROGRAM.

3695
02:45:41,560 --> 02:45:45,960
NEXT SLIDE, PLEASE.

3696
02:45:45,960 --> 02:45:47,400
THE PURPOSE OF TEAM IS INFORM

3697
02:45:47,400 --> 02:45:49,040
PILOT TEST AND USE OF THESE

3698
02:45:49,040 --> 02:45:51,040
TRAINING CHAMPIONS AT NSI TO

3699
02:45:51,040 --> 02:45:54,600
PROVIDE EDUCATIONAL AND CAREER

3700
02:45:54,600 --> 02:45:56,800
DEVELOPMENT AND IN TERMS OF THE

3701
02:45:56,800 --> 02:45:58,160
NAVIGATION FOR UNDER REPRESENTED

3702
02:45:58,160 --> 02:45:59,520
SCHOLARS AND HERE YOU SEE THE

3703
02:45:59,520 --> 02:46:00,840
OBJECTIVES AND WE'LL DELVE INTO

3704
02:46:00,840 --> 02:46:03,600
THESE THREE OUT THE REST OF THE

3705
02:46:03,600 --> 02:46:06,280
AND AS I MENTIONED THE PILOT THE

3706
02:46:06,280 --> 02:46:07,720
USE OF TRAINING CHAMPIONS AND

3707
02:46:07,720 --> 02:46:09,640
THE SECOND OBJECTIVE IS REALLY

3708
02:46:09,640 --> 02:46:10,880
LEVERAGING THEM AND THE

3709
02:46:10,880 --> 02:46:12,920
INSTITUTIONAL SUPPORT TO CONNECT

3710
02:46:12,920 --> 02:46:15,720
A POTENTIAL SCHOLAR GROUP WITH

3711
02:46:15,720 --> 02:46:16,560
MENTORING AND NETWORKING

3712
02:46:16,560 --> 02:46:20,040
OPPORTUNITIES AND LASTLY A

3713
02:46:20,040 --> 02:46:25,800
DIDN'T ADOPTING EDUCATIONAL

3714
02:46:25,800 --> 02:46:26,400
ACTIVITIES.

3715
02:46:26,400 --> 02:46:31,400
TO PROVIDE AND EACH LEVEL

3716
02:46:31,400 --> 02:46:32,800
DISTINCT ROLLS AND POSSIBILITIES

3717
02:46:32,800 --> 02:46:38,240
AS DEFECTED HERE AND WE SEE THE

3718
02:46:38,240 --> 02:46:39,880
TRAINING AND THE LEAKY PIPELINE

3719
02:46:39,880 --> 02:46:44,480
BY SUPPORTING AND CONNECTING AND

3720
02:46:44,480 --> 02:46:47,360
INVESTIGATORS AS WELL AS MENTORS

3721
02:46:47,360 --> 02:46:50,560
AND WITHIN THE INSTITUTION AND

3722
02:46:50,560 --> 02:46:53,240
PROVIDE MORE GRANULAR AND

3723
02:46:53,240 --> 02:46:58,040
TARGETED SUPPORT.

3724
02:46:58,040 --> 02:47:01,000
SO, WE ENVISION THE TRAINING AND

3725
02:47:01,000 --> 02:47:02,600
ONE FULL TIME EQUIVALENT THAT

3726
02:47:02,600 --> 02:47:03,400
WOULD BUILT ON THE GROUND

3727
02:47:03,400 --> 02:47:07,240
SUPPORT TO THE SCHOLARS AND

3728
02:47:07,240 --> 02:47:08,720
ALTERNATIVELY THAT A TEAM OF

3729
02:47:08,720 --> 02:47:10,920
TRAINING AND THAT EQUALS

3730
02:47:10,920 --> 02:47:17,000
FULL-TIME EQUIVALENT AND THEY

3731
02:47:17,000 --> 02:47:18,280
MAY HAVE EX TENSE AVENUE AND

3732
02:47:18,280 --> 02:47:20,760
WORKING CAPABILITIES AT 25% OF

3733
02:47:20,760 --> 02:47:23,760
THE TIME AND 75% OF THE TIME

3734
02:47:23,760 --> 02:47:25,680
DEVOTED TO THE SUPPORT AND

3735
02:47:25,680 --> 02:47:27,240
PEOPLE WHO SUPPORT LOGISTICS AND

3736
02:47:27,240 --> 02:47:29,920
THE CONNECTIONS AND THE

3737
02:47:29,920 --> 02:47:31,400
TRAININGS AND PROVIDE

3738
02:47:31,400 --> 02:47:32,600
ADMINISTRATIVE SUPPORT AND THESE

3739
02:47:32,600 --> 02:47:34,440
INDIVIDUALS CAN BE PART THE

3740
02:47:34,440 --> 02:47:36,760
INSTITUTION AND THEY CAN ALSO BE

3741
02:47:36,760 --> 02:47:39,680
RECRUITED FROM EX CONTINUAL

3742
02:47:39,680 --> 02:47:41,640
OPTION AND SO THE CHAMPIONS WILL

3743
02:47:41,640 --> 02:47:46,280
HAVE THE FULL SUPPORT OF NCI

3744
02:47:46,280 --> 02:47:47,760
PROGRAMS AND THEY WILL RECEIVE

3745
02:47:47,760 --> 02:47:49,480
FORMALIZED TRAINING BE PART OF

3746
02:47:49,480 --> 02:47:50,960
THE TRAINING NAVIGATION THEM

3747
02:47:50,960 --> 02:47:57,320
THAT WILL BE HOUSED AT COCHD.

3748
02:47:57,320 --> 02:47:59,640
SO WE RECOGNIZE THAT IT'S

3749
02:47:59,640 --> 02:48:00,880
CRITICALLY IMPORTANT TO BE ABLE

3750
02:48:00,880 --> 02:48:02,800
TO INCLUDE NOT ONLY MENTORING

3751
02:48:02,800 --> 02:48:05,600
BUT ALSO NETWORKING

3752
02:48:05,600 --> 02:48:06,200
OPPORTUNITIES AND YOU WILL

3753
02:48:06,200 --> 02:48:07,680
THOUGH THE TEAM CONCEPT IS

3754
02:48:07,680 --> 02:48:09,440
CENTERED ON THE SCHOLARS

3755
02:48:09,440 --> 02:48:11,960
INDIVIDUAL GROWTH, WE ALSO

3756
02:48:11,960 --> 02:48:13,120
UNDERSTAND THE IMPORTANCE OF THE

3757
02:48:13,120 --> 02:48:15,040
COLLECTIVE AND THESE EFFORTS ARE

3758
02:48:15,040 --> 02:48:18,800
CAN'T BE CHAMPIONS JUST BY

3759
02:48:18,800 --> 02:48:20,240
INDIVIDUALS SO LONG-TERM

3760
02:48:20,240 --> 02:48:22,160
SUSTAINABILITY WILL HAVE SUPPORT

3761
02:48:22,160 --> 02:48:25,560
THAT LEVERAGES RE SOURCES AT THE

3762
02:48:25,560 --> 02:48:26,720
INSTITUTION LEVEL.

3763
02:48:26,720 --> 02:48:28,480
HE UNDERSTAND HOW IMPORTANT

3764
02:48:28,480 --> 02:48:30,120
GRANTS ARE IN THIS PROCESS AND

3765
02:48:30,120 --> 02:48:33,800
SO THAT WILL ALSO BE A KEY

3766
02:48:33,800 --> 02:48:42,720
OBJECTIVE FOR THIS ASPECT OF THE

3767
02:48:42,720 --> 02:48:43,320
GRANT.

3768
02:48:43,320 --> 02:48:46,240
SO THIS ENCOURAGES INNOVATION

3769
02:48:46,240 --> 02:48:48,040
AND WE'RE EXCITED ABOUT THE

3770
02:48:48,040 --> 02:48:49,400
OPPORTUNITY TO ADAPT OUR

3771
02:48:49,400 --> 02:48:51,560
LEVERAGE CULTURALLY TAILORED

3772
02:48:51,560 --> 02:48:53,320
EDUCATIONAL ACTIVITIES AND OR

3773
02:48:53,320 --> 02:48:55,320
SHORT COURSE THAT'S WILL ENHANCE

3774
02:48:55,320 --> 02:48:58,720
NOT ONLY SUBJECT MATTER

3775
02:48:58,720 --> 02:48:59,920
EXPERTISE AND CAREER DEVELOPMENT

3776
02:48:59,920 --> 02:49:01,560
AND GIVEN THE CURRENT STATE OF

3777
02:49:01,560 --> 02:49:05,960
THE CLIMATE AND RACISM AND WE'RE

3778
02:49:05,960 --> 02:49:07,840
REALLY WANT TO GO PROMOTE

3779
02:49:07,840 --> 02:49:09,440
EFFECTIVENESS MENTOR AND MENTEE

3780
02:49:09,440 --> 02:49:12,160
COMMUNICATION STRATEGIES AND

3781
02:49:12,160 --> 02:49:13,880
STRAIN SCHOLARS AND ETHICS AND

3782
02:49:13,880 --> 02:49:18,080
MIKE OWE AGGRESSION AND

3783
02:49:18,080 --> 02:49:19,400
STRUCTURAL INEQUITIES AND WE ARE

3784
02:49:19,400 --> 02:49:22,040
HOPEFUL THAT THIS OPPORTUNITY

3785
02:49:22,040 --> 02:49:25,160
WOULD PRESENT WITH ENGAGEMENT

3786
02:49:25,160 --> 02:49:28,280
STRATEGIES AND CROWDSOURCING AND

3787
02:49:28,280 --> 02:49:30,880
NETWORK SCIENCE TO OPTIMIZE THE

3788
02:49:30,880 --> 02:49:35,880
LEARNING FOR SCHOLARS.

3789
02:49:35,880 --> 02:49:37,760
SO REGARDING THE BUDGET WE

3790
02:49:37,760 --> 02:49:41,080
PROPOSE THAT UP TO FIVE R25 TEAM

3791
02:49:41,080 --> 02:49:44,600
GRANTEES WILL BE AWARDED AND THE

3792
02:49:44,600 --> 02:49:45,680
IT WOULD BE TO HAVE FIVE YEARS

3793
02:49:45,680 --> 02:49:47,600
WITH 300K IN DIRECT COSTS AND

3794
02:49:47,600 --> 02:49:49,760
500K IN TOTAL COSTS PER REWARD

3795
02:49:49,760 --> 02:49:53,040
PER YEAR AND THE BUDGET WITH

3796
02:49:53,040 --> 02:49:54,880
PHYSICAL CALECHES YEAR 2023 AND

3797
02:49:54,880 --> 02:49:55,240
2028.

3798
02:49:55,240 --> 02:49:59,600
AND ESTIMATED TOTAL COST PER

3799
02:49:59,600 --> 02:50:00,560
YEAR 2-POINT # # WITH ATTEMPT

3800
02:50:00,560 --> 02:50:12,480
COST FOR THE FI -- THIS ISPARTIT

3801
02:50:14,680 --> 02:50:17,120
TRAINING NAVIGATION ACTIVITIES

3802
02:50:17,120 --> 02:50:22,040
AND IN 2018, THEY CONNECTED WITH

3803
02:50:22,040 --> 02:50:23,720
THOSE COORDINATING THAT I

3804
02:50:23,720 --> 02:50:25,960
MENTIONED THROUGH GMAP AND THEY

3805
02:50:25,960 --> 02:50:27,960
WERE THROUGH TRAINING NAVIGATION

3806
02:50:27,960 --> 02:50:32,040
TO THE CONTINUING UMBRELLA AND

3807
02:50:32,040 --> 02:50:33,360
EXPERIENCE PROGRAMS AND AT THAT

3808
02:50:33,360 --> 02:50:36,520
POINT, MULTIPLE AWARDS WERE

3809
02:50:36,520 --> 02:50:39,400
CONSIDERED AND THE PERSON

3810
02:50:39,400 --> 02:50:41,320
APPROVED AND AFTER RECEIVING A

3811
02:50:41,320 --> 02:50:44,000
SUMMARY STATEMENT TO SUPPORT THE

3812
02:50:44,000 --> 02:50:45,800
ALSO MET WITH THE MENTOR AND IN

3813
02:50:45,800 --> 02:50:48,560
THIS PARTICULAR INSTANCE AND IT

3814
02:50:48,560 --> 02:50:51,120
RESULTED IN THE KO1 AWARD IN

3815
02:50:51,120 --> 02:50:53,680
2020 AS WELL AS A LOT OF PAYMENT

3816
02:50:53,680 --> 02:50:56,240
AWARDS AND WE FOCUSED ON NCI

3817
02:50:56,240 --> 02:50:57,240
OPPORTUNITIES WE WANT FOLKS TO

3818
02:50:57,240 --> 02:51:00,600
BE ABLE TO ENGAGE THE FULL

3819
02:51:00,600 --> 02:51:05,440
CAPACITY WITH REGARD TO

3820
02:51:05,440 --> 02:51:05,960
OPPORTUNITIES.

3821
02:51:05,960 --> 02:51:07,920
AND SO, WE WOULD LIKE TO

3822
02:51:07,920 --> 02:51:09,480
GRATEFULLY ACKNOWLEDGE THE

3823
02:51:09,480 --> 02:51:10,680
WONDERFUL DISCUSSION THAT WE

3824
02:51:10,680 --> 02:51:12,600
HAVE WITH OUR BSA REVIEWERS AND

3825
02:51:12,600 --> 02:51:13,920
A FEW OF THE POINTS OF

3826
02:51:13,920 --> 02:51:15,160
DISCUSSION ARE DETAILED ON THIS

3827
02:51:15,160 --> 02:51:16,920
PAGE AND I'M SURE THAT THEY WERE

3828
02:51:16,920 --> 02:51:19,120
GOING TO ADDITIONAL DETAILS AT

3829
02:51:19,120 --> 02:51:22,560
THE SUMMATION OF THIS FORECAST

3830
02:51:22,560 --> 02:51:26,080
PRESENTATION AND WE REALLY DO

3831
02:51:26,080 --> 02:51:27,000
APPRECIATE THE SUGGESTIONS AND

3832
02:51:27,000 --> 02:51:29,400
THE CLARITY THEY SUSPECTED THAT

3833
02:51:29,400 --> 02:51:35,640
THEY SUGGESTED ESPECIALLY WITH

3834
02:51:35,640 --> 02:51:40,640
REGARDS TO RFA AND I'D LIKE TO

3835
02:51:40,640 --> 02:51:43,680
ACKNOWLEDGE THE GROUP OF FOLKS

3836
02:51:43,680 --> 02:51:46,640
AND THE DEVELOPMENT AS WELL AS

3837
02:51:46,640 --> 02:51:50,960
MATURITY AND THE CONCEPT AND

3838
02:51:50,960 --> 02:51:54,880
BEFORE AND CONTEXT WITHIN THE

3839
02:51:54,880 --> 02:51:56,600
CHCDT TEAM AS WELL AS THE EQUITY

3840
02:51:56,600 --> 02:51:58,640
COUNCILOR AND SPECIAL

3841
02:51:58,640 --> 02:52:02,280
CONTRIBUTORS AND FROM OTHER

3842
02:52:02,280 --> 02:52:04,080
DIVISIONS AND AND I WOULD LIKELY

3843
02:52:04,080 --> 02:52:09,760
LIKE TO THINK AND THEY'RE

3844
02:52:09,760 --> 02:52:11,760
HELPFUL GUIDANCE AND BEING.

3845
02:52:11,760 --> 02:52:13,320
>> Connor: CHAMPIONS FOR

3846
02:52:13,320 --> 02:52:14,400
DIVERSITY SO WITH THAT I HAD

3847
02:52:14,400 --> 02:52:17,600
WOULD BE HAPPY TO CONCLUDE AND I

3848
02:52:17,600 --> 02:52:19,160
THANK YOU FOR YOUR TIME AND

3849
02:52:19,160 --> 02:52:19,640
ATTENTION.

3850
02:52:19,640 --> 02:52:22,000
>> GREAT.

3851
02:52:22,000 --> 02:52:27,640
SUZANNE, OPEN THE DISCUSSION.

3852
02:52:27,640 --> 02:52:28,640
>> SURE.

3853
02:52:28,640 --> 02:52:30,360
SO IT WAS A PLEASURE TO CHAIR

3854
02:52:30,360 --> 02:52:32,480
THE SUBCOMMITTEE ALONG WITH

3855
02:52:32,480 --> 02:52:34,400
Dr. FLARE TEE AND CHOW AND I

3856
02:52:34,400 --> 02:52:36,600
WANT TO THANK Dr. BAILEY FOR

3857
02:52:36,600 --> 02:52:38,640
BEING REALLY RESPONSIVE TO OUR

3858
02:52:38,640 --> 02:52:41,040
COMMENTS AND OUR DISCUSSION.

3859
02:52:41,040 --> 02:52:43,760
THE SUBCOMMITTEE DISCUSSED

3860
02:52:43,760 --> 02:52:45,080
TOGETHER BEFORE MEANING OF DOCK

3861
02:52:45,080 --> 02:52:46,680
BAILEY AND WE SENT OUR QUESTIONS

3862
02:52:46,680 --> 02:52:49,880
AND ADVANCE SO THAT SHE WAS VERY

3863
02:52:49,880 --> 02:52:52,840
WELL PREPARED FOR A PRODUCTIVE

3864
02:52:52,840 --> 02:52:56,360
DISCUSSION AND SHE FOLLOWED UP

3865
02:52:56,360 --> 02:52:57,400
WITH NICE SUMMARIES OF HOW SHE

3866
02:52:57,400 --> 02:52:59,240
WAS PLANNING TO ADDRESS THESE

3867
02:52:59,240 --> 02:53:01,280
POINTS AND SHE'S ALREADY REALLY

3868
02:53:01,280 --> 02:53:02,560
TOUCHED ON THE MAIN QUESTIONS

3869
02:53:02,560 --> 02:53:04,080
FROM THIS SUBCOMMITTEE AND THE

3870
02:53:04,080 --> 02:53:06,200
FIRST THING TO SAY IS THAT WE

3871
02:53:06,200 --> 02:53:09,560
WERE UNIFORMLY EXTREMELY

3872
02:53:09,560 --> 02:53:11,200
ENTHUSIASTIC ABOUT THIS VERY

3873
02:53:11,200 --> 02:53:15,000
IMPORTANT INITIATIVE SO CLEARLY

3874
02:53:15,000 --> 02:53:19,440
THIS IS VERY DESPERATELY NEEDED

3875
02:53:19,440 --> 02:53:20,360
AND WELL CONSTRUCTED AND SOME OF

3876
02:53:20,360 --> 02:53:24,080
THE ASPECT THAT'S WE THOUGHT

3877
02:53:24,080 --> 02:53:29,600
WERE PARTICULARLY PROMISING IS

3878
02:53:29,600 --> 02:53:32,600
CHANGES GOING BACK TO THE

3879
02:53:32,600 --> 02:53:34,760
EARLIER STAGES BECAUSE

3880
02:53:34,760 --> 02:53:45,480
EARLIER THAT THE GREAT BUILDINGS

3881
02:53:46,240 --> 02:53:47,520
A BIG PLUS ON THIS APPLICATION

3882
02:53:47,520 --> 02:53:49,120
AND THE STRUCTURE THAT IS

3883
02:53:49,120 --> 02:53:53,880
RELYING ON SOME PROGRAMS THAT

3884
02:53:53,880 --> 02:53:55,080
ARE STRONG AND ALREADY PUT IN

3885
02:53:55,080 --> 02:53:56,560
PLACE AND WE HAVE TO BE RELATED

3886
02:53:56,560 --> 02:53:59,720
TO THE CLARITY OF THE RFA AND

3887
02:53:59,720 --> 02:54:02,240
IT'S DESIGN WRITTEN IN A VERY

3888
02:54:02,240 --> 02:54:05,480
OPEN STYLE TO ENCOURAGE

3889
02:54:05,480 --> 02:54:06,760
CREATIVITY AND INNOVATION AMONG

3890
02:54:06,760 --> 02:54:08,240
THE APPLICANTS THAT I CAN COME

3891
02:54:08,240 --> 02:54:10,600
UP WITH CREATIVE IDEAS ON HOW

3892
02:54:10,600 --> 02:54:12,360
BEST TO LEVERAGE THE RESOURCES

3893
02:54:12,360 --> 02:54:16,400
AND WE THOUGHT IT COULD BE MADE

3894
02:54:16,400 --> 02:54:17,880
A LITTLE BIT MORE CLEAR TO THE

3895
02:54:17,880 --> 02:54:19,960
APPLICANTS THAT EXACTLY WHAT AN

3896
02:54:19,960 --> 02:54:21,080
APPLICATION MIGHT LOOK LIKE

3897
02:54:21,080 --> 02:54:23,240
PERHAPS BY GIVING A FEW EXAMPLES

3898
02:54:23,240 --> 02:54:26,960
OF PARTICULAR FORMATS OR WORK SO

3899
02:54:26,960 --> 02:54:28,480
THEY HAVE AN IDEA OF HOW TO PUT

3900
02:54:28,480 --> 02:54:32,680
THEIR APPLICATIONS AND TOGETHER

3901
02:54:32,680 --> 02:54:34,520
AND WE WERE NOT CLEAR EXACTLY

3902
02:54:34,520 --> 02:54:40,640
WHO THE TRAINING CHAMPIONS MIGHT

3903
02:54:40,640 --> 02:54:42,800
BE WHAT INDIVIDUAL WE THOUGHT IT

3904
02:54:42,800 --> 02:54:45,480
WAS A SENIOR AND WELL FUNDED

3905
02:54:45,480 --> 02:54:46,760
INVESTIGATOR AND Dr. BAILEY

3906
02:54:46,760 --> 02:54:48,800
POINTED OUT THAT THAT PERSON WAS

3907
02:54:48,800 --> 02:54:50,600
OUR CONCERN AND IT MIGHT NOT

3908
02:54:50,600 --> 02:54:51,960
REALLY CENTER THE TIME TO INVEST

3909
02:54:51,960 --> 02:54:53,440
AND THE PROGRAMS THAT THE WAY

3910
02:54:53,440 --> 02:54:56,360
YOU WOULD LIKE THEM TO AND SO

3911
02:54:56,360 --> 02:54:59,520
THEY PLANNED TO PUT IN A MORE

3912
02:54:59,520 --> 02:55:00,400
CLEAR DEFINITION OF THE

3913
02:55:00,400 --> 02:55:01,560
DIFFERENCE WAYS THOSE TRAINING

3914
02:55:01,560 --> 02:55:03,960
CHAMPIONS COULD BE STRUCTURED TO

3915
02:55:03,960 --> 02:55:06,840
BE MORE THAN ONE PERSON AND

3916
02:55:06,840 --> 02:55:10,800
PEOPLE WITH CREDENTIALS AND TO

3917
02:55:10,800 --> 02:55:12,560
ADD DETAILS ON THE SCOPE OF THE

3918
02:55:12,560 --> 02:55:14,120
PROGRAM MIGHT LOOK LIKE AND THAT

3919
02:55:14,120 --> 02:55:16,040
WOULD BE DIFFERENT AND THE

3920
02:55:16,040 --> 02:55:17,720
TRAINING LEVELS AND HOW MANY

3921
02:55:17,720 --> 02:55:22,480
SCHOLARS WOULD BE ENGAGE IN KIND

3922
02:55:22,480 --> 02:55:23,840
OF PROGRAMS THEY WOULD PUT

3923
02:55:23,840 --> 02:55:28,640
TOGETHER AND THIS WOULD BE SOME

3924
02:55:28,640 --> 02:55:31,840
DESCRIPTION AND CREATIVE

3925
02:55:31,840 --> 02:55:34,680
APPLICATIONS AND MAKING A LITTLE

3926
02:55:34,680 --> 02:55:39,760
BIT CLEAR AND EXACTLY WOULD BE

3927
02:55:39,760 --> 02:55:44,200
ABLE TO I'LL LEAVE IT THERE AND

3928
02:55:44,200 --> 02:55:45,640
IF YOU HAVE QUESTION AND.

3929
02:55:45,640 --> 02:55:47,760
>> JUST TO PUT AN EMPHASIS
ON

3930
02:55:47,760 --> 02:55:50,840
THE FACT THAT WE'RE SO

3931
02:55:50,840 --> 02:55:51,800
ENTHUSIASTIC ABOUT THIS

3932
02:55:51,800 --> 02:55:57,880
INITIATIVE THAT I THINK IT'S TO

3933
02:55:57,880 --> 02:56:00,960
RESOURCES AND A SHAWL NUMBER OF

3934
02:56:00,960 --> 02:56:01,840
AWARDS THAT WILL BE OFFERED

3935
02:56:01,840 --> 02:56:03,840
WHICH CREATES A VULNERABILITY

3936
02:56:03,840 --> 02:56:07,240
WHICH IS THAT PER INSTITUTIONS

3937
02:56:07,240 --> 02:56:11,400
AND HE WAS AWARDED A GRANT AND

3938
02:56:11,400 --> 02:56:12,920
THEY'LL BE A TYPE OF EXPERTISE

3939
02:56:12,920 --> 02:56:15,320
THAT IS REPRESENTED IN THAT

3940
02:56:15,320 --> 02:56:18,120
PERSON AND THEY'RE CLINICAL AND

3941
02:56:18,120 --> 02:56:20,560
WITHIN EACH DOMAIN THERE ARE

3942
02:56:20,560 --> 02:56:23,760
MULTIPLE TIMES OF EXPERTISE AND

3943
02:56:23,760 --> 02:56:26,280
THAT ARE DISTINCT AND BE IT

3944
02:56:26,280 --> 02:56:30,800
DISCIPLINE OF CANCER CARE IN THE

3945
02:56:30,800 --> 02:56:32,680
CLINICAL SIDE AND EPIDEMIOLOGY

3946
02:56:32,680 --> 02:56:34,160
AND THE LIKE SO YOU CAN IMAGINE

3947
02:56:34,160 --> 02:56:37,280
VERY DISTINCT CHAMPIONS AND SO,

3948
02:56:37,280 --> 02:56:40,400
A POINT OF IS REALLY INTERACTIVE

3949
02:56:40,400 --> 02:56:43,080
WITH ADAPTABILITY ABOUT WAS

3950
02:56:43,080 --> 02:56:47,320
TRYING TO ENSURE THIS NETWORK

3951
02:56:47,320 --> 02:56:50,720
COMPONENTS RATES SO THAT

3952
02:56:50,720 --> 02:56:53,160
TRAINING IS WHO CAN BENEFIT FROM

3953
02:56:53,160 --> 02:56:55,760
CHAMPIONS AND IT MAY BE BASIC

3954
02:56:55,760 --> 02:57:00,120
TEST UNDER THE OS PISSES OF

3955
02:57:00,120 --> 02:57:02,360
EPIDEMIOLOGIST AND WHO IS VERY

3956
02:57:02,360 --> 02:57:03,520
FOCUSED ON CLINICAL RESEARCH

3957
02:57:03,520 --> 02:57:04,960
INTO THE SPECTRUM AND THAT

3958
02:57:04,960 --> 02:57:06,400
PERSON MIGHT BENEFIT FROM BEING

3959
02:57:06,400 --> 02:57:08,240
ABLE TO REACH OUT ACROSS

3960
02:57:08,240 --> 02:57:10,520
INSTITUTIONS SO PARTICULARLY IN

3961
02:57:10,520 --> 02:57:12,880
THE ERA OF THIS INITIATIVE ARE

3962
02:57:12,880 --> 02:57:14,840
GREAT HOPE OF COURSE IS THAT

3963
02:57:14,840 --> 02:57:17,880
THIS TAKES HOLD AND BEGINS TO

3964
02:57:17,880 --> 02:57:19,280
MULTIPLY AND WITHIN INSTITUTIONS

3965
02:57:19,280 --> 02:57:21,200
AND ACROSS THE NETWORKS SO

3966
02:57:21,200 --> 02:57:25,400
THAT'S JUST ONE ATTENTION TO

3967
02:57:25,400 --> 02:57:27,560
TRYING TO EMPOWER AND TYPE OF

3968
02:57:27,560 --> 02:57:30,680
APPROACH HERE AND IN THE EARLY

3969
02:57:30,680 --> 02:57:30,960
GOING.

3970
02:57:30,960 --> 02:57:32,480
>> THAT WAS ONLY A POINT I
WANT

3971
02:57:32,480 --> 02:57:33,120
TODAY ADD.

3972
02:57:33,120 --> 02:57:34,920
LET'S OPEN UP TO DISCUSSION,

3973
02:57:34,920 --> 02:57:36,600
HOWARD I SAW YOUR HAND UP.

3974
02:57:36,600 --> 02:57:40,200
>> SURE.

3975
02:57:40,200 --> 02:57:44,440
>> SO THE IMAGES YOU
SHOWED, YOU

3976
02:57:44,440 --> 02:57:45,480
KNOW, PORTRAY THIS ABOUT GRANTS

3977
02:57:45,480 --> 02:57:49,480
MAN SHIP FOR SINGLE GRANT

3978
02:57:49,480 --> 02:57:51,800
RECIPIENTS AND I THINK AS KEITH

3979
02:57:51,800 --> 02:57:54,160
STARTED TO SAY I THINK AS I

3980
02:57:54,160 --> 02:57:56,480
UNDERSTOOD HIS COMMENTS, THERE'S

3981
02:57:56,480 --> 02:57:59,240
A LOT MORE OPPORTUNITIES HERE

3982
02:57:59,240 --> 02:58:03,960
FOR MORE VALUES TO THE PATIENT

3983
02:58:03,960 --> 02:58:12,600
POPULATION AND HOW GRANTS

3984
02:58:12,600 --> 02:58:13,040
FUNCTION.

3985
02:58:13,040 --> 02:58:15,120
I'M THINKING ABOUT SOME OF THE

3986
02:58:15,120 --> 02:58:16,360
LIMITATIONS OF SOME OF THE

3987
02:58:16,360 --> 02:58:19,760
MODERN THERAPIES LIKE STEM CELL

3988
02:58:19,760 --> 02:58:21,440
THERAPY FOR DIFFERENT DISEASES

3989
02:58:21,440 --> 02:58:23,280
AND IT HAS BEEN START HE'D IN

3990
02:58:23,280 --> 02:58:27,000
TERMS OF HOW THEY FAIR WHEN THEY

3991
02:58:27,000 --> 02:58:28,680
GO FORWARD AND THERE HAVE BEEN

3992
02:58:28,680 --> 02:58:36,320
TIMES WHERE MENTORING THE THE

3993
02:58:36,320 --> 02:58:37,600
RUNNING IT HAS LED TO

3994
02:58:37,600 --> 02:58:38,920
IMPROVEMENTS AS THEY GO FORWARD

3995
02:58:38,920 --> 02:58:40,560
INTO LARGER POPULATIONS AND

3996
02:58:40,560 --> 02:58:42,280
THAT'S A BIG DEAL BECAUSE WE

3997
02:58:42,280 --> 02:58:44,280
CARE ABOUT GENERALIZABILITY OF

3998
02:58:44,280 --> 02:58:45,240
THESE SPECIFIC THERAPIES THAT

3999
02:58:45,240 --> 02:58:52,840
ARE OFTEN APPROVED WITH SMALL

4000
02:58:52,840 --> 02:59:03,360
SPECIAL INSTEAD OF THE SINGLE

4001
02:59:10,200 --> 02:59:12,120
GRANT RECIPIENTS, I SEE THAT A

4002
02:59:12,120 --> 02:59:14,600
LOT OF GOOD RESEARCH IS BY

4003
02:59:14,600 --> 02:59:14,840
TEAMS.

4004
02:59:14,840 --> 02:59:25,240
IT TAKES A VILLAGE AND IT HAS A

4005
02:59:25,240 --> 02:59:27,120
GROUP MENTORING PROGRAM WHERE

4006
02:59:27,120 --> 02:59:31,000
THEY BRING IN USUALLY A

4007
02:59:31,000 --> 02:59:32,480
BRILLIANT GUY WHO IS DONE A LOT

4008
02:59:32,480 --> 02:59:34,360
OF WONDERFUL GRANTS AND HE

4009
02:59:34,360 --> 02:59:36,880
TEACHES BASICALLY A COURSE THAT

4010
02:59:36,880 --> 02:59:38,200
ANYBODY WHO WANTS TO COME IN CAN

4011
02:59:38,200 --> 02:59:43,280
COME IN AND LEARN ABOUT

4012
02:59:43,280 --> 02:59:44,240
GRANTSMANSHIP AND ABOUT HOW IT

4013
02:59:44,240 --> 02:59:45,960
TAKES A VILLAGE AND HOW TO WORK

4014
02:59:45,960 --> 02:59:49,160
WITHIN THE VILLAGE AND THE

4015
02:59:49,160 --> 02:59:51,560
NURSES, THE CO-WORKERS AND

4016
02:59:51,560 --> 02:59:54,240
PHARMACISTS WHO ARE NEEDED TO

4017
02:59:54,240 --> 02:59:59,920
MANAGE GOOD GRANTS AND TRUCK

4018
02:59:59,920 --> 03:00:00,440
PITCH TEE.

4019
03:00:00,440 --> 03:00:03,680
>> I THINK THOSE ARE ALL

4020
03:00:03,680 --> 03:00:05,240
FABULOUS POINTS AND ONE OF THE

4021
03:00:05,240 --> 03:00:06,840
KEY COMPONENTS OF THE CONCEPT IS

4022
03:00:06,840 --> 03:00:08,760
TO DO JUST THAT AND YOU KNOW,

4023
03:00:08,760 --> 03:00:10,080
WITH THE INTRODUCTION OF COVID

4024
03:00:10,080 --> 03:00:12,680
AND HYBRID PLATFORMS AND THE

4025
03:00:12,680 --> 03:00:14,080
COMMUNICATIONS SOCIAL MEDIA THAT

4026
03:00:14,080 --> 03:00:15,800
CAN LEVERAGED AND WE'RE LOOKING

4027
03:00:15,800 --> 03:00:17,520
FOR MODELS AND INFORMATION CAN

4028
03:00:17,520 --> 03:00:19,840
BE READILY EXPORTED TO THE

4029
03:00:19,840 --> 03:00:21,200
COMMUNITY TO DO EXACTLY WHAT YOU

4030
03:00:21,200 --> 03:00:22,600
ARE SAYING.

4031
03:00:22,600 --> 03:00:26,120
AND TO IDENTIFY CHAMPIONS AND

4032
03:00:26,120 --> 03:00:28,040
MENTORS THAT WILL BE ABLE TO

4033
03:00:28,040 --> 03:00:29,160
PROVIDE THE GUIDANCE AND WILL BE

4034
03:00:29,160 --> 03:00:33,240
ABLE TO PROVIDE THAT CAD RAY OF

4035
03:00:33,240 --> 03:00:33,920
INDIVIDUALS.

4036
03:00:33,920 --> 03:00:35,680
I APOLOGIZE IF THE LAST SLIDE,

4037
03:00:35,680 --> 03:00:37,640
THE NEXT TO LAST SIDE THROUGH

4038
03:00:37,640 --> 03:00:38,520
YOU OFF WITH THE INDIVIDUAL

4039
03:00:38,520 --> 03:00:41,640
BECAUSE WE REALLY ARE WORKING TO

4040
03:00:41,640 --> 03:00:44,320
HAVE MULTIPLE TRAINEES WITHIN

4041
03:00:44,320 --> 03:00:54,000
THESE CADRAYS SO THERE WILL BE

4042
03:00:54,000 --> 03:00:55,600
EXTENSIVE COLLABORATIONS WITH

4043
03:00:55,600 --> 03:00:59,800
ACADEMIC MEDICAL CENTERS, CANCER

4044
03:00:59,800 --> 03:01:00,480
CENTERS, PERHAPS COMMUNITIES

4045
03:01:00,480 --> 03:01:01,560
LIKE WHATEVER IT IS THAT SITE

4046
03:01:01,560 --> 03:01:05,520
WANTS TO FOCUS ON.

4047
03:01:05,520 --> 03:01:08,200
>> THAT LIST YOU GAVE YOU
DIDN'T

4048
03:01:08,200 --> 03:01:11,280
JUST SAY AND FARBETTER COMPANIES

4049
03:01:11,280 --> 03:01:12,440
WHO ARE KEEN ON SUPPORTING THESE

4050
03:01:12,440 --> 03:01:18,520
KINDS OF MENTORING PROGRAMS AND

4051
03:01:18,520 --> 03:01:19,880
AGAIN, THEY HAVE INTEREST IN THE

4052
03:01:19,880 --> 03:01:21,280
RUSE OF THEIR PRODUCTS BUT THEY

4053
03:01:21,280 --> 03:01:29,880
REALLY DO CARE ABOUT THE

4054
03:01:29,880 --> 03:01:40,080
SUCCESSFUL.

4055
03:01:41,320 --> 03:01:42,760
SEEING NO HANDS WE CAN MOVE TO

4056
03:01:42,760 --> 03:01:43,400
VOTING.

4057
03:01:43,400 --> 03:01:44,200
SUZANNE, WOULD YOU LIKE TO MAKE

4058
03:01:44,200 --> 03:01:48,600
A MOTION?

4059
03:01:48,600 --> 03:01:49,720
>> I MOVE TO APPROVE.

4060
03:01:49,720 --> 03:01:50,120
>> SECOND THAT.

4061
03:01:50,120 --> 03:01:59,080
>> ANY FURTHER DISCUSSION?

4062
03:01:59,080 --> 03:02:00,600
THE MOTION IS TO APPROVE.

4063
03:02:00,600 --> 03:02:07,800
ANY VOTES OF DISAPPROVAL.

4064
03:02:07,800 --> 03:02:12,800
YEAH, ANY ABSTENTIONS?

4065
03:02:12,800 --> 03:02:14,480
SEEING NONE.

4066
03:02:14,480 --> 03:02:14,720
PAULETTE.

4067
03:02:14,720 --> 03:02:16,680
>> WE'RE GOING TO GO.

4068
03:02:16,680 --> 03:02:18,040
IT'S UNANIMOUS.

4069
03:02:18,040 --> 03:02:18,360
>> FANTASTIC.

4070
03:02:18,360 --> 03:02:20,520
WE'RE NOT GOOD TO GO ON TIME SO

4071
03:02:20,520 --> 03:02:22,200
I DON'T THINK WE SHOULD TAKE A

4072
03:02:22,200 --> 03:02:23,440
10-MINUTE BREAK BUT WE PROBABLY

4073
03:02:23,440 --> 03:02:25,000
NEED TO GIVE PEOPLE A

4074
03:02:25,000 --> 03:02:25,920
FIVE-MINUTE BREAK OR BREAKING

4075
03:02:25,920 --> 03:02:29,760
SOME KIND OF FEDERAL CODE.

4076
03:02:29,760 --> 03:02:31,360
>> THERE'S NO FEDERAL
CODE.

4077
03:02:31,360 --> 03:02:32,840
>> NO CODE BECAUSE WE'RE

4078
03:02:32,840 --> 03:02:34,200
GOVERNMENT EMPLOYEES.

4079
03:02:34,200 --> 03:02:35,400
>> YOU ARE BEING NICE.

4080
03:02:35,400 --> 03:02:39,520
YOU GIVE THEM FIVE MINUTES.

4081
03:02:39,520 --> 03:02:40,960
I WAS GOING TO LEAVE AND COME

4082
03:02:40,960 --> 03:02:43,000
BACK.

4083
03:02:43,000 --> 03:02:43,320
>> YES.

4084
03:02:43,320 --> 03:02:44,960
>> LET'S TAKE A QUICK

4085
03:02:44,960 --> 03:02:45,640
FIVE-MINUTE BREAK.

4086
03:02:45,640 --> 03:02:47,400
BACK AT 4:08.

4087
03:02:47,400 --> 03:02:48,480
SEE YOU ALL SOON.

4088
03:02:49,080 --> 03:02:50,480
>>WE HAVE ONE LAST NEW
CONCEPT

4089
03:02:50,480 --> 03:02:56,640
FOR THE DAY.

4090
03:02:56,640 --> 03:03:00,760
THIS IS AN RFA, CANCER MOONSHOT

4091
03:03:00,760 --> 03:03:02,040
SCHOLARS DIVERSITY PROGRAM AND

4092
03:03:02,040 --> 03:03:10,960
IT WAS SUPPORTED BY DOCTORS AND

4093
03:03:10,960 --> 03:03:11,720
LEANNE, TAKE IT AWAY.

4094
03:03:11,720 --> 03:03:15,000
>> IT'S BEEN SO LONG SINCE
WE

4095
03:03:15,000 --> 03:03:17,600
CONVEWECONVENED BUT I'M EXCITEDO

4096
03:03:17,600 --> 03:03:19,440
PRESENT THE CANCER MOONSHOT

4097
03:03:19,440 --> 03:03:24,400
SCHOLARS DIVERSITY PROGRAM.

4098
03:03:24,400 --> 03:03:28,240
THIS IS OUR OPPORTUNITY TO

4099
03:03:28,240 --> 03:03:32,360
DISCUSS IT.

4100
03:03:32,360 --> 03:03:34,160
BIOMEDICAL RESEARCH WORKFORCE

4101
03:03:34,160 --> 03:03:35,600
THAT CAPITALIZES ON THE SPECTRUM

4102
03:03:35,600 --> 03:03:38,360
OF THE NATION'S SKILLS, TALENTS

4103
03:03:38,360 --> 03:03:41,080
AND VIEW POINTS IS ESSENTIAL FOR

4104
03:03:41,080 --> 03:03:42,360
SOLVING COMPLEX HEALTH PROBLEMS

4105
03:03:42,360 --> 03:03:43,240
INCLUDING CANCER.

4106
03:03:43,240 --> 03:03:44,840
THE INVOLVEMENT OF INDIVIDUALS

4107
03:03:44,840 --> 03:03:46,680
WITH DIVERSE CULTURAL

4108
03:03:46,680 --> 03:03:47,880
PERSPECTIVES HAS BEEN SHOWN TO

4109
03:03:47,880 --> 03:03:50,160
BE ESSENTIAL AND ORDER TO REACH

4110
03:03:50,160 --> 03:03:51,760
SAID COMMUNITIES AND MAKE

4111
03:03:51,760 --> 03:03:53,440
ADVANCINGMENTS IN ADDRESSING

4112
03:03:53,440 --> 03:03:54,560
CANCER HEALTH DISPARITIES AND

4113
03:03:54,560 --> 03:03:57,880
THE NCI IN ALIGNMENT WITH NIH

4114
03:03:57,880 --> 03:03:59,440
AND THE WHITE HOUSE DEMONSTRATES

4115
03:03:59,440 --> 03:04:07,200
A STRONG COMMITMENT TO ENSURE

4116
03:04:07,200 --> 03:04:08,360
LONG-TERM SUCCESSES IN THE

4117
03:04:08,360 --> 03:04:18,840
CANCER RESEARCH ENTERPRISE.

4118
03:04:24,800 --> 03:04:27,120
SPECIFICALLY THE PROGRAM SEEKS

4119
03:04:27,120 --> 03:04:29,560
TO PROMOTE SCIENTIFIC ADVANCES

4120
03:04:29,560 --> 03:04:31,680
IN CANCER RESEARCH THROUGH THE

4121
03:04:31,680 --> 03:04:32,880
DIVERSIFICATION OF THE POOL

4122
03:04:32,880 --> 03:04:34,920
WITHIN THE PORTFOLIO TO FOCUS ON

4123
03:04:34,920 --> 03:04:36,000
EARLY STAGE INVESTIGATORS FROM

4124
03:04:36,000 --> 03:04:37,720
UNDER REPRESENTED GROUPS, AND AS

4125
03:04:37,720 --> 03:04:39,280
WELL AS TO INCREASE THE NUMBER

4126
03:04:39,280 --> 03:04:41,160
OF FUNDED RO1 INVESTIGATORS FROM

4127
03:04:41,160 --> 03:04:42,680
UNDER REPRESENTED GROUPS ACROSS

4128
03:04:42,680 --> 03:04:53,200
THE CANCER RESEARCH CONTINUUM.

4129
03:04:53,520 --> 03:04:56,360
INDIVIDUALS FROM UNDER

4130
03:04:56,360 --> 03:04:56,920
REPRESENTED GROUPS, BLACK,

4131
03:04:56,920 --> 03:05:00,240
AFRICAN AMERICAN, HISPANIC OR

4132
03:05:00,240 --> 03:05:02,640
LATINO OTHER GROUPS AND ASIAN

4133
03:05:02,640 --> 03:05:03,880
AND HOWEVER, THESE GROUPS ARE

4134
03:05:03,880 --> 03:05:05,680
DIS PURCHASE OR THE ATLY

4135
03:05:05,680 --> 03:05:08,920
REPRESENTED WITHIN THE NCI, RO1

4136
03:05:08,920 --> 03:05:09,280
PORTFOLIO.

4137
03:05:09,280 --> 03:05:10,880
THIS SLIDE SHOWS THE

4138
03:05:10,880 --> 03:05:14,480
DEMOGRAPHICS OF NCI'S FY-20

4139
03:05:14,480 --> 03:05:16,160
EQUIVALENT APPLICANTS AND THE

4140
03:05:16,160 --> 03:05:19,040
TOP ROW AND THE AWARDEES IN THE

4141
03:05:19,040 --> 03:05:19,640
BOTTOM ROW.

4142
03:05:19,640 --> 03:05:25,200
THE RESULTS SHOW THE NUMBER OF

4143
03:05:25,200 --> 03:05:26,720
AGGREGATE UNDER-REPRESENTED

4144
03:05:26,720 --> 03:05:28,000
GROUPS IS LESS THAN THOSE OF NON

4145
03:05:28,000 --> 03:05:30,760
UNDER REPRESENTED GROUPS NOT

4146
03:05:30,760 --> 03:05:34,200
HISPANIC WHITE AND ASIAN

4147
03:05:34,200 --> 03:05:34,640
APPLICANTS.

4148
03:05:34,640 --> 03:05:37,880
THE FIRST CHALLENGE HIGHLIGHTED

4149
03:05:37,880 --> 03:05:40,800
HERE IS THERE IS A DECREASE IN

4150
03:05:40,800 --> 03:05:42,120
THE NUMBER OF APPLICATIONS FROM

4151
03:05:42,120 --> 03:05:43,720
UNDER REPRESENTED GROUPS SUCH AS

4152
03:05:43,720 --> 03:05:45,000
BLACK AND AFRICAN AMERICANS.

4153
03:05:45,000 --> 03:05:47,080
AND THE SECOND IS ADDRESSING THE

4154
03:05:47,080 --> 03:05:48,520
FUNDING GAP WHICH LEADS TO A

4155
03:05:48,520 --> 03:05:51,120
LOWER REPRESENTATION IN NCI

4156
03:05:51,120 --> 03:05:53,360
AWARDEES IN COMPARISON TO THE

4157
03:05:53,360 --> 03:05:53,800
APPLICANT POOLS.

4158
03:05:53,800 --> 03:05:55,920
AND THIS FUNDING GAP WAS

4159
03:05:55,920 --> 03:05:59,560
OBSERVED BY IN 2011 FOR THE NIH

4160
03:05:59,560 --> 03:06:03,640
OVER ALL AND A PER PONDERANCE

4161
03:06:03,640 --> 03:06:05,040
CONFIRMS THAT IT CAN CONTINUES

4162
03:06:05,040 --> 03:06:07,240
AND SO THIS IS NOT SPECIFIC TO

4163
03:06:07,240 --> 03:06:07,400
N.

4164
03:06:07,400 --> 03:06:11,840
>> Catherine: IT'S A
CHALLENGE

4165
03:06:11,840 --> 03:06:13,160
FOR NIH OVER ALL.

4166
03:06:13,160 --> 03:06:23,640
THIS DATA DEPEBBLES SOME OF THE

4167
03:06:23,640 --> 03:06:32,840
THE BIG.

4168
03:06:32,840 --> 03:06:34,400
>> THE CRY YEAR TA WILL BE

4169
03:06:34,400 --> 03:06:36,040
CONSISTENT WITH THE NIH

4170
03:06:36,040 --> 03:06:38,240
DIVERSITY STATEMENT AS LISTED

4171
03:06:38,240 --> 03:06:38,640
HERE.

4172
03:06:38,640 --> 03:06:41,280
AND I'M HAPPY TO REPORT THAT

4173
03:06:41,280 --> 03:06:42,880
THREE PUBLISHED FOAs THAT ALSO

4174
03:06:42,880 --> 03:06:44,880
ARE FOCUSING ON DIVERSE FEE

4175
03:06:44,880 --> 03:06:47,160
UTILIZED THIS CRITERIA AND THIS

4176
03:06:47,160 --> 03:06:48,200
DIVERSITY LANGUAGE HAS BEEN

4177
03:06:48,200 --> 03:06:52,400
APPROVED BY THE OFFICE OF THE

4178
03:06:52,400 --> 03:06:56,760
GENERAL COUNCIL.

4179
03:06:56,760 --> 03:06:58,800
TO CONTINUE WITH THE

4180
03:06:58,800 --> 03:07:00,000
ELIGIBILITY, OUR STAGE

4181
03:07:00,000 --> 03:07:01,320
INVESTIGATORS FROM UNDER

4182
03:07:01,320 --> 03:07:02,600
REPRESENTED GROUPS ARE

4183
03:07:02,600 --> 03:07:05,600
ENCOURAGING TO APPLY AND THERE

4184
03:07:05,600 --> 03:07:09,000
IS NO RESTRICTION AND

4185
03:07:09,000 --> 03:07:10,320
APPLICATIONS FOR PROPOSING

4186
03:07:10,320 --> 03:07:12,320
TOPICS THAT SPAN THE ENTIRE

4187
03:07:12,320 --> 03:07:13,680
CANCER CONTINUUM WILL BE

4188
03:07:13,680 --> 03:07:14,880
CONSIDERED NOT ONLY RESPONSIVE

4189
03:07:14,880 --> 03:07:17,040
AND ALSO ALIGNED WITH THE PAIR

4190
03:07:17,040 --> 03:07:22,560
OF RO1 PROGRAM ANNOUNCEMENT.

4191
03:07:22,560 --> 03:07:25,640
AND APPLICATIONS ARE PERMISSIBLE

4192
03:07:25,640 --> 03:07:28,120
HOWEVER, AN INVESTIGATOR FROM AN

4193
03:07:28,120 --> 03:07:30,200
UNDER REPRESENTED GROUP MUSTING

4194
03:07:30,200 --> 03:07:31,520
DESIGNATED AS THE CONTACT P.I.

4195
03:07:31,520 --> 03:07:33,760
AND AN INSTITUTIONAL ELIGIBILITY

4196
03:07:33,760 --> 03:07:37,680
LETTER MUST BE SUBMITTED BY THE

4197
03:07:37,680 --> 03:07:39,360
APPLICATION INSTITUTION CERTIFY

4198
03:07:39,360 --> 03:07:42,480
THE APPLICANT IS CONSIDERED TO

4199
03:07:42,480 --> 03:07:43,880
BE UNDER REPRESENTED.

4200
03:07:43,880 --> 03:07:46,560
AGAIN, FOR THE PURPOSES OF THIS

4201
03:07:46,560 --> 03:07:50,920
RFA, INVESTIGATORS ARE DEFINED

4202
03:07:50,920 --> 03:07:54,640
ACCORDING TO THE SOMETIMES OF

4203
03:07:54,640 --> 03:07:57,800
INTEREST IN DIVERSITY.

4204
03:07:57,800 --> 03:08:00,520
THE CANCER MOONSHOT SCHOLARS

4205
03:08:00,520 --> 03:08:05,040
DIVERSITY PROGRAM WILL BE LED BY

4206
03:08:05,040 --> 03:08:06,560
CRCHD WITH TRANS INPUT AND

4207
03:08:06,560 --> 03:08:07,840
PARTICIPATION FROM THE DIFFERENT

4208
03:08:07,840 --> 03:08:09,280
DIVISIONS OFFICES AND CENTER

4209
03:08:09,280 --> 03:08:11,560
ACROSS NCI.

4210
03:08:11,560 --> 03:08:13,320
THE TRANS NCI STEERING COMMITTEE

4211
03:08:13,320 --> 03:08:15,160
WILL WORK AS A TEAM AND TO

4212
03:08:15,160 --> 03:08:17,960
REVIEW ALL RO1 APPLICATION AND

4213
03:08:17,960 --> 03:08:19,680
ASSURE APPROPRIATE DOCK

4214
03:08:19,680 --> 03:08:22,800
ASSIGNMENTS DEPENDING UPON THE

4215
03:08:22,800 --> 03:08:24,400
REFERRAL GUIDELINES AND THE

4216
03:08:24,400 --> 03:08:26,080
STEERING COMMITTEE MEMBERS WILL

4217
03:08:26,080 --> 03:08:27,360
ADDITIONALLY CONTRIBUTE TO

4218
03:08:27,360 --> 03:08:28,720
OUTREACH ACTIVITIES TO ENSURE

4219
03:08:28,720 --> 03:08:30,320
THAT A BROAD RANGE OF APPLICANTS

4220
03:08:30,320 --> 03:08:32,240
ARE MADE AWARE OF THE FOA AND

4221
03:08:32,240 --> 03:08:33,760
THIS WILL INCLUDE A COMBINATION

4222
03:08:33,760 --> 03:08:37,480
OF TARGETED SOLICITATIONS AND TO

4223
03:08:37,480 --> 03:08:38,280
INSTITUTIONS AND GRANTEES AS

4224
03:08:38,280 --> 03:08:40,280
WELL AS A BROAD MARKETING

4225
03:08:40,280 --> 03:08:42,040
CAMPAIGN USING SOCIAL MEDIA AND

4226
03:08:42,040 --> 03:08:44,520
OTHER COMMUNICATIONS PLATFORMS.

4227
03:08:44,520 --> 03:08:46,400
SO LIKE THE APPLICATIONS WITHIN

4228
03:08:46,400 --> 03:08:49,360
EACH AREAS OF SCIENCE, BASED ON

4229
03:08:49,360 --> 03:08:51,440
MERIT, AVAILABLE FUNDING AND

4230
03:08:51,440 --> 03:08:54,160
OVER ALL NCI PORTFOLIO GAPS WILL

4231
03:08:54,160 --> 03:08:56,920
BE ANALYZED AND AS PREVIOUSLY

4232
03:08:56,920 --> 03:08:58,000
STATED THERE'S NO RESTRICTION ON

4233
03:08:58,000 --> 03:08:59,480
THE TYPE OF CANCER RESEARCH

4234
03:08:59,480 --> 03:09:01,080
BEING PROPOSED AND WE REALLY

4235
03:09:01,080 --> 03:09:03,320
SEEK TO ENSURE THAT THERE IS A

4236
03:09:03,320 --> 03:09:04,840
BALANCE REPRESENTATION FROM

4237
03:09:04,840 --> 03:09:09,360
BASIC CLINICAL, TRANSLATION AND

4238
03:09:09,360 --> 03:09:10,040
POPULATION SCIENCE.

4239
03:09:10,040 --> 03:09:13,720
NEXT SLIDE, PLEASE.

4240
03:09:13,720 --> 03:09:15,360
CANCER MOONSHOT FUNDS ARE BEING

4241
03:09:15,360 --> 03:09:16,880
REQUESTED TO SUPPORT THIS

4242
03:09:16,880 --> 03:09:18,800
PROGRAM AND THIS WILL BE A

4243
03:09:18,800 --> 03:09:24,440
THROW-YEAR ISSUANCE FOR FY2023

4244
03:09:24,440 --> 03:09:26,440
THROUGH '25 WITH SET ASIDE FUNDS

4245
03:09:26,440 --> 03:09:27,640
OF $9 MILLION IN TOTAL COSTS

4246
03:09:27,640 --> 03:09:30,200
EACH YEAR TO FUND NEW TYPE 1

4247
03:09:30,200 --> 03:09:30,560
AWARDS.

4248
03:09:30,560 --> 03:09:34,160
WE ANTICIPATE UP TO 15 NEW RO1

4249
03:09:34,160 --> 03:09:37,360
AWARDS PER YEAR AND 45RO1 TOTAL

4250
03:09:37,360 --> 03:09:40,040
TO BE FUNDED.

4251
03:09:40,040 --> 03:09:41,320
THIS REQUEST ESTIMATES THAT THE

4252
03:09:41,320 --> 03:09:44,760
AVERAGE RO1 IS 600K IN TOTAL

4253
03:09:44,760 --> 03:09:47,640
COSTS OR 350 IN K IN DIRECT

4254
03:09:47,640 --> 03:09:49,480
COSTS PER YEAR AND THE PROJECT

4255
03:09:49,480 --> 03:09:51,880
PERIOD CAN BE UP TO FIVE YEARS.

4256
03:09:51,880 --> 03:09:55,200
THE ESTIMATES TOTAL COST FOR THE

4257
03:09:55,200 --> 03:09:59,280
RFA PROGRAM IS UP TO 135 AND

4258
03:09:59,280 --> 03:10:03,600
MILLION TOTAL COSTS AND 78.75 IN

4259
03:10:03,600 --> 03:10:04,920
DIRECT COSTS.

4260
03:10:04,920 --> 03:10:09,520
THE ESI-RO1 APPLICATIONS WITH

4261
03:10:09,520 --> 03:10:11,440
SCORE EQUIVALENT OR BETTER THAN

4262
03:10:11,440 --> 03:10:14,880
THE NCI RO1 PAYLINE WILL BE

4263
03:10:14,880 --> 03:10:19,520
ELIGIBLE FOR THE TWO-YEAR

4264
03:10:19,520 --> 03:10:19,760
EXTENSION.

4265
03:10:19,760 --> 03:10:22,280
WE ARE CRITICALLY AWARE OF HOW

4266
03:10:22,280 --> 03:10:24,800
IMPORTANT THE METRICS WILL BE TO

4267
03:10:24,800 --> 03:10:27,000
ASSESS THIS PROGRAM AND SO IF

4268
03:10:27,000 --> 03:10:28,680
YOU EVALUATION CRITERIA ARE

4269
03:10:28,680 --> 03:10:30,480
LISTED HERE AND WE FULLY EXPECT

4270
03:10:30,480 --> 03:10:33,680
AN INCREASE IN THE NUMBER OF

4271
03:10:33,680 --> 03:10:34,960
EARLY STAGE INVESTIGATIVE

4272
03:10:34,960 --> 03:10:36,320
APPLICANTS FROM UNDER

4273
03:10:36,320 --> 03:10:40,080
REPRESENTED GROUPS AND IN THE

4274
03:10:40,080 --> 03:10:42,680
NCI, RO1 POOL AND EARLY STAGE

4275
03:10:42,680 --> 03:10:43,840
INVESTIGATORS AWARDEES FROM

4276
03:10:43,840 --> 03:10:47,760
UNDER REPRESENTED GROUPS IN THE

4277
03:10:47,760 --> 03:10:48,760
NCI/RO1 AWARD RULE AND LASTLY

4278
03:10:48,760 --> 03:10:50,480
THE MONITORING OF THE

4279
03:10:50,480 --> 03:10:54,560
PRODUCTIVITY OF THE FUNDING RO1

4280
03:10:54,560 --> 03:10:55,640
INVESTIGATORS AND THE NUMBER AND

4281
03:10:55,640 --> 03:10:57,480
QUALITY OF PUBLICATION AND

4282
03:10:57,480 --> 03:10:58,840
SCIENTIFIC PRESENTATIONS AND

4283
03:10:58,840 --> 03:11:00,480
SESSIONS WILL BE CRITICAL.

4284
03:11:00,480 --> 03:11:02,240
IN ADDITION TO THE SHORT TERM

4285
03:11:02,240 --> 03:11:04,240
MEASURES OF SUCCESS, WE ALSO

4286
03:11:04,240 --> 03:11:06,720
ANTICIPATE THAT THE RFA WILL

4287
03:11:06,720 --> 03:11:08,040
LEAD TO A SUN TAPED LONG-TERM

4288
03:11:08,040 --> 03:11:10,480
INCREASE IN DIVERSITY AND ALSO

4289
03:11:10,480 --> 03:11:13,040
TO INCREASE THE NUMBER OF UNDER

4290
03:11:13,040 --> 03:11:14,560
REPRESENTED GROUPS AND

4291
03:11:14,560 --> 03:11:16,320
LEADERSHIP POSITIONS AT VARIOUS

4292
03:11:16,320 --> 03:11:17,600
INSTITUTIONS AND THOSE THAT ARE

4293
03:11:17,600 --> 03:11:20,840
ENGAGE IN CANCER RESEARCH AND WE

4294
03:11:20,840 --> 03:11:22,160
ALSO ANTICIPATE THE MENTORING

4295
03:11:22,160 --> 03:11:23,720
THE GRADUATE STUDENTS POSTDOCS

4296
03:11:23,720 --> 03:11:27,000
AND NEW INVESTIGATORS BY THESE

4297
03:11:27,000 --> 03:11:32,520
NEW RO1 HOLDERS.

4298
03:11:32,520 --> 03:11:34,720
AND I WOULD LIKE TO GRATEFULLY

4299
03:11:34,720 --> 03:11:36,240
ACKNOWLEDGE THAT THE INSIGHTFUL

4300
03:11:36,240 --> 03:11:38,080
FEEDBACK IN COMMENTARY FROM OUR

4301
03:11:38,080 --> 03:11:41,280
BSA REVIEWERS AND IT WAS REALLY,

4302
03:11:41,280 --> 03:11:43,200
REALLY INSIGHTFUL AND I AM

4303
03:11:43,200 --> 03:11:48,600
PAIMPACTFUL.THERE WHY ITEMS THEL

4304
03:11:48,600 --> 03:11:49,920
ELABORATE ON WHEN THEY GIVE

4305
03:11:49,920 --> 03:11:51,600
THEIR REVIEW AND I'M SURE

4306
03:11:51,600 --> 03:11:54,960
THEY'LL HIGHLIGHT THOSE SHORTLY.

4307
03:11:54,960 --> 03:11:57,760
IN SUMMARY, I WOULD LIKE TO

4308
03:11:57,760 --> 03:11:59,560
POINT OUT THAT GREAT IDEAS LIKE

4309
03:11:59,560 --> 03:12:01,560
THIS ONE DON'T MATERIALIZE

4310
03:12:01,560 --> 03:12:03,120
OVERNIGHT OR IN ISOLATION.

4311
03:12:03,120 --> 03:12:05,200
THIS PROGRAM IS REALLY THE

4312
03:12:05,200 --> 03:12:15,680
CULMINATION OF MANY YEARS AND

4313
03:12:20,000 --> 03:12:21,440
AND THEIR SUPPORT AND

4314
03:12:21,440 --> 03:12:22,440
CONTRIBUTIONS OVER THE YEARS.

4315
03:12:22,440 --> 03:12:23,920
WHAT YOU SEE REFLECTED ON THIS

4316
03:12:23,920 --> 03:12:26,360
SLIDE IS REALLY THOSE WHO HAVE

4317
03:12:26,360 --> 03:12:35,640
BEEN ADD ROW  VOW KITS AND THISM

4318
03:12:35,640 --> 03:12:46,160
COME TO WITH THAT I'M HAPPY TO

4319
03:12:46,600 --> 03:12:56,840
ANSWER QUESTIONS.

4320
03:13:08,600 --> 03:13:10,040
THIS IS A KIND OF PROGRAM THAT

4321
03:13:10,040 --> 03:13:14,280
IS REALLY IMPORTANT TRYING TO

4322
03:13:14,280 --> 03:13:15,040
PROVIDE PEOPLE WITH

4323
03:13:15,040 --> 03:13:18,040
OPPORTUNITIES AND A GROUP OF US

4324
03:13:18,040 --> 03:13:22,520
MET WITH LEANNE AND WE REALLY

4325
03:13:22,520 --> 03:13:27,960
HAD NO REAL THINGS TO MODIFY IT

4326
03:13:27,960 --> 03:13:38,280
WITH ORB ANYTHING.

4327
03:13:42,720 --> 03:13:46,560
>> THIS IS CRITICALLY
NEEDED FOR

4328
03:13:46,560 --> 03:13:48,000
NUMBER WHO IS LOOKED AT FIGURES

4329
03:13:48,000 --> 03:13:52,680
OVER THE LAST 35 YEARS A IT

4330
03:13:52,680 --> 03:13:54,480
NEEDS TO BE LONGER AND MAYBE WE

4331
03:13:54,480 --> 03:13:58,160
CAN'T MAKE IT LONGER BECAUSE

4332
03:13:58,160 --> 03:13:59,960
WHAT WE ARE, IN ADDITION TO THE

4333
03:13:59,960 --> 03:14:03,160
OBVIOUS, FACING IS THE

4334
03:14:03,160 --> 03:14:07,480
DISCOURAGEMENT IN GENERAL FROM

4335
03:14:07,480 --> 03:14:17,920
MINORITY AND WE NEED TO BE

4336
03:14:45,080 --> 03:14:48,160
PREPARED TO EXTEND THIS BECAUSE

4337
03:14:48,160 --> 03:14:49,800
WE'LL NEED TO TALK TO THE

4338
03:14:49,800 --> 03:14:51,800
GRADUATE STUDENTS AND POSTDOCS

4339
03:14:51,800 --> 03:14:53,560
AND BRING THEM ALONG JUST SO YOU

4340
03:14:53,560 --> 03:14:55,120
DON'T NEED TO GO TO INDUSTRIES

4341
03:14:55,120 --> 03:14:56,880
AND YOU DON'T NEED TO GET TO

4342
03:14:56,880 --> 03:14:58,200
MEDICAL SCHOOL THERE'S A CAREER

4343
03:14:58,200 --> 03:14:59,480
PATH HERE.

4344
03:14:59,480 --> 03:15:06,560
SO WE NEED SUSTAINABILITY.

4345
03:15:06,560 --> 03:15:10,920
>> THIS IS INCREDIBLE.

4346
03:15:10,920 --> 03:15:13,080
I'M READY TO JUMP OUT OF MY

4347
03:15:13,080 --> 03:15:13,280
SEAT.

4348
03:15:13,280 --> 03:15:15,200
THIS IS LONG, LONG, LONG OVERDUE

4349
03:15:15,200 --> 03:15:16,480
OVER IN THE LAST COUPLE OF

4350
03:15:16,480 --> 03:15:21,320
DECADES, AS THE FUNDING LINE HAS

4351
03:15:21,320 --> 03:15:22,600
GOTTEN SMALLER AND SMALLER AND

4352
03:15:22,600 --> 03:15:24,320
CLOSER TO THE SINGLE DIGITS OF

4353
03:15:24,320 --> 03:15:26,480
FUNDING AT THE NCI AND YOU KNOW

4354
03:15:26,480 --> 03:15:27,640
THESE ARE THE INVESTIGATORS WHO

4355
03:15:27,640 --> 03:15:29,920
ARE GETTING SQUEEZED OUT AND IF

4356
03:15:29,920 --> 03:15:31,840
YOU ALL REMEMBER, I GUESS,

4357
03:15:31,840 --> 03:15:32,920
TEMPERATURES TWO DECADES AGO AND

4358
03:15:32,920 --> 03:15:34,880
THE MINORITY SUPPLEMENT STARTED

4359
03:15:34,880 --> 03:15:37,480
THAT WAS THE INTENTION OF THAT

4360
03:15:37,480 --> 03:15:39,640
WAS TO ADD THE MINORITIES ON TO

4361
03:15:39,640 --> 03:15:42,520
THE RO1s AND HOPEFULLY GET

4362
03:15:42,520 --> 03:15:44,040
THEM TO THE PLACE WHERE THEY

4363
03:15:44,040 --> 03:15:54,560
WOULD BE SUCCESSFUL AND GET A IT

4364
03:15:55,200 --> 03:15:56,920
DIDN'T HIT THE MARK AND THE LONG

4365
03:15:56,920 --> 03:15:58,320
RUNWAY IS REALLY IMPORTANT

4366
03:15:58,320 --> 03:16:01,040
BECAUSE THIS IS REALLY GOING TO

4367
03:16:01,040 --> 03:16:02,680
SOLIDIFY AND REALLY CLOSE SOME

4368
03:16:02,680 --> 03:16:04,920
HOLES IN OUR PIPELINE IF WE CAN

4369
03:16:04,920 --> 03:16:07,160
GET THE YOUNG INVESTIGATORS WITH

4370
03:16:07,160 --> 03:16:12,040
MORE 15RO1s IS AMAZING NUMBER

4371
03:16:12,040 --> 03:16:15,280
AND TO BE FUNDED PER YEAR AND IF

4372
03:16:15,280 --> 03:16:17,040
THOSE FOLKS HAVE LABS AND MENTOR

4373
03:16:17,040 --> 03:16:19,160
OTHER FOLKS IN THE 10 YEARS, WE

4374
03:16:19,160 --> 03:16:21,440
CAN MAKE ADVANCED THAT WE HAVE

4375
03:16:21,440 --> 03:16:22,760
NOT HAVE SEEN SO THE RETURN ON

4376
03:16:22,760 --> 03:16:23,880
INVESTMENT ON THIS IS GOING TO

4377
03:16:23,880 --> 03:16:26,680
BE TREMENDOUS AND THAT'S MY

4378
03:16:26,680 --> 03:16:27,520
COMMENT.

4379
03:16:27,520 --> 03:16:29,320
>> THANK YOU.

4380
03:16:29,320 --> 03:16:31,280
>> I'LL ECHO FANTASTIC.

4381
03:16:31,280 --> 03:16:33,520
MY QUESTION IS REALLY JUST FOR

4382
03:16:33,520 --> 03:16:35,320
CLARIFICATION, I REALLY LIKED

4383
03:16:35,320 --> 03:16:37,840
SEEING THE CONCEPT OF THE ESI

4384
03:16:37,840 --> 03:16:40,440
MULTI PI FOR THE RO1 AND

4385
03:16:40,440 --> 03:16:42,880
SOMETIMES ESIs CAN BE

4386
03:16:42,880 --> 03:16:44,600
DISADVANTAGED IF THEY GO MULTI

4387
03:16:44,600 --> 03:16:46,280
PI SO HOW ARE YOU THINKING ABOUT

4388
03:16:46,280 --> 03:16:47,680
THAT OR FOR THIS PARTICULAR

4389
03:16:47,680 --> 03:16:49,720
GROUP THAT WON'T MATTER AND THAT

4390
03:16:49,720 --> 03:16:51,320
IS IF THEY'RE THE CONTACT PI

4391
03:16:51,320 --> 03:16:55,360
THEY'RE THE CONTACT PI?

4392
03:16:55,360 --> 03:16:58,200
>> SO I'M HAPPY TO LET
SOME OF

4393
03:16:58,200 --> 03:17:00,280
MY COLLEAGUES CHIME IN AND

4394
03:17:00,280 --> 03:17:03,040
DURING THE CONVERSATION, IT WAS

4395
03:17:03,040 --> 03:17:04,200
ARTICULATED THAT SOMETIMES,

4396
03:17:04,200 --> 03:17:07,440
UNLESS THERE'S A MULTI-P.I.

4397
03:17:07,440 --> 03:17:08,680
DESIGNATION FOR THE PERSON WHO

4398
03:17:08,680 --> 03:17:12,040
IS UNDER REPRESENTED, THAT THEIR

4399
03:17:12,040 --> 03:17:14,200
CAN BE PERHAPS LESS OF AN

4400
03:17:14,200 --> 03:17:15,560
OPPORTUNITY SO TO REALLY

4401
03:17:15,560 --> 03:17:16,640
ENCOURAGE OWNERSHIP AND REALLY

4402
03:17:16,640 --> 03:17:19,480
TO ENCOURAGE THEM DRIVING IT AND

4403
03:17:19,480 --> 03:17:22,480
SO THAT WAS THE REASON OR THE

4404
03:17:22,480 --> 03:17:24,120
THINKING BEHIND HAVING THAT

4405
03:17:24,120 --> 03:17:27,520
DESIGNATION AND IF OTHERS WOULD

4406
03:17:27,520 --> 03:17:28,680
LIKE TO CHIME INTO ADD SOMETHING

4407
03:17:28,680 --> 03:17:31,400
ELSE, FEEL FREE.

4408
03:17:31,400 --> 03:17:34,840
>> KIM, THIS IS DOUG.

4409
03:17:34,840 --> 03:17:38,200
I WANT TO TRY TO COMPLIMENT WHAT

4410
03:17:38,200 --> 03:17:40,400
LEANNE IS SAYING AND THE

4411
03:17:40,400 --> 03:17:42,040
PREPORTION OF THE OUR AWARDS

4412
03:17:42,040 --> 03:17:45,280
THAT ARE MULTI P.I. AWARDS, HAS

4413
03:17:45,280 --> 03:17:47,760
BEEN GOING UP YEAR BY YEAR AND

4414
03:17:47,760 --> 03:17:58,320
THEY NOW REPRESENT ALL IT'S NOT

4415
03:18:04,600 --> 03:18:06,400
A RANDOMIZED CONTROL TRIAL.

4416
03:18:06,400 --> 03:18:11,560
THAT ESIs WHO ARE PART OF A

4417
03:18:11,560 --> 03:18:14,040
MULTI-MPI AWARD HAVE, IN

4418
03:18:14,040 --> 03:18:17,240
GENERAL, MORE DIFFICULTIES

4419
03:18:17,240 --> 03:18:19,840
GETTING A INDIVIDUAL AWARD

4420
03:18:19,840 --> 03:18:22,080
SUBSEQUENTLY THAN PIs WHO HAVE

4421
03:18:22,080 --> 03:18:31,320
GOTTEN INDIVIDUAL AWARDS.

4422
03:18:31,320 --> 03:18:32,920
IT DOESN'T MEAN IT WILL HAVE TO

4423
03:18:32,920 --> 03:18:34,160
HAPPEN BUT I THINK THAT THE

4424
03:18:34,160 --> 03:18:35,840
NOTION THAT LEANNE IS TALKING

4425
03:18:35,840 --> 03:18:39,640
ABOUT, OF MAKING SURE THAT THE

4426
03:18:39,640 --> 03:18:42,960
ESI IS THE CONTACT PI HOPEFULLY

4427
03:18:42,960 --> 03:18:46,320
WILL GO SUBSTANTIAL WAY TOWARDS

4428
03:18:46,320 --> 03:18:47,600
HELPING NOT JUST WITH GETTING

4429
03:18:47,600 --> 03:18:50,200
THIS AWARD BUT SUBSEQUENT AWARDS

4430
03:18:50,200 --> 03:18:53,480
WHICH OF COURSE, WILL BE

4431
03:18:53,480 --> 03:18:53,800
MERIT-BASED.

4432
03:18:53,800 --> 03:18:54,200
>> GREAT.

4433
03:18:54,200 --> 03:18:54,760
THANK YOU.

4434
03:18:54,760 --> 03:19:00,080
>> I THINK I MISSED YOU.

4435
03:19:00,080 --> 03:19:02,920
SORRY ABOUT THAT.

4436
03:19:02,920 --> 03:19:13,320
YOU ARE MUTED I THINK.

4437
03:19:14,680 --> 03:19:17,600
KEITH, DID YOU JUST SAY MY NAME?

4438
03:19:17,600 --> 03:19:19,800
>> I'M SORRY, I WAS TRYING
TO

4439
03:19:19,800 --> 03:19:24,680
GET EARL THE MIC.

4440
03:19:24,680 --> 03:19:32,160
I CAN'T HEAR YOU.

4441
03:19:32,160 --> 03:19:35,040
LET'S GO TO MELISSA REAL QUICK.

4442
03:19:35,040 --> 03:19:36,680
>> I JUST AM GOING TO ADD
A

4443
03:19:36,680 --> 03:19:37,160
COUPLE THINGS.

4444
03:19:37,160 --> 03:19:43,200
FIRST OF ALL, LEANNE, THAT WAS

4445
03:19:43,200 --> 03:19:44,640
SO NEEDED TO HAVE AN EXTENSION

4446
03:19:44,640 --> 03:19:48,480
OR JUST TO HAVE THIS OPPORTUNITY

4447
03:19:48,480 --> 03:19:49,520
FOR THIS PROGRAM SO I WANT TO

4448
03:19:49,520 --> 03:19:50,400
THANK AND YOU THANK THE

4449
03:19:50,400 --> 03:19:51,720
COMMITTEE FOR ENDORSING THIS

4450
03:19:51,720 --> 03:19:53,480
BECAUSE I REALLY THINK IT'S

4451
03:19:53,480 --> 03:19:53,960
IMPORTANT.

4452
03:19:53,960 --> 03:19:55,200
IN MY DEPARTMENT, I'VE JUST

4453
03:19:55,200 --> 03:19:58,880
HIRED QUITE A FEW NEW SYSTEM

4454
03:19:58,880 --> 03:20:01,160
PROFESSOR WHO URM AND YOU KNOW

4455
03:20:01,160 --> 03:20:02,920
WE'RE GOING THROUGH THEM PUTTING

4456
03:20:02,920 --> 03:20:13,320
IN RO1s AND HAVING TEAM

4457
03:20:16,920 --> 03:20:18,440
SCIENCE EFFORTS AND I THINK

4458
03:20:18,440 --> 03:20:19,960
THAT'S WHAT PROBABLY WOULD

4459
03:20:19,960 --> 03:20:22,280
REQUIRE THEM TO HAVE MULTIPLE

4460
03:20:22,280 --> 03:20:25,360
INVESTIGATORS ON THIS AND I

4461
03:20:25,360 --> 03:20:26,640
ENCOURAGE OUR JUNIOR

4462
03:20:26,640 --> 03:20:29,640
INVESTIGATORS TO HAVE MULTIPLE

4463
03:20:29,640 --> 03:20:30,800
P.I.s BUT FOR THEM TO BE THE

4464
03:20:30,800 --> 03:20:32,800
CONTACT P.I., SO I THINK IT'S

4465
03:20:32,800 --> 03:20:35,240
WHY WE WOULD SEE THEM AND THEM

4466
03:20:35,240 --> 03:20:37,600
BEING THE CONTACT PI IS JUST

4467
03:20:37,600 --> 03:20:39,520
REALLY IMPORTANT BUT IT SHOWS

4468
03:20:39,520 --> 03:20:41,280
TEAM SCIENCE AND THAT IS ALSO

4469
03:20:41,280 --> 03:20:42,480
REALLY IMPORTANT THING BUT I

4470
03:20:42,480 --> 03:20:44,600
ALSO WANTED TO REITERATE TO YOU

4471
03:20:44,600 --> 03:20:45,920
THE IMPORTANCE OF BRINGING

4472
03:20:45,920 --> 03:20:48,040
PEOPLE TOGETHER AND IF THERE'S

4473
03:20:48,040 --> 03:20:50,120
SYMPOSIUM AND OTHER THINGS BUT

4474
03:20:50,120 --> 03:20:52,520
THE IMPORTANCE TO HAVE

4475
03:20:52,520 --> 03:20:55,280
MENTORING, YOU KNOW, EVEN

4476
03:20:55,280 --> 03:20:56,400
MENTORING WITH THEIR OWN PEERS

4477
03:20:56,400 --> 03:20:58,200
AND PEER MENTORING OF OTHERS AND

4478
03:20:58,200 --> 03:20:59,400
I THINK A LOT OF THE

4479
03:20:59,400 --> 03:21:00,520
ORGANIZATIONS DO THAT AND I

4480
03:21:00,520 --> 03:21:02,800
THINK THAT'S IMPORTANT FOR US TO

4481
03:21:02,800 --> 03:21:04,120
MAKE SURE THAT WE KEEP AN EYE

4482
03:21:04,120 --> 03:21:05,680
OUT ON WHO IS GETTING THESE

4483
03:21:05,680 --> 03:21:07,440
AWARDS AND ESPECIALLY IN THIS

4484
03:21:07,440 --> 03:21:09,160
MECHANISMS SO THAT WE CAN MENTOR

4485
03:21:09,160 --> 03:21:11,520
AND MAKE SURE THAT THERE'S

4486
03:21:11,520 --> 03:21:13,840
SUCCESS AND THEY DON'T GO OFF TO

4487
03:21:13,840 --> 03:21:18,480
INDUSTRY AND WE LOSE THEM SO

4488
03:21:18,480 --> 03:21:19,320
THANK YOU.

4489
03:21:19,320 --> 03:21:21,040
>> THOSE ARE GREAT POINTS
AND

4490
03:21:21,040 --> 03:21:22,720
RECENTLY THE EARLY INVESTIGATORS

4491
03:21:22,720 --> 03:21:25,960
ADVANCEMENT PROGRAM THE EAIP WAS

4492
03:21:25,960 --> 03:21:29,160
ALSO FUNDED AND WE NOW HAVE A

4493
03:21:29,160 --> 03:21:31,120
CADRAY OF 20 PEOPLE AND EVERY

4494
03:21:31,120 --> 03:21:32,520
YEAR THERE'S ANOTHER 20, RIGHT

4495
03:21:32,520 --> 03:21:42,200
AND SO THE CULMINATION OF THE

4496
03:21:42,200 --> 03:21:43,600
GOAL TO CONNECT WITH MENTORING

4497
03:21:43,600 --> 03:21:47,080
BECAUSE WE UNDERSTAND THAT THE

4498
03:21:47,080 --> 03:21:57,640
EXPERTISE AND THE ABILITY TO AND

4499
03:22:10,320 --> 03:22:12,040
WITH THE EDUCATION PROGRAMS

4500
03:22:12,040 --> 03:22:13,920
WITHIN THE CANCER CENTER AND THE

4501
03:22:13,920 --> 03:22:15,320
PED THIS WILL BE REALLY

4502
03:22:15,320 --> 03:22:16,320
IMPORTANT AS WE LOOK AT

4503
03:22:16,320 --> 03:22:18,040
WORKFORCE IN OUR CANCER CENTERS

4504
03:22:18,040 --> 03:22:19,680
AND THE EDUCATIONAL PROGRAMS

4505
03:22:19,680 --> 03:22:22,800
THAT WE IMPLEMENT WITHIN OUR OWN

4506
03:22:22,800 --> 03:22:26,160
CANCER CENTERS AND INSTITUTIONS.

4507
03:22:26,160 --> 03:22:29,560
AS YOU CAN TELL FROM Dr. LOIS

4508
03:22:29,560 --> 03:22:31,280
COMMENTS WE HAVE THE SUPPORT OF

4509
03:22:31,280 --> 03:22:32,560
OUR LEADERSHIP AND THE

4510
03:22:32,560 --> 03:22:33,240
UNDERSTANDING IS I THINK THAT

4511
03:22:33,240 --> 03:22:37,200
MOVING FORWARD WE'RE IN A GREAT

4512
03:22:37,200 --> 03:22:37,520
PLACE.

4513
03:22:37,520 --> 03:22:41,200
LET'S TRY AGAIN.

4514
03:22:41,200 --> 03:22:42,840
>> STILL NO.

4515
03:22:42,840 --> 03:22:44,440
IT'S FRUSTRATING.

4516
03:22:44,440 --> 03:22:49,040
WE MIGHT HAVE TO RESORT TO A

4517
03:22:49,040 --> 03:22:55,080
CHAT COMMENT.

4518
03:22:55,080 --> 03:23:05,560
>> LEANNE THANK YOU FOR
THE

4519
03:23:07,600 --> 03:23:11,320
PROGRAM AND I THINK IT'S

4520
03:23:11,320 --> 03:23:15,400
IMPORTANT AND I GUESS WHAT IS

4521
03:23:15,400 --> 03:23:16,840
GOING THROUGH MY MIND, WHEN I

4522
03:23:16,840 --> 03:23:18,800
THINK ABOUT SUCCESS, WE OFTEN

4523
03:23:18,800 --> 03:23:20,840
THINK ABOUT IT AS THE INDIVIDUAL

4524
03:23:20,840 --> 03:23:22,680
EFFORTS SO THE PERSON THAT

4525
03:23:22,680 --> 03:23:25,480
DIDN'T HAVE WHAT IT TAKES TO BE

4526
03:23:25,480 --> 03:23:26,880
SUCCESSFUL AND BUT TIME AND TIME

4527
03:23:26,880 --> 03:23:27,720
AGAIN MY EXPERIENCE SUGGESTS

4528
03:23:27,720 --> 03:23:30,760
THAT A LOT OF THESE

4529
03:23:30,760 --> 03:23:31,480
INSTITUTIONAL POINTS AND THERE

4530
03:23:31,480 --> 03:23:32,920
ARE SUPPORT THAT PEOPLE GET WITH

4531
03:23:32,920 --> 03:23:35,600
THE INSTITUTIONS AND INTERESTS

4532
03:23:35,600 --> 03:23:37,760
THAT EXIST, AND I KNOW IT MADE

4533
03:23:37,760 --> 03:23:39,360
THIS POINT BEFORE BUT IT WOULD

4534
03:23:39,360 --> 03:23:42,000
BE IMPORTANT IN THINGS THAT WE

4535
03:23:42,000 --> 03:23:44,240
CANNOT CONTROL AND A CONTROL IN

4536
03:23:44,240 --> 03:23:46,240
INSTITUTION BUZZ IT'S REALLY

4537
03:23:46,240 --> 03:23:47,640
IMPORTANT TO ADD THAT ON THE

4538
03:23:47,640 --> 03:23:54,600
RADAR IN TERMS OF HOW PEOPLE

4539
03:23:54,600 --> 03:23:55,920
REQUEST NAVIGATE IT TO GET

4540
03:23:55,920 --> 03:23:57,680
THROUGH THE PROCESS OF GOING

4541
03:23:57,680 --> 03:24:00,720
FROM ONE ARROW ON TO THE NEXT

4542
03:24:00,720 --> 03:24:02,520
AND SO I JUST WANT TO PUT THIS

4543
03:24:02,520 --> 03:24:04,680
ON THE RADAR.

4544
03:24:04,680 --> 03:24:05,720
I KNOW YOU KNOW THIS ALREADY BUT

4545
03:24:05,720 --> 03:24:10,680
I WANT TO RAISE IT AS WELL.

4546
03:24:10,680 --> 03:24:10,960
>> GREAT.

4547
03:24:10,960 --> 03:24:11,240
THANK YOU.

4548
03:24:11,240 --> 03:24:13,560
WE GOT THE COMMENT ON THE CHAT.

4549
03:24:13,560 --> 03:24:18,000
ANY FURTHER QUESTIONS?

4550
03:24:18,000 --> 03:24:21,880
WE CAN MOVE TO VOTING.

4551
03:24:21,880 --> 03:24:22,120
MOTION.

4552
03:24:22,120 --> 03:24:23,440
>> YEAH.

4553
03:24:23,440 --> 03:24:25,360
I MAKE A MOTION THAT WE PASS IT

4554
03:24:25,360 --> 03:24:27,680
AND AGAIN, I WANT TO THANK

4555
03:24:27,680 --> 03:24:29,160
LEANNE AND THE GROUP SHE WORKS

4556
03:24:29,160 --> 03:24:32,280
WITH FOR DOING THIS.

4557
03:24:32,280 --> 03:24:33,440
>> THAT'S A MOTION FOR
APPROVAL.

4558
03:24:33,440 --> 03:24:35,320
>> SECOND.

4559
03:24:35,320 --> 03:24:35,600
>> SECOND.

4560
03:24:35,600 --> 03:24:43,840
>> AND ANY FURTHER
DISCUSSION?

4561
03:24:43,840 --> 03:24:44,360
OK.

4562
03:24:44,360 --> 03:24:45,840
THE MOTION IS FORAY TRAVEL

4563
03:24:45,840 --> 03:24:53,760
LA FOR APPROVAL.ANY DISAPPROVALF

4564
03:24:53,760 --> 03:24:54,400
HANDS?

4565
03:24:54,400 --> 03:25:01,760
ANY ABSTENTIONS?

4566
03:25:01,760 --> 03:25:01,960
NONE.

4567
03:25:01,960 --> 03:25:02,280
PAULETTE.

4568
03:25:02,280 --> 03:25:03,680
>> OK IT'S UNANIMOUS.

4569
03:25:03,680 --> 03:25:04,320
>> VERY GOOD.

4570
03:25:04,320 --> 03:25:06,000
WE ARE UP TO OUR FINAL ITEM ON

4571
03:25:06,000 --> 03:25:11,320
THE BSA AGENDA WHICH IS THAT WE

4572
03:25:11,320 --> 03:25:14,080
NEED TO CONSIDER THE PAR REISSUE

4573
03:25:14,080 --> 03:25:17,040
CONCEPT AND WE'LL VOTE TO CON TO

4574
03:25:17,040 --> 03:25:20,480
CONQTO CONCUROR NOT CONCUR.

4575
03:25:20,480 --> 03:25:23,800
>> I'M GOING TO BE VERY
BRIEF.

4576
03:25:23,800 --> 03:25:25,880
WHEN I SAY VERY BRIEF I MEAN

4577
03:25:25,880 --> 03:25:26,960
VERY BRIEF.

4578
03:25:26,960 --> 03:25:30,080
THERE ARE NINE REISSUE PARs

4579
03:25:30,080 --> 03:25:36,240
BUT THE BSA CONSIDERATION TODAY

4580
03:25:36,240 --> 03:25:37,600
AND THE LIST AND THE LINK WAS

4581
03:25:37,600 --> 03:25:39,800
SENT TO BOTH BOARDS PRIOR TO THE

4582
03:25:39,800 --> 03:25:40,520
MEETING.

4583
03:25:40,520 --> 03:25:42,800
AND IF YOU RECALL THIS IS NOW

4584
03:25:42,800 --> 03:25:47,720
NIH POLICY WHICH WAS ESTABLISHED

4585
03:25:47,720 --> 03:25:50,760
IN 2019.

4586
03:25:50,760 --> 03:25:52,560
AND ADDITIONAL, THE BSA

4587
03:25:52,560 --> 03:25:57,760
REQUESTED METRICS EVALUATING THE

4588
03:25:57,760 --> 03:25:59,920
P.A.R. AND IT INCLUDED METRICS

4589
03:25:59,920 --> 03:26:02,600
AS SUCH THE LIST PROVIDED BEFORE

4590
03:26:02,600 --> 03:26:05,560
TODAY'S MEETING ARE ALSO

4591
03:26:05,560 --> 03:26:10,200
INCLUDED LINKS TO EACH OF THE

4592
03:26:10,200 --> 03:26:16,000
CURRENT EPO As, IN THAT

4593
03:26:16,000 --> 03:26:17,600
REGARD, AND AS CHIEF JUSTICE OF

4594
03:26:17,600 --> 03:26:20,840
THE BAS WILL VOTE ON BLOCK TO

4595
03:26:20,840 --> 03:26:22,560
CONQUER WITH THE REISSUANCES.

4596
03:26:22,560 --> 03:26:25,360
I SHOULD NOTE THAT THE NAME OF

4597
03:26:25,360 --> 03:26:28,680
EACH P.A.R. REISSUANCE, WILL BE

4598
03:26:28,680 --> 03:26:30,200
LISTED IN THE MINUTES.

4599
03:26:30,200 --> 03:26:34,760
ARE THERE QUESTIONS?

4600
03:26:34,760 --> 03:26:36,840
>> IF THERE ARE NO
QUESTIONS,

4601
03:26:36,840 --> 03:26:39,200
PLEASE CALL FOR THE VOTE.

4602
03:26:39,200 --> 03:26:40,360
>> WE WILL HAVE TIME FOR

4603
03:26:40,360 --> 03:26:42,440
DISCUSSION IN THE MIDST OF

4604
03:26:42,440 --> 03:26:44,880
VOTING AS WE ALWAYS DO IN TERMS

4605
03:26:44,880 --> 03:26:48,280
OF RULES OF ORDER AND I THINK I

4606
03:26:48,280 --> 03:26:56,160
GUESS I'LL ASK FOR A MOTION OR

4607
03:26:56,160 --> 03:26:57,520
PERHAPS I'LL START SINCE WE

4608
03:26:57,520 --> 03:26:59,160
HAVEN'T HAD DISCUSSION YET.

4609
03:26:59,160 --> 03:27:02,800
MY MOTION WOULD BE TO CONCUR TO

4610
03:27:02,800 --> 03:27:05,160
MAKE IT A SECOND ON THAT.

4611
03:27:05,160 --> 03:27:07,520
>> AS A CHAIR YOU SHOULD
MAKE

4612
03:27:07,520 --> 03:27:08,680
THE MOTION OR SOMEONE ELSE MAKE

4613
03:27:08,680 --> 03:27:09,040
THE MOTION.

4614
03:27:09,040 --> 03:27:11,160
>> I WAS TRYING TO MOVE US

4615
03:27:11,160 --> 03:27:11,360
ALONG.

4616
03:27:11,360 --> 03:27:14,160
>> ANOTHER BAS MEMBER STEP

4617
03:27:14,160 --> 03:27:15,200
FORWARD.

4618
03:27:15,200 --> 03:27:15,520
>> SO MOVED.

4619
03:27:15,520 --> 03:27:17,480
>> MOVE TO CONCUR.

4620
03:27:17,480 --> 03:27:18,480
>> THANK YOU.

4621
03:27:18,480 --> 03:27:19,400
>> SECOND.

4622
03:27:19,400 --> 03:27:19,600
>>

4623
03:27:19,600 --> 03:27:22,280
>> GREAT OK I SEE THAT AND
BOB,

4624
03:27:22,280 --> 03:27:22,640
GREAT.

4625
03:27:22,640 --> 03:27:25,720
SO NOW TIME FOR DISCUSSION.

4626
03:27:25,720 --> 03:27:28,800
HOWARD AND I HAD A SIDE BAR

4627
03:27:28,800 --> 03:27:30,760
GOING INTO TODAY'S CONVERSATION

4628
03:27:30,760 --> 03:27:34,240
SOHOARD YOU HAD A POINT OR TWO

4629
03:27:34,240 --> 03:27:35,360
TO RAISE.

4630
03:27:35,360 --> 03:27:39,200
>> YEAH, ABOUT THE P.A.R.
THAT

4631
03:27:39,200 --> 03:27:42,160
IS DEALING WITH THE RENEWAL OF

4632
03:27:42,160 --> 03:27:44,800
RESEARCH AND CLINICAL --

4633
03:27:44,800 --> 03:27:46,440
>> YOU ARE BREAKING UP.

4634
03:27:46,440 --> 03:27:48,480
WE CAN'T HEAR YOU.

4635
03:27:48,480 --> 03:27:51,000
>> OK.

4636
03:27:51,000 --> 03:27:56,680
THE ONE THAT INCLUDES CLINICAL

4637
03:27:56,680 --> 03:27:58,760
TRIALS, IT IS -- I THINK QUITE

4638
03:27:58,760 --> 03:28:02,440
IF YOU DO THE MATH, IT'S A LOW

4639
03:28:02,440 --> 03:28:06,040
BUDGET PER GRANT AND IT'S LIKE

4640
03:28:06,040 --> 03:28:07,960
200,000 CAP PER YEAR FOR TWO

4641
03:28:07,960 --> 03:28:09,800
YEARS AND AS I HEAD IT IN TERMS

4642
03:28:09,800 --> 03:28:11,200
OF THE NUMBER OF GRANTS VERSUS

4643
03:28:11,200 --> 03:28:13,280
AGAINST THE NUMBER OF DOLLARS.

4644
03:28:13,280 --> 03:28:18,480
AND I JUST WANT TO INVITE NCI

4645
03:28:18,480 --> 03:28:20,200
VERY BRIEFLY HOW TO OPTIMIZE THE

4646
03:28:20,200 --> 03:28:22,680
COST EFFICIENCIES AND THE

4647
03:28:22,680 --> 03:28:25,560
LIKELIHOOD OF PERFORMANCE AND

4648
03:28:25,560 --> 03:28:28,040
ALSO THE LIKELY HID OF

4649
03:28:28,040 --> 03:28:31,320
SUBSEQUENT LARGER FUNDING AND

4650
03:28:31,320 --> 03:28:32,320
PARTNERSHIP WHICH IS SOMETHING

4651
03:28:32,320 --> 03:28:34,040
LIKE THIS IS REALLY HEADED

4652
03:28:34,040 --> 03:28:36,160
TOWARDS AN INDUSTRY PARTNERSHIP

4653
03:28:36,160 --> 03:28:38,320
TO BRING IT FORWARD TO THE MORE

4654
03:28:38,320 --> 03:28:39,960
COSTLY TRIALS AND I MEAN THIS

4655
03:28:39,960 --> 03:28:50,480
BUDGET MIGHT BE GOOD FOR UP TO

4656
03:28:52,560 --> 03:28:55,200
PHASE 1A BUT IT MIGHT BE OTHER

4657
03:28:55,200 --> 03:28:56,640
RESOURCES AND I DO HAVE A

4658
03:28:56,640 --> 03:28:58,200
QUESTION ABOUT OTHER RESOURCES,

4659
03:28:58,200 --> 03:29:01,480
AND THAT IS WHETHER THE

4660
03:29:01,480 --> 03:29:03,320
RECIPIENTS WILL BE ORIENTED

4661
03:29:03,320 --> 03:29:05,520
ABOUT OR ORIENTED ABOUT AND HAVE

4662
03:29:05,520 --> 03:29:13,880
ACCESS TO THE NO OR LOW COST

4663
03:29:13,880 --> 03:29:14,200
NCI.

4664
03:29:14,200 --> 03:29:16,200
SEEING THE MATURING AND THAT

4665
03:29:16,200 --> 03:29:18,680
HAVE IMMUNO ONCOLOGY BIOMARKERS

4666
03:29:18,680 --> 03:29:23,600
THAT ARE VALIDATED AND THINGS

4667
03:29:23,600 --> 03:29:27,120
LIKE THE PEDIATRIC TESTING

4668
03:29:27,120 --> 03:29:30,120
CONSORTIUM OR THE NCI TISSUE

4669
03:29:30,120 --> 03:29:31,680
REPOSITORY IN THESE UPDATING

4670
03:29:31,680 --> 03:29:32,640
DATA COMMONS.

4671
03:29:32,640 --> 03:29:34,160
WILL THESE RECIPIENTS HAVE THE

4672
03:29:34,160 --> 03:29:38,120
KIND OF ACCESS TO THESE THINGS

4673
03:29:38,120 --> 03:29:40,320
WHERE TECH GET THEM AT NO COST

4674
03:29:40,320 --> 03:29:42,960
IF THEY'RE PROPERLY ORIENTED HOW

4675
03:29:42,960 --> 03:29:44,560
TO INTEGRATE THEM AND --

4676
03:29:44,560 --> 03:29:49,360
>> HOWARD, I DON'T MEAN TO
CUT

4677
03:29:49,360 --> 03:29:51,000
YOU OFF.

4678
03:29:51,000 --> 03:29:55,160
THIS PROGRAM ANNOUNCEMENT FOR A

4679
03:29:55,160 --> 03:29:56,400
SPECIFIC IN TERMS OF REFERRAL

4680
03:29:56,400 --> 03:29:59,240
AND REVIEW.

4681
03:29:59,240 --> 03:30:02,400
P.A.R.s DO NOT HAVE SET ASIDE

4682
03:30:02,400 --> 03:30:02,760
DOLLARS.

4683
03:30:02,760 --> 03:30:05,080
AS MUCH, WHEN THE APPLICATIONS

4684
03:30:05,080 --> 03:30:10,080
COME IN, THE LEADERSHIP WILL

4685
03:30:10,080 --> 03:30:14,520
ASCERTAIN OR MAKE A DECISION AS

4686
03:30:14,520 --> 03:30:16,600
TO WHAT THE LEDGER WILL BE SO

4687
03:30:16,600 --> 03:30:19,480
THE ISSUES ARE BRINGING UP NOW,

4688
03:30:19,480 --> 03:30:25,120
WOULD BE MORE GERMANE TO UO1s

4689
03:30:25,120 --> 03:30:28,040
OR MORE GERMANE TO LARGE

4690
03:30:28,040 --> 03:30:29,960
CLINICAL TRIALS THAT ARE

4691
03:30:29,960 --> 03:30:33,240
ESTABLISHED INITIALLY.

4692
03:30:33,240 --> 03:30:33,440
OK.

4693
03:30:33,440 --> 03:30:39,600
>> IF YOU WOULD LIKE TO
DISCUSS

4694
03:30:39,600 --> 03:30:41,600
THIS OFF LINE, AT ANOTHER TIME,

4695
03:30:41,600 --> 03:30:44,680
PLEASE REACH OUT TO ME.

4696
03:30:44,680 --> 03:30:47,120
>> O. I JUST WANT TO OFFER
THAT

4697
03:30:47,120 --> 03:30:49,120
THESE KINDS OF TOPICS I'M VERY

4698
03:30:49,120 --> 03:30:51,160
COMFORTABLE WITH AND I WORKED ON

4699
03:30:51,160 --> 03:30:53,000
THIS WITHIN INDUSTRY WITHIN

4700
03:30:53,000 --> 03:30:53,720
SMALL GRANTS AND.

4701
03:30:53,720 --> 03:30:57,080
>> I UNDERSTAND BUT
PROGRAM

4702
03:30:57,080 --> 03:30:58,240
ANNOUNCEMENTS ARE NOT AT THAT

4703
03:30:58,240 --> 03:30:58,440
LEVEL.

4704
03:30:58,440 --> 03:31:02,160
>> OK.

4705
03:31:02,160 --> 03:31:05,080
>> I AM MISREADING WHAT
WAS SAID

4706
03:31:05,080 --> 03:31:07,800
TO ME FOR REVIEW.

4707
03:31:07,800 --> 03:31:10,080
YOU DO THE MATH ON IT THE NUMBER

4708
03:31:10,080 --> 03:31:12,480
OF DOLLARS ALLOCATE TODAY THAT

4709
03:31:12,480 --> 03:31:13,600
P.A.R. ROW NEWELL AGAINST THE

4710
03:31:13,600 --> 03:31:15,160
NUMBER OF TARGET GRANTS --

4711
03:31:15,160 --> 03:31:17,640
>> I JUST INDICATED THAT
THERE

4712
03:31:17,640 --> 03:31:22,520
ARE NO SET A SIDES PROGRAM

4713
03:31:22,520 --> 03:31:24,520
ANNOUNCEMENTS.

4714
03:31:24,520 --> 03:31:29,000
WE CAN DISCUSS THIS AT ANOTHER

4715
03:31:29,000 --> 03:31:31,120
TIME.

4716
03:31:31,120 --> 03:31:31,280
OK.

4717
03:31:31,280 --> 03:31:31,400
>>

4718
03:31:31,400 --> 03:31:36,480
>> ANY OTHER DISCUSSION
ITEMS?

4719
03:31:36,480 --> 03:31:42,280
>> MOVE TO FINAL VOTING
AND THE

4720
03:31:42,280 --> 03:31:44,480
MOTION IS FOR CONCURRENCE.

4721
03:31:44,480 --> 03:31:47,000
LOOKING FOR ANY VOTES OF NON

4722
03:31:47,000 --> 03:31:54,200
CONCURRENCE AMONGST PSA MEMBERS?

4723
03:31:54,200 --> 03:32:02,120
ANY ABSTENTIONS?

4724
03:32:02,120 --> 03:32:02,360
PAULETTE.

4725
03:32:02,360 --> 03:32:04,960
>> OK.

4726
03:32:04,960 --> 03:32:07,000
I A APOLOGIZE IF I WAS TOO

4727
03:32:07,000 --> 03:32:07,240
BRIEF.

4728
03:32:07,240 --> 03:32:08,240
>> THANK YOU SO MUCH.

4729
03:32:08,240 --> 03:32:09,800
JOHN, A POLL GOES FOR THE RATHER

4730
03:32:09,800 --> 03:32:12,880
DELAYED PASSING OF THE BATON BUT

4731
03:32:12,880 --> 03:32:16,200
IT IS YOURS THE REST OF THE WAY.

4732
03:32:16,200 --> 03:32:20,680
>> OK, KEITH.

4733
03:32:20,680 --> 03:32:23,320
THANK YOU.

4734
03:32:23,320 --> 03:32:24,960
SO THE BOARDS WILL NOW CONSIDER

4735
03:32:24,960 --> 03:32:30,560
ON GOING AND NEW BUSINESS AND WE

4736
03:32:30,560 --> 03:32:32,960
HAVE TWO NCAB SUBCOMMITTEE

4737
03:32:32,960 --> 03:32:34,680
MEETING ON MONDAY THE 13t

4738
03:32:34,680 --> 03:32:35,440
13th THAT INCLUDED THE

4739
03:32:35,440 --> 03:32:37,200
PLANNING AND BUDGET SUBCOMMITTEE

4740
03:32:37,200 --> 03:32:38,920
AS WELL AS THE AD HOC

4741
03:32:38,920 --> 03:32:40,360
SUBCOMMITTEE ON POPULATION

4742
03:32:40,360 --> 03:32:43,440
SCIENCES OF EPIDEMIOLOGY AND

4743
03:32:43,440 --> 03:32:46,080
DISPARITIES AND THE PLANNING AND

4744
03:32:46,080 --> 03:32:47,120
BUDGET SUBCOMMITTEE CHAIR IS

4745
03:32:47,120 --> 03:32:49,160
Dr. ANNA BARKER AND SHE WILL

4746
03:32:49,160 --> 03:32:51,640
GIVE THE REPORT.

4747
03:32:51,640 --> 03:32:53,880
>> THANK YOU, JOHN.

4748
03:32:53,880 --> 03:32:55,480
FIRST THANK YOU TO THE COMMITTEE

4749
03:32:55,480 --> 03:32:59,360
AND SUBCOMMITTEE HAD SOME GOOD

4750
03:32:59,360 --> 03:33:01,720
COMMENTS AND ALSO CERTAINLY TO

4751
03:33:01,720 --> 03:33:05,160
PAT WHO SUPPORTS OUR

4752
03:33:05,160 --> 03:33:06,840
SUBCOMMITTEE ALONG WITH MK WHO

4753
03:33:06,840 --> 03:33:09,000
DOES A GREAT JOB OF ACTUALLY

4754
03:33:09,000 --> 03:33:11,680
EXPLAIN WHAT IS IS EXTRAORDINARY

4755
03:33:11,680 --> 03:33:13,840
COMPLEX PROCESS, ESPECIALLY IN

4756
03:33:13,840 --> 03:33:16,840
2022 AND 2023 AND JUST A FEW

4757
03:33:16,840 --> 03:33:18,600
HIGHLIGHTS THAT THE REPORT IS

4758
03:33:18,600 --> 03:33:20,360
QUITE COMPLETE.

4759
03:33:20,360 --> 03:33:22,280
AGAIN, GREAT JOB ON THE REPORT

4760
03:33:22,280 --> 03:33:24,680
AND I WANT TO POINT OUT A FEW

4761
03:33:24,680 --> 03:33:27,240
THINGS.

4762
03:33:27,240 --> 03:33:30,600
2022 IS -- I HOPE IT WILL BE THE

4763
03:33:30,600 --> 03:33:32,360
CONTINUATION OF A TREND AND IF

4764
03:33:32,360 --> 03:33:34,880
YOU GO BACK TO 2020 IN TERMS OF

4765
03:33:34,880 --> 03:33:37,480
OUR PAYLINE, YOU WILL RECALL WE

4766
03:33:37,480 --> 03:33:39,960
STARTED WHEN A PAYLINE OF 8%

4767
03:33:39,960 --> 03:33:43,080
WHICH IS PRETTY AWFUL AND WE

4768
03:33:43,080 --> 03:33:44,800
COMMITTED, WE COMMITTED FUNDS TO

4769
03:33:44,800 --> 03:33:45,960
ACTUALLY RAISE THAT PAYLINE AND

4770
03:33:45,960 --> 03:33:47,960
WITH THE GOAL OF ACTUALLY

4771
03:33:47,960 --> 03:33:51,280
GETTING THE 15% BY 2025.

4772
03:33:51,280 --> 03:33:55,440
AND WE'VE ARRIVED AT 11% AND AT

4773
03:33:55,440 --> 03:33:57,480
SOME COST AND ACTUALLY AND THAT

4774
03:33:57,480 --> 03:34:00,640
IS ALWAYS IN THE OUT YEAR SO YOU

4775
03:34:00,640 --> 03:34:04,040
HAVE FOUR MORE YEARS AND ANOTHER

4776
03:34:04,040 --> 03:34:07,200
FIVE FOR '21, ET CETERA.

4777
03:34:07,200 --> 03:34:08,920
SOME THINGS HAVE HAPPENED AT OUR

4778
03:34:08,920 --> 03:34:10,400
HAPPENING THAT ARE LIKELY TO

4779
03:34:10,400 --> 03:34:15,000
IMPACT THAT AND TO TURNING TO

4780
03:34:15,000 --> 03:34:18,200
2022 WE GOT A BUDGET IN MARCH.

4781
03:34:18,200 --> 03:34:22,000
IT WAS -- WE GOT 5.4% INCREASE

4782
03:34:22,000 --> 03:34:26,880
AND NIH GOT A 7.6% INCREASE AND

4783
03:34:26,880 --> 03:34:29,280
IN THAT INCREASE, WE HAVE TO BE

4784
03:34:29,280 --> 03:34:30,840
A LITTLE CAUTIOUS ABOUT

4785
03:34:30,840 --> 03:34:31,880
INTERPRETING THE NUMBERS BECAUSE

4786
03:34:31,880 --> 03:34:35,600
IF YOU LOOK AT THE INCREASE IT

4787
03:34:35,600 --> 03:34:39,880
HAS FUNDS IN THERE FROM THE

4788
03:34:39,880 --> 03:34:41,200
MOONSHOT, 194 MILLION AND WE

4789
03:34:41,200 --> 03:34:42,400
HAVE $50 MILLION FOR THE

4790
03:34:42,400 --> 03:34:44,920
PEDIATRIC INITIATIVE AND SO OUR

4791
03:34:44,920 --> 03:34:47,160
BASE BUDGET ACTUALLY IS

4792
03:34:47,160 --> 03:34:49,360
SUBSTANTIALLY LESS THAN THE

4793
03:34:49,360 --> 03:34:54,080
$6.9 BILLION THAT YOU SEE AND

4794
03:34:54,080 --> 03:34:55,480
THE NEWS IS THAT NEXT YEAR IS

4795
03:34:55,480 --> 03:34:56,480
THE LAST YEAR FOR THE

4796
03:34:56,480 --> 03:34:58,400
APPROPRIATION FOR THE MOONSHOT.

4797
03:34:58,400 --> 03:34:59,680
AND WE HAVE A LOT OF

4798
03:34:59,680 --> 03:35:01,040
INFRASTRUCTURE SURROUNDING THAT

4799
03:35:01,040 --> 03:35:04,760
BUT AS DOUG POINTED OUT, THE NCI

4800
03:35:04,760 --> 03:35:06,880
HAS DONE THAT IN AN

4801
03:35:06,880 --> 03:35:07,960
EXTRAORDINARY FRUGAL WAY AND IN

4802
03:35:07,960 --> 03:35:10,560
TERMS OF NOT HAVING A LOT OF

4803
03:35:10,560 --> 03:35:11,320
ADDITIONAL FUNDS THAT ARE GOING

4804
03:35:11,320 --> 03:35:14,360
TO BE APPLIED DUE TO

4805
03:35:14,360 --> 03:35:15,080
ADMINISTRATION.

4806
03:35:15,080 --> 03:35:17,520
SO I COMMEND NCI FOR THAT.

4807
03:35:17,520 --> 03:35:21,960
WE'RE HOPEFUL THAT MOONSHOT 2.0

4808
03:35:21,960 --> 03:35:23,800
WILL COME BACK IN JUST A MINUTE,

4809
03:35:23,800 --> 03:35:25,600
WILL PICK UP THAT AND MAYBE ANNE

4810
03:35:25,600 --> 03:35:29,400
MORE FUND FORGERON THE NCI SO

4811
03:35:29,400 --> 03:35:32,040
2022, I THINK WE CAN COUNT IN

4812
03:35:32,040 --> 03:35:35,000
THE WIN COLUMN FOR US.

4813
03:35:35,000 --> 03:35:37,680
IF WE LOCK FORWARD TO 2023, THIS

4814
03:35:37,680 --> 03:35:40,240
IS PROBABLY ONE OF THE MOST

4815
03:35:40,240 --> 03:35:41,480
UNUSUAL YEARS IN TERMS OF

4816
03:35:41,480 --> 03:35:43,880
UNCERTAINTY THAT I'VE SEEN.

4817
03:35:43,880 --> 03:35:45,560
SO, WE HAVE ONE, WE HAVE A

4818
03:35:45,560 --> 03:35:47,480
BUDGET THAT WE WERE GIVEN IN

4819
03:35:47,480 --> 03:35:49,440
MARCH AND UNFORTUNATELY THE

4820
03:35:49,440 --> 03:35:52,360
PRESIDENT, AS M.K. AND PATRICK

4821
03:35:52,360 --> 03:35:54,240
BOW POINTED OUT THAT BUDGET WAS

4822
03:35:54,240 --> 03:35:56,200
CREATED BY THE PRESIDENT ALL THE

4823
03:35:56,200 --> 03:35:59,080
WAY LONG BEFORE THE OMNIBUS PASS

4824
03:35:59,080 --> 03:36:00,600
IN MARCH SO THE BUDGET THAT WE

4825
03:36:00,600 --> 03:36:04,560
HAVE ON THE TABLE IS FUELLY

4826
03:36:04,560 --> 03:36:06,040
SUBSTANTIALLY LESS THAN WE WOULD

4827
03:36:06,040 --> 03:36:08,520
LIKE BY $199 MILLION IN TERMS OF

4828
03:36:08,520 --> 03:36:13,080
A LOSS AND SO WE BELIEVE, AS HAS

4829
03:36:13,080 --> 03:36:16,680
HAPPENED SO OFTEN IN THE LAST

4830
03:36:16,680 --> 03:36:18,480
SINCE THE CLINTON ERA, CONGRESS

4831
03:36:18,480 --> 03:36:20,600
TENDS TO MOVE THESE BUDGETS UP,

4832
03:36:20,600 --> 03:36:23,200
ESPECIALLY AROUND THE NCI AND SO

4833
03:36:23,200 --> 03:36:25,560
WE'RE DEPENDING ON THAT

4834
03:36:25,560 --> 03:36:27,480
HAPPENING AND WE'RE NOT LOOKING

4835
03:36:27,480 --> 03:36:29,120
FORWARD TO ACTUALLY HAVING OUR

4836
03:36:29,120 --> 03:36:32,840
BUDGET CUTS SUBSTANTIALLY IN

4837
03:36:32,840 --> 03:36:33,240
2023.

4838
03:36:33,240 --> 03:36:34,920
SO I WANT TO TURN THOUGH TO A

4839
03:36:34,920 --> 03:36:36,920
COUPLE ISSUES THAT SHOULD BE ALL

4840
03:36:36,920 --> 03:36:39,120
ON EVERYONE'S PLATE AND

4841
03:36:39,120 --> 03:36:40,520
ESPECIALLY THOSE FOLKS IN THE

4842
03:36:40,520 --> 03:36:43,240
AUDIENCE TODAY WHO ARE THINKING

4843
03:36:43,240 --> 03:36:46,880
ABOUT OUR NCI BUDGET.

4844
03:36:46,880 --> 03:36:48,480
WE HAVE THIS ENORMOUS INCREASE

4845
03:36:48,480 --> 03:36:49,880
IN APPLICATIONS AND THAT IS NOT

4846
03:36:49,880 --> 03:36:52,960
GOING TO CHANGE.

4847
03:36:52,960 --> 03:36:54,360
BECAUSE THE THINGS THAT W JUST

4848
03:36:54,360 --> 03:36:56,920
 ON BSA WE'VE NEVER HAD

4849
03:36:56,920 --> 03:36:57,760
MORE OPPORTUNITIES AND WE'VE

4850
03:36:57,760 --> 03:37:00,680
NEVER HAD MORE OPPORTUNITIES TO

4851
03:37:00,680 --> 03:37:02,320
BRING BETTER ADVANCE TO PATIENTS

4852
03:37:02,320 --> 03:37:03,840
AND THAT'S GOING TO CONTINUE

4853
03:37:03,840 --> 03:37:06,800
PLUS WE HAVE A MOONSHOT 2.0 AND

4854
03:37:06,800 --> 03:37:08,000
EVERY TIME WE HAVE AN INITIATIVE

4855
03:37:08,000 --> 03:37:09,960
LICK THIS, IT BRINGS THE NUMBER

4856
03:37:09,960 --> 03:37:11,760
OF APPLICATIONS UP BECAUSE

4857
03:37:11,760 --> 03:37:12,600
PEOPLE ASSUME THAT THEY'RE GOING

4858
03:37:12,600 --> 03:37:15,080
TO BE RESOURCES AND AT THE

4859
03:37:15,080 --> 03:37:16,480
MOMENT, WE DON'T KNOW HOW THE

4860
03:37:16,480 --> 03:37:18,320
RESOURCES FOR THE MOONSHOT 2.0

4861
03:37:18,320 --> 03:37:21,560
IS GOING TO BE APPROPRIATED ANDS

4862
03:37:21,560 --> 03:37:23,760
DOUG POINTED OUT TO THE

4863
03:37:23,760 --> 03:37:26,360
SUBCOMMITTEE, ALL OF THE VARIOUS

4864
03:37:26,360 --> 03:37:28,920
AGENCIES ARE INVOLVED IN

4865
03:37:28,920 --> 03:37:30,680
MOONSHOT 2.0 AND THAT IS GREAT

4866
03:37:30,680 --> 03:37:32,400
NEWS BECAUSE THEY BRING

4867
03:37:32,400 --> 03:37:34,600
DIFFERENT KINDS OF TALENT AND

4868
03:37:34,600 --> 03:37:37,280
CAPABILITY TO CANCER SO WE LOOK

4869
03:37:37,280 --> 03:37:39,000
FORWARD TO THAT AS WAS BY THE

4870
03:37:39,000 --> 03:37:41,800
WAY DONE IN MOONSHOT THE FIRST

4871
03:37:41,800 --> 03:37:43,240
MOONSHOT WHICH THE VICE

4872
03:37:43,240 --> 03:37:44,240
PRESIDENT UNDERTOOK.

4873
03:37:44,240 --> 03:37:46,520
AND SO, IT'S GOING TO BE REALLY

4874
03:37:46,520 --> 03:37:49,840
IMPORTANT, I THINK, THAT PEOPLE

4875
03:37:49,840 --> 03:37:52,800
UNDERSTAND THAT NCI IS THE PLACE

4876
03:37:52,800 --> 03:37:54,600
THE MOONSHOT SHOULD BE

4877
03:37:54,600 --> 03:37:55,280
HEADQUARTERS.

4878
03:37:55,280 --> 03:37:56,040
WHY THINK ANYONE BELIEVES IT

4879
03:37:56,040 --> 03:37:57,560
SHOULD BE ANYWHERE ELSE AND

4880
03:37:57,560 --> 03:38:02,600
LET'S HOPE THAT'S THE CASE.

4881
03:38:02,600 --> 03:38:05,240
SO, 2023, ALSO IS AN ISSUE FOR

4882
03:38:05,240 --> 03:38:08,920
US BECAUSE OF ARPA-H WHICH HAS

4883
03:38:08,920 --> 03:38:12,400
BEEN APPROVED AND IT IS IN THE

4884
03:38:12,400 --> 03:38:15,880
BUDGET FOR 20 2023 AT A LEVEL TT

4885
03:38:15,880 --> 03:38:17,320
IS LIKELY TO BE FUNDED BUT I

4886
03:38:17,320 --> 03:38:18,720
DON'T THINK THEY'RE GOING TO BE

4887
03:38:18,720 --> 03:38:19,960
ABLE TO SPEND THE MONEY SO WE

4888
03:38:19,960 --> 03:38:22,120
HAD SOME DISCUSSIONS IN THE

4889
03:38:22,120 --> 03:38:24,520
SUBCOMMITTEE ABOUT, AND I ASK MK

4890
03:38:24,520 --> 03:38:26,040
DURING HER PRESENTATION, YOU

4891
03:38:26,040 --> 03:38:28,160
KNOW, HOW DO WE ACCESS THOSE

4892
03:38:28,160 --> 03:38:30,120
FUNDS AND AS INSTITUTE OR

4893
03:38:30,120 --> 03:38:31,880
INDIVIDUAL AND WE DO KNOW YET.

4894
03:38:31,880 --> 03:38:33,640
AND BECAUSE WE DON'T HAVE A

4895
03:38:33,640 --> 03:38:35,240
DIRECTOR AND WE HAVE ONE

4896
03:38:35,240 --> 03:38:39,760
EMPLOYEE OF ARPA-H SO, THEN WE

4897
03:38:39,760 --> 03:38:43,480
HAVE AN OPEN AND NIH

4898
03:38:43,480 --> 03:38:51,960
DIRECTORSHIP AS WELL AND ALSO A

4899
03:38:51,960 --> 03:38:54,840
OPEN NCI DIRECTOR AND I'M

4900
03:38:54,840 --> 03:38:57,920
CONFIDENT THAT THE ADVOCACY

4901
03:38:57,920 --> 03:39:00,080
COMMUNITY WILL WEIGH IN ON THIS

4902
03:39:00,080 --> 03:39:01,680
IN ALL THE PLACES THAT MAKE A

4903
03:39:01,680 --> 03:39:02,080
DIFFERENCE.

4904
03:39:02,080 --> 03:39:06,440
I'M NOT GOING TO SAY MUCH MORE

4905
03:39:06,440 --> 03:39:07,520
ABOUT WHERE WE ARE WITH OUR

4906
03:39:07,520 --> 03:39:10,360
BUDGET BUT I WILL SAY THAT I

4907
03:39:10,360 --> 03:39:14,360
REALLY THINK THAT THE NCI WILL

4908
03:39:14,360 --> 03:39:16,440
BE, I THINK, SHOULD BE THE FOCUS

4909
03:39:16,440 --> 03:39:18,200
OF A LOT OF CONVERSATIONS ON

4910
03:39:18,200 --> 03:39:20,160
CAPITOL HILL IN THE NEXT FEW

4911
03:39:20,160 --> 03:39:21,440
MONTHS BECAUSE WE ARE THE AGENCY

4912
03:39:21,440 --> 03:39:23,880
THAT IS GETTING GRANTS AND WE

4913
03:39:23,880 --> 03:39:27,000
ARE THE AGENCY THAT IS ACTUALLY

4914
03:39:27,000 --> 03:39:28,640
PEOPLE WANT TO HAVE THEIR GRANTS

4915
03:39:28,640 --> 03:39:31,080
FUNDED FROM THE NCI AND FOR

4916
03:39:31,080 --> 03:39:33,480
CANCER AND I'M REALLY HOPEFUL

4917
03:39:33,480 --> 03:39:35,280
THAT PEOPLE WHO ARE ON-LINE

4918
03:39:35,280 --> 03:39:37,120
TODAY WILL TAKE THAT TO HART.

4919
03:39:37,120 --> 03:39:42,360
SO WITH THAT I WILL STOP THERE

4920
03:39:42,360 --> 03:39:43,760
THAT IS A COMPLETE RUN DOWN OF

4921
03:39:43,760 --> 03:39:45,440
THE NUMBERS YOU CAN REVIEW FOR

4922
03:39:45,440 --> 03:39:45,720
YOURSELF.

4923
03:39:45,720 --> 03:39:47,880
Mr. CHAIRMAN, THAT'S MY

4924
03:39:47,880 --> 03:39:48,120
REPORT.

4925
03:39:48,120 --> 03:39:51,760
>> THANK YOU, AND AS Dr.

4926
03:39:51,760 --> 03:39:53,320
BARKER MENTIONED, WE HAVE ACCESS

4927
03:39:53,320 --> 03:39:56,840
TO THE SLIDES THAT WERE

4928
03:39:56,840 --> 03:39:59,880
PRESENTED BY MK AND THE REPORT

4929
03:39:59,880 --> 03:40:01,840
WAS E-MAILED BY RICARDO SO IT

4930
03:40:01,840 --> 03:40:04,960
WAS ALSO E-MAILED THIS MORNING

4931
03:40:04,960 --> 03:40:07,320
SO JUST FOR INFORMATION

4932
03:40:07,320 --> 03:40:08,640
PURPOSES, SO PAULETTE, DO WE

4933
03:40:08,640 --> 03:40:10,760
NODE TO CALL A MOTION TO --

4934
03:40:10,760 --> 03:40:11,320
>> YES.

4935
03:40:11,320 --> 03:40:13,760
>> TO VOTE FOR APPROVAL OF
THE

4936
03:40:13,760 --> 03:40:14,040
REPORT.

4937
03:40:14,040 --> 03:40:16,000
DO WE HAVE A MOTION.

4938
03:40:16,000 --> 03:40:16,840
>> YES.

4939
03:40:16,840 --> 03:40:19,160
>> YOU HAVE TO ACCEPT THE

4940
03:40:19,160 --> 03:40:19,400
REPORT.

4941
03:40:19,400 --> 03:40:20,560
>> RIGHT.

4942
03:40:20,560 --> 03:40:20,760
>> OK.

4943
03:40:20,760 --> 03:40:23,360
>> DO WE HAVE A MOTION TO
ACCEPT

4944
03:40:23,360 --> 03:40:25,400
THE SUBCOMMITTEE REPORT?

4945
03:40:25,400 --> 03:40:27,560
>> SO MOVED.

4946
03:40:27,560 --> 03:40:29,400
>> SECOND.

4947
03:40:29,400 --> 03:40:32,240
>> IT'S BEEN MOVED AND
SECOND.

4948
03:40:32,240 --> 03:40:35,240
WE NOW SHOULD VOTE AND CAN WE

4949
03:40:35,240 --> 03:40:38,440
SEE ANY NAYs?

4950
03:40:38,440 --> 03:40:44,040
ANY ABSTENTION?

4951
03:40:44,040 --> 03:40:44,640
IT'S UNANIMOUS.

4952
03:40:44,640 --> 03:40:47,280
>> OK.

4953
03:40:47,280 --> 03:40:53,560
>> SO NEXT WE HAVE Dr.
PASKETT

4954
03:40:53,560 --> 03:40:55,160
WHO WILL PRESENT ON THE

4955
03:40:55,160 --> 03:40:56,640
POPULATION SCIENCE AND

4956
03:40:56,640 --> 03:40:58,520
EPIDEMIOLOGY AND DISPARITIES.

4957
03:40:58,520 --> 03:41:02,280
>> THANK YOU, VERY MUCH.

4958
03:41:02,280 --> 03:41:04,920
SO, THE FOCUS OF THE MEETING OF

4959
03:41:04,920 --> 03:41:08,120
THE SUBCOMMITTEE WAS TO BRIEF

4960
03:41:08,120 --> 03:41:09,680
EVERYBODY ON THE PROGRESS TO

4961
03:41:09,680 --> 03:41:14,040
DATE OF THE AD HOC WORKING GROUP

4962
03:41:14,040 --> 03:41:17,640
AND SO THE PRESENTATION WAS

4963
03:41:17,640 --> 03:41:21,360
SHARED BY THE THREE CO-CHAIRS

4964
03:41:21,360 --> 03:41:24,120
AND Dr. ELAINE A MARTINEZ AND

4965
03:41:24,120 --> 03:41:27,160
MYSELF AND Dr. MARTINEZ

4966
03:41:27,160 --> 03:41:28,360
REVIEWED THE CHARGE OF THE

4967
03:41:28,360 --> 03:41:31,000
WORKING GROUP AND IT WAS XIPHOID

4968
03:41:31,000 --> 03:41:32,280
AND EVALUATE THE CURRENT STATUS

4969
03:41:32,280 --> 03:41:34,080
OF BARRIERS TO PROGRESS ON

4970
03:41:34,080 --> 03:41:36,400
CANCER RESEARCH AND RACIAL AND

4971
03:41:36,400 --> 03:41:39,640
ETHNIC MINORITIES UNDERSERVED

4972
03:41:39,640 --> 03:41:41,160
POPULATIONS AND REALLY REMINDED

4973
03:41:41,160 --> 03:41:43,720
EVERYBODY THAT THE FOCUS IS ON

4974
03:41:43,720 --> 03:41:45,600
CANCER RESEARCH SO THE WORKING

4975
03:41:45,600 --> 03:41:49,080
GROUP TO DATE, WE HAVE OUR

4976
03:41:49,080 --> 03:41:51,960
MEMBERSHIP CONFIRMED IN APRIL OF

4977
03:41:51,960 --> 03:41:58,240
'21 AND WE STARTED MEETING IN

4978
03:41:58,240 --> 03:42:04,520
JULY AND WITH Dr. CASTLE AND

4979
03:42:04,520 --> 03:42:06,720
WE, THE FULL COMMITTEES ARE

4980
03:42:06,720 --> 03:42:08,280
MONTHLY ALSO AND SO OUR MEETINGS

4981
03:42:08,280 --> 03:42:11,080
HAVE ALSO INCLUDED SPEAKERS AND

4982
03:42:11,080 --> 03:42:14,080
FROM THE CENTER FOR RESEARCH

4983
03:42:14,080 --> 03:42:23,040
STRATEGIES AND DCCPS AND CRCHD

4984
03:42:23,040 --> 03:42:33,120
AND.

4985
03:43:36,440 --> 03:43:39,000
>> WE'VE GOT ALL THE DUCKS
IN A

4986
03:43:39,000 --> 03:43:40,960
ROW NOW AND CENTER OF RESEARCH

4987
03:43:40,960 --> 03:43:42,760
STRATEGY HAS DONE ALL OF THE

4988
03:43:42,760 --> 03:43:47,200
RUNS ON THE ALL THE DIFFERENT

4989
03:43:47,200 --> 03:43:53,640
POPULATIONS AND NEXT MONTH THEY

4990
03:43:53,640 --> 03:43:58,240
HAVE RENPRESENT THE RESULTS TO E

4991
03:43:58,240 --> 03:44:00,560
DISCUSSED SOME EMERGING

4992
03:44:00,560 --> 03:44:01,680
RECOMMENDATIONS THAT ARE COMING

4993
03:44:01,680 --> 03:44:05,360
OUT AND MAINLY GAPS SO FOR

4994
03:44:05,360 --> 03:44:09,640
EXAMPLE, WE WERE NOT ABLE TO

4995
03:44:09,640 --> 03:44:11,960
CATEGORIZE THE RESEARCH ON ARA

4996
03:44:11,960 --> 03:44:13,000
AND OLDER RESULTS AND WE'RE

4997
03:44:13,000 --> 03:44:14,800
LIMITED FOR THE COLLECTION OF

4998
03:44:14,800 --> 03:44:16,600
LGBTQ PLUS RESEARCH AND SO THOSE

4999
03:44:16,600 --> 03:44:18,120
WILL BE IN OUR RECOMMENDATIONS

5000
03:44:18,120 --> 03:44:20,160
AND THAT WE NEED TO REFINE OUR

5001
03:44:20,160 --> 03:44:24,640
ABILITY TO DO THAT AND OUR GOAL

5002
03:44:24,640 --> 03:44:27,000
LAST THING IS THAT OUR GOAL IS

5003
03:44:27,000 --> 03:44:32,600
TO HAVE OUR REPORT TO PRESENT

5004
03:44:32,600 --> 03:44:35,400
AND TO THE SUBCOMMITTEE AND IN

5005
03:44:35,400 --> 03:44:38,720
DECEMBER THAT IS NOW OUR GOAL.

5006
03:44:38,720 --> 03:44:40,720
WE HAD A LIVELY DISCUSSION AND

5007
03:44:40,720 --> 03:44:42,200
IT'S CAPTURED IN THE MINUTES AND

5008
03:44:42,200 --> 03:44:45,920
AGAIN I JUST WANT TO THANK THE

5009
03:44:45,920 --> 03:44:47,800
CO-CHAIRS AND CRS IS REALLY

5010
03:44:47,800 --> 03:44:49,480
DOING A WONDERFUL JOB WORKING ON

5011
03:44:49,480 --> 03:44:51,120
ALL OF THIS FOR US.

5012
03:44:51,120 --> 03:44:52,240
SO, ANYWAY, I DON'T KNOW IF YOU

5013
03:44:52,240 --> 03:44:58,240
WANT TO ADD ANYTHING ELSE.

5014
03:44:58,240 --> 03:45:02,440
>> THANK YOU.

5015
03:45:02,440 --> 03:45:04,240
SO, WE WOULD LIKE TO SEE -- IS

5016
03:45:04,240 --> 03:45:06,280
THERE A MOTION TO ACCEPT THE

5017
03:45:06,280 --> 03:45:08,600
REPORT FROM THE SUBCOMMITTEE ON

5018
03:45:08,600 --> 03:45:09,960
POPULATION SCIENCE EPIDEMIOLOGY

5019
03:45:09,960 --> 03:45:11,520
AND DISPARITIES?

5020
03:45:11,520 --> 03:45:13,120
>> WE ACCEPT THE REPORT.

5021
03:45:13,120 --> 03:45:14,320
>> WE HAVE A MOTION.

5022
03:45:14,320 --> 03:45:14,720
SECOND.

5023
03:45:14,720 --> 03:45:18,640
IT'S BEEN PROPERLY MOVED AND

5024
03:45:18,640 --> 03:45:18,960
SECOND.

5025
03:45:18,960 --> 03:45:20,640
THE NCAB SHOULD VOTE.

5026
03:45:20,640 --> 03:45:25,680
DO WE HAVE ANY NAYs?

5027
03:45:25,680 --> 03:45:29,040
ANYONE WOULD LIKE TO ABSTAIN?

5028
03:45:29,040 --> 03:45:34,680
IF NOT, WE HAVE A UNANIMOUS VOTE

5029
03:45:34,680 --> 03:45:35,400
TO ACCEPT THE REPORT.

5030
03:45:35,400 --> 03:45:45,640
>> THANK YOU.

5031
03:45:56,360 --> 03:46:02,200
DO YOU THINK THE BOARD SHOULD

5032
03:46:02,200 --> 03:46:08,640
ADDRESS THAT ONE THING THAT CAME

5033
03:46:08,640 --> 03:46:10,480
UP WITH OUR DISCUSSION OF PAR

5034
03:46:10,480 --> 03:46:12,680
WAS THIS CONCEPT OF THIS

5035
03:46:12,680 --> 03:46:13,880
STRATEGIC PLAN AND SAYING THINGS

5036
03:46:13,880 --> 03:46:15,920
FIT INTO THE STRATEGIC PLAN OR

5037
03:46:15,920 --> 03:46:18,280
DON'T AND AT SOME POINT, THAT

5038
03:46:18,280 --> 03:46:19,480
MIGHT BE A REALLY NICE

5039
03:46:19,480 --> 03:46:20,720
PRESENTATION AND FOR US TO BE

5040
03:46:20,720 --> 03:46:22,360
ABLE TO SEE WHAT THE OVER ALL

5041
03:46:22,360 --> 03:46:25,160
LOOKS LIKE AND AS WE THINK ABOUT

5042
03:46:25,160 --> 03:46:27,360
HOW A P.A.R. AND RFA FITS IN

5043
03:46:27,360 --> 03:46:28,560
OVER ALL.

5044
03:46:28,560 --> 03:46:30,440
>> THAT'S A TREMENDOUS
POINT AND

5045
03:46:30,440 --> 03:46:33,480
I THINK AND THE QUESTION BEMES

5046
03:46:33,480 --> 03:46:35,600
IS IT THE NCI'S STRATEGIC PLAN

5047
03:46:35,600 --> 03:46:37,480
OR IS IT THE DIRECTOR STRATEGIC

5048
03:46:37,480 --> 03:46:37,760
PLAN.

5049
03:46:37,760 --> 03:46:40,040
>> IT'S ON-LINE AND I SAID
THERE

5050
03:46:40,040 --> 03:46:40,240
ARE.

5051
03:46:40,240 --> 03:46:43,280
>> WILL THE NEW DIRECTOR
REVISIT

5052
03:46:43,280 --> 03:46:45,120
AND I DON'T KNOW, RIGHT BUT IT'S

5053
03:46:45,120 --> 03:46:46,440
A GREAT POINT AND I THINK IT'S

5054
03:46:46,440 --> 03:46:50,040
SOMETHING THAT WE SHOULD

5055
03:46:50,040 --> 03:46:54,520
DEFINITELY TALK ABOUT.

5056
03:46:54,520 --> 03:46:56,080
I SEE THREE ADDITIONAL HANDS.

5057
03:46:56,080 --> 03:46:57,840
>> ONE TOPIC I WOULD LIKE
TO

5058
03:46:57,840 --> 03:46:59,640
DISCUSS IN THE FUTURE IS

5059
03:46:59,640 --> 03:47:01,360
SOMETHING WE TOUCHED ON VERY

5060
03:47:01,360 --> 03:47:05,400
BRIEFLY YESTERDAY, I DO THINK

5061
03:47:05,400 --> 03:47:07,600
WE'RE AT A CRISIS IN AK DEEMIA

5062
03:47:07,600 --> 03:47:10,920
WITH OUR TRAINEE AND THE MASS

5063
03:47:10,920 --> 03:47:12,640
RESIGNATION HAS HIT ACADEMIA AS

5064
03:47:12,640 --> 03:47:16,960
IT IS HITTING OTHER AREAS OF

5065
03:47:16,960 --> 03:47:25,120
BUSINESS AND AND IT MIGHT BE A

5066
03:47:25,120 --> 03:47:26,360
GOOD COMMITTEE REPORT TO WORK

5067
03:47:26,360 --> 03:47:26,520
ON.

5068
03:47:26,520 --> 03:47:30,520
>> SO CLARIFICATION, WHAT
WAS

5069
03:47:30,520 --> 03:47:34,360
THE TIME YOU CAN HAVE.

5070
03:47:34,360 --> 03:47:45,040
>> THEY'RE NOT WANT TO GO
GO

5071
03:47:45,040 --> 03:47:47,240
INTO THE SITUATION IS SUCH THAT

5072
03:47:47,240 --> 03:47:50,080
MANY TRAINEES DON'T EVEN GO INTO

5073
03:47:50,080 --> 03:47:52,040
POSTDOCS THEY'RE GOING STRAIGHT

5074
03:47:52,040 --> 03:47:54,280
FROM PH.D TO INDUSTRY AND OTHER

5075
03:47:54,280 --> 03:47:56,640
AREAS AND I THINK WE HAVE A REAL

5076
03:47:56,640 --> 03:47:56,880
PROBLEM.

5077
03:47:56,880 --> 03:47:58,920
>> THE IMPACT OF THE
BUDGET.

5078
03:47:58,920 --> 03:48:00,720
>> YEAH.

5079
03:48:00,720 --> 03:48:07,720
>> ON CAREER ADVANCEMENT
AND

5080
03:48:07,720 --> 03:48:08,560
CAREER.

5081
03:48:08,560 --> 03:48:11,240
>> IT'S JUST STAGGERING
AND

5082
03:48:11,240 --> 03:48:14,520
PEOPLE WITH RESEARCH AND IN MY

5083
03:48:14,520 --> 03:48:16,520
SCOPE OF THE WORLD INFORMATICS

5084
03:48:16,520 --> 03:48:21,760
OR COMPUTATIONAL MEDICINE ARE

5085
03:48:21,760 --> 03:48:25,600
JUST PAID SOMETHING HAS TO BE

5086
03:48:25,600 --> 03:48:28,480
DONE THE WAY WE REIMBURSE PEOPLE

5087
03:48:28,480 --> 03:48:30,000
AND DEDICATED LEADERSHIP IN THE

5088
03:48:30,000 --> 03:48:32,960
CANCER COMMUNITY AND WITH A

5089
03:48:32,960 --> 03:48:34,240
UNBELIEVABLE BLEE NON

5090
03:48:34,240 --> 03:48:36,560
COMPETITIVE NIH SALARY GAP.

5091
03:48:36,560 --> 03:48:38,560
>> AGREED.

5092
03:48:38,560 --> 03:48:39,120
TOTALLY.

5093
03:48:39,120 --> 03:48:40,280
SO, DUALLY NOTED.

5094
03:48:40,280 --> 03:48:42,520
LET'S GO TO CHRIS.

5095
03:48:42,520 --> 03:48:43,800
>> SURE, THANK YOU, JOHN
AND

5096
03:48:43,800 --> 03:48:45,200
THANK YOU, EVERYBODY FOR YOUR

5097
03:48:45,200 --> 03:48:46,080
LEADERSHIP AND IT'S GREAT TO SEE

5098
03:48:46,080 --> 03:48:46,800
YOU ALL.

5099
03:48:46,800 --> 03:48:48,240
VERY BRIEFLY, THE ELEPHANT IN

5100
03:48:48,240 --> 03:48:51,080
THE ROOM IS ARPA-H, I WOULD LIKE

5101
03:48:51,080 --> 03:48:52,920
TO MOVE THAT WE HAVE THAT ON OUR

5102
03:48:52,920 --> 03:48:54,520
AGENDA FOR THE DECEMBER JOINT

5103
03:48:54,520 --> 03:48:56,720
MEETING AND WE HAVE THE

5104
03:48:56,720 --> 03:48:59,680
APPROPRIATE REPRESENTATIVE FROM

5105
03:48:59,680 --> 03:49:02,520
ARHA-H PRESENT TO US AND IT'S

5106
03:49:02,520 --> 03:49:02,800
CRITICAL.

5107
03:49:02,800 --> 03:49:03,120
>> THANK YOU.

5108
03:49:03,120 --> 03:49:05,880
>> I BELIEVE IT WAS DOUG

5109
03:49:05,880 --> 03:49:07,120
MENTIONED THERE'S A DEPUTY

5110
03:49:07,120 --> 03:49:09,040
DIRECTOR WHO HAS BEEN NAMED AND

5111
03:49:09,040 --> 03:49:10,920
I THINK BETWEEN NOW AND THE NEXT

5112
03:49:10,920 --> 03:49:13,080
MEETING, THE NEXT JOINT MEETING

5113
03:49:13,080 --> 03:49:14,800
IN DECEMBER, MY ASSUMPTION IS

5114
03:49:14,800 --> 03:49:16,920
WE'LL HAVE THAT PERSON IN

5115
03:49:16,920 --> 03:49:19,240
PERHAPS A AND SO I AGREE IT'S A

5116
03:49:19,240 --> 03:49:22,920
GREAT TOPIC AND THEN ANNA --

5117
03:49:22,920 --> 03:49:26,080
>> SO FURS I WANT TO HELP
BSA

5118
03:49:26,080 --> 03:49:27,840
FOR TAKE A REALLY IMPORTANT

5119
03:49:27,840 --> 03:49:33,480
TOPIC AND THAT'S THE MCED AND

5120
03:49:33,480 --> 03:49:36,320
THAT MEANS MCEDs ESSENTIALLY

5121
03:49:36,320 --> 03:49:39,760
MULTIPLE CANCER EARLY DETECTION

5122
03:49:39,760 --> 03:49:44,360
ASSAYS, I THINK THAT THIS IS A

5123
03:49:44,360 --> 03:49:45,360
SIGHS MICK SHIFT IN CANCER

5124
03:49:45,360 --> 03:49:46,920
RESEARCH AND WE'LL LOOK BACK ON

5125
03:49:46,920 --> 03:49:51,120
THIS AND KNOW THAT THIS IS A

5126
03:49:51,120 --> 03:49:52,560
SEISMIC SHIFT AND WE SAID THESE

5127
03:49:52,560 --> 03:49:54,400
THINGS WERE NEVER GOING TO WORK

5128
03:49:54,400 --> 03:49:56,880
BUT THEY ARE AND THEY'RE BEING

5129
03:49:56,880 --> 03:49:58,040
REIMBURSED BY INSURANCE

5130
03:49:58,040 --> 03:50:00,000
COMPANIES AND COMPANIES ARE

5131
03:50:00,000 --> 03:50:00,720
ACTUALLY OFFERING THEM WHITE

5132
03:50:00,720 --> 03:50:02,240
HOUSE IS LOOKING VERY CAREFULLY

5133
03:50:02,240 --> 03:50:05,720
AT IT FOR THE MOONSHOT 2.0 AND

5134
03:50:05,720 --> 03:50:09,880
SO IF WE START THINKING A LITTLE

5135
03:50:09,880 --> 03:50:13,120
DEEPER AND WE SPENT 50 YEARS AND

5136
03:50:13,120 --> 03:50:14,040
UNDERSTANDING, BEGINNING TO

5137
03:50:14,040 --> 03:50:14,760
UNDERSTAND THE GOUGH NOAM AND

5138
03:50:14,760 --> 03:50:16,280
OUR COVERAGE OF GENOME NOW IS

5139
03:50:16,280 --> 03:50:17,920
SUCH THAT CAN YOU DO THESE KINDS

5140
03:50:17,920 --> 03:50:19,320
OF THINGS AND SO THE SCIENCE

5141
03:50:19,320 --> 03:50:22,960
HERE IS COMPELLING AND IF YOU

5142
03:50:22,960 --> 03:50:26,320
LOOK AT THAT THE PUBLIC WILL SEE

5143
03:50:26,320 --> 03:50:28,480
AND YOU TAKE THE BRAILLE ASSAY,

5144
03:50:28,480 --> 03:50:30,760
THEY SAY AND I THINK THEY CAN

5145
03:50:30,760 --> 03:50:33,840
AND THAT THEY CAN DETECT CANCER

5146
03:50:33,840 --> 03:50:37,440
STAGE 1 AT 39% AND STAGE 2 IS

5147
03:50:37,440 --> 03:50:41,440
69% AND STAGE 3 IS 83% AND 92%

5148
03:50:41,440 --> 03:50:43,440
FOR STAGE 4 CANCER WHICH

5149
03:50:43,440 --> 03:50:44,720
SHOULDN'T SURPRISE ANY OF US BUT

5150
03:50:44,720 --> 03:50:45,320
THINK ABOUT THAT.

5151
03:50:45,320 --> 03:50:47,920
THEY DID THE REPERCUSSIONS OF

5152
03:50:47,920 --> 03:50:50,320
THIS AND I THINK THE NCAB

5153
03:50:50,320 --> 03:50:51,360
ESPECIALLY SHOULD HAVE A WORKING

5154
03:50:51,360 --> 03:50:55,200
GROUP ON THIS IN TERMS OF HOW DO

5155
03:50:55,200 --> 03:50:57,760
WE, IT'S A HUGE TOPIC AND ALL

5156
03:50:57,760 --> 03:51:00,320
THE WAY FROM, MIKE BROUGHT IT

5157
03:51:00,320 --> 03:51:01,480
UP.

5158
03:51:01,480 --> 03:51:04,120
THE PRO AN LIT TICKS ON THE

5159
03:51:04,120 --> 03:51:09,760
SAMPLES TO THE HOW DO YOU CANCEL

5160
03:51:09,760 --> 03:51:10,960
PATIENT CANCER INFORM WHAT ARE

5161
03:51:10,960 --> 03:51:12,080
WE GOING TO DO IF YOU TELL

5162
03:51:12,080 --> 03:51:13,760
SOMEONE THAT THEY HAVE A SIGNAL

5163
03:51:13,760 --> 03:51:15,560
FOR CANCER P. THAT IS WHAT WE'RE

5164
03:51:15,560 --> 03:51:17,480
SAYING WITH THE GALLERY ATTEST,

5165
03:51:17,480 --> 03:51:18,080
A SIGNAL.

5166
03:51:18,080 --> 03:51:19,520
WE DON'T KNOW WHAT THAT MEANS.

5167
03:51:19,520 --> 03:51:21,400
WE HAVE NO IDEA YET.

5168
03:51:21,400 --> 03:51:22,760
SO I REALLY THINK THIS IS SUCH

5169
03:51:22,760 --> 03:51:26,120
AN IMPORTANT TOPIC AND I HOPE

5170
03:51:26,120 --> 03:51:27,920
NCI CAN GET IN FRONT OF THIS AND

5171
03:51:27,920 --> 03:51:29,920
I REALLY COMMEND PHIL FOR

5172
03:51:29,920 --> 03:51:31,600
BRINGING THIS FORWARD AND THIS

5173
03:51:31,600 --> 03:51:33,720
TIME AND TAKING THIS UP BECAUSE

5174
03:51:33,720 --> 03:51:35,600
I THINK IT'S GOING TO BE A VERY

5175
03:51:35,600 --> 03:51:37,440
BIG DEAL IN THE FUTURE AND I

5176
03:51:37,440 --> 03:51:44,280
REALLY WANT US TO BE IN FRONT OF

5177
03:51:44,280 --> 03:51:46,400
IT.

5178
03:51:46,400 --> 03:51:47,080
TOTALLY AGREE.

5179
03:51:47,080 --> 03:51:48,280
OUR TOPIC FOR THE NEXT MEETING

5180
03:51:48,280 --> 03:51:50,560
IS THE CREATION OF A WORKING

5181
03:51:50,560 --> 03:51:54,920
GROUP AROUND THIS AREA AND NO

5182
03:51:54,920 --> 03:51:56,280
MICHAEL'S COMMENTS ABOUT ALL OF

5183
03:51:56,280 --> 03:51:58,480
THE DATA SCIENCE ISSUES AROUND

5184
03:51:58,480 --> 03:51:59,600
MOONSHOT TO ME IT'S ANOTHER ONE

5185
03:51:59,600 --> 03:52:02,160
AND I'M GOING TO GIVE MICHAEL

5186
03:52:02,160 --> 03:52:05,000
ONE MINUTE WE'RE REAL CLOSE TO

5187
03:52:05,000 --> 03:52:05,560
ADJOURNING.

5188
03:52:05,560 --> 03:52:07,720
IF YOU CAN KEEP IT SUCCINCT THAT

5189
03:52:07,720 --> 03:52:08,440
WOULD BE GREAT.

5190
03:52:08,440 --> 03:52:11,640
>> JUST YOU KNOW, I AM NOT
A FAN

5191
03:52:11,640 --> 03:52:21,840
OF ARPA-H.

5192
03:52:22,640 --> 03:52:24,360
FUDGEDDED FEDERAL MANDATE

5193
03:52:24,360 --> 03:52:26,360
RESEARCH PROGRAMS AND BY THREE

5194
03:52:26,360 --> 03:52:28,240
AND THAT TO ME IS AN INDICATION

5195
03:52:28,240 --> 03:52:29,960
THAT NIH IS NOT DOING ITS JOB SO

5196
03:52:29,960 --> 03:52:33,040
WE'VE GOT TO DOUBLE DOWN ON OUR

5197
03:52:33,040 --> 03:52:34,280
EFFORTS TO LOOK ACROSS

5198
03:52:34,280 --> 03:52:36,320
INSTITUTES AND CENTERS IN THE

5199
03:52:36,320 --> 03:52:38,680
NIH AND GET JIGGY AND REAL AND

5200
03:52:38,680 --> 03:52:40,520
ABOUT INTER INSTITUTE

5201
03:52:40,520 --> 03:52:42,200
COLLABORATION AND NCI WILL BE A

5202
03:52:42,200 --> 03:52:45,040
LEADER IN THIS AND I WISH I

5203
03:52:45,040 --> 03:52:47,040
COULD CLAIM THREE PAPEL ABLE

5204
03:52:47,040 --> 03:52:48,800
SUCCESS THIS IS WHICH

5205
03:52:48,800 --> 03:52:50,840
INTERAGENCY APPROACHES AND HAVE

5206
03:52:50,840 --> 03:52:55,080
REALLY YIELD SUSTAINABLE, COMMON

5207
03:52:55,080 --> 03:52:56,440
INFRASTRUCTURE TO FUEL SCIENCE

5208
03:52:56,440 --> 03:52:57,880
IN THIS NEW DECADE.

5209
03:52:57,880 --> 03:52:59,160
IT'S A CONSIDERABLE CHALLENGE

5210
03:52:59,160 --> 03:53:00,720
AND A HUGE ELEPHANT IN THE ROOM

5211
03:53:00,720 --> 03:53:02,960
AND BY THE WAY, THESE ARE OUR

5212
03:53:02,960 --> 03:53:04,760
TAX DOLLARS AND WE CAN'T KEEP

5213
03:53:04,760 --> 03:53:06,560
ASKING FOR MORE AND WE HAVE TO

5214
03:53:06,560 --> 03:53:07,880
ESSENTIALLY BE MORE EFFICIENT

5215
03:53:07,880 --> 03:53:10,560
WITH WHAT WE HAVE AND I KNOW

5216
03:53:10,560 --> 03:53:12,360
THAT IS CURRENT TO THE WAY NCI

5217
03:53:12,360 --> 03:53:14,240
HAS APPROACHED THIS BUT AS A

5218
03:53:14,240 --> 03:53:15,560
TAXPAYERS AND A STEWARD OF WHAT

5219
03:53:15,560 --> 03:53:18,040
IS THERE, IT'S DIZZYING HOW

5220
03:53:18,040 --> 03:53:19,680
CONFUSING IT IS FOR RESEARCHERS

5221
03:53:19,680 --> 03:53:23,160
TO GET THE DATA AND TO GET THE

5222
03:53:23,160 --> 03:53:23,880
INFRASTRUCTURE, COMPUTE

5223
03:53:23,880 --> 03:53:25,640
INFRASTRUCTURE AND TO

5224
03:53:25,640 --> 03:53:26,560
ESSENTIALLY DEVELOP A.I.

5225
03:53:26,560 --> 03:53:27,680
STRATEGIES THAT ARE WINNING FOR

5226
03:53:27,680 --> 03:53:32,000
THEIR PATIENTS AND THEIR

5227
03:53:32,000 --> 03:53:32,280
PROGRAMS.

5228
03:53:32,280 --> 03:53:35,680
>> TOTALLY  TOTE GROW.

5229
03:53:35,680 --> 03:53:39,680
IT WILL BE GREAT TO HEAR FROM

5230
03:53:39,680 --> 03:53:40,360
ARPA-H.

5231
03:53:40,360 --> 03:53:41,320
I THIS IT'S HERE AND I DON'T

5232
03:53:41,320 --> 03:53:43,000
KNOW WHAT CAN BE DONE AT THIS

5233
03:53:43,000 --> 03:53:45,400
POINT AND IT IS HERE AND YOU

5234
03:53:45,400 --> 03:53:47,360
KNOW, I THINK IT'S OUR ROLE AND

5235
03:53:47,360 --> 03:53:49,400
TO ENSURE THAT THE NCI HAS WHAT

5236
03:53:49,400 --> 03:53:51,760
IS NEEDS, RIGHT, TO ADVANCE

5237
03:53:51,760 --> 03:53:53,480
CANCER AND REDUCE MORTALITY

5238
03:53:53,480 --> 03:53:53,840
RATES.

5239
03:53:53,840 --> 03:53:56,320
WE'RE AT THE HOUR.

5240
03:53:56,320 --> 03:53:58,560
PAULETTE, I BELIEVE, WE SHOULD

5241
03:53:58,560 --> 03:54:00,720
MOVE TOWARDS ADJOURNING AND

5242
03:54:00,720 --> 03:54:03,720
PLEASE, PLEASE, THIS DOES NOT

5243
03:54:03,720 --> 03:54:04,920
MEAN THAT YOU ARE INPUT AND

5244
03:54:04,920 --> 03:54:07,960
QUESTIONS AND COMMENTS AREN'T

5245
03:54:07,960 --> 03:54:08,240
IMPORTANT.

5246
03:54:08,240 --> 03:54:09,960
YOU KNOW, I IMPLORE YOU TO

5247
03:54:09,960 --> 03:54:11,120
E-MAIL PAULETTE AND IF YOU HAVE

5248
03:54:11,120 --> 03:54:12,800
SOMETHING THAT YOU WOULD LIKE TO

5249
03:54:12,800 --> 03:54:14,160
ADD AND WE'LL MAKE SURE THAT IT

5250
03:54:14,160 --> 03:54:16,280
GETS ON THE AGENDA AND DON'T

5251
03:54:16,280 --> 03:54:18,160
JUST THINK THAT BECAUSE YOUR

5252
03:54:18,160 --> 03:54:22,120
NAME WASN'T CALLED THAT IT'S NOT

5253
03:54:22,120 --> 03:54:23,200
IMPORTANT AND WE'RE A MINUTE

5254
03:54:23,200 --> 03:54:26,320
OVER RIGHT NOW AND I DO FEEL THE

5255
03:54:26,320 --> 03:54:29,880
PRIVILEGE TO BE THE FIRST TO SAY

5256
03:54:29,880 --> 03:54:32,000
ALTHOUGH THE AUGUST-SEPTEMBER

5257
03:54:32,000 --> 03:54:34,040
MEETING WILL BE VIRTUAL THE

5258
03:54:34,040 --> 03:54:35,920
DECEMBER HAD BEEN HYBRID SO I'M

5259
03:54:35,920 --> 03:54:37,120
EXCITED ABOUT THAT TO HAVE THE

5260
03:54:37,120 --> 03:54:40,360
OPPORTUNITY TO GET IN ROOM AND

5261
03:54:40,360 --> 03:54:41,800
MEET AND SEE PEOPLE FACE-TO-FACE

5262
03:54:41,800 --> 03:54:45,480
AND I'M EXCITED ABOUT THAT AND

5263
03:54:45,480 --> 03:54:48,760
THERE BEING NO FURTHER BUSINESS,

5264
03:54:48,760 --> 03:54:50,360
PAULETTE, I WOULD LIKE TO

5265
03:54:50,360 --> 03:54:56,200
ADJOURN THE JOINT MEETING FOR.

5266
03:54:56,200 --> 03:54:57,840
>> IT'S YOUR PLEASURE TO
DO TO.

5267
03:54:57,840 --> 00:00:00,000
>HAVE A GREAT SUMMER.